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ABSTRACT 
 
This thesis aimed to define and manipulate epigenetic stability of human embryonic 
stem cells (hESCs). The allele-specific expression of 22 imprinted genes was 
examined in 22 hESC lines by distinguishing parental single nucleotide 
polymorphisms in genomic DNA and cDNA. Half of the genes examined (PEG10, 
PEG1, MESTIT1, IGF2, H19, GTL2, NESP55, PHLDA2 and ATP10C) showed 
variable allele-specific expression between cell lines, indicating vulnerability to 
disrupted imprinting. However, 8 genes (KCNQ1OT1, NDN, NDNL1, SNRPN, IPW, 
PEG3, KCNQ1 and CDKN1C) showed consistent monoallelic expression. Moreover, 
4 genes (TP73, IGF2R, WT1 and SLC22A18) known to be monoallelically expressed 
or to exhibit polymorphic imprinting in human tissues were always biallelically 
expressed. MEST isoform 1, PEG10 and NESP55 showed an association between the 
variability observed in interline allele-specific expression status and DNA methylation 
at their imprinting regulatory regions. These evidences demonstrate gene-specific 
differences in the stability of imprinted loci in hESC lines and identify disrupted DNA 
methylation as one potential mechanism.  
 
hESOD1 (human embryonic stem cells overexpressing DNMT1) cell lines were 
established to manipulate epigenetic stability of hESCs. Of ~ 2,200 CpG loci 
examined by restriction landmark genomic scanning (RLGS), cell lines (cultured over 
23 passages) having only endogenous DNMT1 showed in vitro culture induced DNA 
methylation alterations at 6 loci. However, hESOD1 cell lines showed DNA 
methylation alterations at only 1 or 2 loci, indicating that overexpression of exogenous 
DNMT1 resulted in increased epigenetic stability. Of 14 imprinting regulatory regions, 
10 tumour-suppressor gene promoters and 3 repetitive sequences examined, 3 loci 
(DAPK-1, MGMT and TIMP-3) were indentified to be hypermethylated in hESOD1 
cell lines, whereas other 21 loci showed normal methylation levels. These evidences 
demonstrate that overexpression of exogenous DNMT1 can prevent hESCs from 
accumulating DNA methylation changes upon in vitro culture and cause locus-specific 
hypermethylation.  
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1. INTRODUCTOIN 
 
In the last two decades, several pluripotent cell lines (embryonal carcinoma cell lines, 
embryonic stem cell lines, embryonic germ cell lines and induced pluripotent cell 
lines) have been established in the human (Andrews et al., 1984; Park et al., 2008; 
Shamblott et al., 1998; Takahashi et al., 2007; Thomson et al., 1998; Yu et al., 2007). 
Regardless of their origins, all cell lines share similar morphological characteristics, 
express key pluripotency markers (e.g. OCT4 and NANOG), are capable of long-term 
self-renewal in vitro and have an ability to differentiate into multi-lineages in vitro 
and in vivo. Thus, these cell lines are thought to be a model for understanding 
mechanisms of differentiation of human tissues, and a material for pharmaceutical 
screening and for human therapeutic applications (reviewed by Fenno et al., 2008; 
Pera, 2001; Thomson and Odorico, 2000).  
 
Despite these merits, however, several limitations have been exposed while human 
embryonic stem cells (hESCs) are propagated and differentiated in vitro. Firstly, in 
order to grow them in vitro, animal-derived compounds have typically added into 
culture media that are not acceptable for safe human transplantation (Amit et al., 
2004; Ludwig et al., 2006b; Xu et al., 2001). Secondly, in terms of differentiation, 
optimised protocols and conditions have not been discovered to yield homogeneous 
populations (Anderson et al., 2007; Burridge et al., 2007; Denning et al., 2006). 
Thirdly, they are prone to accumulate karyotypic abnormalities (especially gain of 
chromosomes 17q and 12) over extended culture (Baker et al., 2007; Draper et al., 
2004). Finally, there are indicators of epigenetic variations in hESCs upon in vitro 
culture (Allegrucci et al., 2004; Bibikova et al., 2008; Pannetier and Feil, 2007; Rugg-
Gunn et al., 2007), the consequences of which are not yet defined.  
 
A larger number of studies in various species have suggested that epigenetic errors in 
at least some imprinted genes of preimplantation stage embryos and their derived 
foetuses, placentae (Khosla et al., 2001a; Mann et al., 2004; Sato et al., 2007; Young 
et al., 2001) and ESCs (Dean et al., 1998; Fujimoto et al., 2006; Humpherys et al., 
2001; Mitalipov et al., 2007) can occur when assisted reproduction technology (ART) 
procedures including superovulation, in vitro maturation (IVM), in vitro culture (IVC), 
in vitro fertilisation (IVF) are applied. These errors cause phenotypic abnormalities, 
growth defects and Large offspring syndrome (LOS) during prenatal and postnatal 
 14 
development (Dean et al., 1998; Fernandez-Gonzalez et al., 2004; Young et al., 2001). 
Current methods for establishing and culturing hESC lines rely on ART procedures 
(reviewed by Fenno et al., 2008; Hoffman and Carpenter, 2005), implicating that at 
least some hESC lines may have epigenetic errors at imprinted loci.  
 
Because epigenetic errors at imprinted loci are known to be closely associated with 
tumourigenesis and several congenital disorders in the human (reviewed by Feinberg, 
2007; Horsthemke and Ludwig, 2005; Jelinic and Shaw, 2007; Robertson, 2005), 
comprehensive studies are required to indentify whether hESC lines are epigenetically 
stable while they are in vitro cultured. There are conflicting data about the epigenetic 
stability of in vitro cultured hESCs (Allegrucci et al., 2007; Bibikova et al., 2006; 
Calvanese et al., 2008; Maitra et al., 2005; Mitalipov, 2006; Plaia et al., 2006; Rugg-
Gunn et al., 2005; Sun et al., 2006). Preliminary studies of a limited number of 
imprinted genes in few hESC lines detect little or no epigenetic variations and 
disruptions (Mitalipov, 2006; Plaia et al., 2006; Rugg-Gunn et al., 2005; Sun et al., 
2006). However, recent studies have detected epigenetic instability at certain CpG 
islands, ribosomal DNA and tumour-suppressor gene promoters by increasing the 
number of hESC lines and genes examined (Allegrucci et al., 2007; Bibikova et al., 
2006; Calvanese et al., 2008; Maitra et al., 2005).  
 
1.1 Human embryonic stem cell line 
 
1.1.1 Derivation  
 
The first derivation of hESC lines was reported by Thomson et al., (1998). hESC lines 
were established from inner cell masses (ICMs) of human blastocyst stage embryos 
that were in vitro fertilised and cultured (Thomson et al., 1998). Embryos were 
donated from infertile couples who underwent IVF procedures. The zona pellucidae 
(ZP) of 20 blastocysts were removed by pronase, and 14 ICMs were isolated by 
immunosurgery and plated onto mouse embryonic fibroblasts (MEFs) mitotically 
inactivated by irradiation. Following 9 to 15 days in culture, ICM-derived outgrowths 
were dissociated into clumps either by exposure to Ca2+/Mg2+-free PBS or dispase, or 
mechanical dissociation, and then re-plated onto fresh MEFs to continue their 
expansion. Finally, 5 hESC lines (H1, H7, H9, H13 and H14) were established 
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(Thomson et al., 1998). hESCs showed prominent nucleoli and a high ratio of nucleus 
to cytoplasm and express high levels of telomerase activity and cell-surface markers 
(e.g. SSEA-3, SSEA-4) (Thomson et al., 1998). They were capable of prolonged 
symmetrical self-renewal in vitro and had a capacity to differentiate into derivatives of 
all primitive embryonic germ layers (ectoderm, mesoderm and endoderm) in vivo, as 
demonstrated from teratoma formation (Thomson et al., 1998).  
 
Based on initially designed conditions by Thomson et al., (1998), numerous hESC 
lines have been established. Currently, ~ 400 hESC lines are presumed to be 
established in over 20 countries (reviewed by Allegrucci and Young, 2007). The 
majority of cell lines are generated from the ICMs of blastocyst stage embryos. 
However, some cell lines are generated from single blastomeres of 8- to 10- cell stage 
embryos or morula stage embryos (Chung et al., 2008; Klimanskaya et al., 2006; 
Strelchenko et al., 2004). Very recently, 6 patient-specific hESC lines have been 
established from pathenogenetic derived blastocyst stage embryos (Revazova et al., 
2007). Furthermore, it has been clearly confirmed that SCNT-hES-1, previously 
shown to be derived by somatic cell nuclear transfer (SCNT) (Hwang et al., 2004), is a 
pathenogenetically derived-stem cell line, as determined by genome-wide single 
nucleotide polymorphisms (SNPs) and DNA methylation analyses at three imprinted 
loci (KvDMR1, H19 DMR and SNRPN DMR) (Kim et al., 2007a).  
1.1.2 Characterisation  
 
Established hESC lines need to be characterised within at least six criteria (reviewed 
by Hoffman and Carpenter, 2005; Laslett et al., 2003). The criteria are (1) the 
expression of hESC-specific cell surface makers (e.g. SSEA-3, SSEA-4, TRA-1-60, 
TRA-1-60, TRA-1-81 and alkaline phosphatase), (2) high level of telomerase activity, 
(3) a normal euploid karyotype over extended culture, (4) the expression of  
pluripotent transcription factors (e.g. OCT3/4 and NANOG), (5) teratoma formation 
(with components of all three germ layers) after injection into severe combined 
immunodeficient (SCID) mice, and (6) spontaneous differentiation into three germ 
layers under in vitro conditions. These criteria are important to determine whether 
hESC lines have proliferative, pluripotency, differentiative capacities and karyotypic 
stability (reviewed by Hoffman and Carpenter, 2005; Laslett et al., 2003). Although 
investigators realise the importance of characterisation for maintaining hESC lines, 
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some of newly derived cell lines have not been fully characterised. For example, 
teratoma formation, karyotyping and telomerase activity analyses are frequently 
omitted (Chung et al., 2008; Ludwig et al., 2006b; Richards et al., 2002). Importantly, 
each laboratory uses different protocols and materials to characterise their derived cell 
lines, implicating batch-to-batch and data variations between laboratories. Thus, a 
recent study by the international stem cell initiative (ISCI) has compared 59 hESC 
lines derived from 17 laboratories using same protocols and materials (e.g. antibodies) 
to identify common characteristics between lines (Adewumi et al., 2007) that can 
define the hESCs characteristics.  
1.1.3 Culture conditions  
 
hESC lines are usually derived and cultured on MEFs as feeder cells in medium 
containing foetal bovine serum (FBS) (Thomson et al., 1998). Importantly, FBS is a 
complex mixture containing undefined compounds, has a batch-to-batch variation and 
may contain factors to induce differentiation of hESCs (reviewed by Unger et al., 
2008). Furthermore, to isolate ICM from the blastocyst stage embryo, immunosurgery 
needs to be performed using antibodies raised from animal species (Solter and 
Knowles, 1975). Therefore, current methods and materials for deriving and culturing 
hESC lines are not independent of animal-derived components and hence the transfer 
of animal pathogens to hESC lines can be a potential risk. In fact, a study by Martin et 
al., (2005) has demonstrated that hESC lines can incorporate an immunogenic 
nonhuman sialic acid, N-glycolylneuraminic (Neu5Gc), from mouse feeder cells, FBS 
and/or KnockOut SR (KSR) that they are cultured with. Thus, new culture conditions 
(serum-, animal product- and feeder cell-free) are required for safe human 
transplantation.  
1.1.3.1 Serum-free 
 
A study by Amit et al. (2000) has suggested that basic fibroblast growth factor (bFGF) 
is an essential component to maintain an undifferentiated state of hESCs in serum-free 
condition. Thus, FBS was replaced with the bFGF and KSR (serum replacement) 
(Amit et al., 2000). Based on above condition, 17 HUES-lines (HUES1 to HUES17) 
and HS293 and HS306 cell lines were established (Cowan et al., 2004; Inzunza et al., 
2005). However, feeder cells such as MEFs and postnatal human fibroblasts are still 
required to support hESCs self-renewal in this condition. Furthermore, KSR contains 
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AlbuMAX which is a lipid-enriched bovine serum albumin (BSA) (Amit et al., 2000; 
Unger et al., 2008). Thus, this system is not animal-derived component independent. 
1.1.3.2 Feeder cell-free 
 
A feeder cell-free culture condition was firstly introduced by Xu et al., (2001). The 
feeder cells were replaced with either matrigel, which was a solubilised basement 
membrane preparation extracted from mouse Engelbreth-Holm-Swarm (EHS) 
sarcoma (Kleinman and Martin, 2005), or human laminin (Xu et al., 2001). Thus, 
hESCs can be maintained on either matrigel or laminin in the MEF-conditioned 
medium (CM) containing KSR and bFGF. Within this condition, hESCs exhibit long-
term maintenance in vitro with the inhibition of spontaneous differentiation (Xu et al., 
2001). However, MEFs need to be cultured in the medium containing FBS to obtain 
MEF-CM, and KSR still needs to be added. Thus, this condition is also not animal-
derived component independent. 
1.1.3.3 KSR-free 
 
Recently, two cell lines (WA15 and WA16) have been derived in a serum- and KSR-
independent culture medium which is named as TeSR1 (Ludwig et al., 2006a; Ludwig 
et al., 2006b). Five factors, bFGF, LiCl (lithium chloride), GABA (γ-aminobutyrid 
acid), pipecolic acid and TGFβ, are components of TeSR1 (Ludwig et al., 2006a; 
Ludwig et al., 2006b). However, several limitations have been exposed in this 
condition. The WA15 cell line has a karyotypic abnormality over extended culture 
(Ludwig et al., 2006a; Ludwig et al., 2006b). Moreover, the costs of some components 
are very expensive for everyday research use generally. Therefore, a new variant, 
mTeSR1, that contains BSA and cloned zebrafish basic fibroblast growth factor 
(zbFGF) has been developed for culture of hESCs on Matrigel (Ludwig et al., 2006a).  
1.1.4 Differences between mouse and human ESCs 
 
Morphological differences between human and mouse ESCs have been reported on 
the basis of manual passage methods (Ginis et al., 2004). mESCs form thick layers up 
to ten cells over feeder cells, whereas hESCs form thin layers from two to four cells 
(Ginis et al., 2004). Moreover, hESCs form round, flat and loose colonies with well-
defined edges, whereas mESCs form more spherical and tight colonies (Ginis et al., 
 18 
2004; Reubinoff et al., 2000). The population-doubling (PD) time of hESCs (24h to 
72h) is much longer than that of mESCs (~ 12h) (Cowan et al., 2004). Although 
almost all stem cell markers including SSEA-3/4, TRA-1-60/81/254, GTCM-2, TG-
30/343 and alkaline phosphatase are expressed in hESCs, only SSEA-1 and alkaline 
phosphatase are present in mESCs (Henderson et al., 2002; Laslett et al., 2003). In 
addition, class 1 major histocompatbility (MHC) and Thy1 antigens are expressed 
only in hESCs (Draper et al., 2002).  
 
The pluripotency of both mESCs and hESCs is guided by distinct signalling pathways. 
Activin/Nodal/TGFβ (transforming growth factor β) pathways are essential for 
maintaining the undifferentiated state of hESCs (Beattie et al., 2005; James et al., 
2005; Vallier et al., 2005; Xiao et al., 2006), and thus bFGF needs be added in the 
hESC culture medium (Xu et al., 2005). However, mESCs rely on JAK (janus-
associated tyrosine kinase)/STAT (signal transducers and activators of 
transcription)/BMP (bone morphogenetic protein) pathways to maintain an 
undifferentiated state without feeder cells (Williams et al., 1988; Ying et al., 2003a), 
and thus LIF (leukemia inhibitory factor) should be added in the mESC culture 
medium (Williams et al., 1988). BMP4 in combination with LIF has shown to be 
sufficient to maintain mESCs (serum- and feeder-free) in an undifferentiated state 
(Ying et al., 2003a). However, LIF and BMPs are not able to maintain an 
undifferentiated state of hESCs in the feeder-free culture condition (Pera et al., 2004; 
Reubinoff et al., 2000; Xu et al., 2002).  
 
Recently, mouse and rat epiblast stem cells (EpiSCs) have been derived from the late 
epiblast layer of postimplantation embryos (5.75 dpc and 7.5 dpc, respectively) (Brons 
et al., 2007). Interestingly, the Activin/Nodal signalling pathway was required for 
maintaining pluripotency of EpiSCs within the chemically defined medium, indicating 
similarity to hESCs. Also, EpiSCs were morphologically distinct from mESCs but 
similar to hESCs, showing compacted and round colonies (Brons et al., 2007). 
However, SSEA-1 is expressed in EpiSCs which is not present in hESCs (Brons et al., 
2007). 
1.1.5 Differences between human pluripotent cell lines  
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Years before the derivation of hES and human embryonic germ (hEG) cell lines 
(Shamblott et al., 1998; Thomson et al., 1998), the human embryonal carcinoma 
(hEC) cell line provides a in vitro model to understand mechanisms of differentiation 
of human tissues (Przyborski et al., 2000). The hEC cell line is derived from a 
testicular germ cell tumour (Andrews et al., 1984). This cell line contains 
undifferentiated stem cell components of teratocarcinomas (Pal and Ravindran, 2006; 
Sperger et al., 2003). Thus, the hEC cell line is generally considered as malignant 
counterparts of embryonic stem cells. hEG cell lines are derived from primordial germ 
cells (PGCs) isolated from the developing gonadal ridges and mesenteries of 5- to 9- 
week embryos (Shamblott et al., 1998). Very recently, induced pluripotent stem (iPS) 
cell lines are derived from somatic cells by viral introduction of transcriptional factors 
including OCT3/4 and SOX2 with either NANOG and LIN28 (Yu et al., 2007), or 
MYC and KLF4 (Park et al., 2008; Takahashi et al., 2007). Although they are derived 
from different sources, they share many parts of common features including 
pluripotency, and in vivo and in vitro differentiative capacity. However, they have 
distinct differences between cell lines.  
 
hES, hEC  and iPS cells share a similar morphology that is distinct from hEG cells 
(Andrews et al., 1984; Ginis et al., 2004; Shamblott et al., 1998; Takahashi et al., 
2007; Thomson et al., 1998). hEG cells form tight and more spherical colonies that are 
difficult to be dissociated into single cells, whereas hES, hEC and iPS cells form 
relatively flat, loose and round colonies that are easily dissociated into single cells by 
trypsin and other enzymes. At the molecular level, hES, hEC and iPS cells express all 
cell-surface markers except for SSEA-1, but hEG cells express all makers including 
SSEA-1 (Andrews et al., 1984; Thomson et al., 1998; Thomson et al., 1995). OCT3/4 
and NANOG are expressed in hES, hEC and iPS cells, but their expression are still 
unknown in hEG cells (Andrews et al., 1984; Shamblott et al., 1998; Takahashi et al., 
2007; Thomson et al., 1998). Furthermore, hEC cells frequently contain karyotypic 
abnormalities, often with gain of chromosome 17q and the presence of one or more 
isochromosomes 12p (Andrews et al., 1984; Draper et al., 2004). hES cells retain 
normal karyotypes at earlier passages but have similar karyotypic abnormities of hECs 
under the feeder-free condition (Baker et al., 2007; Draper et al., 2004). hEG and iPS 
cells retain normal karyotypes at earlier passages, but it has not confirmed yet at later 
passages (Park et al., 2008; Shamblott et al., 1998; Yu et al., 2007). Finally, hEC cells 
 20 
form teratoma containing simple structures, whereas hES and iPS cells form teratoma 
with the variety of tissues representative of all three embryonic germ layers (Andrews 
et al., 1984; Park et al., 2008; Thomson et al., 1998; Yu et al., 2007). Teratoma 
formation has not been examined in hEG cells (Shamblott et al., 1998).  
 
Table 1-1. Comparison of human pluripotent stem cells 
Marker hES cells hEC cells iPS cells hEG cells 
Morphology 
 
Flat, loose and round 
colony 
Flat, loose and round 
colony 
Flat, loose and round 
colony 
Tight and spherical 
colony 
SSEA-1 - - - + 
SSEA-3 + + + + 
SSEA-4 + + + + 
TRA-1-60 + + + + 
TRA-1-81 + + + + 
Alkaline 
phosphatase + + + + 
OCT3/4 + + + Unknown 
NANOG + + + Unknown 
Karyotype Normal Abnormal Normal Normal 
Teratoma 
formation + + + Unknown 
+; expresssed, -; not expresssed 
1.2 Epigenetic modifications 
 
In the last decade, epigenetic mechanisms have been extensively studied with different 
model systems to understand how gene transcription is regulated and mediated in 
nuclei of mammalian cells. Genes need to be inactive or active depending on the 
tissue type, and this process is guided by epigenetic modifications. DNA methylation 
and histone modifications are known to be critical epigenetic modifications of the 
genome that can directly modulate chromatin structure (e.g. heterochromatin and 
euchromatin) and regulate gene expression in mammalian cells (reviewed by Bird, 
2002).  
 
The term “epigenetic” describes heritable changes in gene expression that occur 
without genotypic changes during development (reviewed by Jaenisch and Bird, 2003; 
Li, 2002; Reik, 2007; Surani, 2001). In mammals, epigenetic marks inherited from 
parents are thought to be erased at the early stages of germ cell development 
(reviewed by Constancia et al., 2004; Ferguson-Smith and Surani, 2001; Reik et al., 
2001). Subsequently, neo epigenetic marks at DNA and histones are differentially set 
up among lineages, resulting in differential gene expression of each cell. Lineage-
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specific gene expression allows stem cells to be differentiated into various types of 
tissues, together with the production of tissues-specific transcriptional factors.  
 
Recently, the ‘Human epigenome project (see http://www.epigenome.org/)’ has 
emerged (2008; Brena et al., 2006) and ‘Human genome project (see 
http://genomics.energy.gov/)’ has been completed (Lander et al., 2001; Venter et al., 
2001). A number of techniques have been newly developed to investigate epigenetic 
modifications in detail, revealing that aberrant epigenetic modifications in the genome 
might be associated with many types of human diseases (reviewed by Feinberg, 2007; 
Robertson, 2005).  
1.2.1 DNA methylation  
 
DNA methylation is known to be a major epigenetic process in the mammalian 
genome and is responsible for diverse biological phenomena including embryonic 
development, genomic imprinting, X-inactivation, host-defence against transposable 
elements and tissue-specific gene expression (reviewed by Bird, 2002; Feinberg, 
2007; Jaenisch and Bird, 2003; Reik, 2007; Surani, 2001). DNA methylation occurs 
by covalent addition of a methyl group (CH3) from the methyl donor, S-adenosy-L-
methionine (AdoMet) to the 5-position of cytosine in the pyrimidine ring of a 
symmetrical cytosine-guanine (CpG) dinucleotide, resulting in the formation of 5-
methylcytosine (m5C) (Figure 1-1) (reviewed by Bestor, 2000; Cheng and Blumenthal, 
2008). Less frequently, DNA methylation can also occur in non-CpG dinucleotides 
such as CpNpG and non-symetrical CpA and CpT (Ramsahoye et al., 2000). The 
enzymatic reaction of DNA methylation is carried out by DNA methyltranferases 
(DNMTs) (Bestor et al., 1988; Okano et al., 1998a).  
 
In the human genome, 60 ~ 90% of cytosine residues are located in CpG dinucleotides 
and approximately 50 million CpG dinucleotides are present (Lander et al., 2001; 
Venter et al., 2001; Zhao and Zhang, 2006). Over 10% of CpG dinucleotides are 
concentrated on CpG rich regions designated as CpG islands which are normally 
unmethylated, whereas over 80 % of CpG dinucleotides are not associated with CpG 
islands and highly methylated (Zhao and Zhang, 2006). Takai and Jones (2002) have 
defined that a CpG island is a region of 500 base pairs in size with GC content of at 
least 55% and a ratio of observed/expected CpG frequency of at least 0.65. By 
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computational analysis of the human genome sequence, 29,000 CpG islands are 
predicted in the human genome (Lander et al., 2001; Venter et al., 2001). Most human 
chromosomes contain between 5 to 15 CpG islands per megabase (Mb), but some 
chromosomes including Y chromosome, chromosome 16, 17, 22 and 19 contain more 
or less CpG islands in a range 2.9 to 43 CpG islands per Mb  (Lander et al., 2001).  
 
Figure 1-1. The formation of 5-methylcytosine  
The DNA methyltransferases (DNMTs) catalyses the methylation of the 5 position of 
the cytosine ring by using S-adenosy-L-methionine (AdoMet) as the donor molecule 
for the methyl group (CH3).  
1.2.2 DNA methylation and transcriptional control 
 
Methylated CpG islands are not randomly distributed in the genome but are clustered 
in the specific chromatin, heterochromatin, containing repetitive sequences and 
transposable elements (Yoder et al., 1997b). This is to ensure transcriptional silencing 
of potentially harmful transposons or viral sequences (reviewed Bird, 2002; Jaenisch 
and Bird, 2003). In the euchromatin regions, however, unmethylated CpG islands are 
typically found near 5' end regions of genes such as untranslated regions (UTRs), 
promoters and the first exon and intron (Marino-Ramirez et al., 2004), and most of 
them overlap the transcriptional start sites, resulting in gene expression (Figure 1-2 A).  
1.2.2.1 Monoallelic methylation 
 
Exceptions are CpG islands involved in genomic imprinting and genes on the inactive 
X chromosome in females. Genomic imprinting is monoallelic expression of a subset 
of genes that can be mediated by methylation of one parental allele at specific 
regulatory regions (reviewed by Constancia et al., 2004; Ferguson-Smith and Surani, 
2001; Reik and Walter, 2001; Surani, 2001). Thus, the imprinted allele is generally 
(but not always) silenced by methylation, but the other allele of imprinted genes is 
expressed and unmethylated. In terms of X inactivation, the promoter region of the 
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transcriptionally active Xist allele on the inactive X chromosome is unmethylated, 
whereas that of the transcriptionally inactive Xist allele on the active X chromosome is 
methylated (reviewed by Avner and Heard, 2001). Thus, gene loci related to genomic 
imprinting and X chromosome inactivation are monoallelically methylated on their 
regulatory regions to result in monoallelic expression.  
1.2.2.2 Hypermethylation 
 
Hypermethylation has frequently been found at the promoter regions of tumour-
suppressor genes (TSGs) and miRNA genes in various types of cancers, resulting in 
transcriptional silencing (Figure 1-2 B) (reviewed by Bibikova et al., 2008; Esteller, 
2007; Feinberg, 2007; Reik, 2007). For instance, ESR1 (Estrogen receptor), CDH1 
(E-Cadherin) and TIMP-3 (tissue inhibitor of metalloproteinase-3) promoters are 
hypermethylated in cancers derived over 15 different human tissues and in most cases 
these genes are transcriptionally silenced, although they are expressed and 
unmethylated in normal tissues (Ohm et al., 2007). Furthermore, mir-9-1, mir124a3, 
mir-148a, mir-152 and mir-663 promoters are hypermethylated in human breast 
cancers that is associated with transcriptional silencing of these genes (Lehmann et al., 
2008).  
 
Figure 1-2. Typical DNA methylation patterns of CpG dinucleotides in the 
human genome  
(A) In normal cells, CpG islands at the promoter region of gene are unmethylated 
permitting gene expression, whereas CpG islands at repetitive sequences within the 
heterochromatic region are hyper-methylated. (B) In cancer cells, the promoter region 
of the gene is hyper-methylated resulting in gene silencing, whereas CpGs within 
repetitive sequences are hypo-methylated. Red rectangles indicate repetitive 
sequences in heterochromatin. Blue rectangles indicate exons of a tumour suppressor 
gene in euchromatin. Vertical bars indicate CpG dinucleotides. Filled circles represent 
methylated CpG dinucleotides. Arrows indicate transcription. Adapted from Esteller 
(2007). 
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1.2.2.3 Mechanisms 
 
At least three mechanisms are thought to be involved in transcriptional regulation 
mediated by DNA methylation. Firstly, transcription factors such as major late 
transcription factor (MLTF) and upstream transcription factor (USF) are not able to 
access their binding sites in some genes due to the epigenetic modification of cytosine 
bases to 5-methylcytosine (Watt and Molloy, 1988). This prevents these genes from 
being transcribed. Secondly, particular transcriptional insulators, CTCF (CCCTC-
biding factor) and YY1, bind to only unmethylated DNA (Donohoe et al., 2007; 
Fedoriw et al., 2004; Kim et al., 2006; Schoenherr et al., 2003). Their bindings do not 
allow enhancers to access to promoter regions of genes, resulting in gene silencing. 
Finally, methyl-CpG binding domain proteins (MBD1, MBD2, MBD3, MBD4 and 
MeCP2)  bind only methylated DNA and recruit chromatin remodelling complexes to 
form a transitionally repressive structure that leads to gene silencing (Fujita et al., 
2003).  
1.2.3 DNA methyltransferases (DNMTs) 
 
DNA methylation is enzymatically catalysed by DNA methyltransferases (DNMTs) 
(reviewed by Bestor, 2000; Li, 2002). So far, three active DNMTs (DNMT1, 
DNMT3A and DNMT3B) have been identified in both the human and mouse (Bestor 
et al., 1988; Okano et al., 1998a). DNMT1 maintains DNA methylation patterns 
during the progression of replication at the S phase using hemimethylated CpG 
dinucleotides as substrates in the nascent strand of DNA (reviewed by Bestor, 2000; 
Li, 2002). Thus, it is popularly known as a maintenance methyltransferase. DNMT3A 
and DNMT3B are thought to be involved in the creation of new methylation patterns 
at unmethylated CpG dinucleotides as substrates (Okano et al., 1999; Okano et al., 
1998a). Thus, they are generally named as de novo methyltransferases. Additionally, 
DNMT3L and DNMT2 have been identified, but no methyltransferase enzymatic 
activities have been confirmed yet in mammals (Aapola et al., 2000; Aapola et al., 
2002; Okano et al., 1998b). Instead, DNM3L acts as a methylation mediator by 
stimulating the methylation activity of DNMT3A and DNMT3B (Hata et al., 2002; 
Suetake et al., 2004). DNMT2 acts as a RNA methyltransferase which methylates 
tRNAAsp (Goll et al., 2006; Jurkowski et al., 2008).   
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1.2.3.1 DNMT1 
 
1.2.3.1.1 Alternative transcripts 
 
The first mammalian Dnmt1 cDNA was identified from mouse by Bestor et al., (1988). 
Dnmt1 encodes for a protein of 1620 amino acids and 190 kDa in molecular weight 
(Bestor et al., 1988). Dnmt1 has tissue-specific splicing transcripts, somatic- (Dnmt1s), 
pachytene spermatocyte- (Dnmt1p) and oocyte-specific Dnmt1 (Dnmt1o) isoforms, 
which are derived from sex-specific promoters (Mertineit et al., 1998). Dnmt1o (175 
kDa in molecular weight) is a truncated form 118 N-terminal amino acids of Dnmt1s 
(Mertineit et al., 1998). Dnmt1o has an enzymatic activity and is present in 
unfertilised oocytes and preimplantation embryos (Mertineit et al., 1998). Dnmt1o 
protein is localised in the cytoplasm of the metaphase II oocyte and preimplantation 
stage embryos, but it is in the nucleus at the 8-cell stage only (Cardoso and Leonhardt, 
1999; Howell et al., 2001; Mertineit et al., 1998). In human, expression of an oocyte-
specific DNMT1 mRNA is detected in mature oocytes and embryos at the 2-cell, 4-
cell and blastocyst stages, but not in somatic tissues (Hayward et al., 2003). The 
expression and distribution of DNMT1o protein has not been examined yet in human 
oocytes and preimplantation stage embryos.   
 
In initial studies, no DNMT1s protein is detected in mouse oocytes and 
preimplantation stage embryos, although its transcript is present (Cardoso and 
Leonhardt, 1999; Mertineit et al., 1998). Thus, it is believed that only Dnmt1o can 
maintain DNA methylation patterns during preimplantation stage development. 
However, recent studies by Kurihara et al. (2008) and Cirio et al. (2008) have found 
that Dnmt1s protein is present in the nucleus of mouse oocytes and preimplantation 
stage embryos. Moreover, Kurihara et al. (2008) has demonstrated that inactivation of 
Dnmt1s in mouse embryos by either RNA-mediated knockdown or antibody 
neutralisation leads to loss of methylation at the H19 DMR and intracisternal A-type 
particle (IAP), indicating that Dnmt1s can be involved in the maintenance of DNA 
methylation patterns at imprinted loci and repetitive sequences during preimplantation 
development (Kurihara et al., 2008).  
1.2.3.1.2 de novo methylation 
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DNMT1 can also act as a de novo methyltrasferase to methylate unmethylated CpG 
dinucleotides, although in vitro assays have indicated a 10 to 50 fold preference for 
hemimethylated CpG sites (Bacolla et al., 1999; Pradhan et al., 1999; Yoder et al., 
1997a). For example, the over-expression of Dnmt1 in mESCs and human lung 
fibroblasts (IMR90/SV40) shows a significant increase in both maintenance and de 
novo DNA methyltransferase activities, resulting in hypermethylation of repetitive 
elements, tumour-suppressor gene promoters and imprinted loci (Biniszkiewicz et al., 
2002; Vertino et al., 1996). Furthermore, of 1749 CpG loci examined by restriction 
landmark genomic scanning (RLGS), an additional 373 loci (21%) are de novo 
methylated in human lung fibroblasts overexpressing DNMT1 (HMT17, HMT19 and 
HMT1E1 lines) (Feltus et al., 2003). 
1.2.3.1.3 Role in development and differentiation 
 
Gain- and loss-of-function studies of DNMT1 in the mouse and human have 
demonstrated that appropriate DNMT1 expression is essential for embryonic 
development and lineage-specific differentiation. mESCs overexpressing Dnmt1 
exhibit hypermethylation at repetitive sequences (centromeres and IAP) and loss of 
imprinting of Igf2 and H19 (but not Igf2r, Peg3, Snrpn and Grf1) that leads to 
embryonic lethality after diploid and tetraploid blastocyst injection (Biniszkiewicz et 
al., 2002). Moreover, the inactivation of Dnmt1 in mESCs show extensive 
perturbations of DNA methylation (at repetitive sequences, sub-telomeric domains 
and imprinted loci) and genomic imprinting that leads to elongated telomeres, failure 
of differentiation towards hematopoietic and cardiomyocyte lineages, and embryonic 
lethality (Chen et al., 2003; Gonzalo et al., 2006; Jackson et al., 2004). Furthermore, 
Dnmt1 knockout (KO) MEFs show demethylation at IAP elements and loss of 
imprinting that gives rise to growth retardation and cell death mediated by p53 
(Jackson-Grusby et al., 2001). In the human, complete deletion of DNMT1 in the 
human colon cancer cell line (HCT116) leads to chromosomal defects, cell cycle 
arrest and cell death (Chen et al., 2007).  
1.2.3.2 Overlapping functions of DNMTs 
 
If one of DNMTs is functionally lost by mutation or deletion, it appears that they can 
compensate for each other to maintain DNA methylation patterns, although the 
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supporting data is contradictory. Single KOs of Dnmt3a and Dnmt3b in mESCs and 
MEFs show no apparent changes in global methylation levels (Okano et al., 1999; 
Dodge et al., 2005). Only certain classes of minor satellite sequences are demethylated 
(Okano et al., 1999). In contrast to single KOs, however, Dnmt3a and Dnmt3b double 
knockout (DKO) mESCs and Dnmt1, Dnmt3a and Dnmt3b triple knockout (TKO) 
mESCs show substantial loss of methylation at imprinted loci, retroviral sequences, 
and major and minor satellite repeats (Okano et al., 1999; Tsumura et al., 2006). In the 
human, DNMT1 and DNMT3B DKO in HCT116 show significantly reduced 
methyltransferase activity and loss of genomic DNA methylation (about 95%), but 
single KOs of DNMT1 and DNMT3B in HCT116 exhibit only 20% and 3% loss of 
methylation, respectively (Rhee et al., 2002; Rhee et al., 2000). The methylation of 
promoter regions of p16INK4a (a prototypic INK4 protein), TIMP-3 and IGF2 is not or 
little changed in single KO cells, whereas these regions were completely demethylated 
in DKO cells (Rhee et al., 2002). Importantly, single KOs of Dnmt3a and Dnmt3b in 
mESCs have no perturbation of undifferentiated stem cell states, showing normal 
morphology and expected expression and promoter unmethylation of transcriptional 
factors (Oct4 and Nanog) (Jackson et al., 2004; Li et al., 2007; Okano et al., 1999). 
These cells retain an ability to differentiate into hematopoietic and cardiomyocyte 
lineages and Oct4 and Nanog promoters are methylated after differentiation (Jackson 
et al., 2004; Li et al., 2007). Unlike in single KOs, Dnmt3a and Dnmt3b DKO mESCs 
show reduced ability to form embryo bodies and differentiate into hematopoietic and 
cardiomyocyte lineages (Jackson et al., 2004; Li et al., 2007). This has been defined 
by abnormal expression of trophoblast-, mesodermal- and endodermal markers 
(Jackson et al., 2004; Li et al., 2007). The promoter regions of Oct4 and Nanog remain 
unmethylated and the genes are still expressed after differentiation (Jackson et al., 
2004; Li et al., 2007). Collectively, the inactivation of one of the DNMTs does not 
affect global DNA methylation and cellular differentiation capacity. This may be due 
to the fact that DNMTs can compensate for each other to maintain normal DNA 
methylation patterns in the mammlian genome. This also indicates that they may share 
the target sites to be methylated.  
 
Notably, there are contrasting data. Chen et al., (2003) has showed that in Dnmt3a and 
Dnmt3b DKO J1 mESCs, endogenous C-type retrovirus (pMO), minor satellite and 
IAP repeats are demethylated. These demethylated loci can be remethylated by 
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overexpression of either Dnmt3a or Dnmt3b cDNA, but not with Dnmt1 cDNA (Chen 
et al., 2003). Furthermore, loci demethylated by inactivation of Dnmt1 can be 
remethylated by overexpression of Dnmt1 cDNA, but not with Dnmt3a and Dnmt3b 
cDNA, respectively (Chen et al., 2003). Thus, Chen et al., (2003) has suggested that 
the role of Dnmt1, Dnmt3a and Dnmt3b can not be overlapped and their target sites 
are different, and thereby they are required cooperative expression to maintain normal 
DNA methylation patterns in the mammalian genome. On the other hand, of 1300 
CpG sites examined by RLGS, an additional 236 loci are detected, indicating 
demethylation in Dnmt1 KO cells (Hattori et al., 2004). In addition, the same loci are 
identified to be demethylated in Dnmt3a and Dnmt3b DKO cells, suggesting Dnmt1, 
Dnmt3a and Dnmt3b can share same target sites to be methylated (Hattori et al., 2004).  
1.2.3.3 Structure of DNMTs and associated functional domains 
 
1.2.3.3.1 DNMT1 
 
DNMT1 consists of two domains namely a regulatory, N-terminal domain and a 
catalytic, C-terminal domain (reviewed by Bestor, 2000; Cheng and Blumenthal, 
2008). Both domains are linked by a short stretch of repeated Gly-Lys (GK) 
dipeptides (Figure 1-3). The C-terminal domain of DNMT1 contains six conserved 
motifs (I, IV, VI, VIII, IX and X) that allows transfer of methyl groups from AdoMet 
to cytosine, mostly within CpG dinucleotides (Bacolla et al., 1999; Posfai et al., 1989; 
Pradhan et al., 1999). In detail, motifs I and X fold together to form AdoMet binding 
sites, motif IV contains the prolylcysteinyl dipeptide providing the cytosine thiolate at 
active sites, motif VI contains the glutamyl residue that protonates the 3 position of 
the target cytosine, motif IX maintains the structure of the target recognition domain 
that makes base-specific contacts in the major groove, and VIIIs’ function is not clear 
yet (Lauster et al., 1989; Posfai et al., 1989; Yoder et al., 1997a). The N-terminal 
domain of DNMT1 contains a number of functional domains including a proliferating 
cell nuclear antigen (PCNA) binding domain (PBD), a nuclear localisation signal 
(NLS), a DNA replication foci targeting sequence (RFT or TS), a cysteine-rich Zn2+ 
binding motif (ATRX), and a polybromo homology domain (PBHD) (Bestor, 2000; 
Cheng and Blumenthal, 2008). Thus, the N-terminal domain allows targeting to 
replication foci, discriminating between hemimethylated and unmethylated CpG 
dinucleotides, and associating with chromatin modifiers, while DNA is replicated 
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(reviewed by Bestor, 2000; Cheng and Blumenthal, 2008). Furthermore, the N-
terminal domain is responsible for recruiting Dnmt1 to DNA repair sites (Mortusewicz 
et al., 2005).  
 
Figure 1-3. The structure of the member of the mammalian DNMT family  
The N-terminal domain contains a proliferating cell nuclear antigen (PCNA)-binding 
domain (PBD) shown as a purple rectangle, a nuclear localisation signal (NLS) shown 
as a blue rectangle, an a cysteine-rich Zn2+ binding motif (ATRX) shown as a grey 
rectangle, a polybromo homology domain (PBHD) shown as a green rectangle, a 
DNA replication foci targeting sequence (RFT or TS) shown as a red rectangle and a 
tetrapeptide (proline-tryptophan-tryptophan-proline) motif (PWWP) shown as a 
yellow rectangle. The C-terminal domain contains six conserved motifs (I, IV, VI, 
VIII, IX and X). Both domains are linked by a short stretch of repeated Gly-Lys (GK) 
dipeptides. I is involved in the formation of the AdoMet binding sites, IV binds to 
substrate cytosine at the active site, VI contains the glutamyl residue serving as a 
proton donor, IX maintains the structure of the substrate-biding sites, X participates in 
the formation of the AdoMet binding sites. VIIIs’ function is not clear yet. aa is as 
amino acids. Adapted from Bestor (2002), and Cheng and Blumenthal (2008) 
 
The N-terminal domain of DNMT1 possesses the capability of transcriptional 
repression, independent of catalyzing DNA methylation (Rountree et al., 2000). The 
transcriptional repression activity can be enhanced by interacting with histone 
deacetylases (HDAC1 and HDAC2) which remove acetyl groups from the tail of 
histones and help to maintain condensed chromatin structure and transcriptional 
silenced states (Fuks et al., 2000; Rountree et al., 2000). Moreover, DNMT1 interacts 
with the number of proteins, including heterochromatin protein 1β (HP1β), histone 
methyltransferases (SUV39H1 and G9A), tumour suppressor protein 53 (p53), 
retinoblastoma (Rb), DNMT3A/3B and DNA methyltransferase 1 associated protein 1 
(DMAP1) (Esteve et al., 2005; Esteve et al., 2006; Fuks et al., 2000; Fuks et al., 2003; 
Kim et al., 2002; Pradhan and Kim, 2002; Rountree et al., 2000) that enhances 
transcriptional repression activity of DNMT1. For example, DMAP1 (encoding for 
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467 amino acids and 53 kDa in molecular weight) was isolated as a DNMT1 
interacting protein by yeast two-hybrid screening (Rountree et al., 2000). A luciferase 
activity assay has demonstrated that transcriptional repression activity of DNMT1 can 
be stimulated by a direct interaction of 212 - 422 amino acids of DMAP1 with the first 
120 amino acids of DNMT1 (Liu and Fisher, 2004; Rountree et al., 2000). Therefore, 
a specific interaction between DNMT1 and other proteins related to histone 
modifications, cell cycle and apoptosis might be essential to mediate transcriptional 
regulation of genes in mammalian nuclei. 
1.2.3.3.2 DNMT3A and DNMT3B 
 
DNMT3A and DNMT3B share a structural similarity with DNMT1 (reviewed by 
Bestor, 2000; Cheng and Blumenthal, 2008) (Figure 1-3). Both DNMT3A and 
DNMT3B proteins are organised into a large regulatory N-terminal domain and a 
smaller catalytic C-terminal domain (Figure 1-3). Two domains are linked by a short 
stretch of repeated Gly-Lys (GK) dipeptides (reviewed by Bestor, 2000; Cheng and 
Blumenthal, 2008). The C-terminal domain of DNMT3A and DNMT3B contains six 
conserved motifs (I, IV, VI, VIII, IX and X). Their regulatory N-terminal domains 
contain NLS, ARTX and PWWP (proline-tryptophan-tryptophan-proline motif) 
(Bestor, 2000; Cheng and Blumenthal, 2008).  
 
A truncation mutant study of Dnmt3a and Dnmt3b has suggested that the PWWP 
domain is essential for the association with heterochromatin at the S phase to maintain 
DNA methylation patterns at pericentric heterochromain regions (Chen et al., 2004). 
Moreover, the PWWP domain of Dnmt3a and Dnmt3b is associated with 
transcriptioanlly silenced and condensed mitotic chromatin during mitosis (Ge et al., 
2004). Recently, point mutation (serine 270) of the PWWP domain has been found in 
Japanese patients who suffering from the ICF (immunodeficiency, centromeric 
instability, and facial anomalies) syndrome (Shirohzu et al., 2002), which is 
characterised by loss of methylation at pericentromeric heterochromatin of 
chrosomosomes 1, 9 and 16 (Chen et al., 2004; Xu et al., 1999).  
 
DNMT3A and DNMT3B can repress gene transcription by means, independent of 
catalyzing de novo DNA methylation (Bachman et al., 2001; Fuks et al., 2001; Fuks et 
al., 2003). Their transcriptional repression activities are mediated by ARTX-like 
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PBHD of the N-terminal domain (Bachman et al., 2001; Fuks et al., 2001). The 
transcriptional repression activity of DNMT3A and DNMT3B can be enhanced by 
interacting with each other, histone-modifying enzymes, histone-remodelling enzymes 
or other co-repressors. Specifically, DNMT3A and DNMT3B interact with 
DNMT1/3L, HDACs, RP58 (sequence-specific transcriptional repressor), hSNF2H 
(ATP-dependent chromatin remodelling enzyme), HP1β and SUV39H1 (Bachman et 
al., 2001; Fuks et al., 2000; Fuks et al., 2001; Fuks et al., 2003; Geiman et al., 2004; 
Kim et al., 2002). These interactions allow forming of heterochromatin and 
stimulating of transcriptional repression activity.  
1.2.3.3.3 DNMT3L 
 
Another methyltransferase like protein (DNMT3L) has been identified in the human 
and mouse (Aapola et al., 2000; Aapola et al., 2001). Like Dnmt3a and Dnmt3b, 
Dnmt3l is highly expressed in the germ cell and embryonic stem cell (Bourc'his et al., 
2001; Kaneda et al., 2004; La Salle et al., 2004). Dnmt3l is essential for establishing 
and maintaining DNA methylation patterns at imprinted loci, unique nonpericentric 
heterochromatic sequences and repetitive sequences (Arnaud et al., 2006; Bourc'his et 
al., 2001; Hata et al., 2002; Webster et al., 2005). DNMT3L also consist of two 
domains as same as other DNMTs have, and both domains are linked by GK 
dipeptides (Figure 1-3). However, DNMT3L has only few components in both 
domains. The N-terminal domain of DNMT3L contains only ARTX and NLS, and 
only four conserved motifs (I, IV, VI and VIII) are present in the C-terminal domain. 
Thus, this can be explained why DNMT3L lacks the enzymatic activity to transfer 
methyl groups to DNA (Bestor, 2000; Margot et al., 2003; Suetake et al., 2004). 
Interestingly, even if DNMT3L has a NLS domain (156-159 amino acid), it is shown 
to be localised in both the cytoplasm and nucleus of NIH3T3, COS-7 and human 
rhabdomyosarcoma (RD) cell line (Aapola et al., 2002; Hata et al., 2002).  
1.2.3.3.4 DNMT2 
 
DNMT2 is the smallest methyltransferase and has only the C-terminal domain 
containing six conserved motifs (reviewed by Bestor, 2000). In contrast to the other 
DNMTs, DNMT2 is localised to the cytoplasm of transfected NIH3T3, indicating that 
it does not directly contact with genomic DNA (Goll et al., 2006). No methylation or 
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phenotypic changes are detected in Dnmt2 KO mice and no endogenous DNA 
methyltransferase activity has been confirmed yet (Okano et al., 1998b). However, 
interestingly, transgenic flies and Drosophila S2 cells overexpressing mouse and 
Drosophila Dnmt2 cDNA show an increased methylation activity and 
hypermethylation at two loci (CG8547 and CG8553) (Narsa Reddy et al., 2003; Tang 
et al., 2003). Furthermore, recently it has been reported that DNMT2 can methylate to 
C5 position of cytosine 38 (C38) in tRNAAsp, suggesting that it may function as an 
active RNA methyltransferase (Goll et al., 2006). Conserved motifs IV, VI and VII of 
DNMT2 catalyses methylation to tRNAAsp (Jurkowski et al., 2008).  
1.2.4 Histone modifications 
 
Within eukaryotic nuclei, genomic DNA needs to be tightly compacted and organised 
into a structure, chromatin (Bernstein et al., 2005; Lachner et al., 2003). The 
nucleosome (the fundamental unit of chromatin) is composed of 146 base pairs of 
DNA wrapped around an octamer that consists of two copies each of core histone 
H2A, H2B, H3 and H4 (Bernstein et al., 2005; Lachner et al., 2003). The nucleosomes 
are linked together by the linker DNA and histone H1. Although the core region of the 
histone octamer remains inside the nucleosome, the N-terminal tails of histones are 
exposed and post-translationally modified by acetylation, methylation, 
phosphorylation, ubiquitylation and sumoylation (Bernstein et al., 2005; Lachner et al., 
2003). For example, histone H3 can be methylated at lysines 4, 9, 27, 36, and 79, and 
histone H4 can be methylated at lysine 20 (Lachner et al., 2003).  
 
Histone modifications co-operate to form a specific chromatin structure and to 
regulate gene transcription (reviewed by Jaenisch and Bird, 2003; Li, 2002; Reik, 
2007). For instance, both acetylation of H3 and H4, and methylation of H3 at lysine 4 
(H3-K4), at lysine 36 (H3-K36) and at lysine 79 (H3-K79) are closely associated with 
active genes and frequently found in euchromatin regions, whereas methylation of H3 
at lysine 27 (H3-K27) and methylation of H3 at lysine 9 (H3-K9) and at lysine 20 
(H3-K20) are co-related with transcriptional repression of genes and the formation of 
large constitutive heterochromatin domains (Bernstein et al., 2005; Peters et al., 2001; 
Rice et al., 2003; Schotta et al., 2004). 
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Different degrees of methylation at the same residue may influence different degrees 
of chromatin structures. Histone methylation takes place on the lysine (K) residues. 
Lysine residues can be mono-, di-, and try-methylated (Peters et al., 2003; Rice et al., 
2003; Schotta et al., 2004; Wu et al., 2005). H3-K9 trimethylation is predominantly 
localised in pericentric heterochromatin regions, whereas H3-K9 mono- and 
dimethylation are enriched at early replicating euchromatin regions (Rice et al., 2003; 
Wu et al., 2005). In addition, H3-K27 monomethylation and H4-K20 trimethylation 
are largely localised in heterochromatin regions, whereas H3-K27 di- and 
trimethylation, and H4-K20 mono- and dimethylation are present in euchromatin 
regions (Peters et al., 2003; Schotta et al., 2004).  
1.2.5 Histone methyltransferases (HMTs) 
 
Histone methylation is catalysed by the number of histone methyltransferases (HMTs). 
Five histone methyltransferases (Suv39h1, Suv39h2, G9a, Eset and Eu-HMTase) have 
been identified in mammals (Dodge et al., 2004; Peters et al., 2001; Tachibana et al., 
2001). Interestingly, although all histone methyltransferases can transfer methyl 
groups at K residues of histone H3 and H4, they have distinct enzymatic activities and 
localisation patterns in mammalian nuclei. Suv39h1 and Suv39h2 tend to be localised 
in the pericentric heterochromatin region, whereas G9a and Eset are localised in the 
euchromatic region (Dodge et al., 2004; Lehnertz et al., 2003; Tachibana et al., 2001; 
Tachibana et al., 2002). An in vitro activity assay has demonstrated that G9a has a 10- 
to 20-fold strong enzymatic activity, compared to Suv39h1 (Tachibana et al., 2001). In 
addition, G9a can methylate both H3-K27 and H3-K9, whereas Suv39h1 and Suv39h2 
preferentially methylates only H3-K9 (Rice et al., 2003; Tachibana et al., 2001; 
Tachibana et al., 2002).  
 
KO studies in mice have suggested that Suv39h1, Suv39h2, G9a and Eset are essential 
for early embryonic development and germ cell differentiation (Dodge et al., 2004; 
Lehnertz et al., 2003; Peters et al., 2003; Peters et al., 2001; Tachibana et al., 2002). 
G9a KO mice showed loss of H3-K9 methylation in the euchromatic region and 
apoptosis that leads to embryonic lethality between 9.5 - 12.5 dpc (Peters et al., 2003; 
Tachibana et al., 2002). Eset KO mice also result in embryonic lethality between 3.5 
and 5.5 dpc (Dodge et al., 2004). Suv39h1/2 DKO mice show loss of H3-K9 
 34 
methylation in the heterochromatin region, chromosomal instability and impaired 
spermatogenesis (Lehnertz et al., 2003; Peters et al., 2001).  
1.2.6 Histone modifications associated with DNA methylation 
 
Histone modifications have an important role to maintain DNA methylation patterns 
in the genome. In the fungus (Neurospora crassa), inactivation of DIM-5 (defective in 
methylation 5; encoding a H3-K9 methyltransferase) leads to loss of DNA 
methylation at ζ-η, 63, 1D21, 9A20 and rDNA (Tamaru and Selker, 2001). Moreover, 
in Arabidopsis thaliana, the mutation of KRYPTONITE (a H3-K9 methyltransferase) 
shows loss of DNA methylation at CpNpG trinucleotides (but not CpG dinucleotides) 
(Jackson et al., 2002) and the deletion of DDM1 (decrease in DNA methylation), a 
SWI2/SNF2-like protein, causes 70% reduction of genomic methylation at repetitive 
sequences (Jeddeloh et al., 1999). In mammals, Suv39h1 and Suv39h2 DKO mESCs 
show loss of DNA methylation at pericentric satellite repeats (but not at minor 
satellites or endogenous C-type retroviruses) (Lehnertz et al., 2003). Furthermore, 
G9a KO mESCs show loss of maternal methylation at the Snrpn DMR, resulting in 
loss of imprinting of Snrpn (Xin et al., 2003). The mutation of Lsh (lymphoid specific 
helicase, a member of the SNF2 chromatin remodelling family) in mice shows 
substantial loss of DNA methylation at the repetitive sequences, promoter regions of 
single copy genes (b-Globin and Pgk-2), and an imprinted locus (H19 DMR) (Dennis 
et al., 2001). These evidences indicate DNA methylation and histone modifications 
(chromatin remodelling) are interdependent and the interplay between them is 
required for regulating gene transcription in mammals. 
1.3 Genomic imprinting  
 
1.3.1 Imprinted genes 
 
Genomic imprinting describes an epigenetic process, resulting in the parent of origin-
specific monoallelic expression of a subset of genes (reviewed by Constancia et al., 
2004; Reik and Walter, 2001; Surani, 2001). Although most genes in mammals are 
expressed from both parental alleles, imprinted genes are preferentially expressed 
from either the paternal or maternal allele (reviewed by Ferguson-Smith and Surani 
2001). Since the first imprinted genes, mouse insulin-like growth factor 2 (Igf2), its 
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neighbouring gene H19, and Igf2 receptor (Igf2r) have been discovered (Barlow et al., 
1991; Bartolomei et al., 1991; DeChiara et al., 1991), so far ~ 80 imprinted genes in 
mice and ~ 50 imprinted genes in humans have been identified (Morison et al., 2005). 
This number is continually increasing. A study by using large-scale expression 
profiling has estimated that a larger number of candidate transcripts (over 2,000)  in 
the mouse and human genome are imprinted (Nikaido et al., 2003), although allele-
specific expression of these candidates has not been examined. Table 1-1 summarises 
known human imprinted genes. Briefly, human imprinted genes have been identified 
on at least 10 human chromosomes. Most of them are clustered in specific 
chromosomes (e.g. chromosomes 7, 11, 15), whereas some of them are randomly 
disributed in the rest of chromosomes. Approximately, half of genes are expressed 
from the maternal allele and the other half are expressed from the paternal allele.  
 
Table 1-2. Known human imprinted genes  
locus Transcript Functional 
component Imprinting status Expressed allele 
1p36 TP73  I M 
1p31 ARHI  I P 
HYMAI  I P 
6q24 
PLAGL1  I P 
6q25 IGF2R  PI M 
7p12 GRB10  I P or Ma 
CALCR  PD M 
SGCE  I P 
PEG10  I P 
PPP1R9A  I M 
PON1  PD P 
7q21 
DLX5  I M 
CPA4  I M 
MEST  I P or Ma 
MESTIT1  I P 
7q32 
COPG2IT1  I P 
10q22 CTNNA3  PD M 
H19  I M 
IGF2  I P 
IGF2AS  I P 
INS  I P 
TRPM5  PD P 
KCNQ1  I M 
KCNQ1OT1  I P 
CDKN1C  I M 
SLC22A1LS  PD M 
SLC22A18  I M 
PHLDA2  I M 
OSBPL5  I M 
11p15 
ZNF215  PD M 
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WT1  I P 
11p13 
WT1AS  I P 
DLK1  I P 
14q32 
MEG3  I M 
MKRN3  I P 
MAGEL2  I P 
NDN  I P 
SNURF I P 
SNRPN I P 
HBII-436 I P 
HBII-13 I P 
HBII-437 I P 
HBII-438A I P 
PWCR1 I P 
HBII-52 I P 
HBII-438B I P 
SNURF-SNRPN 
UBE3A-AS I P 
UBE3A  I M 
15q11 
ATP10A  I M 
18q21 TCEB3C  I M 
PEG3  I P 
19q13 
ZIM2  I P 
20q11 NNAT  I P 
L3MBTL  I P 
NESP55 I M 
GNASXL I P 
Exon-1A I P 
GNAS1 
GS-α I M 
20q13 
SANG  I P 
I, imprinted; NI, not imprinted; PI, polymorphic imprinted; PD, provisional data; M, 
maternal; P, paternal; a imprinting is isoform dependent. Adopted from Morison et al., 
(2005).  
 
Detailed summaries of known imprinted genes, their functions and expression patterns 
are available in following websites; (1) Mammalian Genetics Unit, MRC, Harwell, 
Oxfordshire, UK; (http://www.har.mrc.ac.uk/research/genomic_imprinting/), (2) 
Cancer Genetic Laboratory, Department of Biochemistry, University of Otago, 
Dunedin, New Zealand; (http://igc.otago.ac.nz/home.html), (3) Jirtle Laboratory, 
Duke University, Durham, USA, the Geneimprint; (http://www.geneimprint.com/), 
and (4) Laboratory for Genome Exploration Research Group, RIKEN Genomic 
Research Center, Yokohama, Japan; (http://fantom2.gsc.riken.go.jp/imprinting/).  
1.3.2 Human chromosome 11p15 
 
Most imprinted genes (at least 80%) are not randomly distributed within the genome 
but are clustered in specific chromosomes, which is thought to influence their 
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coordinated transcriptional regulations within clusters (Reviewed by Ferguson-Smith 
and Surani, 2001; Reik and Walter, 2001; Surani, 2001). Some clusters are very large 
(several megabases in size) and are highly conserved between the human and mouse. 
Within clusters, maternally and paternally imprinted genes, as well as non-imprinted 
genes are localised together. For example, 10 imprinted genes (6 maternally expressed 
genes and 4 paternally expressed genes) and 7 non-imprinted genes have been 
identified on human chromosome 11p15 (Table 1-1 and Figure 1-4). This cluster 
consists of two independent imprinting sub-domains, domain 1 containing MRPL23, 
H19, IGF2, IGF2AS and INS genes and domain 2 containing NAPIL4, TSSC3, TSSC5, 
CDKN1C/p57KIP2, KCNQ1, KCNQ1OT1/LIT1, TSSC4 and CD81. The allele-specific 
expression of these genes are guided by two imprinting control regions (ICRs; ICR1 
and ICR2) located on KCNQ1-KCNQ1OT1 and IGF2-H19 loci, and differentially 
methylated regions (DMRs) located on the upstream of the IGF2 gene (reviewed by 
Reik and Walter, 2001; Robertson, 2005; Surani, 2001).  
 
Figure 1-4. Human chromosome 11p15  
7 non-imprinted genes (NAPL4, TSSC4, CD81, RHEMX, ASCL2, TH, MRPL23) and 
10 imprinted genes can be found within this locus. Within the 10 imprinted genes, 6 
(OSBPL5, TSSC3, SLC22A18, CDKN1C, KCNQ1, H19) are maternally expressed and 
4 (KCNQ1OT1, INS, IGF2, IGF2AS) are paternally expressed. Imprinted gene 
expression in this locus is controlled by ICRs (imprinting control regions), DMRs 
(differentially methylated regions), CTCF (CCCTC-binding factor) proteins and 
enhancers. ICR2 is also known as KvDMR1 and is maternally methylated and 
paternally unmethylated. ICR1 is also known as H19 CTCF and is paternally 
methylated and maternally unmethylated. Upstream of IGF2, three DMRs (DMR0, 
DMR1, DMR2) have been characterised in the human. DMR0 is maternally 
methylated, whereas DMR1 and DMR2 are paternally methylated. Adapted from 
Robertson (2005).  
 
The CTCF (CCCTC-binding factor) proteins are also involved in the regulation of 
imprinted gene expression within two domains. They bind to only unmethylated 
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alleles of both ICR1 and ICR2 and act as insulators to prevent enhancers from binding 
to the promoter region of corresponding genes (Fitzpatrick et al., 2007; Prawitt et al., 
2005; Sparago et al., 2004). For example, once the CTCF protein binds to the 
unmethylated maternal allele of ICR1, enhancers are not able to access to the 
promoter region of IGF2. Thus, IGF2 is transcriptionally silenced from the maternal 
allele, whereas the H19 gene can be expressed. On the paternal allele of ICR1, DNA 
methylation blocks CTCF binding that allows enhances to access to the promoter 
regions of IGF2, resulting in IGF2 expression from the paternal allele and H19 
silenced (Reviewed by Ferguson-Smith and Surani, 2001; Reik and Walter, 2001).  
1.3.3 Differentially methylated regions (DMRs)  
 
The allele-specific expression of imprinted genes is controlled by DNA methylation at 
their regulatory regions (reviewed by Li, 2002; Reik and Walter, 2001). In imprinted 
loci, DNA methylation usually occurs in a specific region named as differentially 
methylated region (DMR). The DMR is differentially methylated between parental 
alleles to direct monoallelic expression of its corresponding imprinted genes. For 
example, the SNRPN gene is paternally expressed and maternally silenced in 
association with paternal unmethylation and maternal methylation at the SNRPN DMR 
(El-Maarri et al., 2001; Geuns et al., 2003; Lucifero et al., 2002). So far, at least 15 
DMRs have been identified in the human and mouse and they are largely conserved 
between species (Table 1-2). Most of them are localised in promoter regions of their 
relevant imprinted genes. However, some DMRs are localised in intronic regions (e.g. 
KvDMR1 and Igf2r DMR2) that are associated with the expression of antisense 
transcripts (e.g. KCNQ1OT1 and Air) (Horike et al., 2000; Lee et al., 1999; Smilinich 
et al., 1999; Vu et al., 2004; Wutz et al., 1997). Not all DMRs are associated with 
allele-specific expression of imprinted genes. For instance, IGF2R DMR2 is 
differentially methylated, but biallelic expression of IGF2R is frequently found in 
human tissues, indicating that other epigenetic mechanisms such as hisone 
modifications may be involved in IGF2R imprinting (Monk et al., 2006a; Vu et al., 
2004).  
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Table 1-3. Known DMRs and timing of establishment of their imprints 
Imprinting marks 
Gene 
Human Mouse 
Reference 
IGF2R-AIR 
locus - 
S (DMR1), 
G (DMR2; M in oocyte, U in 
sperm) 
(Arnaud et al., 2006; Lucifero et 
al., 2002; Stoger et al., 1993) 
PEG1 G (M in oocyte, U in sperm) G (M in oocyte,  U in sperm) 
(Kerjean et al., 2000; Li et al., 
2002; Lucifero et al., 2002; Sato 
et al., 2007) 
SLC22A18 - S (Lewis et al., 2004) 
CDKN1C - S (Lewis et al., 2004) 
KvDMR1 G (M in oocyte, U in sperm) G (M in oocyte,  U in sperm) 
(Geuns et al., 2007b; Khoureiry 
et al., 2008; Lewis et al., 2004; 
Sato et al., 2007; Umlauf et al., 
2004) 
IGF2 S (DMR0, DMR2) S (DMR0, DMR2) (Murrell, 2006; Oswald et al., 2000) 
RASFRF1  G (M in sperm, U in oocyte) (Yoon et al., 2002) 
U2AF1-RS1 - S and Ga (Shibata et al., 1997) 
IGF-H19 
locus 
G 
(M in sperm, U in oocyte) 
G 
(M in sperm, U in oocyte) 
(Borghol et al., 2006; Davis et 
al., 2000; Hartmann et al., 2006; 
Kerjean et al., 2003; Kerjean et 
al., 2000; Lucifero et al., 2002; 
Olek and Walter, 1997; Sato et 
al., 2007; Ueda et al., 2000) 
DLK1-GTL2 
locus G (M in sperm, U in oocyte) G (M in sperm and U in oocyte) 
(Geuns et al., 2007a; Lin et al., 
2003) 
NDN G (PM in oocyte, U in sperm) 
G 
(PM in oocyte, U in sperm) 
(El-Maarri et al., 2001; Hanel 
and Wevrick, 2001) 
SNRPN G
b  (M in oocyte, U in 
sperm) G (M in oocyte, U in sperm) 
(El-Maarri et al., 2001; Geuns et 
al., 2003; Lucifero et al., 2002) 
PEG3 - G (M in oocyte, U in sperm) (Arnaud et al., 2006; Lucifero et 
al., 2002) 
NESP55 - S or Gc (Hayward et al., 2001; Liu et al., 2000) 
a
 dependent on regions examined; b conflicting data; c dependent on isoforms; -, Not 
examined yet; M, methylated; U, unmethylated; PM, partially methylated; G, germline 
DMRs; S, somatic DMRs 
 
Histone modifications can also occur at DMRs and ICRs that may regulate imprinted 
gene expression (Fournier et al., 2002; Grandjean et al., 2001; Gregory et al., 2001; 
Hu et al., 2000; Lewis et al., 2004). Repressive histone marks such as methylation at 
histone H3 lysine 9 (H3-K9) and lysine 27 (H3-K27) tend to be found in the 
methylated allele of ICRs and DMRs, whereas active histone marks such as H3 and 
H4 acetylation can be found in the unmethylated allele of ICRs and DMRs. For 
example, in Igf2r, Igf2-H19, Snrpn, and U2af1-rs1 locus, acetylation of H3 and H4 are 
present on the unmethylated alleles of their DMRs, whereas methylation of H3-K9 
can be found in the methylated alleles (Fournier et al., 2002; Grandjean et al., 2001; 
Gregory et al., 2001; Hu et al., 2000; Lewis et al., 2004).  
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1.3.4 The life cycle of imprint 
 
1.3.4.1 Erasure 
 
In gametes, before the acquisition of differential DNA methylation patterns on both 
parental alleles, pre-existing DNA methylation patterns from the previous generation 
require to be erased (reviewed by Constancia et al., 2004; Ferguson-Smith and Surani, 
2001; Reik and Walter, 2001; Surani, 2001). In the mouse, this occurs when 
primordial germ cells (PGCs) migrate from the genital ridge to the gonad (at 
approximately days 10.5 to 13.5 of gestation) (Hajkova et al., 2002; Li et al., 2004; 
Szabo et al., 2002). This timing corresponds to the 5- to 11-weeks in the human 
(Onyango et al., 2002). A study by Hajkova et al., (2002) has examined DNA 
methylation patterns at DMRs of Peg3, Lit1, Snrpn, H19 and non-imprinted gene (α-
actin) in developing germ cells. All of above genes are demethylated between 10.5 
and 13.5 dpc. This is associated with the allele-specific expression of imprinted genes 
(Snrpn, Igf2 and H19), showing that monoallelically expressed genes become 
biallelically expressed between 10.5 and 13.5 dpc (Szabo et al., 2002). Furthermore, 
embryo cloning (SCNT, somatic cell nuclear transfer) using PGCs as donor cells 
shows that imprints at different loci examined including Peg1, Meg3, Peg3 and H19 
are erased between 10.5 and 13.5 dpc (Lee et al., 2002; Yamazaki et al., 2003).  
1.3.4.2 Establishment and maintenance 
 
Following this erasure, DNA methylation imprints are established at two different 
developmental time points, during gametogenesis and during embryogenesis to result 
in monoalleleic expression of imprinted genes. At most DMRs, DNA methylation 
patterns are established when germ cells are differentiating (reviewed by Reik and 
Walter, 2001; Surani, 2001). These DMRs are termed as ‘germline DMRs or primary 
DMRs’. However, at ‘somatic DMRs’ (also known secondary DMRs or post-zygotic 
DMRs), DNA methylation patterns are established after fertilization or at post-
implantation stages of development. Table 1-2 summaries the timing of establishment 
of imprints at known DMRs. For example, Igf2r DMR2 is methylated in oocytes and 
unmethylated in sperm, indicating that it is a germline DMR, whereas Igf2r DMR1 is 
considered as a somatic DMR that is unmethylated in both oocytes and sperm (Stoger 
et al., 1993).  
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In germline DMRs, the establishment of genomic imprints occurs at different 
developmental time points between female and male. In male germline, acquisition of 
methylation at H19, Rasgrf1 and Gtl2 DMRs begins to be initiated in prenatal 
prospermatogonia before the start of meiosis and is completed prior to the end of the 
pachytene phase of meiosis (between 13.5 and 18.5 dpc) (Davis et al., 2000; Li et al., 
2004; Oakes et al., 2007; Ueda et al., 2000). In female germ line, DNA methylation 
begins to be acquired in the growing oocyte (10 ~ 25 days after birth) following the 
pachytene phase of meiosis, but this may continue after fertilization in the female 
pronulceus of the zygote (El-Maarri et al., 2001; Lucifero et al., 2002; Obata and 
Kono, 2002). Once imprints are established, they can be maintained throughout 
mammalian development.  
 
This whole process termed as ‘the life cycle of imprint’ has been well reviewed by 
Constancia et al., (2004) and Ferguson-Smith and Surani, (2001).  If this process does 
not progress properly during development and differentiation of gametes and embryos 
due to either mutation or deletion of imprinted regulatory regions, diseases such as 
congenital disorders and cancers occur in humans and animals (see section 1.3.5).  
1.3.4.3 Imprint formation and DNMTs 
 
During development of gametes, the PGCs genome is globally demethylated between 
10.5 and 13.5 days of mouse gestation, although repetitive sequences including 
intracisternal A particle (IAP), long interspersed nuclear element 1 (LINE1) and minor 
satellites appear to be only partially demethylated (Hajkova et al., 2002; Kafri et al., 
1992; Li et al., 2004; Szabo et al., 2002). At the same time, DNA methylation imprints 
are erased in PGCs. Following demethylation, genomes in PGCs are subsequently de 
novo methylated between 15.5 and 18.5 days of gestation, as determined by 
immunostaining against 5-methylcytosine (5mC) (Coffigny et al., 1999). At the same 
time, DMRs within imprinted loci begin to acquire DNA methylation in male germ 
cells (Davis et al., 2000; Li et al., 2004; Oakes et al., 2007; Ueda et al., 2000), 
although maternal imprints are acquired in growing oocytes after birth (El-Maarri et 
al., 2001; Lucifero et al., 2002; Obata and Kono, 2002). Thus, genome-wide 
demethylation and de novo methylation are associated with the erasure and 
establishment of imprints in developmental timeline.  
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During embryogenesis, in only few hours later after fertilisation (at the pronuclear 
stage), the paternal genome is actively demethylated, whereas the maternal genome is 
passively demethylated in a manner dependent of DNA replication and this may 
continue up to 16-cell stage (Mayer et al., 2000; Oswald et al., 2000; Santos et al., 
2002). Following further cleavages of embryos, de novo methylation occurs to 
establish tissue-specific epigenetic marks (Mayer et al., 2000; Oswald et al., 2000; 
Santos et al., 2002). However, sex-specific imprints are preserved from genome-wide 
demethylation and de novo methylation, although almost all non-imprinted genes are 
demethylated and subsequently de novo methylated (Gaudet et al., 2004; Lane et al., 
2003). It is unclear yet how imprints are resistant to the waves of DNA demethylation 
and de novo methylation in the genome. One possible explanation is that unmethylted 
alleles can be protected from de novo methylation by interaction with CTCF proteins 
or other proteins (e.g. YY1) recognising unmethylated CpG loci (Donohoe et al., 
2007; Fedoriw et al., 2004; Fitzpatrick et al., 2007; Kim and Kim, 2008; Kim et al., 
2006). Alternately, the methylated alleles can be protected from demethylation by 
interacting methyl-CpG biding domain proteins (e.g. MBDs) or other proteins 
recognising methylated CpG loci (reviewed by Bird, 2002).  
 
Studies by the deletion and mutation of Dnmts have demonstrated that the acquisition 
and maintenance of DNA methylation patterns at imprinted loci are guided by Dnmts 
(Bourc'his et al., 2001; Howell et al., 2001; Kaneda et al., 2004; Kurihara et al., 2008; 
Lucifero et al., 2007). Dnmt1o KO in mice show loss of methylation at maternally 
methylated DMRs with biallelic expression of maternally imprinted genes in embryos, 
indicating that Dnmt1o is important for the maintenance of maternal imprints during 
early embryonic development (Howell et al., 2001). In addition, inactivation of 
Dnmt1s in preimplantation stage embryos leads to loss of methylation at the H19 
DMR (Kurihara et al., 2008). Moreover, Dnmt3a KO in germ cells show loss of 
methylation at both maternal and paternal imprinted loci (Kaneda et al., 2004). 
Inactivation of Dnmt3L in mice leads to loss of imprinting of all maternally imprinted 
genes including Snrpn, Ndn, Zfp127, Kcnq1ot1 and Peg3 in oocytes and 
preimplantation embryos (Bourc'his et al., 2001; Hata et al., 2002). Thus, all Dnmts 
are required to establish and maintain normal imprints during gametogenesis and 
embryogenesis.   
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1.3.5 Imprinting disruption associated with human disease 
 
The disruption of imprinting and dysfunction of one or more imprinted loci are 
associated with a range of human congenital disorders, including Prader-Willi 
syndrome (PWS), Angelman syndrome (AS), Silver-Russel syndrome (SRS), and 
Beckwith-Wiedemann syndrome (BWS), Transient Neonatal Diabetes Mellitus 
(TNDM), Albrights hereditary osteodystrophy (AHO), Pseudohypothyroidism type 1a 
(PHP-1a) and type 1b (PHP-1b), Biparental complete hydatidiform mole (BiCHM) 
(reviewed by Robertson, 2005). In addition, imprinting disruption is also associated 
with human cancers (reviewed by Feinberg, 2007; Holm et al., 2005; Jelinic and Shaw, 
2007). Table 1-3 summaries imprinted genes associated with human diseases.  
 
Table 1-4. Known imprinted genes associated with human diseases 
Location Gene Disease type 
1p36 TP73 Cancer 
HYMAI TNDM 6q24 
PLAGL1 TNDM 
6q25 IGF2R Cancer 
7p12 GRB10 SRS 
PEG10 Cancer 7q21 
DLX5 Rett syndrome 
MEST SRS, Cancer, BiCHM, AgCHM 7q32 
MESTIT1 SRS 
11p13 WT1 Cancer 
H19 BWS, Cancer 
IGF2 BWS, Cancer 
KCNQ1 BWS, RWS, JLNS 
KCNQ1OT1 BWS, Cancer, TNDB, BiCHM, AgCHM 
CDKN1C BWS, Cancer 
TSSC3 Cancer 
SLC22A18 Cancer 
11p15 
ZNF215 BWS 
DLK1 Cancer 14q32 
MEG3 Cancer 
NDNL1 PWS 
NDN PWS 
SNRPN PWS, BiCHM, AgCHM 
IPW PWS 
ATP10C AS, Cancer 
15q11 
UBE3A AS 
19q13.4 PEG3 Cancer, BiCHM, AgCHM 
L3MBTL Cancer 20q13 
GNAS1 AHO, PHP-IA, PHP-IB, BiCHM, AgCHM, MAS 
PWS, Prader-Willi syndrome; AS, Angelman syndrome; SRS, Silver-Russel 
syndrome; BWS, Beckwith-Wiedemann syndrome; TNDM, Transient Neonatal 
Diabetes Mellitus; AHO, Albrights hereditary osteodystrophy; PHP-1A, 
Pseudohypothyroidism type 1B; PHP-1B, Pseudohypothyroidism type 1B; BiCHM, 
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Biparental complete hydatidiform mole; RWS, Romano-Ward syndrome; JLNS, 
Jervell and Lange-Nielsen syndrome; MAS, McCune-Albright syndrome 
1.3.5.1 Beckwith-Wiedemann syndrome (BWS) 
 
BWS is predominantly a maternally transmitted disorder that is characterised by 
congenital overgrowth with a large tongue (macroglossia), large organs 
(visceromegaly), large body size (macrosomia), as well as increased predisposition to 
develop of embryonal Wilms’ tumours (Bliek et al., 2001; DeBaun et al., 2003; Lee et 
al., 1999; Robertson, 2005; Weksberg et al., 2003). Most BWS cases are due to 
epigenetic alternations at imprinted genes on chromosome 11p15 (reviewed by 
Robertson, 2005). Half of BWS patients have loss of methylation at KvDMR1 and 
consequently loss of imprinting of KCNQ1OT1 (Bliek et al., 2001; Lee et al., 1999; 
Smilinich et al., 1999; Weksberg et al., 2003). Less frequently, gain of methylation on 
the maternal allele of ICR1 (IGF2/H19 locus) can be found in BWS patients that is 
associated with transcriptional silencing of H19 and biallelic expression of IGF2 
(Reik et al., 1995; Weksberg et al., 1993). Moreover, altered gene expression and 
methylation of CDKN1C have been reported in some BWS patients (Diaz-Meyer et al., 
2005).  
1.3.5.2 Prader-Willi syndrome (PWS) & Angelman syndrome (AS) 
 
PWS and AS known as neuro-developmental disorders are associated with genetic and 
epigenetic mutations on human chromosome 15q11-13 (reviewed by Robertson, 2005). 
PWS is characterised by weak muscle tone (hypotonia), incomplete sexual 
development, mental retardation, feeding difficulties in early infancy, followed in later 
infancy or early childhood by excessive eating and obesity. Genetic alterlations such 
as maternal uniparental disomy (UDP), chromosomal deletions and gene mutations 
have commonly found in PWS patients, (reviewed by Robertson, 2005). Less 
frequently, epigenetic alterations at the SNRPN DMR can be found that is associated 
with loss of imprinting of SNRPN and its neirboring genes, ZNF127, IPW, NDN and 
NDNL1 (Reis et al., 1994; Sutcliffe et al., 1994). AS is characterised by 
developmental delay, severe mental retardation, absent speech, ataxia and aggressive 
behaviour (Orstavik et al., 2003; Robertson, 2005). The majority of AS patients is 
arisen by molecular defects such as deletions of maternal chromosome 15q11-13, 
paternal UPD and germline UBE3A (ubiquitin protein ligase E3A) mutation. In only 
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5% of AS patients, loss of methylation at the SNRPN DMR has been reported (Cox et 
al., 2002; Orstavik et al., 2003).  
1.3.5.3 Cancers 
 
Imprinting disruptions can be frequently found in tumours and cancer cell lines in the 
human (reviewed by Feinberg, 2007 ; Jelinic and Shaw, 2007 ; Robertson, 2005 ). A 
PCR-RFLP (Restriction Fragment Length Polymorphism) analysis using a MnlI 
restriction enzyme site in exon 9 of PEG3 (paternally expressed gene 3) has revealed 
that PEG3 is monoallelically expressed in normal cell lines and tissues, but it is 
biallelically expressed in choriocarcinoma (JEG3 and BeWo), glioma (HTB-16, HTB-
17, and CRL-1620) and endometrial cervical ovarian cell lines (RL-95, C33A, ME180, 
Ovcar-3 and Ovcar-5) (Dowdy et al., 2005; Maegawa et al., 2001). Loss of imprinting 
of PEG3 is associated with loss of methylation at the PEG3 DMR (Dowdy et al., 
2005; Maegawa et al., 2001). Moreover, PEG1 (MEST) is expressed from the paternal 
allele in normal tissues and cells, but biallelic expression can be detected in invasive 
breast carcinomas and lung caners (Nakanishi et al., 2004; Pedersen et al., 2002). 
IGF2 and H19 are the most commonly affected genes in the various human cancers 
(reviewed by Feinberg, 2007).  
1.3.6 Imprinting disruption associated with ART 
 
Assisted reproductive technology (ART) procedures are designed to overcome the 
human infertility (reviewed by Horsthemke and Ludwig, 2005; Lucifero et al., 2004a; 
Maher, 2005). ART procedures include isolation, manipulation, and culture of 
gametes and embryos in in vitro. Additionally, superovulation, cryopreservation and 
intracytoplasmic sperm injection (ICSI) are also involved in ART procedures. It has 
been reported that ART procedures have detrimental effects on the baby such as a 
higher frequency of preterm delivery, reduced birth weight, and increased perinatal 
mortality compared to natural singleton pregnancies (Schieve et al., 2002). Moreover, 
recent studies have suggested that ART procedures may cause genetic and epigenetic 
disruptions at imprinted loci (reviewed by Horsthemke and Ludwig, 2005; Maher, 
2005; Maher et al., 2003). Currently, derivation and culture of hESC lines have relied 
on ART procedures (reviewed by Allegrucci et al., 2004), implicating that hESC lines 
can have epigenetic errors at imprinted loci.  
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1.3.6.1 Intracytoplasmic sperm injection (ICSI) 
 
ICSI is a technique used to inject a spermatozoa into the cytoplasm of an oocyte using 
a micromanipulator that bypasses almost all of natural fertilisation (Cox et al., 2002; 
Manning et al., 2000). Thus, ICSI may have physically deleterious effects to oocytes 
and sperm. For example, to perform ICSI, cumulus cells around oocytes need be 
denuded prior to micromanipulation. Moreover the sperm acrosome reaction into 
oocytes is completely bypassed and this may disturb the oocyte activation (reviewed 
by Horsthemke and Ludwig, 2005; Maher, 2005).  
1.3.6.1.1 Oligospermia 
 
Spermatozoa used in ISCI often originate from infertile men who sometimes have 
abnormal semen parameters (Hartmann et al., 2006; Kobayashi et al., 2007). A study 
by Kobayashi et al., (2007) has demonstrated that of 97 infertile men analysed, 16 
(16.4%) show moderate oligospermia (defined as sperm count, 5-20 ×106/ml) and 
severe oligospermia (<5×106/ml), although normal spermia is determined by ≥ 
20×106/ml. Kobayashi et al., (2007) has compared the methylation status at 7 
imprinting regulatory regions between normal spermia and oligospermia. Although 
KvDMR1 and PEG3 DMRs are normally methylated in both, aberrant methylation at 
H19 (LOM), GTL2 (LOM), PEG1 (GOM), ZAC (GOM) and SNRPN (GOM) DMRs 
are detected in 16 oligospermia patients (Kobayashi et al., 2007). Margues et al., 
(2004) has examined that of 123 infertile men investigated, 96 patients show 
oligospermia (46 were moderately and 50 were severely affected). Of 96 oligospermia 
examined, 23 show gain of methylation at the H19 DMR, although the MEST DMR is 
normally methylated in all oligospermia. Thus, impaired spermatogenesis is closely 
linked to imprinting disruption that should be carefully considered before a 
spermatozoa use for ISCI (Hartmann et al., 2006).   
1.3.6.1.2 Superovulation  
 
Oocytes used in ICSI usually originate from women who have undergone an ovarian 
hyperstimulation with gonadotrophin. Gonadotrophin is commonly used in 
superovulation to collect sufficient numbers of oocytes for ART in the human and for 
experimental research in various animal species. Recent studies have suggested that 
superovulation can be associated with epigenetic disruptions of imprinted loci in 
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oocytes and their derived embryos (Fortier et al., 2008; Kerjean et al., 2003; Sato et al., 
2007). A study by Sato et al., (2007) has analysed the DNA methylation status at 
PEG1 and H19 DMRs in superovulated human oocytes. Of 16 human oocytes 
examined, 6 show loss of maternal methylation at the PEG1 DMR and 2 show gain of 
methylation at the H19 DMR (Sato et al., 2007). In mouse superovulated oocytes, gain 
of methylation is detected at the H19 DMR, although other loci including Peg1, Lit1 
and Zac are normally methylated (Sato et al., 2007). Furthermore, a study by Kerjean 
et al., (2003) has examined the DNA methylation status at Igf2r, Peg1 and H19 DMRs 
in 2-cell mouse embryos generated from superovulated oocytes. All loci are aberrantly 
methylated in embryos, showing loss of methylation at Peg1 and Igf2r DMRs and 
gain of methylation at the H19 DMR (Kerjean et al., 2003). Thus, superovulation 
might disturb the establishment of imprints (Lucifero et al., 2004a; Sato et al., 2007) 
that may be due to artificially enforced oogenesis and folliculogenesis.  
1.3.6.2 In vitro culture (IVC) 
 
There is evidence from animal studies of preimplantation embryos that in vitro culture 
(IVC) of embryos in medium containing undefined factors (e.g. serum) influences not 
only epigenetic alterations of imprinted loci but also phenotypic abnormalities during 
prenatal and postnatal development (Dean et al., 1998; Doherty et al., 2000; 
Fernandez-Gonzalez et al., 2004; Khosla et al., 2001a; Mann et al., 2004; Young et al., 
2001).  
1.3.6.2.1 Serum 
 
Studies by Khosla et al., (2001) and Fernandez-Gonzalez et al., (2004) have 
investigated the effect of fetal calf serum (FCS) during development of both 
preimplantation and postimplantation stage mouse embryos. Embryos are in vitro 
cultured up to the blastocyst stage in chemically defined M16 medium without and 
with 10% FCS and then transfer into the uterus of recipient mice (Khosla et al., 
2001a). The foetuses (day 14 of gestation) derived from blastocyst stage embryos 
cultured in presence of FCS show decreased expression of H19 and Igf2 that is 
associated with gain of methylation on the maternal allele of H19 ICR1 (Khosla et al., 
2001a). In addition, aberrant expression of Grb10 and Grb7 genes is detected in theses 
foetuses (Khosla et al., 2001a). Khosla et al., (2001) has found that the weight of 
foetuses derived from blastocyst stage embryos cultured in presence of FCS is lighter 
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than foetuses derived from blastocyst stage embryos cultured in absence of FCS. 
Fernandez-Gonzalez et al., (2004) has also found that the levels of mRNA expression 
of growth-related imprinted genes (Igf2, Mest, H19 and Grb10) are significantly 
down-regulated in blastocyst stage embryos cultured in presence of FCS, compared 
with blastocyst stage embryos cultured in absence of FCS. Fernandez-Gonzalez et al., 
(2004) has found that the weight of mice derived from blastocyst stage embryos 
cultured in presence of FCS is significantly heavier than mice derived from blastocyst 
stage embryos cultured in absence of FCS. In sheep, loss of methylation at IGF2R 
DMR has been reported as a consequence of in vitro culture of ovine embryos in 
medium containing serum that is associated with Large Offspring syndrome (LOS) 
(Young et al., 2001). Thus, poorly defined factors in serum can alter imprinted gene 
expression and methylation that causes phenotypic abnormalities during prenatal and 
postnatal development. 
1.3.6.2.2 Amino acids  
 
The allele-specific expression of imprinted genes and DNA methylation at their 
regulatory regions have been examined in mouse embryos in vitro cultured up to the 
blastocyst stage in two different media (Whitten’s and KSOMAA; KSOM 
supplemented with amino acids) (Doherty et al., 2000; Mann et al., 2004). The 
Whitten’s medium is previously known to lack methionine and other amino acids 
supplements, compared to KSOMAA  (Doherty et al., 2000; Mann et al., 2004; 
Rinaudo and Schultz, 2004). Over 60% of embryos cultured in the Whitten’s medium 
have  loss of imprinting of H19 (associated with loss of methylation at the H19 DMR) 
and loss of methylation at the Snrpn DMR (but monoallelic), whereas only 14% of 
embryos cultured in the KSOMAA medium have these imprinting defects (Doherty et 
al., 2000; Mann et al., 2004). In addition, a microarray analysis has revealed that 
embryos cultured in the Whitten’s medium have aberrant expression of 114 genes, 
whereas only 29 genes are aberrantly expressed in blastocysts cultured in KSOMAA 
(Rinaudo and Schultz, 2004). Mann et al., (2004) has also examined the imprinting 
and DNA methylation status in foetuses (day 9.5 of gestation) derived from embryos 
cultured in the Whitten’s medium. Aberrant imprinted gene expression and DNA 
methylation are detected at H19, Snrpn, Ascl2 and Peg3 loci (Mann et al., 2004). Thus, 
genetic and epigenetic changes in in vitro cultured embryos can be occurred due to the 
lack of key amino acids supplied in the culture medium.  
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1.3.6.3 In vitro fertilisation (IVF) 
 
A study by Li et al., (2005) has demonstrated that of 23 in vitro fertilised mouse 
embryos examined, 9 embryos show loss of imprinting of H19 and gain of DNA 
methylation at the maternal allele of the H19 DMR. However, 1 of 14 in vivo fertilised 
embryos shows loss of imprinting of H19 (Li et al., 2005b). Moreover, 2 of 23 IVF-
derived embryos have aberrant imprinting of Igf2, whereas none of 14 in vivo 
fertilised embryos show aberrant imprinting of Igf2 (Li et al., 2005b). Of other 
imprinted genes (Cdkn1c and Slc22a1L) examined, all have normal imprinting status 
in both in vitro and in vivo fertilised embryos. Furthermore, mESC lines derived from 
IVF embryos show gain of methylation at the H19 DMR, whereas mESC lines derived 
from in vivo fertilised embryos show normal methylation at the H19 DMR (Li et al., 
2005b). Thus, IVF can also be associated with epigenetic disruption at some imprinted 
loci.   
1.3.6.4 ART procedures associated with human congenital disorders  
 
In the human, case-controlled cohort studies have demonstrated that children born 
from ART procedures (e.g. ICSI and IVF) have an increased incidence of imprinting 
defects (reviewed by Lucifero et al., 2004a; Maher, 2005). An initial study did not 
observe imprinting defects in ART-conceived children (Manning et al., 2000). 
However, recent studies of registered children with imprinting defects have 
demonstrated that ART-conceived BWS and AS children are associated with 
epigenetic disruption at three DMRs (KvDMR1, H19 DMR and SNRPN DMR) on 
human chromosome 15q11-13 (Cox et al., 2002; DeBaun et al., 2003; Gicquel et al., 
2003; Orstavik et al., 2003). For example, of 149 BWS patients examined, six were 
born following ART (2 were born by ICSI and 4 were born by IVF) and they have 
loss of methylation at KvDMR1 (Gicquel et al., 2003). Moreover, Maher et al., (2003) 
has reported that 6 of 149 BWS patients are born following ART (3 were born by ISCI 
and 3 were born by IVF) and 2 of 6 have loss of methylation at KvDMR1. DeBaun et 
al., (2003) has demonstrated that of 7 IVF and ICSI-conceived BWS children 
examined (5 were born by ICSI and 2 were born by IVF), 5 show loss of methylation 
at KvDMR1 and gain of methylation at the H19 DMR (DeBaun et al., 2003). In 
addition, loss of methylation on the maternal allele of the SNRPN DMR is found in 
ICSI-conceived AS children (Cox et al., 2002; Orstavik et al., 2003). Thus, overall, 
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ART procedures are associated with an increased susceptibility to epigenetic 
disruption at KvDMR1, H19 and SNRPN DMRs that may lead to human congenital 
disorders.   
1.3.7 Genomic imprinting in human oocytes and embryos 
 
1.3.7.1 Maternal methylation imprint 
 
The methylation status of KvDMR1 in the human oocytes and preimplantation stage 
embryos has been examined (Geuns et al., 2007b; Khoureiry et al., 2008). KvDMR1 is 
methylated in oocytes and unmethylated in sperm (Geuns et al., 2007b). A similar 
maternal methylation imprint has been reported in the SNRPN DMR (El-Maarri et al., 
2001; Geuns et al., 2003). The SNRPN DMR is methylated in human oocytes (GV, MI 
and MII stages), but it is unmethylated in sperm (El-Maarri et al., 2001; Geuns et al., 
2003). In fertilised embryos (day 2 to 6), the SNRPN DMR is differentially methylated 
that is associated with monoallelic expression of SNRPN (Geuns et al., 2003; Huntriss 
et al., 1998). PEG1, LIT1 and ZAC DMRs are also methylated in human oocytes but 
unmethylated in sperm, indicating maternal methylation imprints (Kerjean et al., 
2000; Li et al., 2002; Sato et al., 2007).  
1.3.7.2 Paternal methylation imprint 
 
Paternally inherited methylation imprints have been reported at H19 and GTL2 DMRs 
(Geuns et al., 2007a; Kerjean et al., 2000). The H19 DMR is differentially methylated 
in primary germ cell lines obtained from the gonadal ridges of 5- to 11-week post-
fertilisation of female embryos (Onyango et al., 2002). However, the H19 DMR 
become unmethylated in fetal spermatogonia and oogonia (Kerjean et al., 2000). Then, 
the acquisition of methylation imprint at the H19 DMR appears only in a subset of 
adult spermatogonia (Kerjean et al., 2000). This paternal methylation imprint is 
maintained up to mature spermatozoa (Kerjean et al., 2000). A similar paternal 
methylation imprint can be found at the GTL2 DMR (Geuns et al., 2007a). The GTL2 
DMR is unmethylated in oocytes (GV, MI and MII stages), whereas it is methylated in 
sperm (Geuns et al., 2007a).  
1.3.8 Genomic imprinting in embryonic stem cell lines 
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1.3.8.1 Mouse and monkey embryonic stem cells 
 
Mouse and monkey studies have raised concerns about the stability of epigenetic 
marks at imprinted loci in in vitro cultured ESC lines (Dean et al., 1998; Feil et al., 
1997; Fujimoto et al., 2006; Humpherys et al., 2001; Mitalipov et al., 2007; Mitalipov, 
2006). In vitro cultured mESC lines show gain of methylation of H19 ICR1 and Igf2 
DMR2 and loss of methylation at the U2af1-rs1 DMR that leads to loss or gain of 
imprinting of their corresponding genes (Dean et al., 1998; Feil et al., 1997). A study 
by Humpherys et al., (2001) has demonstrated variable expression patterns of H19 and 
Mest genes between individual mESC subclones. Moreover, in vitro cultured monkey 
ES cell lines show loss of imprinting of IGF2 and H19 mediated by aberrant 
methylation at the IGF2 DMR (Fujimoto et al., 2006; Mitalipov et al., 2007; 
Mitalipov, 2006). Since IGF2, H19 and SNRPN in monkey blastocyst stage embryos 
are monoallelically expressed (Fujimoto et al., 2006), imprinting errors in monkey 
ESC lines are most likely to originate during in vitro culture. Thus, imprinted gene 
expression and methylation patterns appear to be variable and unstable upon in vitro 
propagation of mouse and monkey ESC lines.  
1.3.8.2 Human embryonic stem cells 
 
Initial studies on hESCs regarding imprint stability reached different conclusions 
compared to mouse and monkey ESCs studies (Mitalipov, 2006; Plaia et al., 2006; 
Rugg-Gunn et al., 2005; Sun et al., 2006). The allele-specific expression of 6 
imprinted genes (IGF2, H19, KCNQ1OT1, TSSC5, IPW and NESP55) and DNA 
methylation of three imprinting control regions (KvDMR1, SNRPN DMR and H19 
DMR) observed “normal” imprinting and methylation status in all 4 hESC lines 
studied (hSF-6, H9, H7 and HES-3) (Rugg-Gunn et al., 2005). Moreover, three 
additional studies made the same conclusions that hESCs have a substantial degree of 
imprinting stability in both the differentiated and undifferentiated states (Mitalipov, 
2006; Plaia et al., 2006; Sun et al., 2006). For example, Sun et al., (2006) has 
examined the allele-specific expression of 4 imprinted genes (PEG10, H19, KCNQ1 
and NDNL1) in SHhES-1 and HUES7. All genes are monoallelically expressed (Sun 
et al., 2006). This monoallelic expression persists through differentiation into 
embryoid bodies (EBs) (Sun et al., 2006). Moreover, Mitalipov (2006) has examined 
the allele-specific expression of IGF2 and H19 in BGN2 and H1 and Plaia et al., 
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(2006) has examined the DNA methylation status of SNRPN, DLK1 and H19 DMRs 
in BG01V. All genes are normally imprinted in both studies (Mitalipov 2006; Plaia et 
al., 2006). 
1.4 Thesis aims  
 
The overall aim of this thesis is to investigate the stability of a wider range of 22 
imprinted genes and 3 non-imprinted genes in in vitro cultured 22 hESC lines 
(Chapter 3) and also to provide mechanistic insight into imprinting instability by 
analysing DNA methylation at potential imprinting regulatory regions (Chapter 4). 
Another aim is to determine whether overexpression of a full-length DNMT1 cDNA in 
hESCs may increase the epigenetic stability upon in vitro prolonged culture (Chapter 
5). 
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2 MATERIALS AND METHODS 
 
2.1 Human embryonic stem cell lines 
 
22 human embryonic stem cell (hESC) lines and 1 human embryonic carcinoma 
(hEC) cell line (NTERA2) were used for this thesis (Table 2-1). 16 HUES-lines 
(HUES1, HUES2, HUES3, HUES4, HUES5, HUES6, HUES7, HUES8, HUES9, 
HUES10, HUES12, HUES13, HUES14, HUES15, HUES16 and HUES17) were 
provided by Dr. Chad Cowan (Harvard University) and cultured as previously 
described in Cowan et al., (2004). BG01 was derived from the BresaGen, Inc. and 
cultured as previously described in Mitalipova et al., (2003). H1 was derived from the 
Wisconsin Alumni Research Foundation (WiCell Research Institute) and cultured as 
previously described in Thomson et al., (1998). Both NL-HESC1 and HES-2 cell 
pellets were provided by Dr. Christine Mummery (Hubrecht Laboratory) (Reubinoff 
et al., 2000; van de Stolpe et al., 2005). Both NOTT1 and NOTT2 were derived and 
cultured in University of Nottingham (Allegrucci et al., 2007; Burridge et al., 2007). 
NTERA2 was cultured as previously described in Andrews et al., (1984). Table 2-1 
summarise the characteristics and culture methods of each cell line. A human colon 
cancer cell line, HCT116, was cultured and provided by Dr. Hazel Cruickshanks 
(University of Nottingham).  
 
Table 2-1. Human embryonic stem cell lines  
Cell line Gender Passage passage method Growth matrix Reference 
HUES1 Female 31 Trypsin MEFs 
HUES2 Female 27 Trypsin MEFs 
HUES3 Male 37 Trypsin MEFs 
HUES4 Male 26 Trypsin MEFs 
HUES5 Female 30 Trypsin MEFs 
HUES6 Female 35 Trypsin MEFs 
HUES7 Male 26 Trypsin MEFs 
HUES8 Male 37 Trypsin MEFs 
HUES9 Female 30 Trypsin MEFs 
HUES10 Male 29 Trypsin MEFs 
HUES12 Male 28 Trypsin MEFs 
HUES13 Female 32 Trypsin MEFs 
HUES14 Female 27 Trypsin MEFs 
HUES15 Female 31 Trypsin MEFs 
HUES16 Male 29 Trypsin MEFs 
HUES17 Male 35 Trypsin MEFs 
(Cowan et al., 2004) 
BG01 Male 45 Mechanical MEFs (Mitalipova et al., 2003) 
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H1 Male 26 Trypsin Matrigel (Thomson et al., 1998) 
HESC-NL1 Female 22 Mech+Disp MEFs (van de Stolpe et al., 2005) 
HES-2 Female 56 Mech+Disp MEFs (Reubinoff et al., 2000) 
NOTT1 Female 25 Trypsin Matrigel 
NOTT2 Male 32 Trypsin Matrigel 
(Allegrucci et al., 2007; 
Burridge et al., 2007) 
NTERA2 Male 70 Mechanical MEFs (Andrews et al., 1984) 
MEFs: mouse embryonic fibroblasts, Mech: mechanical passaging, Disp: dispase 
2.2 Antibodies 
 
Antibodies were used for Western blot and immunostaining analyses. Table 2-2 and 2-
3 summarise suppliers, immunised hosts and dilution factors of each antibody.   
 
Table 2-2. Primary antibodies  
Dilution factor 
Antibody Supplier Cat. No. Immunised host Western Blot Immunostaining 
DNMT1a NEB M0231 Rabbit 1:2000 - 
DNMT3A ABGENT AP1034a Rabbit 1:200 - 
DNMT3B ABGENT AP1035a Rabbit 1:200 - 
α-Tubulin Calbiochem CP06 Mouse 1:2000 - 
OCT3/4 Santa Cruz SC-5279 Mouse 1:500 1:200 
NANOGa R&D system AF1997 Goat 1:200 1:200 
SSEA4 Chemicon MAB4304 Mouse 1:100 1:100 
SOX1a R&D system AF3369 Goat 1:1000 - 
SOX17a R&D system AF1924 Goat 1:1000 - 
BRACHYURYa R&D system AF2085 Goat 1:1000 - 
5-Methylcytosinea Calbiochem NA81 Mouse 1:1000 1:1000 
a Following initial thaw, aliquots were made to avoid freeze and thaw repeats and 
stored at -20 ºC. Other antibodies were stored in the 4 ºC fridge.  
 
Table 2-3. Secondary antibodies  
Dilution factor 
Antibody Supplier Cat. No. Immunised host Western Blot Immunostaining 
Anti-rabbit-HRP GE Healthcare NA934 Donkey 1:17,500 - 
Anti-mouse-HRP GE Healthcare NA931 Sheep 1:10,000 - 
Anti-goat-HRP Santa Cruz G2704 Donkey 1:10,000 - 
Cy3 conjugated 
anti-mouse 
Jackson 
ImmunoResearch 115-165-068 Goat - 1:250 
FITC conjugated 
anti-mouse 
Jackson 
ImmunoResearch 115-095-068 Goat - 1:200 
FITC conjugated 
anti-goat Novus Biologicals NB710-F Rabbit - 1:200 
Horseradish Peroxidase (HRP) conjugated secondary antibodies were stored in the 4 
ºC fridge. Other florescence antibodies were stored in the -20 ºC freezer under the 
dark condition.  
 
2.3 Oligonucleotide 
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All oligonucleotides were synthesised and purchased from Sigma-Genosys 
(http://www.sigmaaldrich.com/Brands/Sigma_Genosys.html) in the 0.05 µmol 
synthesis scale and desalt purification. Particular oligonucleotides used for Southern 
blot (Table 2-7) were purified by high-performance liquid chromatography (HPLC). 
For Southern blot, oligonucleotides were resuspended in RNase/DNase free water 
(Sigma, W4502) to give a final mass of 100 ng. Other oligonucleotides for PCR 
(polymerase chain reaction) were resuspended in RNase/DNase free water to give a 
final concentration of 100 µM. Individual stock dilutions of forward and reverse 
primers were prepared to be a concentration of 10 µM. For PCR, 10 µM of forward 
primer and 10 µM of reverse primer were mixed at a 1:1 ratio to be a concentration of 
5 µM. Oligonucleotides and optimal PCR conditions are summarised in Table 2-4, 2-5, 
2-6, 2-7 and 2-8.  
 
 
 
 
 
 
 
 
 
 
 
 Table 2-4. Primers used for genotyping and allelic specific expression 
Band size (bp) Optimised PCR Condition 
Gene Polymorphism Primer sequence (5’→3’) 
gDNA cDNA MgCl2  (mM) Temp. (°C) Cycle No. 
Reference 
TP73 StyI 
Genotyping 
F:CAGGAGGACAGAGCACGAG 
R:CGAAGGTGGCTGAGGCTAG 
Allele-specific expression 
F:GGGCTGCGACGGCTGCAGAGC 
R:GAGAGCTCCAGAGGTGCTC 
229 161 1.5 
gDNA: 55 
 
cDNA: 58 
40 (Mai et al., 1998a) 
AclI F:TTCAACAACGTTAGGCCAGCTGGGTTAATTTC R:GTCCTCCCAGTTAAGGGAGGCTGA 178 178 2.5 60 38 
IGF2R 
MscI F:TTTGATGGCCACACTGGTGCAAGATGGATGAG R:CGCTAAAACCACTACCTGCTGCGCT 120 120 2.5 60 38 
(Vu et al., 2004) 
SLC22A1 C/T 
Genotyping 
F:GCAAGCCTTCCTCATCTTATG 
R:GTTCCAGTCCACTTCATAGC 
Allele-specific expression 
Genotyping F 
R2:CAGGAGTCAGCACACACCAG 
232 381 1.5 55 35 (Monk et al., 2006a) 
PEG10 C/T F:TCATTTTCCTGCCTGGTTGC R:GGAGCCTCTCATTCACAGC 406 406 1.5 63 38 (Sun et al., 2006) 
PEG1 G/C 
Genotyping 
F:AGTGTCGATTCTGGATGACC 
R:TCAACCTTAGTCAGAGCTCC 
Allele-specific expression 
(Isoform1) F:CATGGGATAACGCGGCCATG 
Genotyping R 
(Isoform2) F:GGTCTTACCTGAATCAGGATG 
Genotyping R 
281 
Isoform 1: 
1209 
Isoform 2: 
1183 
gDNA: 1.5 
Isoform 1: 
1.5 
Isoform 2: 
2.5 
gDNA: 55 
Isoform 1: 
60 
Isoform 2: 
55 
38 
MESTIT1 G/A 
Genotyping 
F:GATTCACAACAGTGGTATGG 
R:TCAGGGATATGTTGGGTGAA 
Allele-specific expression 
F:GAGGAAACTACCGCCTATAA 
Genotyping R 
520 1359 1.5 55 38 
(Nakabayashi et al., 2002) 
WT1 HinfI F:AATCAGAGAGCAAGGCATCG R:GTGCAAGGAGGTATGTACATC 319 319 2.5 62 40 (Mitsuya et al., 1997) 
 AluI 
F:TACAACCACTGCACTACCTG 
R:TGGCCATGAAGATGGAGTCG 
or 
F:TGCTGCACTTTACAACCACTG 
R:GTGGCCATGAAGATGGAGTC 
228 
 
239 
148 
 
159 
1.5 58 40 
H19 
RsaI F:CGGACACAAAACCCTCTAGCTTGGAAA R:GCGTAATGGAATGCTTGAAGGCTGCTC 704 624 1.5 60 38 
(Chen et al., 2000a; 
Hashimoto et al., 1995; 
Morison et al., 2000) 
IGF2 ApaI F:CTTGGACTTTGAGTCAAATTGG R:GGTCGTGCCAATTACATTTCA 292 292 2.5 58 38 
(Cui et al., 1998; 
Hashimoto et al., 1995; 
Onyango et al., 2002) 
TSSC4 G/A 
Genotyping 
F:GAGATGGCCCAGCCTGACCCCACTGGC 
R:AACCTTTATTGTCCCTACCAGGGAGCC 
Allele-specific expression 
F:CCTTGAGCCGTTGAGCAGCTG 
Genotyping R 
235 1410 1.5 60 35 
KCNQ1 G/A 
Genotyping 
F:CTGTCACTGCCTGCACTTTG 
R:GCCGTTTGGCCGTGCCCAC 
Allele-specific expression 
F:CTTCGCCGAGGGACCTGGACCTG 
R:GATGAACAGTGAGGGCTTCC 
190 271 1.5 58 38 
(Monk et al., 2006a) 
KCNQ1OT1 G/A F:GATCCTCTCCAGGCAGCTTCTTCCACA R:CATAAGGTAGGTAAGTTTGTGTCCCTG 268 268 2.5 62 38 (Lee et al., 1999) 
CDKN1C G/A F:CTAGCCAGCAGGCATCGAG R:CTCCATCGTGGATGTGCTG 270 270 1.5 58 40 (Monk et al., 2006a) 
PHLDA2 T/C 
Genotyping 
F:ATGAAATCCCCCGACGAGG 
R:TTGCAATGGGCACAGTGAT 
Allele-specific expression 
Genotyping F 
R:GGTCCGACTCGTCCAGCGT 
916 494 1.5 58 40 (Qian et al., 1997) 
NAP1L4 G/C 
Genotyping 
F:GTTTCCAGCCCGCTGAATCTG 
R:CTCAGGGCACCAAGGTGGTTC 
Allele-specific expression 
F:GAGGAGGAATTAGAAGGTGAC 
Genotyping R 
278 848 1.5 55 38 (Monk et al., 2006a) 
 SLC22A18 G/C 
Genotyping 
F:CTTCAGCAGGGACAGCAGTCAGG 
R:GAGGAGGCTGCTCCACTCGCTGG 
Allele-specific expression 
F:GCTCTTCATGGTCATGTTCTCCA 
R:GGAGCAGTGGTTGTACAGAGG 
260 365 1.5 62 40 (Onyango et al., 2002) 
DLK1 C/T F:CCGGCTTCATCGACAAGAC  R:CACCACAAAGATTAGGACAGACC 640 640 1.5 63 38 (Kobayashi et al., 2000) 
GTL2 A/G F:GTGTGTACCTTGGTTGGTGACTC R:GAGGCATATATTTGAGTTACACATACCCCTTAGTCC 368 368 1.5 62 38 (Wylie et al., 2000) 
NDN MboI F:GCCCGAATACGAGTTCTTTT R:CACACATCATCAGTCCCATA 540 540 2.5 60 38 
(MacDonald and Wevrick, 
1997) 
NDNL1 C/A F:AAGCCCTATCCAGGTCTCG R:TTGATAACCAAAGGCACACTC 453 453 1.5 60 40 (Sun et al., 2006) 
SNRPN BstUI F:AACCAGGCTCCATCTACTCTTTG R:TCTTGCAGGATACATCTCATTCTA 925 217 2.5 60 35 (Morison et al., 2000) 
IPW HphI F:CTGCATGATTTTTTTTCAAAAA R:ATATAGGGAGGTTCATTGCACA 390 390 1.5 56 38 (Wevrick et al., 1994) 
ATP10C AvaII F:GGCTCAGTGTAGGTCCCAAG R:AGGCTGAGGAAACCAGGAC 204 204 1.5 65 40 (Meguro et al., 2001) 
PEG3 MnlI F:CCCTCCCCTCGCATAATAACTA R:TCTTCTGTCTGTCTCCTCTCCC 338 338 2.5 58 38 (Dowdy et al., 2005) 
NESP55 C/T 
Genotyping 
F:GGCTCCTTGTGCTGTCTGTCTTGTAG 
R:CCACACAAGTCGGGGTGTAGCTTA 
Allele-specific expression 
F:TCGGAATCTGACCACGAGCA 
R:CACGAAGATGATGGCAGTCAC 
233 1141 1.5 60 38 (Hayward et al., 2001) 
 
Table 2-5. Primers used for bisulphite sequencing  
Optimised PCR Condition 
Bisulphite region  Primer sequence (5’→3’) Band size (bp) 
MgCl2  (mM) Temp. (°C) Cycle No. 
Reference 
TP73 promoter F:GTTTGGGGGATAGTAGGGAGTT R:ACCCTAAACCTCCTACCTACAACC 552 1.5 55 38 (Dong et al., 2002) 
PEG1 promoter F:TYGTTGTTGGTTAGTTTTGTAYGGTT R:AAAAATAACACCCCCTCCTCAAAT 290 1.5 55 38 (Kerjean et al., 2000) 
 GTL2 CTCF biding site F:ATTGATAGGTTATAAGTGTTAGTTGTGTG R:AAATTTCTACTTTTCCCATAACAAA 490 2.5 55 38 
GTL2 CpG2  F:GTAAGTTTTATAGGTTGTAAAGGGGGTGTT R:CCACAACTAATAACTAAAAAAATAAACATT 216 2.5 55 38 
(Kawakami et al., 2006) 
SLC22A18 promoter F:GGGTAGGATTTAAGTTGGAGG R:CAACAAACACRTCAAAAACACC 427 1.5 55 40 
KCNQ1 promoter  F:GGGGTTGGTAGTAGTGGTTG R:CRCCCTCCRCCAACTCCAAC 233 1.5 55 40 
KvDMR1  F:TGATGTGTTTATTATTTYGGGG R:CCCTAAAATCCCAAATCCTC 304 2.5 55 38 
CDKN1C promoter F:GTTTTAAATTGYGAGGAGAGGGG R:CCTCTCRAATCTCCRAAC 284 2.5 55 40 
(Monk et al., 2006a) 
NDN promoter 
F1:TTAAATTAATTTTGGATATATTTAGGTAAG 
R1:TCAAATCCTTACTTTATTCTAACATATCT 
Nested PCR 
F2:TATATTTTTTTAGTTTAAATAGGAAAT 
R2:TCTAACAAAAACAAAACCTCTA 
 
448 
 
280 
 
2.5 55 38 (El-Maarri et al., 2001) 
NESP55 DMR F:TTTTTGTAGAGTTAGAGGGTAGGT R:AAAAAAAACAACTCAAAATCTACC 344 2.5 55 38 (Judson et al., 2002) 
IGF2 DMR0 F:TTGGTGTTGGAAAGTGTTTG R:CTATAACRTCCAAACCCTCTA 300 2.5 55 40 (Monk et al., 2006b) 
IGF2 DMR2 F:GGGATTGGGTTAGGAGAAGTTT R:CCCCCAAAAATAACCAACAAT 164 2.5 57 40 
PEG3 DMR F:GGAAAGAAAATTTTTATAGGTAGGATAGT R:AAACCCTAAACCTCCTAAACTAAATCTAA 173 2.5 57 40 
PEG10 DMR F:GGTGTAATTTATATAAGGTTTATAGTTTG R:AACAAAAAAAATAAAATCCCACAC 234 2.5 55 38 
IGF2R DMR 1 F:AGGAGTTTTTGGGGTTTTTAAGT R:ACTAAAATTCCTACCTCCAACTTTC 287 2.5 57 40 
IGF2R DMR 2 F:GTAGTTTTTGTTTGGTTTTTGTTTG R:CCTATTCACACATAAAATAACCCCT 285 2.5 57 40 
H19 CTCF6 F:TATGGGTATTTTTGGAGGTTTTTT R:AAATCCCAAACCATAACACTAAAAC 311 2.5 57 40 
SNURF/SNRPN DMR F:TAGGTTGTTTTTTGAGAGAAGTTAT R:AAAAAAACTAAAACCCCTACACTAC 236 2.5 57 40 
(Kim et al., 2007b) 
 
 Table 2-6. Primers used for methylation-specific PCR  
Optimised PCR Condition 
Gene Primer sequence  (5’→3’) Band size (bp) 
MgCl2  (mM) Temp. (°C) Cycle No. 
Reference 
Methylated F TTAGGTTAGAGGGTTATCGCGT 
Methylated R TAACTAAAAATTCACCTACCGAC 
116 
Unmethylated F TAATTTTAGGTTAGAGGGTTATTGT 
CDH1  
Unmethylated R CACAACCAATCAACAACACA 
97 
2.5 60 41 (Herman et al., 1996) 
Methylated F CGTTTCGTTATTTTTTGTTTTCGGTTTC 
Methylated R CCGAAAACCCCGCCTCG 
116 
Unmethylated F TTTTGTTTTGTTATTTTTTGTTTTTGGTTTT 
TIMP3 
Unmethylated R CCCCCAAAAACCCCACCTCA 
119 
2.5 60 41 
Methylated F GGATAGTCGGATCGAGTTAACGTC 
Methylated R CCCTCCCAAACGCCGA 
98 
Unmethylated F GGATAGTTGGATTGAGTTAATGTC 
DAPK1  
Unmethylated R CAAATCCCTCCCAAACACCAA 
103 
2.5 60 41 
(Zochbauer-Muller et al., 
2001) 
Methylated F GTATAGTTTCGTAGTTTGCGTTTAGC 
Methylated R AACTCGCGACTCGAATCCCCG 
 102 
Unmethylated F TTTGTATAGTTTTGTAGTTTGTGTTTAGT 
GATA4 
Unmethylated R CCCAACTCACAACTCAAATCCCCA 
 101 
2.5 60 41 
Methylated F AGTTCGTTTTTAGGTTAGTTTTCGGC 
Methylated R CCAATACAACTAAACGAACGAACCG 
 103 
Unmethylated F TGGAGTTTGTTTTTAGGTTAGTTTTTGGT 
GATA5 
Unmethylated R CAAACCAATACAACTAAACAAACAAACCA 
 101 
1.5 60 41 
(Akiyama et al., 2003) 
Methylated F TCGGTTTTCGCGTTTTGTTCGT 
Methylated R AACCGAAAACTATCAACCCTCG 
95 
Unmethylated F TTGGGTTTGGTTTTTGTGTTTTG 
HIC1 
Unmethylated R CACCCTAACACCACCCTAAC 
118 
2.5 60 41 (Dong et al., 2001) 
CCND1  Methylated F TACGTGTTAGGGTCGATCG 276 2.5 55 41 (Evron et al., 2001) 
 Methylated R CGAAATATCTACGCTAAACG 
Unmethylated F GTTATGTTATGTTTGTTGTATG 
Unmethylated R TAAAATCCACCAACACAATCA 
222 
Methylated F ATTTGTTTTCGTCGGGTC 
Methylated R ATTAAAAACGACGCAACG 
107 
Unmethylated F GTATTTGTTTTTGTTGGGTT 
ESR1  
Unmethylated R CCAAAATTAAAAACAACACA 
114 
2.5 55 41 (Imura et al., 2006) 
Methylated F TTATTAGAGGGTGGGGCGGATCGC 
Methylated R GACCCCGAACCGCGACCGTAA 
150 
Unmethylated F TTATTAGAGGGTGGGGTGGATTGT 
P16 
Unmethylated R CAACCCCAAACCACAACCATAA 
151 
1.5 58 41 (Zochbauer-Muller et al., 2001) 
Methylated F TTTCGACGTTCGTAGGTTTTCGC 
Methylated R GCACTCTTCCGAAAACGAAACG 
81 
Unmethylated F TTTGTGTTTTGATGTTTGTAGGTTTTTGT 
MGMT 
Unmethylated R AACTCCACACTCTTCCAAAAACAAAACA 
93 
2.5 60 41 (Zochbauer-Muller et al., 2001) 
 
Table 2-7. Oligonucleotides used for Southern blot 
Gene Oligonucleotide probe Reference 
α-Satellite GAAACACTCTTTTTGTAGAATCTGCAAGTGGA (Chen et al., 2007) 
Satellite 2 TCGAGTCCATTCGATGAT 
Satellite3 TCCACTCGGGTTGATT 
(Saito et al., 2001, 2002) 
 
Table 2-8. Primers used for RT-PCR 
Optimised PCR Conditions Gene Primer sequence  (5’→3’) Band size (bp) 
MgCl2  (mM) Temp. (°C) Cycle No. 
Reference 
Forward GGCCGAAACTGAGTATGTGC 
MGMT 
Reverse CCTTTAATACAGCGGTGCCT 
99 1.5 60 31 
Forward GCAGCAAGCAGATAGACTCA 
TIMP-3 
Reverse CTTCCCTCCCTCACTCTTAC 
116 1.5 60 28 
(Imura et al., 2006) 
 Forward CGTGCGACAAGAGCTACAAG 
HIC-1 
Reverse ATGTGGCTGATGAGGTTGCG 
304 1.5 60 33 (Kanai et al., 1999) 
Forward CTGGCCTGTCATCTCACTACG 
GATA4 
Reverse GGTCCGTGCAGGAATTTGAGG 
263 1.5 60 30 
Forward TCGCCAGCACTGACAGCTCAG 
GATA5 
Reverse TGGTCTGTTCCAGGCTGTTCC 
290 1.5 60 35 
Forward GACCACAGTCCATGCCATCAC 
GAPDH 
Reverse GTCCACCACCCTGTTGCTGTA 
457 1.5 60 25 
(Bai et al., 2000) 
 63 
2.4 General methods 
 
2.4.1 Genomic DNA extraction 
 
Genomic DNA was isolated by either the standard phenol/chloroform extraction or 
DNeasy® Tissue kit (Qiagen: 69504). For the phenol/chloroform extraction, cell 
pellets were harvested by 0.05% Trypsin EDTA (Invitrogen: 25300-054), washed with 
PBS (Invitrogen: 14190) once, and centrifuged at 150 g for 4 min. Washed cell pellets 
were resuspended in 2 ml of lysis buffer (see section 8.1.1.22) and incubated at 37 °C 
overnight with agitation. The following day, an equal volume of phenol/chloroform 
(1:1, see section 8.1.1.13) was added to cell lysates and mixed with vortexing. To 
separate between organic and aqueous phases, centrifugation was performed at 800 g 
for 15 min. Only aqueous phases were taken out and placed into a new tube. The 
phenol/chloroform exaction was repeated until to get clean aqueous phases. Genomic 
DNA was precipitated by adding 1 in 10 of the volume of 3M NaOAc (see section 
8.1.1.12) and 2 volumes of 100% ethanol (see section 8.1.1.16). Genomic DNA 
pellets were visualised by inverting the tube, placed into a new tube using a pipette tip, 
and centrifuged at 16,000 g for 15 min. DNA pellets were washed once with 70% 
ethanol and leaved to be air-dried. Dried pellets were resuspended in appropriate 
amounts of RNase/DNase free water (Sigma: W4502) with flicking. For the DNeasy® 
Tissue kit, genomic DNA was extracted according to the manufacturer’s ‘purification 
of total DNA from cultured animal cells’ protocol (see the DNeasy® Tissue Handbook, 
March 2004). To elute genomic DNA, 100 ul of RNase/DNase free water was added 
into a column, incubated for 1 min and centrifuged at 8,000 g for 1 min. Genomic 
DNA was quantified by a NanoDrop® 1000 spectrophotometer (Thermo Scientific) 
and stored at -20 ºC. 
2.4.2 RNA extraction and cDNA synthesis 
 
Total RNA was extracted from cells using the RNeasy® Mini kit (Qiagen: 74104) with 
QIAshredder (Qiagen: 79654), following manufactuter’s ‘RNeasy mini protocol for 
isolation of total RNA from animal cells’ protocol (see the RNeasy Mini Handbook, 
June 2001). Cell pellets were harvested using 0.05% Trypsin EDTA, washed with 
PBS once, centrifuged, and resuspended in the RLT buffer (provided in the kit) 
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containing 10 µl·ml-1 of β-Mercaptoethanol (Sigma: M3148). The small residual 
amounts of DNA were removed by the RNase-Free DNase Set kit (Qiagen: 79254). 
RNA was eluted in 30 µl of RNase-free water. The concentration of RNA was 
quantified by a NanoDrop® 1000 spectrophotometer. 1 µg of total RNA was reverse 
transcribed into complimentary DNA (cDNA). The reverse transcription (RT) was 
performed by the First-Strand cDNA Synthesis Kit (GE Healthcare: 27-9621-01) with 
pd(N)6 random hexamer primer (provided in the kit), according to the manufacturer’s 
protocol. cDNA was stored at -20 ºC. 
2.4.3 Polymerse chain reaction (PCR)  
 
PCR was performed in a 25 µl reaction volume, with 0.625 Units of Hotstar Taq® 
DNA polymerase (Qiagen: 203205), 1X supplied reaction buffer, 0.5 µM of each 
primer (see Table 2-4, 2-5, 2-6, 2-7 and 2-8), 1.5 ~ 2.5 mM of MgCl2, 0.25 mM of 
dNTP (Invitrogen: R725-01) and 50 ng of each template in a thermal cycler 
(TECHNE TC-512). The PCR cycling conditions were 95 oC for 15 min followed by 
30 ~ 41 cycles (95 oC for 1 min, X oC for 30 s, 72 oC for 1 min) and a final extension 
step at 72 oC for 9 min. Optimised PCR conditions are summarised in Table 2-4, 2-5, 
2-6, 2-7 and 2-8.  
2.4.4 Gel electrophoresis  
 
To visualise genomic DNA and PCR products, gel electrophoresis was performed in 
0.8% ~ 3% agarose gels (Invitrogen: 15510-027) prepared in 1X TBE (see section 
8.1.1.1) containing 0.2 µg·ml-1 ethidium bromide (Sigma: E1510) using the Scie-Plas 
Maxi Horizontal Gel Unit with removable casting trays (SLS Ltd: ELE8170). 1X TEB 
was used as a gel electrophoresis buffer. PCR products and genomic DNA were mixed 
with Gel Loading Dye (Sigma: G2526) and loaded into each lane of the gels. Gel 
electrophoresis was performed at 60 ~ 130 V using a Consort E835 power supply 
(SLS Ltd). PCR products and DNA were visualised by a Fujifilm LAS-100 Gel 
Documentation system and a CCD camera. Images were captured by a Fujifilm LAS-
100 software and quantified by an Aida Image Analyser v.4.15 (Raytek Scientific Ltd, 
Sheffield) software. For the quantification of each band, a rectangular region of 
interest was drawn around each PCR band. The signal density was measured and 
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normalised with local background measurement around a rectangular region of 
interest. Then, normalised values were exported into Microsoft Excel for analysis.  
2.4.5 Genotyping and allelic specific expression  
 
Genotyping was performed by either PCR-RFLP (restriction fragment length 
polymorphism) or direct sequencing, according to previous publications described in 
Table 2-4. For PCR-RFLP, amplified PCR products were digested with appropriate 
restriction enzymes described in Table 2-4. 2% ~ 3% Agarose (Invitrogen: 15510-
027) gels were used for gel electrophoresis. The predominantly monoallelic 
expression was defined when the allelic ratio was >3:1 (Cui et al., 1998). Direct 
sequencing was performed by either forward or reverse primer, as described in section 
2.5.9. 
2.4.6 Bisulphite modification 
 
500 ng to 1 µg of genomic DNA was digested with either BamHI (Roche: 10 220 612 
001) or EcoRI (Roch: 10 703 737 001) overnight at 37 oC. The digested DNA was 
placed into a sterile screw-cap tube, incubated at 100 oC for 5 min for DNA 
denaturation and then immediately placed on ice. 2.5 µl of 3 M NaOH (see section 
8.1.1.8) was added to each tube and incubated at 37 oC for 20 min. During incubation, 
the bisulphite solution was prepared. 3.8 g of sodium bisulphite (BDH: 103564D) was 
mixed with 5.5 ml of RNase/DNase free water (Sigma: W4502) and 1 ml of 3 M 
NaOH using a tube roller under dark condition. At the same time, 110 mg of 
hydroquinone (Sigma: H9003) was dissolved in 1 ml of RNase/DNase free water by 
heating at 55 oC for 10 min. The dissolved hydroquinone was added to the bisulphite 
solution and mixed together. 270 µl of the freshly prepared bisulphite solution was 
added to denatured DNA. Incubation was performed at 55 oC for 5 h under dark 
condition. Following incubation, bisulphite treated DNA was added into a 2 ml sterile 
tube (Eppendorf: 0030 120.094) containing 600 µl of RNase/DNase free water (see 
section 8.1.1.20), 90 µl of 3 M sodium acetate (see section 8.1.1.12) and 1 µl of Pellet 
PaintTM (Novagen: 69049-3). Then, 900 µl of ethanol (see section 8.1.1.16) was added 
and mixed by inversion. Centrifugation was performed at 14,000 g for 20 min. DNA 
pellets were washed with 500 µl of 70% ethanol and centrifuged for 10 min at 14,000 
g. The pellets were air-dried for 10 min and resuspended in 50 µl of RNase/DNase 
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free water. 5 µl of 3 M NaOH was added into dissolved pellets for desulfonation of 
DNA and incubated at 37 oC for 15 min. Finally, bisulphite-converted DNA was 
purified using the QIAquick PCR purification kit (Qiagen: 28104) according to 
manufacturer’s protocol. DNA was eluted in 30 µl of RNase/DNase free water. 
Bisulfite modified DNA was stored at -20 oC and used for PCR. 
2.4.7 Combined bisulphite restriction analysis (COBRA)  
 
2 µl of bisulphite modified DNA was used for PCR (see 2.5.6 and 2.5.3). Primers for 
COBRA are described in Table 2-5. Following PCR, PCR products were digested 
with appropriate restriction enzymes described in Table 2-9. Gel electrophoresis was 
performed and gel images were visualised, captured and analysed, as previously 
described in section 2.5.4.  
 
Table 2-9. Restriction enzymes used for COBRA 
Gene Restriction enzyme Supplier Catalogue Number 
TP73 AclI NEB R0598S 
IG2R BstUI NEB R0518S 
BstUI NEB R0518S 
PEG10 
AciI NEB R0551S 
AclI NEB R0598S 
PEG1 
HpyCH4IV NEB R0619S 
SLC22A18 BstUI NEB R0518S 
CDKN1C HpyCH4IV NEB R0619S 
BstUI NEB R0518S 
KvDMR1 
HpyCH4IV NEB R0619S 
HpyCH4IV NEB R0619S 
IGF2 DMR0 
AciI NEB R0551S 
AclI NEB R0598S 
Acil NEB R0551S IGF2 DMR2 
HpyCH4IV NEB R0619S 
HpyCH4IV NEB R0619S 
H19 CTCF 
AciI NEB R0551S 
AclI NEB R0598S 
GTL2 CpG2 
HpyCH4IV NEB R0619S 
SNRPN AciI NEB R0551S 
HpyCH4IV NEB R0619S 
PEG3 
AciI NEB R0551S 
NESP55 AclI NEB R0598S 
AciI NEB R0551S 
GNAS1 XLαs 
BstUI NEB R0518S 
 
2.4.8 Methylation-specific PCR (MSP) 
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2 µl of bisulphite modified DNA was used for MSP. Primers for MSP were described 
in Table 2-6. PCR and gel electrophoresis were performed as previously described in 
sections 2.5.3 and 2.5.4. For the positive control, genomic DNA was in vitro 
methylated by SssI methylase (NEB: M0226S). 1 µl of S-adenosy-L-methionine 
(SAM) was added into 19 µl of RNase/DNase free water to give a final concentration 
of 1600 µM. In a 20 µl reaction volume, 5 µl of genomic DNA (1 µg), 2 µl of 10X 
buffer, 1 µl of SssI methylase, 2 µl of SAM and 10 µl of RNase/DNase free water 
were added in the tube and mixed with flicking. Then, incubation was performed at 37 
oC for 2 h, followed by enzyme inactivation at 60 oC for 20 min. DNA was purified 
using the QIAquick PCR purification kit (Qiagen: 28104) according to manufacturer’s 
protocol. 
2.4.9 Sequencing 
 
For direct sequencing, PCR products were purified by the QIAquick Gel Extraction 
Kit (Qiagen: 28704) according to manufacturer’s protocol (see OIAquick® spin 
Handbook, March 2006). Elution was performed in 20 µl of RNase/DNase free water. 
Purified PCR products were quantified by a NanoDrop® 1000 spectrophotometer. 20 
ng of PCR products and either forward or reverse primer were sent to the DNA 
sequencing laboratory (University of Nottingham). For clonal sequencing, PCR 
products were purified by the QIAquick Gel Extraction Kit, cloned into PCR® XL-
TOPO vector (Invitrogen: K4750-20), and subsequently transformed into One Shot® 
TOP10 Chemically Competent E. coli (Invitrogen: C4040-03). Individual colonies 
were inoculated into 2 ml of LB medium containing Kanamycin (50 µg/ml, see 
section 8.1.1.14) and cultured overnight in a 37oC shaking incubator. The following 
day, plasmids were extracted using the QIAprep Spin Miniprep Kit (Qiagen: 27104) 
according to manufacturer’s protocol (see QIAprep Miniprep Handbook, June 2005). 
10 insert-containing colonies determined by EcoRI digestion were sequenced using 
the M13 forward primer. Sequencing results were analysed by a Chromas Lite v2.01 
software (http://www.technelysium.com.au/chromas_lite.html).  
2.4.10 Transformation 
 
One Shot® TOP10 Chemically Competent E. coli (Invitrogen: C4040-03) for bisulfite 
clonal sequencing (see section 2.5.9) and Sub cloning EfficiencyTM 
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DH5αTM  Competent cells (Invitrogen: 18265-017) for the construction of pCAG-
DNMT1-IRES-PAC and pCAG-DsRed2-C1-DNMT1-IRES-PAC plasmids (see 
section 2.5.14 and Chapter 5) were used. Once competent cells thawed, 0.5 µl of 
either PCR products or plasmids were added into cells and mixed by flicking the tube. 
The tube was incubated for 30 min on ice, followed by incubation for 1 min at 42 ºC. 
Then, 1 ml of SOC medium was added into the tube. The tube was incubated for 1 h at 
37 ºC with shaking. Following incubation, 200 µl was spread onto an agar plate 
containing an antibiotic (see 2.4.1.14 and 2.4.1.15). A plate was placed upside down 
and incubated overnight at 37 ºC.  
2.4.11 Protein extraction and quantification 
 
Total proteins were extracted using the RIPA buffer (see section 8.1.2.14). Extracted 
proteins were quantified by the Bradford assay (see section 8.1.2.17). Trypsinized cell 
pellets were placed into an eppendorf tube, washed once with PBS and centrifuged at 
150 g for 4 min. Cell pellets were resuspended in 20 ~ 50 µl of RIPA buffer 
containing Complete, EDTA-free Protease Inhibitor Cocktail (Roche: 11 873 580 001). 
Incubation was performed for 20 min on ice. Then, the tube was placed into liquid 
nitrogen (LN2) for 30 sec for snap-freezing and placed into slushy water to thaw. The 
tube was grated in an eppendorf rack at least 5 times. Snap freezing and grating were 
repeated at least 3 times. Then, centrifugation was performed at 16,000 g for 30 min at 
4 ºC. Only supernatant was taken out and placed into a new tube and stored at – 80 ºC.  
2.4.12 Western blot 
 
30 µg of each protein extract was mixed with the protein loading buffer (see section 
8.1.2.15), boiled at 100 ºC for 5 min and loaded onto 4 ~ 8 % SDS-PAGE (sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis) gels. 6 µl of Prestained Protein 
Marker, Broad Rage (6-175 kDa), (NEB: P7708S) was used for the determination of 
the molecular mass. Electrophoresis was performed at 80V ~ 100V for 2 h within 1X 
protein electrophoresis buffer (see section 8.1.2.1). The electrophoretically separated 
proteins on the gel were confirmed by Commassie blue gel staining (see section 
8.1.2.8). Proteins were transferred to the Hybond ECL Nitrocellulose Membrane (GE 
Healthcare: RPN203D) by a wet-transfer system at 25V overnight. The membrane 
was stained by Poncea S (see section 8.1.2.18). The membrane was incubated in 5% 
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Skim milk (see section 8.1.2.5) for 3 h at room temperature and then probed with a 
primary antibody (see Table 2-2) for 3 h at room temperature with agitation. The 
membrane was washed 5 times for 1 h with TBST (see section 8.1.2.4), and incubated 
with a HRP-conjugated secondary antibody (see Table 2-3) for 1 h at room 
temperature with agitation. The membrane was washed 5 times with TBST for 1 h, 
treated with 1 ml of ECL AdvanceTM Western Blotting Detection reagent (GE 
Healthcare: RPN2135), and exposed to a Kodak BioMax XAR film (Sigma: F5388). 
Antibodies used in western blot and their dilution factors were described in Table 2-2 
and 2-3.  
2.4.13 Southern blot  
 
Each 5 µg of genomic DNA was digested with either HpaII (Roche: 10 239 291 001) 
or MspI (Roche: 10 633 518 001) overnight at 37 ºC. Phenol/chloroform extraction 
and ethanol precipitation were performed to purify digested genomic DNA. DNA was 
resuspended in 20 µl of RNase/DNase free water and 5 µl of Gel Loading Dye 
(Sigma: G2526) was mixed into 20 µl DNA. Gel electrophoresis was performed at 60 
V for 5 h. Then, the gel was stained by 0.2µg·ml-1 ethidium bromide (Sigma: E1510) 
for 10 min and subsequently destained for 10 min with distilled water. The 
electrophoretically separated genomic DNA was visualised by a Gel Documentation 
system and a CCD camera (see section 2.5.4). The membrane transfer was set-up as 
previously described (Southern, 2006). The membrane transfer was performed within 
0.4 mM NaOH (see section 8.1.4.10) overnight. The membrane (Hybond-XL; 
Amersham RPN203S) was washed with 2X SSC (see section 8.1.4.2) for 2 min with 
agitation and air-dried between two filter papers (Fisher Scientific) for 20 min. The 
membrane was baked in a gel dryer (Bio-Rad: 165-1746) connected with a 
HydorTechTM vacuum pump (Bio-Rad: 165-1781) at 80 ºC for 2 h. For hybridisation, 
the membrane was placed in the hybridisation bottle and washed with 2X SSC once. 
50 ml of pre-hybridisation solution (see 2.4.4.8) was added into the hybridisation 
bottle and incubated at 65 ºC for 4 h with rotation in a hybridisation oven. The probe 
was prepared, while incubation was in progress. In the first tube, 5 µl of 1 mgml-1 
Random Hexamers (NEB: S1230S), 5 µl of 100 ng LINE probe provided by Dr. Hazel 
Cruickshanks (University of Nottingham), and 4 µl of RNase/DNase free water were 
added, mixed together with flicking several times, incubated at 100 ºC for 5 min and 
placed into ice for 2 min. In a second tube, 2.5 µl of 10X buffer, 5 µl of 0.5 mM 32P-
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dCTP (PerkinElmer), 2.5 µl of 0.5 mM dNTPs less dCTP, and 1 µl of Klenow (NEB: 
M0210S) were added and mixed together with flicking several times. The Klenow 
filled mixture in the second tube was placed into the first tube, mixed together with 
flicking several times and incubated at room temperature for 4 h in a perspex box. 
Before 1 h for probing, 25 ml of pre-hybridisation solution was taken out from the 
hybridisation bottle and placed into a new tube, and 2.25 g of Dextran sulphate 
(Sigma: D8906) was dissolved into this tube with rotation (see section 8.1.4.9). After 
4 h incubation, 1 µl of 0.5 M EDTA (see 2.4.1.6) was added into in the tube to 
inactivate the Klenow enzyme. Then, unincorporated nucleotides were removed by a 
ProbeQuantTM G-50 Micro Column (GE Healthcare: 27-5335-01), according to 
manufacturer’s protocol. The probe was denatured at 100 ºC for 5 min and placed into 
ice for 2 min, added into the Dextran sulphate dissolved hybridisation solution, and 
mixed together. 25 ml of pre-hybridisation solution was poured off from the 
hybridisation bottle and this probe mixture was added into the bottle. Hybridisation 
was performed overnight at 65 ºC. Following day, the membrane was washed twice 
with a low stringency wash buffer, 2X SSC/0.1% SDS (see section 8.1.4.11), at room 
temperature for 20 min with rotation and washed twice with a high stringency wash 
buffer, 0.1X SSC/0.1%SDS (see section 8.1.4.12), at 65 ºC for 15 min. Finally, the 
membrane was washed once in 2X SSC (see section 8.1.4.2), exposed to a Kodak 
BioMax MS film (Sigma: Z363049).  
2.4.14 Plasmid construction 
 
pCAG-DNMT1-IRES-PAC and pCAG-DsRed2-C1-IRES-PAC plasmids were 
genereated. With the DsRed2 expression, it is easy to discriminate positive cell lines 
expressing exogenous DNMT1 using fluorescence microscopy. Furthermore, 
immunocytochemistry and fluorescence-activated cell scanner (FACS) analyses are 
available for analysing living or fixed cells without a specific antibody (Liew et al., 
2007; Ren et al., 2006; Smith et al., 2008; Zaragosi et al., 2007). However, due to the 
potential cytotoxic effect of fluorescent reporter proteins in mammalian cells (Liu et 
al., 1999; Vallier et al., 2004b), a plasmid without DsRed2 was also utilised in this 
thesis.  
2.4.14.1 pCAG-DNMT1-IRES-PAC 
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The pDsRed2-C1-hDNMT1 plasmid was produced during a previous project in the 
laboratory of Prof. Yong-Mahn Han (KAIST). This plasmid contains a 5.2kb full-
length human DNMT1 cDNA. The pDsRed2-C1-hDNMT1 plasmid was digested with 
EcoRI (Roche: 11 175 084 001) and RsrII (Roche: 11 292 595 001) with appropriate 
buffers. Then, gel electrophoresis was performed in a 0.8% agarose gel. A 5.2kb band 
of DNMT1 cDNA was cut out by a blade. To purify DNMT1 cDNA from the gel, gel 
extraction was performed using the QIAquick Gel Extraction Kit (Qiagen: 28704) 
according to manufacturer’s protocol (see OIAquick® spin Handbook, March 2006).  
 
The p336 plasmid (see section 5.2.1.1) provided by Prof. Chris Denning (University 
of Nottingham) was digested with EcoRI. Following gel electrophoresis on a 0.8% 
Agarose gel, the linearized  p336 plasmid (6.3kb) was purified from the gel by the 
QIAquick Gel Extraction Kit (Qiagen: 28704). Shrimp Alkaline Phosphatase (SAP, 
Promega: M1821) was used to treat into the digested plasmid to prevent self-ligation. 
 
Human DNMT1 cDNA (EcoRI) and p336 (EcoRI-SAP) were ligated using the Quick 
LigationTM Kit (NEB: M2200S) according to manufacturer’s protocol. Transformation 
was performed with Sub cloning EfficiencyTM DH5αTM  Competent cells (Invitrogen: 
18265-017) (see section 2.5.10). 20 colonies were handpicked up by pipette tips and 
inoculated into 2 ml of LB medium containing 100 µg·ml-1 Ampicillin. Then, 
incubation was performed at 37 ºC overnight with vigorous shaking. The following 
day, Miniprep was performed by the QIAprep Spin Miniprep Kit (Qiagen: 27104) 
according to manufacturer’s protocol (see QIAprep Miniprep Handbook, June 2005). 
To elute each plasmid, 50 µl of RNase/DNase free water (Sigma: W4502) was added 
into the column. Following elution, 2 µl of each plasmid was subjected to restriction 
enzyme digestions with EcoRI (Roche: 11 175 084 001), PciI (NEB: R0595S), XcmI 
(NEB: R0533S) and SacI (Roche: 10 669 792 001) to confirm the correct insertion of 
DNMT1 cDNA into p336.  
2.4.14.2 pCAG-DsRed2-C1-DNMT1-IRES-PAC 
 
The pDsRed2-C1-hDNMT1 plasmid was digested with SalI (NEB: R0138S), and 
Klenow (NEB: M0210S) was used to treat into SalI sites to make blunt ends from 
sticky ends. Then, AgeI (NEB: R0552S) digestion was performed with the SalI-
digested and Klenow-filled pDsRed2-C1-hDNMT1 plasmid. Gel electrophoresis was 
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performed in a 0.8% agarose gel. A 5.9 kb band of DsRed2-DNMT1 cDNA was cut 
out from the gel by a blade. DsRed2-DNMT1 cDNA was purified using the QIAquick 
Gel Extraction Kit (Qiagen: 28704).  
 
The p336+linker (p388) plasmid (see section 5.2.1.1) provided by Prof. Chris Denning 
(University of Nottingham) was double digested with PmeI (NEB: 0560S) and AgeI. 
Gel electrophoresis was performed on a 0.8% agarose gel. A 6,469 bp band of p388 
was cut out from the gel by a blade. The digested plasmid was purified using the 
QIAquick Gel Extraction Kit (Qiagen: 28704). Then, ligation between DsRed2-
DNMT1 cDNA (SalI-Klenow-AgeI) and p388 (PmeI-AgeI), and transformation were 
performed. Individual 12 colonies were handpicked up by pipette tips and inoculated 
into 2 ml of LB medium containing 100 µg·ml-1 Ampicillin. Incubation was 
performed at 37 ºC overnight with vigorous shaking. Then, Miniprep was performed. 
12 plasmids were subjected to restriction enzyme digestions with BamHI (Roche: 10 
220 612 001), SacI and EcoRI to confirm the correct insertion of DsRed2-DNMT1 
cDNA into p388.  
2.4.15 Mouse embryonic fibroblasts (MEFs) culture  
 
The MEFs 43 batch established in our laboratory was used for producing conditioned 
medium (BG-K CM). MEFs were cultured in the T75 flask (Fisher Scientific: TKT-
130-190W) and split at a ratio of 1:3. Once MEFs were confluent, the MEFs medium 
was aspirated and MEFs were washed once with 10 ml of Dulbecco Phosphate 
Buffered Saline (DPBS, Invitrogen: 14190-169). Then, 2 ml of 0.05% Trypsin EDTA 
(Invitrogen: 25300-062) was added in the flask and incubated for 3 min at 37 ºC in an 
incubator. The flask was tapped gently to dislodge the cells and 8 ml of MEFs 
medium was added to inactivate Trypsin EDTA. The medium was pipetted over the 
flask surface vigorously and placed into the universal tube. Centrifugation was 
performed at 200 g for 4 min. The medium was aspirated and cell pellets were 
resuspended in 2 ml of MEFs medium. The cell suspension was added into a new T75 
flask containing 13ml of MEFs medium. Then, MEFs were incubated in a 37 ºC 
incubator until they were confluent.  
 
To prepare BG-K CM, MEFs were mitotically inactivated for 2.5 h at 37 ºC with 10 
µg·ml-1 Mitomycin C (Sigma: M4287, see section 8.1.5.2). At the same time, 10 ml of 
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0.1% gelatine solution (see section 8.1.5.7) was added into a new T75 flask and 
incubated at 37 ºC for 2.5 h. Mitotically inactivated MEFs were washed with PBS 
three times and harvested by 0.05% Trypsin EDTA. Cells were counted by a 
Neubauer haemocytometer (Fisher scientific: MNK-504-020P). Cells were 
centrifuged at 150 g for 4 min and resuspended in appreciate amounts of MEF 
medium. 4.8 x 106 cells were seeded into a gelatine-coated T75 flask.  
2.4.16 BG-K CM medium collection 
 
The BG-K medium (see section 8.1.5.3) was conditioned by mitotically inactivated 
MEFs (see section 8.1.5.2). 25ml of the BG-K medium was added to mitotically 
inactivated MEFs in a T75 flask. Following incubation overnight, the BG-K CM 
medium was collected and placed into a 150 ml Sterilin Container (SLS Ltd: 
CON7572). bFGF (Sigma: F0291) was added into the BG-K CM medium to give a 
final concentration of 4 ng·ml-1. 10 ml aliquots were stored at -80 ºC. BG-K CM was 
normally collected during 7 days.  
2.4.17 HUES7 culture  
 
To generate hESOD1 cell lines (see Chapter 5), HUES7 cells were cultured by 
trypsin-passaging on matrigel in the BG-K CM medium as previously described 
(Allegrucci et al., 2007; Anderson et al., 2007; Burridge et al., 2007). HUES7 cells 
were usually cultured in the T25 flask (Fisher Scientific: TKT-130-150L), and split at 
a ratio of 1:3. Once HUES7 cells were confluent, the medium was aspirated and cells 
were washed once with 5 ml of PBS. Then, 1 ml of 0.05% Trypsin EDTA (Invitrogen: 
25300-062) was added in the flask and incubated for 1 min at 37 ºC in an incubator. 
Then, the flask was banged to dislodge the cells from the flask and 4 ml of the BG-K 
medium (see section 8.1.5.3) were added to inactivate Trypsin EDTA. The medium 
was pipetted up and down over the flask surface vigorously and placed into a 
universal tube. Centrifugation was performed at 150 g for 4 min. The medium was 
aspirated and cell pellets were resuspended in 3 ml of BG-K CM medium. 1 ml of cell 
suspension was added into a new T25 flask containing 4 ml of the BG-K CM medium. 
Cells were incubated in a 37 ºC incubator. The medium was changed everyday until 
cells were confluent.   
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2.4.18 OCT3/4, NANOG and SSEA4 staining  
 
HUES7 cells were seeded at a density of 1×104 cells per well onto a 8-well chamber 
slide (Nunc Labtek: 177402). Cells were cultured for 24 ~ 48 h until fixation. The 
medium was aspirated, and cells were washed once with PBS and fixed with 4% PFA 
(see section 8.4.3.8) for 30 min at room temperature. Cells were washed three times 
with 0.2% Tween 20 in PBS. Then, cells were permeabilised with 0.2% Triton X-100 
for 30 min at room temperature and washed once with 0.2% Tween 20 in PBS. 
Blocking was performed for 1 h at room temperature with 2% BSA/0.1% Tween 20 in 
PBS. Then, primary antibodies, OCT3/4 (Santa Cruz: SC-5279), NANOG (R&D 
system: AF1997) and SSEA4 (Chemicon: MAB4304), were treated at 1:200, 1:200 
and 1:100 dilutions and incubated for 1 h at room temperature (see Table 2-2). Cells 
were washed three times with 0.2% Tween 20 in PBS. Secondary antibodies, FITC-
conjugated anti-mouse secondary antibody (1:200 dilution, Jackson ImmunoResearch: 
115-095-068), Cy3-conjugated anti-mouse secondary antibody (1:250 dilution, 
Jackson ImmunoResearch: 115-165-068), and FITC-conjugated anti-goat secondary 
antibody (1:200 dilution, Novus Biologicals: NB710-F) were treated and incubated at 
room temperature for 30 min (see Table 2-3). Cells were washed three times with 
0.2% Tween 20 in PBS and mounted using VECTASHIELD® mounting medium with 
DAPI (Vector Laboratories: H1200).  
2.4.19 Transfection and puromycin selection  
 
Cells were harvested by 0.05% Trypsin EDTA. The number of cells was counted by a 
Neubauer haemocytometer (Fisher scientific: MNK-504-020P). 1×106 cells were 
resuspended in 750 µl of hypo-osmolar buffer (Eppendorf: 4308 070.501), and 
incubated at room temperature for 20 min. 50 µg of a linearized plasmid was added 
into the cell suspension and mixed together. The mixture was placed into a Geneflow 
Electroporation Cuvette (Geneflow: E6-0070). Electroporation was performed by 
using previously optimised conditions, 600V/30 µs (Anderson et al., 2007). Cells were 
seeded into one of 6 wells. The following day, the medium containing 300 ng·ml-1 of 
Puromycin (Sigma: P8833) was added into cells to select puromycin-resistant colonies. 
Following medium change everyday, puromycin-resistan colonies were handpicked 
up by pipette tips and transferred into one of 24 wells. Once cells were confluent in 
one of 24 wells, each colony was trypsinised, seeded into one of 24 wells (Fisher 
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scientific: TKT-190-010Y). Cells were expanded to be confluent in a T25 flask 
(Fisher scientific: TKT-130-150L).   
 
Transiently transfection was performed by a GeneJammerTM (Stratagene: 204130) 
according to manufacturer’s protocol.  
2.4.20 Cell cycle analysis  
 
Cells harvested by 0.05% Trypsin EDTA were resuspended in 1 ml of PBS. To fix the 
cells, 2.5 ml of 100% ethanol was added into resuspended cells to give a final 
concentration of 70%. Incubation was performed on ice for 15 min to prevent 
clustering of cells during fixation. Cells were pelleted by centrifugation at 150 g for 4 
min. The cell pellets were resuspended in 500 µl of the solution containing 50 µgml-1 
Propidium Iodide (PI, Sigma P4170), 0.1 mgml-1 Ribonuclease A (RNase A, Sigma 
P6513), and 0.05% Triton X-100 and incubated at 37 ºC for 40 min. Following 
incubation, 3 ml of PBS was added into the solution to wash briefly. Cells were 
pelleted by centrifugation at 150 g for 4 min and resuspended in 500 µl of PBS. The 
cell cycle analysis was carried by a CYTOMICSTM FC500 Flow Cytometer 
(Beckmen Coulter). Data were analysed by WinMDI v2.8 
(http://facs.scripps.edu/software.html) and Cylchred v1.0.2 programmes.  
2.4.21 Statistical analysis  
 
All statistically analyses were performed using SPSS 15.0 for windows (SPSS Inc., 
Chicago, USA). All results are presented as mean ± 1 standard deviation (SD) unless 
otherwise stated. The Post Hoc, Mann-Whitney and Kruskal-Wallis tests were 
performed on all samples. A non-parametric Kruskal-Wallis test and a Mann-Whitney 
test were used for between-groups analysis. Where a statistically significant result 
(p<0.05) was returned, a Post Hoc test was used to perform pairwise comparisons.  
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3 ALLELE-SPECIFIC EXPRESSION OF IMPRINTED GENES IN 
HUMAN EMBRYONIC STEM CELL LINES 
 
3.1 Introduction 
 
3.1.1 Allele-specific expression of imprinted genes 
 
Although most autosomal genes are expressed from both parental alleles, imprinted 
genes are known be monoallelic expressed in a parent-of-origin-dependent manner 
(reviewed by Reik and Walter, 2001; Surani, 2001). The allele-specific expression of 
imprinted genes is guided by allele-specific differential epigenetic marks on their 
regulatory regions (reviewed by Constancia et al., 2004; Li, 2002). In the human, ~ 50 
genes have been identified to be imprinted (see Table 1-1) (reviewed by Morison et al., 
2005). However, imprinted genes are not always monoallelically expressed. Genes 
can be imprinted in a tissue-specific, isoform-specific, promoter-specific or 
polymorphic manner (reviewed by Constancia et al., 2004; Murrell, 2006). For most 
human imprinted genes, the allele-specific expression status in the inner cell mass 
(ICM) of blastocyst stage embryos is unknown and therefore the expected status of 
human embryonic stem cells (hESCs) is undefined yet.  
3.1.1.1 Tissue-specific imprinting 
 
Some imprinted genes show either monoallelic or biallelic expression depending on 
the tissue.  This is defined as ‘tissue-specific imprinting’. For example, WT1 (Wilms’ 
tumour 1) is monoallelically expressed in lymphocytes from peripheral blood, 
fibroblasts from fetal skin, body and umbilical cord, and placenta, whereas it is 
biallelically expressed in kidney and fetal brain (Jinno et al., 1994; Mitsuya et al., 
1997). Furthermore, UBE3A (ubiquitin protein ligase E3A) is know to be imprinted in 
brain, but other tissues show biallelic expression (Rougeulle et al., 1997). Other 
imprinted genes including ATP10C/ATP10A (Meguro et al., 2001), GNAS1 (G protein 
α subunit 1) (Hayward et al., 2001), GRB10 (growth factor receptor-bound 10) 
(Blagitko et al., 2000) and KCNQ1 (potassium voltage-gated channel, KQT-like 
subfamily, member 1) (Gould and Pfeifer, 1998) are previously known to have tissue-
specific imprinting in the human. 
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3.1.1.2 Isoform-specific imprinting 
 
Some genes can be imprinted in an isoform-specific manner. For example, PEG1 
(paternally expressed gene 1)/MEST (mesoderm specific transcript) has two isoforms 
(isoform 1 and 2) derived from their unique first exons (exon A and exon 1) in the 
human (Kosaki et al., 2000). PEG1 isoform 1 is monoallelically expressed in most 
human tissues, whereas PEG1 isoform 2 is biallelically expressed (Kosaki et al., 2000; 
Nakabayashi et al., 2002). Moreover, the GRB10 gene consists of 4 different splicing 
variants (GRB10β, GRB10γ, GRB10ε and GRB10σ) and they have distinct allele-
specific expression patterns (Blagitko et al., 2000; Hikichi et al., 2003). For instance, 
GRB10γ1 is expressed from the maternal allele in the skeletal muscle, whereas other 
variants are expressed from two alleles (Blagitko et al., 2000). 
3.1.1.3 Promoter-specific imprinting 
 
Some genes can be imprinted in a promoter-specific manner. The IGF2 (Insulin-like 
growth factor 2) gene was first identified to have promoter-specific imprinting 
(Ekstrom et al., 1995; Vu and Hoffman, 1994). In liver and chondrocytes, the IGF2 
transcript derived from the P1 promoter is expressed from both parental alleles, 
whereas other IGF2 transcripts derived from P2, P3 and P4 promoters are 
monoallelically expressed (Ekstrom et al., 1995; Vu and Hoffman, 1994). 
3.1.1.4 Polymorphic imprinting 
 
Some genes can have polymorphic imprinting (defined as inter-individual variations 
of imprinting) in the same tissues (reviewed by Murrell 2006). For example, IGF2R 
(insulin-like growth factor 2 receptor) shows various expression patterns (monoallelic, 
predominant monoallelic and biallelic) between a range of term placentae examined 
(Monk et al., 2006a; Xu et al., 1993). Moreover, PHLDA2 (pleckstrin homology-like 
domain, family A, member 2)/TSSC3 (tumor suppressing subtransferable candidate 
3)/IPL (imprinted in placenta and liver) is monoallelically or biallelically expressed in 
adult brain and blood (Muller et al., 2000; Qian et al., 1997). Other imprinted genes 
including and TSSC5 (tumour suppressing subtransferable candidate 5)/SLC22A18 
(Solute carrier family 22, member 18) (Cooper et al., 1998) and WT1 (Jinno et al., 
1994) are previously known to have polymorphic imprinting in the human. 
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3.1.2 Determination of allele-specific expression 
 
The allele-specific expression status of human imprinted genes can be determined by 
either polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP) or direct sequencing (Cui et al., 1998; Monk et al., 2006a; Onyango et al., 
2002).  
3.1.2.1 Genotyping  
 
Genotyping is required to identify the sample having a heterogeneous genotype, 
because this type is only informative for analysing allele-specific expression of an 
imprinted gene. In this manner, DNA need to be amplified by PCR at the region 
containing a polymorphic site that allows determining a genotype followed by either a 
restriction enzyme digestion recognising a polymorphic site or direct sequencing (Cui 
et al., 1998; Monk et al., 2006a; Onyango et al., 2002). 
3.1.2.2 Allele-specific expression  
 
Once a sample has been determined as a heterozygous genotype and thus informative 
for an imprinted gene, allele-specific expression of the gene can be determined by 
PCR-RFLP and direct sequencing. In this time, cDNA need to be amplified by PCR 
and then either a restriction enzyme digestion or direct sequencing allows determining 
monoallelic, predominant monoallelic or biallelic expression of the gene (Cui et al., 
1998; Monk et al., 2006a; Onyango et al., 2002). The allele-specific expression of the 
gene can be determined by the relative band intensity between two alleles in PCR-
RFLP or the relative peak height between two alleles in direct sequencing (Cui et al., 
1998; Monk et al., 2006a; Onyango et al., 2002). In PCR-RFLP, loss of imprinting is 
determined as a ratio of less than 3:1 between the more-abundant and less-abundant 
alleles, according to Cui et al., (1998). In direct sequencing, the electrophoretogram 
shows that both peaks are present at a polymorphic site with the same height. This is 
defined as loss of imprinting (Monk et al., 2006a; Onyango et al., 2002). 
3.1.3 Allele-specific expression associated with biological 
consequences 
 
The allele-specific expression of some imprinted genes identified in the human is 
closely associated with several biological consequences including congenital disorders, 
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PWS (Prader-Willi syndrome), BWS (Beckwith-Wiedemann syndrome) and AS 
(Angelman syndrome) (reviewed by Robertson, 2005; Weksberg et al., 2003) and 
cancer formation (reviewed by Feinberg, 2007; Jelinic and Shaw, 2007). Moreover, 
some imprinted genes are involved in embryonic and placental development, cell 
proliferation, cell death and behaviour (reviewed by Reik and Walter, 2001; Surani, 
2001).  
3.1.3.1 Genes related to human cancers 
 
The allele-specific expression of TP73, PEG1, IGF2, SLC22A18 and PEG3 is 
associated with human tumourigenesis (Chi et al., 1999; Dowdy et al., 2005; Kaghad 
et al., 1997; Lee et al., 1998; Maegawa et al., 2001; Mai et al., 1998a; Mai et al., 
1998b; Nakanishi et al., 2004; Pedersen et al., 2002; Schwienbacher et al., 2000). In 
detail, TP73 (tumour protein 73) is located in human chromosome 1p 36.3 that is 
paternally imprinted (Kaghad et al., 1997). TP73 is monoallelically expressed in 
normal tissues, whereas it is biallelically expressed in diverse human cancers, 
including lung, prostate and kidney carcinomas (Chi et al., 1999; Kaghad et al., 1997; 
Mai et al., 1998a; Mai et al., 1998b). PEG1 is located in human chromosome 7q32 
that is maternally imprinted (Kerjean et al., 2000; Kosaki et al., 2000; Riesewijk et al., 
1997). Loss of imprinting of PEG1 is often found in invasive breast and lung cancers 
(Nakanishi et al., 2004; Pedersen et al., 2002). IGF2 is maternally imprinted on human 
chromosome 11p15 (Giannoukakis et al., 1993; Ohlsson et al., 1993). Loss and gain of 
imprinting of IGF2 has been commonly found in ovarian, lung, liver and colon 
carcinomas (reviewed by Feinberg, 2007; Jelinic and Shaw, 2007). SLC22A18/TSSC5 
is located in human chromosome 11p15 that is imprinted in a tissue-specific manner 
(Lee et al., 1998). Gain of imprinting of SLC22A18 has been found in 
hepatocarcinomas (Schwienbacher et al., 2000). SLC22A18 is biallelically expressed 
in normal liver tissues, whereas it is predominatly monoallelically expressed in 
hepatocarcinomas (Schwienbacher et al., 2000). PEG3 (paternally expressed gene 3) 
is maternally imprinted on human chromosome 19q13 (Dowdy et al., 2005; Maegawa 
et al., 2001). Loss of imprinting of PEG3 is frequently found in glioma, ovarian, 
cervical and choriocarcinoma cell lines (Dowdy et al., 2005; Maegawa et al., 2001). 
3.1.3.2 Genes related to human disorders  
 
 80 
KCNQ1OT1 (KCNQ1 overlapping transcript 1)/LIT1 (long QT intronic transcript 1), 
which is maternally imprinted in human chromosome 11p15, is an imprinted antisense 
RNA of the KCNQ1 gene (Lee et al., 1999; Smilinich et al., 1999). Loss of imprinting 
of KCNQ1OT1 mediated by loss of methylation at KvDMR1 is frequently found in 
BWS patients (Lee et al., 1997; Smilinich et al., 1999). Less frequently, loss of 
imprinting of IGF2 and H19 can be found in BWS patients (Reik et al., 1995; 
Weksberg et al., 1993).  
  
SNRPN (small nuclear ribonucleoprotein-associated polypeptide N) contains multiple 
discrete functional components including SNURF and UBE3A-AS (reviewed by 
Morison et al., 2005). IPW (imprinted in Prader-Willi syndrome) is an untranslated 
RNA (Wevrick et al., 1994) and ATP10C encodes for an aminophospholipid-
transporting ATPase (Meguro et al., 2001). These genes are maternally imprinted and 
located in the PWS and AS critical region on human chromosome 15q11-13 (Figure 
3-1). Loss of imprinting of SNRPN, IPW and ATP10C are closely associated with 
PWS and AS (Meguro et al., 2001; Orstavik et al., 2003; Reis et al., 1994; Sutcliffe et 
al., 1994; Wevrick et al., 1994). Furthermore, NDN and NDNL1, members of the 
MAGE (melanoma antigen) protein family, are also maternally imprinted on human 
chromosome 15q11-13, are potentially involved in PWS and AS (MacDonald and 
Wevrick, 1997). 
 
Figure 3-1. The Prader-Willi syndrome/Angelman syndrome locus 
 
The GNAS1 gene located in human chromosome 20q13 contains multiple discrete 
functional components including NESP55 (neuroendocrine secretory protein 55), 
NESP55AS (NESP55 antisense), XLas (Golgi-specific Gsα isoform), Exon 1A 
(untranslated RNA), and Gsα (G protein alpha-subunit) (Hayward et al., 2001; Liu et 
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al., 2000). Loss of imprinting of Exon 1A and NESP55 is associated with 
Pseudohypoparathyroidism type 1b (PHP-1b). Moreover, loss of imprinting of 
Gsα can be found in Albright hereditary osteodystrophy (AHO) and PHP-1a (Bastepe 
et al., 2005; Hayward et al., 2001; Patten et al., 1990). 
3.1.3.3 Genes related to tissue development and differentiation 
 
TP73 has an important role in the regulation of cell cycle and apoptosis (Kaghad et al., 
1997). CDKN1C encodes for a cyclin-dependent kinase (CDK) inhibitor that plays an 
important role in the regulation of cell cycle (Hatada and Mukai, 1995; Matsuoka et 
al., 1995). PEG10 (paternally expressed gene 10), a retrotransposon-derived gene, 
have an important role in liver regeneration and embryonic development (Okabe et al., 
2003; Tsou et al., 2003). WT1 plays an important role in urogenital development and 
hamatopoietic differentiation (Kreidberg et al., 1993; Park et al., 1993; Pritchard-
Jones et al., 1990). DLK1, which encodes for a cell-surface transmembrane protein 
containing six epidermal growth factor (EGF) repeat motifs, plays an important role in 
the regulation of adipocyte differentiation, and hematopoietic differentiation and 
proliferation (Kawakami et al., 2006; Li et al., 2005a). PEG3 has an important role in 
the regulation of apoptosis mediated by p53, embryonic development and 
differentiation of neuronal cells (Deng and Wu, 2000; Li et al., 1999). NDN and 
NDNL1 have an important role in regulation of neuronal differentiation (Boccaccio et 
al., 1999; Kobayashi et al., 2002). 
3.1.4 Allele-specific expression in human oocytes and embryos 
 
Although allele-specific expression of imprinted genes has been extensively studied in 
mouse oocytes and preimplantation stage embryos, only few studies are available in 
the human. So far, allele-specific expression of 4 imprinted genes has been examined 
in human oocytes and preimplantation stage embryos. IGF2 and SNRPN are 
monoallelically expressed in preimplantation stage embryos (Huntriss et al., 1998; 
Lighten et al., 1997; Salpekar et al., 2001) in association with differential methylation 
at the SNRPN DMR (El-Maarri et al., 2001; Geuns et al., 2003). PEG1 is 
monoallelically expressed in preimplantation stage embryos (Monk and Salpekar, 
2001) that is associated with differential DNA methylation at the PEG1 DMR 
(Kerjean et al., 2000; Sato et al., 2007). However, XIST is expressed from both 
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parental alleles in human oocytes and preimplantation embryos (Daniels et al., 1997; 
Ray et al., 1997). Monoallelic DNA methylation at KvDMR1 (Geuns et al., 2007b; 
Khoureiry et al., 2008), H19 (Kerjean et al., 2000; Sato et al., 2007), ZAC (Sato et al., 
2007), GTL2 (Geuns et al., 2007a) DMRs has been reported in human oocytes and 
preimplantation stage embryos, implicating that their corresponding genes could be 
monoallelically expressed.  
3.1.5 Allele-specific expression in human embryonic germ cell lines 
 
The allele-specific expression of H19, TSSC5, SNRPN and IGF2 has been examined 
in human embryonic germ (hEG) cell lines (LV.EB, SL.RC, EU.EE, SD.EP and 
SD.EC) derived from primordial germ cells (PGCs) isolated from the developing 
gonadal ridges and mesenteries of 5- to 9- weeks embryos (Onyango et al., 2002; 
Shamblott et al., 1998). All genes are monoallelic or predominant monoallelic 
expressed in 1 to 2 informative lines (see Table 3-1). In detail, TSSC5 is 
monoallelically expressed in LV.EB (Onyango et al., 2002). H19 is monoallelically 
expressed in SD.EP and SD.EC lines that is associated with differential methylation at 
the H19 DMR (Onyango et al., 2002). SNRPN is monoallelically expressed in SL.RC. 
Predominant monoallelic expression of IGF2 is observed in two cell lines, LV.EB and 
SL.RC, showing an allele ratio of 4:1 or 5:1. Thus, Onyango et al., (2002) has 
suggested hEG cell lines have stable imprinting status that may not be a significant 
barrier to hEG used in human therapeutic applications. 
3.1.6 Allele-specific expression in human embryonic stem cell lines 
 
The allele-specific expression of imprinted genes has been reported in human 
embryonic stem cell lines (Mitalipov, 2006; Plaia et al., 2006; Rugg-Gunn et al., 2005; 
Sun et al., 2006). Rugg-Gunn et al., (2005) has examined the allele-specific 
expression of 6 imprinted genes (IGF2, IPW, KCNQ1OT1, H19, TSSC5 and NESP55) 
in 1 to 3 informative cell lines (total 4 cell lines examined; hSF-6, H9, H7 and HES-3) 
with a wide range of passages (passages from 42 to 155; see Table 3-1). Sun et al., 
(2006) has examined the allele-specific expression of 4 imprinted genes (H19, 
KCNQ1, NDNL1 and PEG10) in sHhES-1 and HUES-7 cell lines at passages 21 to 62 
(see Table 3-1). Mitalipov et al. (2006) has examined the allele-specific expression of 
H19 and IGF2 in BGN2 and H1. All genes studied are monoallelically or predominaly 
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monoreallically expressed in all cell lines examined (Mitalipov, 2006; Plaia et al., 
2006; Rugg-Gunn et al., 2005; Sun et al., 2006). 
 
In contrast to data from other mammalian ESC lines previously shown to exhibit 
imprinting errors (Dean et al., 1998; Feil et al., 1997; Fujimoto et al., 2006; 
Humpherys et al., 2001; Mitalipov et al., 2007; Mitalipov, 2006), hESC lines possess 
a substantial degree of imprinting stability (Mitalipov, 2006; Plaia et al., 2006; Rugg-
Gunn et al., 2005; Sun et al., 2006). However, there are limitations in human hESC 
studies that preclude the general conclusion of imprint stability in hESC lines. 
Because over 400 hESC lines have been currently established, the few cell lines (total 
9 cell lines) examined can not be extrapolated to generalise the imprinting status of all 
hESC lines. Within 9 cell lines, only one or two cell lines are informative for 
imprinted genes (Table 3-1) that is also difficult to generalise ‘normal’ imprinting 
status in hESC lines. Moreover, although ~ 50 imprinted genes have been identified in 
the human (Morison et al., 2005), only few imprinted genes are employed to 
determine imprinting stability of hESC lines (Table 3-1) 
3.1.7 Chapter aims 
 
The overall aim of this chapter is to perform the most comprehensive assessment to 
date of allele specific expression of 22 imprinted genes and 3 non-imprinted genes in 
22 hESC lines, because imprinting disruptions in hESCs may induce spontaneous 
differentiation, prevent from in vitro and in vivo differentiation into a specific lineage, 
and form a certain type of cancers that are not acceptable for human safe 
transplantation (Allegrucci et al., 2004). 
 
22 human imprinted genes were selected in this Chapter (see Table 3-2), because they 
are functionally known to be important for early embryonic development and 
differentiation, or to be closely associated with several human congenital disorders 
and tumours (see section 1.3.5 and 3.1.3).  
 
In total, 22 hESC lines are examined in this Chapter (see Table 2-1). 16 HUES-lines 
were derived from the Harvard University and cultured (on MEFs with trypsin 
passage) under same protocols and materials, and passage numbers are similar (from 
26 to 37) (Cowan et al., 2004). Additional 6 cell lines (BG01, H1, NOTT1, NOT2, 
HES-2 and NL-HES-1) were independently derived from five different laboratories 
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and cultured in various culture conditions and methods (Allegrucci et al., 2007; 
Burridge et al., 2007; Mitalipova et al., 2003; Reubinoff et al., 2000; Thomson et al., 
1998; van de Stolpe et al., 2005). Their passage numbers were variable from 25 to 45. 
(Allegrucci et al., 2007; Burridge et al., 2007; Mitalipova et al., 2003; Reubinoff et al., 
2000; Thomson et al., 1998; van de Stolpe et al., 2005).  
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Table 3-1. Imprinting status of mammalian embryonic stem cell lines 
Imprinted genes 
Species Cell line 
PEG10 IGF2 H19 KCNQ1 KCN1OT1 TSSC5 NDN NDNL1 DLK1 SNRPN IPW NESP55 U2AF1-RS1 IGF2R 
Reference 
LV.EB - PM - - - M - -  - - - - - 
SL.RC - PM - - - - - -  M - - - - 
EU.EE - - - - - - - -  - - - - - 
SD.EP - - M - - - - -  - - - - - 
EG 
SD.EC - - M - - - - -  - - - - - 
(Onyango et al., 
2002) 
hSF-6 - M (p49~p86) - - - - - -  - M (p49~p86) - - - 
H9 - - M (p42 ~p62)          PM, B (p66~p101) - M (p58~p96) - - -  - M (p61~p87) - - - 
H7 - - M (p58~p155) - M (p58~p155) PM (p58~p155) - -  - - - - - 
HES-3 - - M (p92~p101) - - - - -  - - M, PM (p92~p101) -  
SHhES-1 M (p21~p47) - M (p24~p47) M (p24~p47) - - - M (p24~p62)  - - - - - 
HUES7 M (p21~p47) - M (p21~p47) - - - - -  - - - - - 
BGN2 - - M - - - - -  - - - - - 
H1 - PM - - - - - -  - - - - - 
Human 
ES 
BG01V - - M - - - - - M M - - - - 
(Mitalipov, 2006; 
Plaia et al., 2006; 
Rugg-Gunn et al., 
2005; Sun et al., 
2006) 
ORMES-1 - B - - - - - - - M - - - - 
ORMES-3 - B - - - - - - - - - - - - 
ORMES-5 - B M - - - - - - - - - - - 
ORMES-6 - B B - - - M - - M - - - - 
ORMES-7 - B - - - - M - - M - - - - 
ORMES-8 - B B - - - M - - M - - - - 
Primate ES 
ORMES-10 - B B - - - M - - - - - - - 
(Fujimoto et al., 
2006) 
SF-1-1 - PM PM - - - - - - - - - PM B 
SF-1-3 - PM PM - - - - - - - - - PM B 
SF-1-8 - PM PM - - - - - - - - - PM B 
Mouse ES 
SF-1-G - M M - - - - - - - - - M B 
(Dean et al., 
1998) 
M, monoallelic expression; PM, predominant monoallelic expression; B, biallelic expression; passage number in parenthesises
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3.2 Results 
 
To investigate the allele-specific expression of 22 imprinted genes and 3 non-
imprinted genes (see Table 3-2), PCR-RFLP and direct sequencing were performed, 
according to previous publications described in Table 2-4. 
 
Table 3-2. Imprinted genes and none-imprinted genes used in this 
chapter 
Location Gene Imprinting Expressed 
allele Protein name or description 
Accession 
number 
1p36.33 TP73 I Maternal Tumour related protein NM_005427 
SLC22A1 PD or NR - Organic cation transporter NM_003057 
6q25.3 
IGF2R PI Biallelic Insulin-like growth factor 2 receptor NM_000876 
7q21 PEG10 I Paternal Retroviral gag pol homologue XM_496907 
PEG1 I Paternal Alpha/β hydrolase fold family NM_015068 
7q32 
MESTIT1 I Paternal - AF482998 
11p13 WT1 I Paternal Zinc finger protein AY245105 
NAPIL4 NI Biallelic Nucleosome assembly protein NM_005969 
PHLDA2 PD Maternal Pleckstrin homology-like domain AF019953 
SLC22A18 I Maternal Organic cation transporter AF059663 
CDKN1C I Maternal Cyclin-dependent kinase inhibitor NM_000076 
KCNQ1OT1 I Paternal - AJ0006345 
KCNQ1 I Maternal Voltage-gated potassium channel BC111847 
TSSC4 NI Biallelic Tumor suppressing candidate AF125568 
IGF2 I Paternal Insulin-like growth factor 2 X07868 
11p15.5 
H19 I Maternal - AF087017 
DLK1 I Paternal Delta-like 1 homolog NM_003836 
14q32 
GTL2 I Maternal Gene trap locus 2 AL117190 
NDN I Paternal Necdin, neuronal growth suppressor U35139 
NDNL1 I Paternal MAGE-like protein NM_019066 
SNRPN I Paternal Small nuclear ribonucleoprotein NM_022806 
IPW I Paternal - U12897 
15q11-
q13 
ATP10C I Maternal ATPase, Class V AH010630 
19q13.4 PEG3 I Paternal Zinc-finger protein NM_006210 
20q13.2 NESP55 I Maternal Neuroendocrine secretory protein 55 M21741 
Abbreviations: I, imprinted; NI, not imprinted; PI, polymorphic imprinting; PD, 
provisional data, NR, no reports of imprinting status, Adopted from Morison et al., 
(2005). 
3.2.1 TP73 
 
The allele-specific expression of TP73 was analysed by a StyI polymorphism (Mai et 
al., 1998a). 9 informative cell lines (HUES1, HUES6, HUES7, HUES8, HUES10, 
HUES16, HES-2, NOTT2 and NTERA2) were identified by genotyping after genomic 
PCR amplification, followed by StyI digestion (Figure 3-1 A). The allelic specific 
expression of TP73 in 9 cell lines was determined by RT-PCR, followed by StyI 
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digestion (Figure 3-1 B). Biallelic expression of TP73 was detected in all informative 
cell lines, indicating an allele ratio of less than 3:1 of the two alleles. The biallelic 
expression of TP73 was maintained during in vitro prolonged culture of HES-2 
(passages 56, 65 and 96). 
 
Figure 3-2. TP73 imprinting in hESC lines  
(A) Genotyping. PCR amplification with genomic DNA of each cell line, followed by 
StyI digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
was carried out, followed by StyI digestion. 50bp DNA ladder is denoted as the letter, 
M. Digestion with StyI is indicated +, digested and -, not digested. The letter, N 
indicates a negative control of RT-PCR. 
3.2.2 IGF2R 
 
The allele-specific expression of IGF2R was analysed by both an AclI polymorphism 
located in the promoter region and a MscI polymorphism located in the intronic DMR 
(Vu et al., 2004). 12 informative cell lines (HUES1, HUES2, HUES3, HUES4, 
HUES5, HUES12, HUES13, HUES14, BG01, HESC-NL1, NOTT2 and H1) for an 
AclI polymorphism and 3 informative cell lines (HUES5, HUES9 and HES-2) for a 
MscI polymorphism were identified by PCR-RFLP (Figure 3-2 A and C). Of these 
informative cell lines examined, all cell lines showed biallelic expression, indicating 
an allele ratio of less than 3:1 of the two alleles (Figure 3-2 B and D). The biallelic 
expression retained during in vitro prolonged culture of HESC-NL1 (passages 22 and 
58) and HES-2 (passages 56 and 96). 
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Figure 3-3. IGF2R imprinting in hESC lines  
(A) Genotyping for an AclI polymorphism. (B) Allele-specific expression of IGF2R 
for an Acl I polymorphism (C) Genotyping for a MscI polymorphism. (D) Allele-
specific expression of IGF2R for a MscI polymorphism. (A and C) PCR amplification 
with genomic DNA of each cell line, followed by AclI and MscI digestion respectively 
distinguished between homozygous and heterozygous genotypes. (B and D) RT-PCR 
with cDNA of informative heterozygous cell lines, followed by AclI and MscI 
digestion respectively. 50bp DNA ladder is denoted by the letter, M. Digestion with 
AclI or MscI is indicated +, digested and -, not digested. The letter, N indicates 
negative control of RT-PCR. 
3.2.3 PEG10 
 
The allele-specific expression of PEG10 was examined by a C/T polymorphism 
located in exon 12 (Sun et al., 2006). Of 4 informative cell lines (HUES5, HUES7, 
HUES10 and HUES12) examined, 3 showed monoallelic expression, indicated by 
only either the C or T allele at a polymorphic site (Figure 3-3 A and B). However, in 
HUES5, PEG10 was biallelically expressed, indicated by both C and T peaks at a 
polymorphic site (Figure 3-3 B). 
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Figure 3-4. PEG10 imprinting in hESC lines  
(A) Genotyping. Chromatograms distinguished genotypes after PCR amplification of 
each cell line followed by direct sequencing. (B) Allele-specific expression. RT-PCR 
with cDNA of informative heterozygous cell lines, followed by direct sequencing. A 
circle indicates a polymorphic site.  
3.2.4 PEG1 (MEST) 
 
The isoform-specific imprinting of PEG1 was examined by direct sequencing (Kosaki 
et al., 2000; Nakabayashi et al., 2002). 13 informative cell lines (HUES1, HUES2, 
HUES7, HUES10, HUES12, HUES15, HUES16, HUES17, BG01, NTERA2, HES-2, 
NOTT1 and NOTT2) were identified by a G/C polymorphism located in exon 12 of 
PEG1 (Figure 3-4 A). Of 13 cell lines examined, 10 cell lines showed monoallelic 
expression and 1 cell line (HUES10) showed predominant monoallelic expression 
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indicated by a higher G peak than a C peak at a polymorphic site. NOTT2 and 
NTERA2 showed biallelic expression indicated by both G and C peaks at a 
polymorphic site (Figure 3-4 B). PEG1 isoform 2 was expressed from two alleles in 
10 of 13 informative cell lines examined (Figure 3-4 C). However, it was 
predominantly monoallelically expressed in HUES16 indicated by a higher C peak 
than a G peak at a G/C polymorphic site. NOTT1 and NTERA2 showed monoallelic 
expression indicated by only either the C or G allele at a polymorphic site (Figure 3-4 
C). Isoform-specific imprinting status of PEG1 persisted during in vitro prolonged 
culture of HES-2 (passages 56, 65 and 96) (Figure 3-4 B and C). 
3.2.5 MESTIT1 (PEG1-AS) 
 
The allele-specific expression of MESTIT1 was examined by a G/A polymorphism 
located in exon 2 of MESTIT1 (Nakabayashi et al., 2002). 12 informative cell lines 
(HUES2, HUES4, HUES7, HUES9, HUES10, HUES12, HUES15, HUES16, 
HUES17, HES-2, NOTT1 and NOTT2) were identified by genotyping (Figure 3-5 A). 
Of 12 informative cell lines examined, 9 cell lines showed monoallelic expression and 
2 cell lines (HUES12 and NOTT1) showed predominantly monoallelic expression. 
However, MESTIT1 was biallelically expressed in HUES15, indicated by both G and 
A peaks at a polymorphic site (Figure 3-5 B). 
3.2.6 WT1 
 
The allele-specific expression of WT1 was determined by a HinfI polymorphism 
located in exon 1 of WT1 (Mitsuya et al., 1997). 6 cell lines (HUES2, HUES3, HUES5, 
HUES8, HUES9 and BG01) were informative (Figure 3-6 A). Of 6 cell lines 
examined, all cell lines showed biallelic expression, indicating an allele ratio of less 
than 3:1 of the two alleles (Figure 3-6 B). 
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Figure 3-5. PEG1 imprinting in hESC lines  
(A) Genotyping. Chromatograms distinguished genotypes after PCR amplification of 
each cell line followed by direct sequencing (B) Allele-specific expression of PEG1 
isoform 1. (C) Allele-specific expression of PEG1 isoform 2. (B and C) RT-PCR with 
cDNA of informative heterozygous cell lines, followed by direct sequencing. A circle 
indicates a polymorphic site.  
3.2.7 H19 
 
The allele-specific expression of H19 was determined by both AluI and RsaI 
polymorphisms (Hashimoto et al., 1995; Morison et al., 2000). 11 informative cell 
lines (HUES1, HUES3, HUES5, HUES7, HUES9, HUES10, HUES14, HUES15, 
HES-2, NOTT1 and NOTT2) for a AluI polymorphism and 13 informative cell lines 
(HUES1, HUES3, HUES4, HUES5, HUES7, HUES9, HUES10, HUES14, HUES15, 
BG01, HES-2, NOTT1 and NOTT2) for a RsaI polymorphism were identified by 
PCR-RFLP (Figure 3-7 A). Of all informative cell lines examined, most cell lines 
sowed monoallelic expresion, except for NOTT2 and HES-2. NOTT2 and HES-2 
showed biallelic expression (an allele ratio from 1.8:1 to 2.8:1) at both polymorphic 
sites (Figure 3-7 B). Biallelic expression of H19 persisted during in vitro prolonged 
culture of HES-2 (passages 65 and 96). 
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Figure 3-6. MEST1OT1 imprinting in hESC lines  
(A) Genotyping. Chromatograms distinguished genotypes after PCR amplification of 
each cell line followed by direct sequencing. (B) Allele-specific expression. RT-PCR 
with cDNA of informative heterozygous cell lines followed by direct sequencing. A 
circle indicates a polymorphic site.  
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Figure 3-7. WT1 imprinting in hESC lines 
 (A) Genotyping. PCR amplification with genomic DNA of each cell line followed by 
HifI digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by HifI digestion. 50bp DNA ladder is denoted by the letter, M. Digestion 
with HifI is indicated +, digested and -, not digested. The letter, N indicates a negative 
control of RT-PCR. 
3.2.8 IGF2 
 
The allele-specific expression of IGF2 was determined by an ApaI polymorphism 
located in exon 9 (Hashimoto et al., 1995; Onyango et al., 2002). 10 cell lines 
(HUES1, HUES5, HUES6, HUES8, HUES9, HUES16, HUES17, HESC-NL1, HES-2 
and NOTT2) were informative (Figure 3-8 A). Of 10 cell lines examined, 9 cell lines 
showed biallelic expression, indicating an allele ratio of less than 3:1 of the two alleles. 
However, HUES9 showed predominant monoallelic expression (an allele ratio 3.7:1) 
(Figure 3-8 B). The biallelic expression of IGF2 persisted during in vitro prolonged 
culture of HES-2 (passages 56, 65 and 96). 
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Figure 3-8. H19 imprinting in hESC lines  
(A) Genotyping for a H19 AluI polymorphism. (B) Allele-specific expression of H19 
AluI RFLP. (C) Genotyping for a H19 RsaI polymorphism. (D) Allele-specific 
expression of H19 RsaI RFLP. (A and C) PCR amplification with genomic DNA of 
each cell line followed by AluI and RsaI digestion distinguished between 
heterozygous and homozygous cell line. (B and D) RT-PCR with cDNA of 
informative heterozygous cell lines followed by AluI and RsaI digestion. 50bp DNA 
ladder is denoted by the letter, M. Digestion with AluI and RsaI is indicated +, 
digested and -, not digested. The letter, N indicates negative control of RT-PCR. 
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Figure 3-9. IGF2 imprinting in hESC lines  
(A) Genotyping. PCR amplification with genomic DNA of each cell line followed by 
ApaI digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by ApaI digestion. 50bp DNA ladder is denoted by the letter, M. Digestion 
with ApaI is indicated +, digested and -, not digested. The letter, N indicates a 
negative control of RT-PCR. 
3.2.9 KCNQ1 (KvLQT1) 
 
The allele-specific expression of KCNQ1 was determined by a G/A polymorphism 
(Sun et al., 2006). 8 informative cell lines (HUES1, HUES2, HUES6, HUES8, 
HUES9, HUES12, HUES13 and NOTT1) were identified by direct sequencing 
(Figure 3-9 A). Of 8 cell lines examined, all cell lines showed monoallelic expression, 
indicated by either G or A allele at a polymorphic site (Figure 3-9 B). 
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Figure 3-10. KCNQ1 imprinting in hESC lines  
(A) Genotyping at the G/A polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
3.2.10 KCNQ1OT1 (LIT1) 
 
The allele-specific expression of KCNQ1OT1 was examined by two G/A and C/T 
polymorphisms (Lee et al., 1999). 12 cell lines (HUES1, HUES2, HUES7, HUES8, 
HUES9, HUES10, HUES12, HUES13, HUES17, H1, BG01 and HES-2) were 
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informative for a G/A polymorphism (Figure 3-10 A). Other 12 cell lines (HUES2, 
HUES4, HUES7, HUES9, HUES10, HUES14, HUES15, HUES16, HUES17, BG01, 
HESC-NL1 and HES-2) were informative for a C/T polymorphism (Figure 3-11 A). 
Of all informative cell lines examined, all showed monoallelic expression (Figure 3-
10 B and 3-11 B). Monoallelic expression of KCNQ1OT1 is maintained during in 
vitro prolonged culture of HESC-NL1 (passages 22 and 58) and HES-2 (passages 56, 
65 and 96). 
3.2.11 CDKN1C (p57KIP2) 
 
The allele-specific expression of CDKN1C was examined by a G/A polymorphism of 
CDKN1C (Monk et al., 2006a). Of 3 informative cell lines (HUES04, HUES14 and 
HUES15) identified by direct sequencing (Figure 3-12 A), all showed predominantly 
monoallelically expression (Figure 3-12 B). 
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Figure 3-11. KCNQ1OT1 imprinting in hESC lines (G/A polymorphism)  
(A) Genotyping at the G/A polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing.  (B) Allele-
specific expression of KCNQ1OT1 at the G/A polymorphism. RT-PCR with cDNA of 
informative heterozygous cell lines followed by direct sequencing. A circle indicates a 
polymorphic site.  
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Figure 3-12. KCNQ1OT1 imprinting in hESC lines (C/T polymorphism) 
 (A) Genotyping at the C/T polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
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Figure 3-13 CDKN1C imprinting in hESC lines  
(A) Genotyping at the G/A polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site. 
3.2.12 PHLDA2 (TSSC3/IPL) 
 
The allele-specific expression of PHLDA2 was examined by a T/C polymorphism 
(Qian et al., 1997). 10 informative cell lines (HUES1, HUES2, HUES4, HUES5, 
HUES8, HUES14, HUES15, HUES16, HUES17 and HESC-NL1) were identified by 
direct sequencing (Figure 3-13 A). Of 10 cell lines examined, 4 cell lines (HUES1, 
HUES2, HUES8 and HESC-NL1) showed predominantly monoallelic expression but 
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6 cell lines (HUES4, HUES5, HUES14, HUES15, HUES16 and HUES17) showed 
biallelic expresion (Figure 3-13 B). 
 
Figure 3-14. PHLDA2 imprinting in hESC lines  
(A) Genotyping at the T/C polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
3.2.13 SLC22A18 (TSSC5) 
 
The allele-specific expression of SLC22A18 was examined by a G/C polymorphism 
located in exon 11 (Onyango et al., 2002). 7 informative cell lines (HUES5, HUES12, 
HUES13, HUES14, HUES15, HESC-NL1 and NOTT2) were identified by direct 
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sequencing (Figure 3-14 A). Of 7 cell lines examined, all showed biallelic expression, 
indicated by both G and C peaks at a polymorphic site (Figure 3-14B). 
 
Figure 3-15. SLC22A18 imprinting in hESC lines  
(A) Genotyping at the G/C polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
3.2.14 DLK1 (PEG9) 
 
The allele-specific expression of DLK1 was determined by a C/T polymorphism 
located in the 3’ UTR region (Kobayashi et al., 2000). By direct sequencing, no 
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informative cell lines were identified, showing all homozygous types, T/T (Figure 3-
15). Thus, the allele-specific expression of this gene could not be determined. 
 
Figure 3-16. DLK1 imprinting in hESC lines  
Chromatograms showed all T/T genotypes in the hESC line and NTERA2 after PCR 
amplification, followed by direct sequencing. A circle indicates a polymorphic site.  
3.2.15 GTL2 (MEG3) 
 
The allele-specific expression of GTL2 was determined by an A/G polymorphism 
located in exon 5 of GTL2 (Wylie et al., 2000). 11 cell lines (HUES3, HUES7, 
HUES10, HUES12, HUES13, HUES14, HUES15, HUES17, HESC-NL1 and 
NOTT1) were informative (Figure 3-16 A). Of 10 cell lines examined, 8 cell lines 
showed monoallelic expression, 1 cell line (HUES14) showed predominant 
monoallelic expression, and 1 cell line (HUES15) showed biallelic expression (Figure 
3-16 B). 
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Figure 3-17. GTL2 imprinting in hESC lines  
(A) Genotyping at the A/G polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing.  (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
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3.2.16 NDN 
 
The allele-specific expression of NDN was examined by a MboI polymorphism 
(MacDonald and Wevrick, 1997). 7 cell lines (HUES4, HUES8, HUES15, HUES17, 
BG01, NOTT2 and H1) were informative, as determined by PCR-RFLP (Figure 3-17 
A). Of 7 cell lines examined, all showed monoallelic expression (Figure 3-17 B). 
 
Figure 3-18. NDN imprinting in hESC lines  
(A) Genotyping. PCR amplification with genomic DNA of each cell line followed by 
MboI digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by MboI digestion. 50bp DNA ladder is denoted by the letter, M. Digestion 
with MboI is indicated +, digested and -, not digested. The letter, N indicates a 
negative control of RT-PCR. 
3.2.17 NDNL1 (MAGEL2) 
 
The allele-specific expression of NDNL1 was determined by a C/A polymorphism 
(Sun et al., 2006). Only HUES9 was identified as an informative cell line (Figure 3-18 
A). In this cell line, NDNL1 was monoallelically expressed, indicated by only A peak 
at a polymorphic site (Figure 3-18 B). 
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Figure 3-19. NDNL1 imprinting in hESC lines  
(A) Genotyping at the C/A polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
3.2.18 SNRPN 
 
The allele-specific expression of SNRPN was determined by a BstUI polymorphism 
located in the 5’UTR of exon 2 (Morison et al., 2000). 11 cell lines (HUES3, HUES4, 
HUES5, HUES6, HUES7, HUES10, HUES12, HUES17, BG01, NOTT1, NOTT2 and 
H1) were identified as informative cell lines (Figure 3-19 A). Of 11 cell lines 
examined, SNRPN was monoallelically expressed in all cell lines (Figure 3-19 B). To 
identify the possibility of PCR and restriction enzyme bias, monoallic expression of 
SNRPN was confirmed by direct sequencing (Figure 3-19 C). 
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Figure 3-20. SNRPN imprinting in hESC lines 
(A) Genotyping. PCR amplification with genomic DNA of each cell line followed by 
BstUI digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by BstUI digestion. 50bp DNA ladder is denoted by the letter, M. Digestion 
with BstUI is indicated +, digested and -, not digested. The letter, N indicates a 
negative control of RT-PCR. (C) SNRPN imprinting confirmed by direct sequencing. 
RT-PCR with cDNA of informative heterozygous cell lines followed by direct 
sequencing. A circle indicates a polymorphic site.  
3.2.19 IPW 
 
The allele-specific expression of IPW was determined by a HphI polymorphism 
located in exon 3 (Wevrick et al., 1994). 12 cell lines (HUES1, HUES3, HUES6, 
HUES7, HUES10, HUES12, HUES15, HUES17, BG01, HESC-NL1, HES-2 and 
NOTT2) were informative (Figure 3-20 A). Of 12 cell lines examined, 11 cell lines 
showed monoallelic expression and 1 cell line (HUES10) showed predominant 
monoallelic expression (Figure 3-20 B). The monoallelic expression of IPW was 
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stably maintained during in vitro prolonged culture of HESC-NL1 (passages 22 and 
58), HES-2 (passages 56, 65 and 96) and NOTT2 (passages 14, 26 and 32). 
 
Figure 3-21. IPW imprinting in hESC lines  
(A) Genotyping. PCR amplification with genomic DNA of each cell line followed by 
HphI digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by HphI digestion. 50bp DNA ladder is denoted by the letter, M. Digestion 
with HphI is indicated +, digested and -, not digested. The letter, N indicates a 
negative control of RT-PCR. 
3.2.20 ATP10C (ATP10A) 
 
The allele-specific expression of ATP10C was determined by an AvaII polymorphism 
(Meguro et al., 2001). 12 informative cell lines (HUES2, HUES5, HUES6, HUES7, 
HUES10, HUES15, HUES16, HUES17, HESC-NL1, NOTT1, NOTT2 and NTERA2) 
were identified by PCR-RFLP (Figure 3-21 A). Of 12 cell lines examined, 8 cell lines 
showed biallelic expression (an allelic ratio from 1.0:1 to 1.7:1), 2 cell lines (HUES6 
and HUES16) showed predominant monoallelic expression (each allelic ratio, 5.0:1 
and 6.6:1), and 2 cell lines (HUES5 and HUES7) showed monoallelic expression. The 
biallelic expression of ATP10C was maintained during in vitro prolonged culture of 
HL-HESC-1 (passages 22 and 58) and NOTT1 (passages 25 and 29). 
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Figure 3-22. ATP10C imprinting in hESC lines  
(A) Genotyping. PCR amplification with genomic DNA of each cell line followed by 
AvaII digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by AvaII digestion. 50bp DNA ladder is denoted by the letter, M. Digestion 
with AvaII is indicated +, digested and -, not digested. The letter, N indicates a 
negative control of RT-PCR. 
3.2.21 PEG3 (ZIM2) 
 
The allele-specific expression of PEG3 was determined by a MnlI polymorphism 
located in exon 9 (Dowdy et al., 2005). 6 cell lines (HUES4, HUES6, BG01, HESC-
NL1, NOTT2 and NTERA22) were informative (Figure 3-22 A). Of 6 cell lines 
examined, 5 cell lines showed monoallelic expression but one cell line (NTERA2) 
showed biallelic expression (Figure 3-22 B). 
 
Figure 3-23. PEG3 imprinting in hESC lines  
(A) Genotyping. PCR amplification with genomic DNA of each cell line followed by 
MnlI digestion distinguished between heterozygous and homozygous cell line. (B) 
Allele-specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by MnlI digestion. 50bp DNA ladder is denoted by the letter, M. Digestion 
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with MnlI is indicated +, digested and -, not digested. The letter, N indicates a 
negative control of RT-PCR. 
3.2.22 NESP55 
 
The allele-specific expression of NESP55 was examined by a T/C polymorphism 
(Rugg-Gunn et al., 2005). 9 cell lines (HUES1, HUES4, HUES5, HUES9, HUES12, 
HUES14, HUES15, BG01 and HESC-NL1) were informative (Figure 3-23 A). Of 9 
cell lines examined, 8 cell lines showed monoallelic expression, and one cell line 
(HUES5) showed biallelic expression, indicated by both C and T peaks at a 
polymorphic site (Figure 3-23 B). The monoallelic expression of NESP55 is 
maintained during in vitro prolonged culture of HESC-NL1 (passage 22 to 58). 
3.2.23 SLC22A1 
 
The allele-specific expression of SLC22A1 was determined by a C/T polymorphism 
(Monk et al., 2006a). 9 cell lines (HUES1, HUES7, HUES10, HUES13, HUES16, 
HUES17, H1, HESC-NL1 and HES-2) were informative (Figure 3-24 A). Of 9 cell 
lines examined, 4 cell lines (HUES1, HUES10, HUES13 and HES-2) showed 
monoallelic expression, 2 cell lines (HUES16 and HUES17) showed predominant 
monoallelic expression, and 2 cell lines (BG01 and HUES7) showed biallelic 
expression (Figure 3-24 B). 
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Figure 3-24. NESP55 imprinting in hESC lines  
(A) Genotyping at the T/C polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
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Figure 3-25. SLC22A1 imprinting in hESC lines  
(A) Genotyping at the C/T polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
3.2.24 TSSC4 
 
The allele-specific expression of TSSC4 was examined by a G/A polymorphism. 3 
informative cell lines (HUES16, HUES17 and H1) were identified by direct 
sequencing (Figure 3-25 A). Of 3 cell lines examined, all showed biallelic expression 
(Figure 3-25 B). 
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Figure 3-26. TSSC4 imprinting in hESC lines  
(A) Genotyping at the G/A polymorphic site. Chromatograms distinguished genotypes 
after PCR amplification of each cell line followed by direct sequencing. (B) Allele-
specific expression. RT-PCR with cDNA of informative heterozygous cell lines 
followed by direct sequencing. A circle indicates a polymorphic site.  
3.2.25 NAPIL4 
 
The allele-specific expression of NAPIL4 was determined by a G/C polymorphism 
(Monk et al., 2006a). 9 informative cell lines (HUES1, HUES2, HUES4, HUES5, 
HUES6, HUES12, HUES13, H1 and HES-2) were identified (Figure 3-26 A), Of 9 
cell lines examined, all cell lines showed biallelic expression. 
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Figure 3-27. NAPIL4 imprinting in hESC lines  
(A) Genotyping. Chromatograms distinguished genotypes after PCR amplification of 
each cell line followed by direct sequencing. (B) Allele-specific expression. RT-PCR 
with cDNA of informative heterozygous cell lines followed by direct sequencing. A 
circle indicates a polymorphic site.  
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Table 3-3. Summary of genotyping and allele-specific expression of human embryonic stem cell lines 
Cell line 
Loci Gene Polymorphism 
and DNA 
HUES1 HUES2 HUES3 HUES4 HUES5 HUES6 HUES7 HUES8 HUES9 HUES10 HUES12 HUES13 HUES14 HUES15 HUES16 HUES17 BG01 H1 HESC-NL1 HES-2 NOTT1 NOTT2 NTERA2 
gDNA A/B B/B B/B B/B B/B A/B A/B A/B B/B A/B B/B B/B B/B B/B A/B B/B B/B B/B B/B A/B B/B A/B A/B 
1p36.33 TP73 StyI 
cDNA A/B     A/B A/B A/B  A/B     A/B     A/B  A/B A/B 
gDNA C/T T/T C/C T/T T/T T/T C/T T/T T/T C/T T/T C/T T/T T/T C/T C/T T/T C/T C/T C/T T/T T/T T/T 
SLC22A1 C/T 
cDNA C/-      C/T   -/T  -/T   C>T C>T  C/- C/T C/-    
gDNA A/B A/B A/B A/B A/B A/A A/A B/B B/B A/A A/B A/B A/B A/A A/A A/A A/B A/B A/B B/B B/B A/B B/B 
AclI 
cDNA A/B A/B A/B A/B A/B      A/B A/B A/B    A/B A/B A/B   A/B  
gDNA A/A A/A A/A A/A A/B A/A A/A A/A A/B A/A A/A A/A A/A A/A A/A A/A A/A A/A A/A A/B A/A A/A A/A 
6q25.3 
IGF2R 
MscI 
cDNA     A/B    A/B           A/B    
gDNA C/C C/C C/C C/C C/T C/C C/T C/C C/C C/T C/T C/C C/C C/C C/C C/C C/C C/C T/T C/C C/C C/C C/C 
7q21 PEG10 C/T 
cDNA     C/T  -/T   -/T C/-             
gDNA G/C G/C G/G G/G C/C C/C G/C G/G G/G G/C G/C G/G C/C G/C G/C G/C G/C C/C C/C G/C G/C G/C G/C 
cDNA1 -/C G/-     G/-   G>C -/C   -/C -/C -/C G/-   G/- -/C G/C G/C PEG1 G/C 
cDNA2 G/C G/C     G/C   G/C G/C   G/C G<C G/C G/C   G/C -/C G/C G/- 
gDNA G/G G/A G/G G/A A/A A/A G/A G/G G/A G/A G/A G/G A/A G/A G/A G/A G/G A/A A/A G/A G/A G/A G/A 
7q32 
MEST1OT1 G/A 
cDNA  G/-  G/-   -/A  G/- G/- G<A   G/A -/A -/A    G/- G<A G/- ND 
gDNA B/B A/B A/B B/B A/B B/B A/A A/B A/B A/A A/A A/A B/B B/B B/B B/B A/B B/B B/B A/A A/A A/B B/B 
11p13 WT1 HinfI 
cDNA  A/B A/B  A/B   A/B A/B        A/B     ND  
gDNA G/C G/C G/G G/C G/C G/C C/C G/G C/C C/C G/C G/C G/G G/G G/G G/G C/C G/C G/G G/C G/G G/G G/G 
NAPIL4 G/C 
cDNA G/C G/C  G/C G/C G/C     G/C G/C      G/C  G/C    
gDNA C/T C/T T/T C/T C/T T/T T/T C/T T/T T/T T/T T/T C/T C/T C/T C/T T/T C/C C/T T/T ND C/C T/T 
PHLDA2 C/T 
cDNA C<T C<T  C/T C/T   C<T     C/T C/T C/T C/T   C<T     
gDNA G/G G/G C/C G/G G/C G/G G/G G/G G/G G/G G/C G/C G/C G/C G/G G/G G/G G/G G/C C/C C/C G/C C/C 
SLC22A18 G/C 
cDNA     G/C      G/C G/C G/C G/C     G/C   G/C  
gDNA G/G G/G G/G G/A G/G G/G G/G G/G G/G G/G G/G G/G G/A G/A G/G G/G G/G G/G G/G G/G G/G G/G G/G 
CDKN1C G/A 
cDNA    A>G         A<G A<G          
gDNA G/A G/A G/G G/G A/A A/A G/A G/A G/A G/A G/A G/A A/A A/A G/A G/A G/A G/A G/G G/A A/A A/A A/A 
KCNQIOTI G/A 
cDNA -/A G/-     -/A -/A -/A -/A G/- G/-   ND -/A G/- -/A  G/-    
gDNA G/A G/A G/G A/A G/G G/A G/G G/A G/A G/G G/A G/A G/G G/G G/G G/G G/G G/G G/G G/G G/A A/A G/G 
KCNQ1 G/A 
cDNA G/- -/A    -/A  G/- -/A  G/- G/-         -/A   
gDNA G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/A G/A G/G G/A G/G G/G G/G G/G G/G 
TSSC4 G/A 
cDNA               G/A G/A  G/A      
gDNA A/B A/A A/A A/A A/B A/B A/A A/B A/B A/A A/A A/A A/A A/A A/B A/B A/A A/A A/B A/B A/A A/B B/B 
IGF2 ApaI 
cDNA A/B    A/B A/B  A/B A<B      A/B A/B   A/B A/B  A/B  
gDNA A/B B/B A/B B/B A/B A/A A/B A/A A/B A/B B/B B/B A/B A/B A/A A/A B/B A/A A/A A/B A/B A/B A/A 
AluI 
cDNA -/B  A/-  -/B  -/B  -/B -/B   A/- A/-      A/B -/B A/B  
11p15.5 
H19 
RsaI gDNA A/B B/B A/B A/B A/B A/A A/B A/A A/B A/B B/B B/B A/B A/B A/A A/A A/B A/A A/A A/B A/B A/B A/A 
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cDNA -/B  A/- A/- -/B  -/B  -/B -/B   A/- A/-   -/B   A/B -/B A/B  
gDNA T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T ND T/T T/T T/T T/T T/T T/T 
DLK1 C/T 
cDNA                        
gDNA G/G A/A A/G G/G G/G G/G A/G G/G G/G A/G A/G A/G A/G A/G G/G A/G G/G A/G A/G G/G A/G G/G A/A 
14q32 
GTL2 A/G 
cDNA   -/G    A/-   -/G A/- A/- A>G A/G  -/G  ND A/-  -/G   
gDNA C/C C/C C/C C/C C/C C/C C/C C/C C/A C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C 
NDNL1 C/A 
cDNA         -/A               
gDNA B/B B/B B/B A/B B/B B/B B/B A/B B/B B/B B/B B/B A/A A/B B/B A/B A/B A/B B/B B/B B/B A/B B/B 
NDN MboI 
cDNA    -/B    A/-      -/B  -/B A/- A/-    A/-  
gDNA A/A B/B A/B A/B A/B A/B A/B A/A B/B A/B A/B A/A B/B B/B B/B A/B A/B A/B B/B A/A A/B A/B A/A 
SNRPN BstUI 
cDNA   -/B -/B A/- -/B A/-   A/- -/B     -/B A/- -/B   -/B -/B  
gDNA A/B A/A A/B A/A B/B A/B A/B B/B A/A A/B A/B B/B A/A A/B A/A A/B A/B A/A A/B A/B A/A A/B B/B 
IPW HphI 
cDNA -/B  A/-   A/- A/-   A>B A/-   -/B  A/- -/B  A/- A/-  -/B  
gDNA B/B A/B B/B B/B A/B A/B A/B B/B B/B A/B A/A A/A B/B A/B A/B A/B B/B B/B A/B B/B A/B A/B A/B 
15q11-
q13 
ATP10C AvaII 
cDNA  A/B   A/- A<B A/-   A/B    A/B A>B A/B   A/B  A/B A/B A/B 
gDNA B/B B/B B/B A/B B/B A/B B/B A/A A/A B/B B/B B/B B/B B/B A/A A/A A/B B/B A/B B/B B/B A/B A/B 
19q13.4 PEG3 MnlI 
cDNA    -/B  -/B           A/-  A/-   -/B A/B 
gDNA T/C T/T T/T T/C T/C T/T C/C T/T T/C C/C T/C T/T T/C T/C C/C C/C T/C C/C T/C T/T C/C T/T C/C 
20q13.2 NESP55 C/T 
cDNA -/C   T/- T/C    T/-  T/-  T/- T/-   -/C  -/C     
gDNA e.g. A/B: alleles are informative heterogeneous (A/B); alleles are homogenous wild type (A/A); alleles are homogeneous mutant type 
(B/B). cDNA e.g. A/B: monoallelic expression (A/- or -/B); predominant monoallelic expressions(A<B or A>B); biallelic expression (A/B) 
determined by Cui et al. (1998). a PEG1 isoform 1, b PEG1 isoform 2
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3.3 Discussion 
 
The purpose of this study was to investigate the imprinting stability in 22 in vitro 
cultured hESC lines by analysing the allele-specific expression of 22 imprinted genes 
and 3 non-imprinted genes. Of 23 imprinted genes examined, 9 genes (PEG10, PEG1, 
MESTIT1, IGF2, H19, GLT2, NESP55, PHLDA2 and ATP10C) were variably 
imprinted between hESC lines, whereas other genes showed stable imprinting (Table 
3-3 and 3-4), indicating gene-specific imprinting disruption. Moreover, of 22 hESC 
lines examined, 12 cell lines (HUES1, HUES2, HUES5, HUES6, HUES7, HUES9, 
HUES15, HUES16, HESC-NL1, HES-2, NOTT1 and NOTT2) showed that 
imprinting was disrupted at least one imprinted locus. Thus, in contrast to previous 
studies, which showed imprinting stability in hESC lines (Mitalipov, 2006; Plaia et al., 
2006; Rugg-Gunn et al., 2005; Sun et al., 2006), imprinting instability can be detected 
by increasing the number of cell lines and imprinted genes examined. 
 
Table 3-4. Imprinting stability of human embryonic stem cell lines 
Imprinted gene Monoallelic Partial-
allelic Biallelic 
No. of cell 
lines analysed 
Imprinting 
stability 
KCNQ1OT1 12   12 
NDN 7   7 
NDNL1 1   1 
SNRPN 12   12 
IPW 11 1  12 
PEG3 5   5 
WT1   6 6 
Stable 
PEG10 3  1 4 
PEG1 isoform1 10 1 1 12 
PEG1 isoform2 1 1 10 12 
MESTIT1 9 2 1 12 
IGF2  1 9 10 
Unstable 
Paternally 
expressed 
gene 
DLK1    - - 
KCNQ1 8   8 
CDKN1C  3  3 
TP73   8 8 
IGF2R   14 14 
SLC22A18   7 7 
Stable 
H19 11  2 13 
GTL2 8 1 1 10 
NESP55 8  1 9 
PHLDA2  4 6 10 
Maternally 
expressed 
gene 
ATP10C 2 2 7 11 
Unstable 
NAPIL4   9 9 
TSSC4   3 3 
Stable Non-
imprinted 
gene SLC22A1 5 2 2 9 Variable 
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3.3.1 Genes that are stably imprinted 
 
3.3.1.1 Genes that are monoallelically expressed 
 
8 imprinted genes, NDN, NDNL1, SNRPN, IPW, PEG3, KCNQ1, KCNQ1OT1 and 
CDKN1C, were identified to be monoallelically expressed in all informative hESC 
lines, indicating that the genes are stably imprinted and maintained upon in vitro 
culture. This concurred with the imprinting stability previously observed for SNRPN, 
IPW, NDNL1, KCNQ1 and KCNQ1OT1 imprinting in a range of studies which 
examined between 1 and 24 informative cell lines (Adewumi et al., 2007; Mitalipov, 
2006; Rugg-Gunn et al., 2005; Sun et al., 2006). 
 
Interestingly, NDN, NDNL1, SNRPN and IPW genes are known to be clustered on 
human chromosome 15q11 ~ q13. (El-Maarri et al., 2001; MacDonald and Wevrick, 
1997; Sutcliffe et al., 1994; Wevrick et al., 1994). Furthermore, KCNQ1, KCNQ1OT1 
and CDK1NC genes are also clustered on human chromosome 11p15 (Lee et al., 
1999; Lee et al., 1997; Mitsuya et al., 1999; Smilinich et al., 1999). In mouse and 
monkey ESC lines, the imprinting stability has been reported in their orthologous 
regions (Dean et al., 1998; Fujimoto et al., 2006; Schumacher and Doerfler, 2004). 
These evidences indicate that imprinting stability can be regionalised in mammalian 
ESC lines. The reason for such a regionalised stability is not clear, but one possibility 
is that stably established methylation imprints at imprinting control regions (ICRs) in 
blastocyst stage embryos can be inherited into mammalian ESCs and this can be 
maintained with monoallelic expression of their corresponding genes upon in vitro 
culture. Indeed, KvDMR1 and SNRPN DMR are known as ICRs in the human and 
mouse, and their maternal methylation imprints are stably established during 
oogenesis (Geuns et al., 2003; Geuns et al., 2007b; Lucifero et al., 2002; Sato et al., 
2007). These stable imprints are maintained throughout preimplantation stage embryo 
development with monoallelic expression of their relative genes (Geuns et al., 2003; 
Geuns et al., 2007b; Huntriss et al., 1998; Lewis et al., 2004; Salpekar et al., 2001). 
Therefore, these imprints can be stably inherited into ESCs and this may be not 
susceptible to DNA methylation changes upon in vitro culture. 
3.3.1.2 Genes that are biallelically expressed 
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Unexpectedly, 4 imprinted genes, TP73, IGF2R, WT1, and SLC22A18, were 
biallelically expressed in all informative hESC lines (Table 3-4). There are two 
possibilities to explain this. Firstly, their imprints have not been established in 
blastocyst stage embryos and thus their derived hESC lines are still biallelically 
expressed. Currently, the allele-specific expression of TP73, IGF2R, WT1, and 
SLC22A18 has not been examined in human gametes and preimplantation embryos to 
confirm this possibility. Secondly, it can be also explained by tissue-specific 
imprinting. TP73, IGF2R, WT1, and SLC22A18 are imprinted in a tissue-specific 
manner (Chen et al., 2000b; Cooper et al., 1998; Dong et al., 2002; Jinno et al., 1994; 
Mitsuya et al., 1997; Monk et al., 2006a; Xu et al., 1993). For example, WT1 and 
IGF2R are biallelically expressed in normal placentas and kidneys, although other 
tissues show monoallelic expression (Jinno et al., 1994; Mitsuya et al., 1997; Monk et 
al., 2006a; Xu et al., 1993). Moreover, TP73 is biallelically expressed in normal brain, 
ovary and cervix tissues (Chen et al., 2000b; Dong et al., 2002), although it 
monoallelically expressed in normal gastric, pancreatic and thymus tissues (Kang et 
al., 2000; Mai et al., 1998a). Thus, the biallelic expression of IGF2R, WT1, SLC22A18 
and TP73 could be normal in hESC lines. 
 
In this Chapter, 3 non-imprinted genes (TSSC4, NAPIL4 and SLC22A1) were used as 
control for biallelic expression. TSSC4 and NAPIL4 were biallelically expressed in all 
informative lines. This was consistent with previous observations in hESCs and fetal 
tissues (Monk et al., 2006a; Rugg-Gunn et al., 2005). However, SLC22A1, which was 
previously identified to be not imprinted in human and mouse tissues (Monk et al., 
2006a), showed variable imprinting in hESC lines. SLC22A1 was monoallelically or 
predominant monoallelically expressed 7 of 9 informative cell lines. Only 2 cell lines 
(HUES7 and HESC-NL1) showed biallelic expression. Thus, SLC22A1 may be 
potentially imprinted or polymorphically imprinted in early embryonic cells.  
3.3.2 Genes that are unstably expressed 
 
9 imprinted genes (H19, GTL2, PEG1 isoform 1 and 2, PEG10, MESTIT1, NESP55, 
ATP10C, PHLDA2 and IGF2) showed unstable imprinting status  in some informative 
cell lines (see Table 3-3 and 3-4). This concurred with the imprinting instability 
previously observed for H19, IGF2, GTL2, PEG1 and NESP55 imprinting in 7 to 20 
informative cell lines examined (Adewumi et al., 2007). 
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3.3.2.1 Loss of imprinting 
 
Of 9 genes, 6 imprinted genes (PEG10, PEG1 isoform 1, MESTIT1, H19, GTL2 and 
NESP55) were identified to have loss of imprinting in at least one hESC lines. In 
detail, PEG10 was monoallelically expressed in 3/4 informative cell lines, but it was 
biallelically expressed in HUES5, indicating loss of imprinting. NESP55 was 
monoallelically expressed in 8/9 informative cell lines. Only one cell line, HUES5 
showed biallelic expression, indicating loss of imprinting. PEG1 isoform 1 was 
monoallelically expressed in 11/12 cell lines, but NOTT2 showed biallelic expression, 
indicating loss of imprinting. H19 was monoallelically expressed in almost all 
informative cell lines, but HES-2 and NOTT2 showed biallelic expression. MESTIT1 
was monoallelically expressed in 11/12 informative cell lines. HUES15 showed 
biallelic expression of MESTIT1, indicating loss of imprinting. GTL2 was 
monoallelically expressed in 9/10, but HUES15 showed biallelic expression, 
indicating loss of imprinting. 
 
Loss of imprinting of PEG10, PEG1 isoform 1, MESTIT1, H19, GTL2 and NESP55 is 
known to be associated with various cancers and congenital disorders (Bastepe et al., 
2005; Gicquel et al., 2005; Nakanishi et al., 2004; Okabe et al., 2003; Pedersen et al., 
2002; Tsou et al., 2003; Weksberg et al., 1993). For example, loss of imprinting of 
PEG1 isoform 1 is associated with human breast and lung carcinomas (Nakanishi et 
al., 2004; Pedersen et al., 2002). Moreover, loss of imprinting of H19, GTL2, NESP55 
and MESTIT1 is associated with human cancers, BWS patients and SRS patients 
(Bliek et al., 2001; Chen et al., 2000a; Gicquel et al., 2005; Reik et al., 1995). In this 
Chapter, NOTT2 have loss of imprinting of PEG1 isoform 1 and H19. HUES5 have 
loss of imprinting of PEG10 and NESP55. HUES15 have loss of imprinting of 
MESTIOT1 and GTL2. HES-2 has loss of imprinting of H19. Although developmental 
consequences have not examined in the Chapter, these cell lines need to be carefully 
considered to be excluded for human therapeutic applications.  
3.3.2.2 Gain of imprinting 
 
4 imprinted genes, IGF2, PEG1 isoform 2, PHLDA2 and ATP10C, appeared to have 
gain of imprinting in at least one informative line. In detail, IGF2 was biallelically 
expressed in almost all informative hESC lines (9/10). Only one cell line, HUES9, 
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showed predominantly monoallelic expression, indicating gain of imprinting. 
Moreover, PEG1 isoform 2 is normally biallelically expressed in human tissues 
(Kosaki et al., 2000; McMinn et al., 2006; Nakabayashi et al., 2002). Consistently, 
biallelic expression of PEG1 isoform 2 was detected in 10/12 cell lines. However, 
HUES16 and NOTT1 showed monoallelic or predominantly monoallelic expression, 
indicating gain of imprinting. In addition, of 10 informative cell lines examined, 
PHLDA2 was biallelically expressed in almost informative cell lines. However, 
HUES1, HUES2, HUES7 and HESC-NL1 showed predominantly monoallelic 
expression, indicating gain of imprinting. Finally, ATP10C was biallelically expressed 
in 7/11 informative cell lines. However, HUES5, HUES6, HUES7 and HUES16 
showed monoallelic or predominantly monoallelic expression, indicating gain of 
imprinting. 
 
The imprinting disruption of IGF2, PEG1, PHLDA2 and ATP10C is known to be 
associated with congenital disorders and cancers (Gicquel et al., 2005; Meguro et al., 
2001; Muller et al., 2000; Nakanishi et al., 2004; Sparago et al., 2004; Weksberg et al., 
1993). Thus, HUES1, HUES2, HUES6, HUES7, HUES9, HUES16, HESC-NL1 and 
NOTT1 cell lines, identified to have gain of imprinting of at least one imprinted locus, 
also need to be considered to be excluded for human therapeutic applications. 
 
Interestingly, IGF2, which was previously known to be monoallelically expressed in 
most human and mouse tissues (Giannoukakis et al., 1993; Ohlsson et al., 1993), was 
biallelically expressed in hESC lines. There are three scenarios that could explain 
biallelic expression of IGF2 in hESC lines. One is that the in vitro culture conditions 
lead to loss of imprinting of IGF2. In monkey ESC lines, of 7 informative cell lines 
examined, loss of imprinting of IGF2 was detected in all informative lines, as a 
consequence of in vitro culture conditions (Fujimoto et al., 2006). Another 
explanation is that the IGF2 imprint was not established yet in the ICMs of blastocyst 
stage embryos. Indeed, IGF2 was reported to be biallelically expressed in mouse and 
human blastocyst stage embryos, but it became monoallelically expressed after 
postimplantation (Murrell, 2006; Oswald et al., 2000). Finally, the IGF2 expression in 
hESCs could be in a dosage-dependent manner. A recent study has demonstrated that 
IGF2 is one of key factors to regulate for stem cell survival (Bendall et al., 2007). 
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Thus, biallelic expression of IGF2 may be required to grow hESCs and maintain them 
in an undifferentiated state. 
3.3.3 Imprinting errors associated with in vitro culture 
 
Available data from mouse preimplantation stage embryos and their-derived stem cell 
lines have suggested that imprinting errors can be accumulated during in vitro 
prolonged culture (Dean et al., 1998; Humpherys et al., 2001; Khosla et al., 2001a; Li 
et al., 2005b). Similarly, altered IGF2 and H19 imprinting has been detected in hESC 
lines during in vitro long-term culture (Adewumi et al., 2007; Rugg-Gunn et al., 2005). 
Adewumi et al., (2007) have found that IGF2 is monoallelically expressed at earlier 
passages of the CCTL-9 cell line, but it become biallelically expressed at later 
passages. Moreover, Rugg-Gunn et al., (2005) has found H19 is biallelically 
expressed in H9 at later passages, although it was monoallelic at earlier passages. In 
this study, HESC-NL1 (passages 22 and 58) and HES-2 (passages 56, 65 and 96) were 
used to confirm this possibility. However, no imprinting changes were detected at H19 
and IGF2 loci. Furthermore, of other imprinted genes examined, none showed 
imprinting changes upon in vitro prolonged culture. Instead, in this Chapter, 
imprinting errors were observed at earlier passages of hESC lines. The passage 
numbers of  cell lines, which are identified to have imprinting errors, are 22 to 35 (see 
Table 2-1), suggesting that short period in in vitro culture may be sufficient to cause 
imprinting errors in hESC lines. 
3.3.4 Imprinting errors derived from donor embryos 
 
In this Chapter, 16 HUES-lines were included to examine the imprinting stability. 
Interestingly, 8 cell lines (HUES1, HUES2, HUES5, HUES6, HUES7, HUES9, 
HUES15 and HUES16) appeared to be unstable, but the other 8 cell lines (HUES3, 
HUES4, HUES8, HUES10, HUES12, HUES13, HUES14 and HUES17) appeared to 
be stable, although they were derived and cultured in same methods and materials 
(Cowan et al., 2004). The passage numbers are also similar (from 26 to 37). Only 
known variations between cell lines are donor embryos.  
 
Previous reports have demonstrated that oocytes and preimplantation stage embryos 
can have imprinting errors, when ART procedures (e.g. IVF and IVC) are applied 
(Horsthemke and Ludwig, 2005; Khosla et al., 2001b; Lucifero et al., 2004a; Maher, 
 124 
2005; Young and Fairburn, 2000). These imprinting errors in mouse embryos are 
stably inherited into ESCs (Li et al., 2005). All 16 HUES-lines are derived from 
embryos in vitro fertilised and cultured up to blastocyst stage (Cowan et al., 2004). 
Thus, it is possible that some blastocyst stage embryos used for derivation of 16 
HUES-lines can have imprinting errors, while they are in vitro fertilised and cultured. 
These errors can be stably inherited into some HUES-lines (Allegrucci et al., 2004).  
 
Another possibility is that 16 HUES-lines are derived from slightly different stage of 
blastocyst stage embryos (Cowan et al., 2004), implicating that some imprints were 
not fully established in some blastocyst stage embryos. Moreover, 16 HUES-lines 
have derived from frozen and thawed low-grade embryos having different blastocysts 
grade scores (3AA to 4CB), as classified by Gardner et al., (2000). These factors can 
also influence that some cell lines appear to be stable but some cell lines are not. 
3.3.5 Imprinting errors and other factors 
 
It has been suggested that, imprinting of maternally expressed genes (e.g. H19 and 
NESP55) can be easily disrupted in in vitro long-term culture of hESC lines (Rugg-
Gunn et al., 2005). In this Chapter, of 11 paternally expressed genes examined, 4 
genes (PEG10, PEG1, MESTIT1 and IGF2) showed unstable imprinting in hESC lines. 
Of 10 maternally expressed genes examined, 5 genes (H19, GTL2, NESP55, PHLDA2 
and ATP10C) showed unstable imprinting in hESC lines. This indicates no 
relationship between imprinting disruption and typical parental expression status (i.e. 
maternal or paternal). Moreover, the imprinting disruption between hESC lines 
showed no relationship with karyotypic aberrations, chromosomal locations, genders, 
and culture conditions (see Table 2-1). 
3.3.6 Further works needed 
 
Previously, it has been reported that mice derived from mESCs having imprinting 
errors, have widespread cancer formation (Holm et al., 2005). In this Chapter, it was 
not examined whether imprinting errors in hESC lines can be associated with 
developmental consequences during lineage-specific differentiation and post-
transplantation. To investigate this, in vivo and in vitro differetnation studies need to 
be examined with hESC lines having imprinting defects. The allele-specific 
expression of imprinted genes is guided by differential epigenetic marks (e.g DNA 
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methylation and histone modifications) at their imprinting regulatory regions. This 
needs to be examined to understand mechanistic insight into imprinting instability of 
some hESC lines.  
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4 DNA METHYLATION AT IMPRINTING REGULATORY 
REGIONS IN HUMAN EMBRYONIC STEM CELL LINES 
 
4.1 Introduction 
 
The allele-specific expression of imprinted genes can be regulated by allele-specific 
differential DNA methylation at their regulatory regions (reviewed by Constancia et 
al., 2004; Ferguson-Smith and Surani, 2001; Reik and Walter, 2001; Surani, 2001). 
Thus, this chapter aimed to determine whether overall DNA methylation in selected 
12 imprinting regulatory regions is associated with the allele-specific expression status 
of imprinted genes in hESC lines examined in Chapter 3.  
4.1.1 DNA methylation associated with imprinted gene expression 
 
DNA methylation is responsible for regulating the allele-specific expression of 
imprinted genes, although histone lysine methylation and H3 and H4 acetylation have 
been reported to be involved in this (Carr et al., 2007; Fournier et al., 2002; Lau et al., 
2004; Lewis et al., 2004; Umlauf et al., 2004; Vu et al., 2004). DNA methylation at 
imprinted loci occurs in a specific region named as a differentially methylated region 
(DMR) (Fitzpatrick et al., 2002; Lin et al., 2003; Sparago et al., 2004). Often DMRs 
contain more than one CpG island (Fitzpatrick et al., 2002; Lin et al., 2003; Sparago et 
al., 2004). The DMR is differentially methylated between parental alleles to direct the 
allele-specific expression of its relative imprinted genes (reviewed by Reik and Walter, 
2001; Surani, 2001). For example, PEG1 (paternally expressed gene 1) is expressed 
from the paternally allele mediated by paternal unmethylation at the PEG1 DMR 
(Kosaki et al., 2000; Nakabayashi et al., 2002; Pedersen et al., 2002; Riesewijk et al., 
1997). On the other hand, maternal methylation at the PEG1 DMR directs 
transcriptional silencing of PEG1 from the maternal allele.  
 
So far, ~ 15 DMRs have been identified in the human and mouse (see Table 1-2). 
Most DMRs are frequently found in the promoter region of imprinted genes, but some 
DMRs are located in the intronic region of imprinted genes that is associated with the 
expression of antisense transcripts (Mancini-Dinardo et al., 2006; Sleutels et al., 2002; 
Smilinich et al., 1999; Wutz et al., 1997; Zwart et al., 2001). The imprinting control 
region (ICR), which is also differentially methylated on both parental alleles, act as a 
regional imprinting controller that can direct allele-specific expression of its 
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surrounding genes (Gicquel et al., 2005; Lin et al., 2003; Schoenherr et al., 2003; 
Sparago et al., 2004). For example, on human chromosome 11p15.5 (mouse distal 
chromosome 7), two ICRs (ICR1 also known as H19 DMR and ICR2 also known as 
KvDMR1) have been identified to direct the allele-specific expression of more than 13 
imprinted genes (see Figure 1-4).  
4.1.2 Imprinting regulatory regions  
 
4.1.2.1 KvDMR1 (ICR2) 
 
The KvDMR1 (potassium voltage differentially methylated region 1), a ~2kb CpG 
island, is located in intron 10 of KCNQ1 (potassium voltage-gated channel, KQT-like 
subfamily, member 1) on human chromosome 11p15.5 (mouse distal chromosome 7) 
(Lee et al., 1999; Smilinich et al., 1999; Umlauf et al., 2004). In the human and mouse, 
KvDMR1 is known to be a germ-line DMR which is methylated in oocytes but is 
unmethylated in sperm (Geuns et al., 2007b; Khoureiry et al., 2008; Lewis et al., 
2004), indicating that the maternal allele-specific methylation at KvDMR1 is 
established during gametogenesis. This germ-line specific methylation at KvDMR1 is 
maintained throughout mammalian development (Geuns et al., 2007b; Khoureiry et al., 
2008; Lewis et al., 2004).  
 
Deletion studies in the mouse and human have revealed that the paternal allele of 
KvDMR1 is essential for regulating the allele-specific expression of 9 imprinted genes 
in the centromeric region of a cluster (Fitzpatrick et al., 2002; Horike et al., 2000; 
Lewis et al., 2004; Mancini-Dinardo et al., 2006). In mice, for example, the deletion 
of unmethylated paternal allele of KvDMR1 leads to transcriptional silencing of 
Kcnq1ot1 and biallelic expression of Tssc3/Ipl, Slc22a18/Tssc5, Cdkn1c/p57Kip2, 
Kcnq1, Tssc4, Osbpl5, Cd81 and Ascl2/Mash2 (Fitzpatrick et al., 2002; Lewis et al., 
2004; Mancini-Dinardo et al., 2006). However, the deletion of methylated maternal 
allele of KvDMR1 shows no changes in allele-specific expression of these imprinted 
genes. Similar results have been reported in the human (Horike et al., 2000). The 
deletion of KvDMR1 on the paternally inherited chromosome in chicken DT40 cells 
leads to transcriptional silencing of KCNQ1OT1 and increased expression of both 
CDKN1C and KCNQ1 genes, implicating loss of imprinting of  CDKN1C and KCNQ1 
(Horike et al., 2000). Importantly, Fitzpatrick et al., (2002) and Horike et al., (2000) 
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have demonstrated that the deletion of KvDMR1 show no perturbation of the 
imprinting status of the IGF2-H19 domain located in the more telomeric region of a 
cluster, indicating that KvDMR1 is associated with allele-specific expression of 
imprinted genes within the centromeric region of a cluster (see Figure 4-1).  
 
Loss of maternal methylation at KvDMR1 leads to loss of imprinting of KCNQ1OT1 
that has been frequently found in BWS patients and Wilms’ tumours (Bliek et al., 
2001; Lee et al., 1999; Smilinich et al., 1999). Moreover, gain of imprinting of 
CDKN1C has been reported as a consequence of loss of methylation at KvDMR1 that 
is frequently found in hepatocarcinomas (Schwienbacher et al., 2000). 
 
Figure 4-1. KvDMR1 in the human and mouse 
 (A) Human KvDMR1 in chromosome 11p15.5. (B) Mouse KvDMR1 in distal 
chromosome 7. KvDMR1 know as ICR2 which is paternally unmethylated (maternally 
methylated) that directs the allele-specific expression of imprinted genes (OSBPL5, 
NAP1L4, SLC22A18, CDK1NC, KCNQ1, KCNQ1OT1, TSSC4, CD81 and ASCL2) in 
a cluster. Maternally expressed genes shown in red. A gene (KCNQ1OT1) is 
paternally expressed shown in blue. Genes are biallelically expressed shown in black. 
The CTCF protein binds to the unmethylated paternal allele of KvDMR1. Vertical bars 
indicate CpG dinucleotides. Filled circles represent methylated CpG dinucleotides. 
Unfilled circles represent unmethylated CpG dinucleotides.  
4.1.2.2 H19 DMR (ICR1) 
 
The H19 DMR (ICR1), a ~2kb CpG island, is located in the more telomeric region of 
a cluster on human chromosome 11p15.5 and in the orthologous region on mouse 
distal chromosome 7 (Olek and Walter, 1997; Pant et al., 2004; Thorvaldsen et al., 
1998). The H19 DMR lies between ~ 2 kb upstream of the H19 promoter and ~ 90kb 
 129 
downstream of the IGF2 gene (Thorvaldsen et al., 1998). In the human and mouse, the 
H19 DMR is known to be a germ-line DMR which is methylated in matured 
spermatogonia but unmethylated in oocytes (Borghol et al., 2006; Kerjean et al., 2000; 
Olek and Walter, 1997; Ueda et al., 2000), indicating that paternal allele-specific 
methylation at the H19 DMR is established during gametogenesis. This germline-
specific methylation at the H19 DMR is maintained throughout mammalian 
development (Fedoriw et al., 2004; Kerjean et al., 2000; Li et al., 2004; Szabo et al., 
2002).  
 
Deletion studies in the mouse and human have revealed that the H19 DMR is 
responsible for regulating the allele-specific expression of both H19 and IGF2 genes 
(Schoenherr et al., 2003; Sparago et al., 2004; Thorvaldsen et al., 1998). The deletion 
of the H19 DMR on the paternally inherited allele leads to loss of imprinting of H19 
and reduced expression of Igf2 (Thorvaldsen et al., 1998). Furthermore, the deletion of 
the H19 DMR on the maternally inherited allele leads to loss of imprinting of Igf2 and 
reduced expressed of H19 (Schoenherr et al., 2003; Thorvaldsen et al., 1998). Thus, 
both parental alleles at H19 DMR are required for regulating the allele-specific 
expression of IGF2 and H19 genes in the human and mouse.  
  
The CTCF (CCCTC-binding factor) proteins and enhancer elements are also required 
for regulating the monoallelic expression of both IGF2 and H19 genes (Figure 4-2 A). 
Seven CTCF biding sites have been identified in the human H19 DMR (four CTCF 
biding sites in the mouse H19 DMR) (Hark et al., 2000). Two enhancer elements are 
identified which lie between 7 and 9 kb downstream of the H19 promoter and ~100 kb 
downstream of the Igf2 promoter (Figure 4-2 A). The CTCF proteins bind to the 
unmethylated maternal allele of their biding sites in the H19 DMR and acts as an 
insulator that blocks interaction between the Igf2 promoter and enhancer elements on 
the maternal allele (Hark et al., 2000; Schoenherr et al., 2003; Sparago et al., 2004). 
Thus, IGF2 is transcriptionally silenced from the maternal allele, whereas H19 is 
transcriptionally active. On the other hand, the methylated paternal allele of the H19 
DMR suppresses the accessibility of CTCF proteins that allows enhance elements to 
bind to the IGF2 promoter, resulting in paternal expression of IGF2 and 
transcriptional silencing of H19 (Hark et al., 2000; Schoenherr et al., 2003; Sparago et 
al., 2004). Deletion and mutation studies have revealed that the CTCF proteins have 
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an important role for maintaining DNA methylation patterns at the H19 DMR 
(Fedoriw et al., 2004; Pant et al., 2004; Pant et al., 2003; Schoenherr et al., 2003). The 
inactivation of CTCF proteins and point mutation of their biding sites lead to de novo 
methylation at the unmethylated maternal allele of the H19 DMR that is associated 
with loss of imprinting of H19 and IGF2 genes (Fedoriw et al., 2004; Pant et al., 2004; 
Pant et al., 2003; Schoenherr et al., 2003).  
 
Aberrant DNA methylation patterns at the H19 DMR can be found in patients who are 
suffering from Silver-Russell syndrome (SRS), BWS and various cancers (Bliek et al., 
2001; Gicquel et al., 2005; Reik et al., 1995; Weksberg et al., 2003). For example, in 
SRS patients, loss of paternal methylation at the H19 DMR has been detected in 
association with reduced expression of IGF2 and biallelic expression of H19 (Gicquel 
et al., 2005). Moreover, gain of methylation at the H19 DMR has been detected in 
some BWS patients and Wilms’ tumours that is associated with reduced expression of 
H19 and biallelic expression of IGF2 (Bliek et al., 2001; Prawitt et al., 2005; Reik et 
al., 1995; Weksberg et al., 1993).  
 
The H19 DMR in preimplantation stage embryos and their derived ESCs is known to 
be highly susceptible to DNA methylation changes upon in vitro culture that leads to 
phenotypic abnormalities during prenatal and postnatal development (Dean et al., 
1998; Doherty et al., 2000; Fernandez-Gonzalez et al., 2004; Khosla et al., 2001a; Li 
et al., 2005b; Mitalipov et al., 2007; Rugg-Gunn et al., 2005). For instance, 
hypermethylation at the H19 DMR (associated with transcriptional silencing of H19 
and biallelic expression of IGF2) has been detected in mouse blastocyst stage embryos 
and mESCs as a consequence of in vitro culture conditions (Dean et al., 1998; Doherty 
et al., 2000; Khosla et al., 2001a; Mann et al., 2004). Their derived foetuses have 
phenotypic abnormities including polyhydramnios, poor mandible development, 
interstitial bleeding and increased fetal mass (Dean et al., 1998 and Khosla et al., 
2001a).  
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Figure 4-2. IGF2-H19 and DLK1-GTL2 DMRs  
(A) IGF2-H19 domain on human chromosome 11p15.5. (B) DLK1-GTL2 domain on 
human chromosome 14q32. IGF2 and DLK2 are paternally expressed, whereas H19 
and GTL2 are maternally expressed. IGF2 and DLK1 are protein encoding genes, 
whereas H19 and GTL2 are non-coding genes. The monoallelic expression of these 
genes is mediated by allele-specific differential methylation at DMRs, CTCF proteins 
and enhancer elements. Vertical bars indicate CpG dinucleotides. Filled circles 
represent methylated CpG dinucleotides. Arrows on rectangular boxes indicate gene 
transcription. 
4.1.2.3 GTL2 DMR (IG-DMR) 
 
The GTL2 (gene trap locus 2) DMR (also known as IG-DMR), a ~4kb CpG island, is 
located in human chromosome 14q32 (mouse distal chromosome 12) (Astuti et al., 
2005; Kawakami et al., 2006; Lin et al., 2003; Takada et al., 2002). In the human and 
mouse, the GTL2 DMR is known to be a germ-line DMR which is methylated in 
sperm but unmethylated in GV, MI and MII stage oocytes (Geuns et al., 2007a; Lin et 
al., 2003), indicating that paternal allele-specific methylation at the GTL2 DMR is 
established during gametogenesis. This germ-line specific methylation at the GTL2 
DMR is maintained throughout mammalian development (Geuns et al., 2007a; Lin et 
al., 2003; Takada et al., 2002; Wylie et al., 2000).  
 
A deletion study in mice has suggested that the maternal allele of the Gtl2 DMR is 
essential for regulating the allele-specific expression of its surrounding 4 imprinted 
genes within a cluster on mouse distal chromosome 12 (Lin et al., 2003). The deletion 
of the Gtl2 DMR from the maternally inherited allele leads to biallelic expression of 
Dlk1 (delta, drosophila, homolog-like 1), Dio3 (deiodinase iodothyronine type 3) and 
Rtl1 (retrotransposon-like 1), and transcriptional silencing of Gtl2 (Lin et al., 2003). 
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However, the deletion of the Gtl2 DMR from the paternally inherited allele shows no 
changes in allele-specific expression of these genes (Lin et al., 2003). Interestingly, 
additional two CpG islands (CpG1 and CpG2) have been identified in the DLK1-
GTL2 domain (Astuti et al., 2005; Carr et al., 2007; Kawakami et al., 2006; Takada et 
al., 2002; Wylie et al., 2000). However, it has not been examined yet whether they can 
direct allele-specific expression of imprinted genes within a cluster.   
 
Spatial, structural, epigenetic characteristics of the DLK1-GTL2 domain are similar to 
those of the IGF2-H19 domain (Figure 4-2). IGF2 and DLK2 are expressed on the 
paternally inherited allele, whereas H19 and GTL2 are maternally expressed 
(Bartolomei et al., 1991; DeChiara et al., 1991; Kobayashi et al., 2000; Miyoshi et al., 
2000). IGF2 and DLK1 are protein encoding genes, whereas H19 and GTL2 encode 
for non-coding RNA (ncRNA) (Bartolomei et al., 1991; Kalscheuer et al., 1993; 
Wylie et al., 2000). The allele-specific expression of these genes is mediated by 
differential allele-specific methylation at H19 and GTL2 DMRs (Lin et al., 2003; 
Sparago et al., 2004; Thorvaldsen et al., 1998; Wylie et al., 2000). Moreover, similar 
to the H19 DMR, there are CTCF binding sites (located 1131 bp and 840 bp, 
respectively, upstream of a GTL2 transcription start site) and enhancer elements 
(located 8.9 kb and 10.7 kb, respectively, downstream of a GTL2 transcription start 
site) within the GTL2 DMR (Figure 4-2) (Takada et al., 2002; Wylie et al., 2000), 
implicating that allele-specific expression of DLK1 and GTL2 genes may be guided by 
CTCF proteins and enhancer elements.   
 
Aberrant DNA methylation patterns at the GTL2 DMR have been reported in human 
cancers and oligospermia patients (Astuti et al., 2005; Kawakami et al., 2006; 
Kobayashi et al., 2007). Gain of methylation at the unmethylated maternal allele of the 
GTL2 DMR has been found in neuroblastomas, phaeochromocytoma, renal cell 
carcinomas and Wilms’ tumours (Astuti et al., 2005; Kawakami et al., 2006). 
Moreover, loss of paternal methylation at the GTL2 DMR has been detected in 
oligospermia patients, as a consequence of impaired spermatogenesis (Kobayashi et 
al., 2007).  
4.1.2.4 PEG1 DMR 
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The PEG1 (paternally expressed gene 1) DMR, a ~600 bp CpG island, is located in 
the promoter and exon 1 of PEG1 on human chromosome 7q32 (mouse chromosome 
6) (Riesewijk et al., 1997). In the human and mouse, the PEG1 DMR is known to be a 
germ-line DMR which is methylated in oocytes but unmethylated in sperm (Kerjean et 
al., 2003; Kerjean et al., 2000; Lucifero et al., 2004b; Obata and Kono, 2002; Sato et 
al., 2007). This indicates maternal allele-specific methylation at the PEG1 DMR is 
established in the germ line. This germ-line specific methylation at the PEG1 DMR is 
maintained throughout mammalian development (McMinn et al., 2006; Nakabayashi 
et al., 2002; Pedersen et al., 2002).  
 
MESTIOT1 (MEST intronic transcript 1)/PEG1-AS, which is maternally imprinted, 
has been identified to be transcribed in the opposite direction to PEG1 and shares the 
promoter region of PEG1 isoform 1 (Li et al., 2002; Nakabayashi et al., 2002). Thus, 
it has been suggested that maternal allele-specific methylation at the PEG1 DMR can 
also direct the paternal expression of MESTIOT1 (Li et al., 2002; Nakabayashi et al., 
2002). However, clear evidences about this have not been reported yet.  
 
Aberrant DNA methylation at the PEG1 DMR can be found in oligospermia patients 
(Kobayashi et al., 2007; Marques et al., 2004) and superovulated oocytes (Kerjean et 
al., 2003; Sato et al., 2007). This may be due to impaired spermatogenesis and 
oogenesis. Moreover, loss of imprinting of PEG1 has been detected in breast and lung 
carcinomas that is associated with loss of maternal methylation at the PEG1 DMR 
(Nakanishi et al., 2004; Pedersen et al., 2002). 
 
Figure 4-3. PEG1 DMR in the human  
The PEG1 DMR is maternally methylated, but it is paternally unmethylated. PEG1 
isoform 1 transcribed from exon 1 is paternally expressed, whereas PEG1 isoform 2 
transcribed from exon A is expressed from both parental alleles. Paternal-specific 
unmethylation at thePEG1 DMR is responsible for expression of PEG1 isoform 1 and 
MESTIT1 from the paternal chromosome. MESTIT1 is located on an intron of PEG1 
isoform 2, shares the promoter region of PEG1 isoform 1 and is transcribed in the 
opposite direction to PEG1. Vertical bars indicate CpG dinucleotides. Filled circles 
represent methylated CpG dinucleotides. Arrows indicate gene transcription. 
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4.1.2.5 IGF2R DMR1 and DMR2 
 
The Igf2r (insulin-like growth factor2 receptor) gene contains two DMRs (DMR1 and 
DMR2) in mouse proximal chromosome 17 (Barlow et al., 1991; Kalscheuer et al., 
1993; Stoger et al., 1993) (Figure 4-4). DMR1 is located in the promoter region of the 
Igf2r gene which is methylated on the paternal chromosome but unmethylated on the 
maternal chromosome (Stoger et al., 1993). DMR2, a ~ 2kb CpG island, is located in 
intron 2 of Igf2r, which is methylated on the maternal allele but unmethylated on the 
paternal allele (Stoger et al., 1993). In the mouse, paternal allele-specific methylation 
at the Igf2r DMR1 is acquired after fertilization, indicating that it is a somatic DMR 
(Stoger et al., 1993). However, maternal allele-specific methylation at the Igf2r 
DMR2 is acquired during gametogenesis, indicating that it is a germ-line DMR 
(Lucifero et al., 2002; Stoger et al., 1993). This has not been examined in human 
gametes and preimplantation embryos.  
 
Deletion studies in mice have revealed that differential methylation at the Igf2r DMR2 
and the presence of the Air transcript are essential for regulating allele-specific 
expression of Igf2r, Air, and two placental-specific imprinted genes (Slc22a2 and 
Slc22a3) in a cluster (Sleutels et al., 2003; Sleutels et al., 2002; Wutz et al., 1997; 
Zwart et al., 2001). For example, the deletion of the Igf2r DMR2 in mice leads to loss 
of imprinting of Igf2r, Slc22a2 and Slc22a3 and transcriptional silencing of Air (Wutz 
et al., 1997; Zwart et al., 2001). Moreover, the deletion of the Air transcript leads to 
loss of imprinting of Igf2r, Slc22a2 and Slc22a3 (Sleutels et al., 2003; Sleutels et al., 
2002).  
 
In the human, only IGF2R DMR2 has been reported to be differentially methylated on 
human chromosome 6q26, whereas IGF2R DMR1 is completely unmethylated on 
both parental alleles (Smrzka et al., 1995), implicating that IGF2R DMR2 may direct 
monoallelic expression of IGF2R. However, biallelic expression of IGF2R has been 
mostly detected in lymphoblastoid cells and fetal and adult tissues including placentae, 
heart and liver, although preferential expression of the maternal allele of IGF2R has 
been reported in some tissues (Kalscheuer et al., 1993; Monk et al., 2006a; Xu et al., 
1993). This indicates no correlation between IGF2R imprinting and differential 
methylation at IGF2R DMR2. Thus, recent studies have suggested that other 
epigenetic marks at histones may be involved in IGF2R imprinting (Monk et al., 
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2006a; Vu et al., 2004). Alternatively, the lack of methylation at IGF2 DMR1 may be 
associated with the biallelic expression of IGF2R (Hu et al., 1998).  
 
In the mouse, aberrant DNA methylation at Igf2r DMR2 has been detected in 
superovulated oocytes, and in vitro cultured embryos and mESCs (Dean et al., 1998; 
Kerjean et al., 2003). This may be due to impaired oogenesis and in vitro culture 
conditions. Moreover, loss of methylation at the IGF2R DMR2 has been reported in 
sheep, as a consequence of in vitro culture of ovine embryos that is associated with 
Large Offspring syndrome (LOS) (Young et al., 2001).  
 
Figure 4-4. IGF2R DMR1 and DMR2 in the mouse and human  
(A) In the mouse, DMR1 is paternally methylated but maternally unmethylated. 
DMR2 is maternally methylated but paternally unmethylated. (B) In the human, 
DMR1 is completely unmethylated, whereas DMR2 is differentially methylated. No 
AIR transcript is detected in the human. Vertical bars indicate CpG dinucleotides. 
Filled circles represent methylated CpG dinucleotides. Arrows indicate gene 
transcription. 
4.1.2.6 PEG3 DMRs 
 
The PEG3 (paternally expressed gene 3) DMR, a 364bp CpG island, is located in the 
promoter and exon1 of PEG3 on human chromosome 19q13.4 (mouse proximal 
chromosome 7) (Dowdy et al., 2005; Kim et al., 2003; Li et al., 1999; Maegawa et al., 
2001). In the mouse, the Peg3 DMR is know to be a germ-line DMR which is 
methylated in oocytes but unmethylated in sperm (Arnaud et al., 2006; Lucifero et al., 
2002), indicating that maternal specific methylation at Peg3 DMR is acquired in the 
germ line. This has not been determined in human gametes and preimplantation stage 
embryos.  
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In the mouse, 5 additional imprinted genes (Usp29, Zf264, Zim1, Zim2 and Zim3) have 
been indentified within the surrounding Peg3 DMR (Kim et al., 2000a; Kim et al., 
2001; Kim et al., 2003; Kim et al., 2000b), implicating that the Peg3 DMR may act as 
a ICR in a cluster on chromosome 7 to direct allele-specific expression of these genes. 
To examine this possibility, deletion and mutation studies are required. In the human, 
ZIM2 has been reported to be imprinted, whereas the imprinting status of other genes 
has not been identified (Kim et al., 2000a; Kim et al., 2001).  
 
Interestingly, the Gli-type transcription factor, YY1, has been reported to bind to the 
unmethylated allele of the Peg3 DMR (Kim and Kim, 2008; Kim et al., 2003; Kim et 
al., 2006). Similar to the CTCF protein, YY1 acts as a methylation sensitive insulator 
that can regulate allele-specific expression of Peg3 and its neighbouring genes (Kim 
and Kim, 2008; Kim et al., 2003; Kim et al., 2006). The inactivation of the YY1 
protein in mice leads to down-regulation of Peg3 expression mediated by gain of 
methylation at the Peg3 DMR (Kim and Kim, 2008), indicating that YY1 is essential 
for maintaining an unmethylated state at the paternal allele of the Peg3 DMR.  
 
Loss of methylation at the PEG3 DMR has been detected in  various cancer cell lines 
including JEG3 and BeWo, HTB-16, HTB-17, and CRL-1620, RL-95, C33A, ME180, 
Ovcar-3 and Ovcar-5 that is associated with loss of imprinting of PEG3 (Dowdy et al., 
2005; Maegawa et al., 2001).  
4.1.2.7 NDN and SNRPN DMRs 
 
The NDN DMR, a 880bp CpG island, is located in the promoter region of NDN 
(Boccaccio et al., 1999; El-Maarri et al., 2001; Lau et al., 2004). The SNRPN DMR, a 
~4.3kb CpG island, is located in the promoter and exon1 of SNRPN (El-Maarri et al., 
2001; Sutcliffe et al., 1994). Both NDN and SNRPN DMRs are maternally methylated 
but paternally unmethylated in normal tissues on human chromosome 15q11 (mouse 
chromosome 7) (MacDonald and Wevrick, 1997; Tsai et al., 1999). In the human and 
mouse, both DMRs are known as germ-line DMRs which are methylated in oocytes 
but unmethylated in sperm (El-Maarri et al., 2001; Geuns et al., 2003; Hanel and 
Wevrick, 2001; Lucifero et al., 2002), indicating that maternal allele-specific 
methylation at NDN and SNRPN DMRs is acquired during gametogenesis. This germ-
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line specific DNA methylation is maintained during mammalian development (El-
Maarri et al., 2001; Geuns et al., 2003; Huntriss et al., 1998; Salpekar et al., 2001).  
 
Aberrant DNA methylation at NDN and SNRPN DMRs has been reported in PWS, AS 
and oligospermia patients (Cox et al., 2002; Kobayashi et al., 2007; Orstavik et al., 
2003; Sutcliffe et al., 1994). For example, loss of methylation at NDN and SNRPN 
DMRs has been found in some PWS patients that is associated with loss of imprinting 
of SNRPN (El-Maarri et al., 2001; Reis et al., 1994; Sutcliffe et al., 1994). Moreover, 
loss of methylation at the SNRPN DMR is frequently found in ART-conceived AS 
children (Cox et al., 2002; Orstavik et al., 2003). Gain of methylation at the SNRPN 
DMR has been reported in oligospermia patients, as a consequence of impaired 
spermatogenesis (Kobayashi et al., 2007).  
4.1.3 DNA methylation at DMRs in ESCs 
 
In vitro derived and cultured mouse and rhesus monkey ESCs have been identified to 
have imprinting errors associated with aberrant DNA methylation at imprinting 
regulatory regions (Dean et al., 1998; Feil et al., 1997; Fujimoto et al., 2006; 
Humpherys et al., 2001). In contrast to mouse and rhesus monkey ESCs, 5 hESC lines 
exhibit a substantial degree of imprinting stability in association with normal 
monoallelic DNA methylation patterns at SNRPN, H19, GTL2, NESP55 and KvDMR1 
DMRs (Plaia et al., 2006; Rugg-Gunn et al., 2005). Only one cell line, H9, shows gain 
of methylation at the H19 DMR at later passages (p66 ~ p101) that is not associated 
with biallelic expression of H19 (Rugg-Gunn et al., 2005).  
4.1.4 Chapter aims 
 
Unstable and variable imprinting has been detected by increasing the number of hESC 
lines and imprinted genes examined in Chapter 3. Thus, the aim of this Chapter is to 
determine whether imprinting instability in hESC lines are correlated to DNA 
methylation changes at potential imprinting regulatory regions.   
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4.2 Results 
 
Direct bisulphite sequencing was performed to give an overview of the mean 
methylation status at TP73, KCNQ1, CDKN1C and SLC22A18 promoters, and 
KvDMR1, PEG1, PEG10, IGF2, GTL2, NDN and NESP55 DMRs in all informative 
cell lines characterised in Chapter 3. Clonal bisulphite sequencing and combined 
bisulphite restriction analysis (COBRA) were performed to confirm DNA methylation 
at the NESP55, PEG1, PEG10, GTL2 and NESP55 DMRs.  
4.2.1 Direct bisulphite sequencing electrophoretograms 
 
Figure 4-5 shows direct bisulphite sequencing electrophoretograms at the PEG1 DMR 
in HUES7, HUES12, HUES17, BG01 and NOTT2. The degree of DNA methylation 
in each CpG dinucleotide is determined by the relative peak height of C (cytosine) and 
T (thymine) as follows: 1) If a C peak is higher than a T peak in a CpG dinucleotide, 
the CpG dinucleotide is defined to be predominantly methylated (yellow rectangle). 2) 
If a T peak is higher than a C peak in a CpG dinucleotide, the CpG dinucleotide is 
defined to be predominantly unmethylated (blue rectangle). 3) If both C and T peaks 
are present at the equal height in a CpG dinucleotide, the CpG dinucleotide is defined 
to be monoallelically methylated (grey rectangle). 4) If a C peak alone is present in a 
CpG dinucleotide, the CpG dinucleotide is defined to be methylated (black rectangle). 
5) If a T peak alone is present in a CpG dinucleotide, the CpG dinucleotide is defined 
to be unmethylated (white rectangle). 6) A red rectangle indicates the mutation of 
CpG dinucleotides. Six criteria were previously defined by Frigola et al., (2006). On 
the basis of these criteria, direct bisulphite sequencing was performed in selected 12 
imprinting regulatory regions.  
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Figure 4-5. Direct bisulphite sequencing electrophoretograms  
PCR with bisulphite modified DNA of HUES7, HUES12, HUES17, BG01 and 
NOTT2 and direct sequencing were performed to give an overview of the mean DNA 
methylation status of the PEG1 DMR. Sequencing data were analysed by Chromas 
Lite v2.01. The CpG dinucleotides are numbered as 2 to 12. The degree of 
methylation in each CpG dinucleotide is determined by the relative peak height of C 
and T. C>T indicates predominant methylation (yellow rectangles). C<T indicates 
predominant unmethylation (blue rectangles). C=T indicates hemimethylation (grey 
rectangles). C alone indicates complete methylation (black rectangles). T alone 
indicates complete unmethylation (white rectangles). Three types (C>T, C<T and 
C=T) are defined to be differentially methylated at CpG dinucleotides. 
4.2.2 TP73 promoter 
 
DNA methylation at 50 CpG dinucleotides within the TP73 promoter was analysed by 
direct bisulphite sequencing (Dong et al., 2002). PCR with bisulphite modified 
genomic DNA of 8 informative cell lines (see section 3.2.1, HUES1, HUES6, HUES7, 
HUES8, HUES10, HUES16, HES-2 and NOTT2), HESC-NL1 (passages 22, 58) and 
NTERA2, and direct sequencing were performed. The degree of methylation was 
determined by the relative peak height of C and T. 50 CpG dinucleotides in the 
promoter region of TP73 were completely unmethylated in all hESC lines (Figure 4-6 
A). However, NTERA2 showed predominant methylation at 27/50 CpG dinucleotides. 
No methylation changes were detected in in vitro prolonged culture of HES-2 
(passages 56, 65, 96) and HESC-NL1 (passages 22, 58) (Figure 4-6 A and B).  
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Figure 4-6. DNA methylation at the TP73 promoter  
(A) DNA methylation at the TP73 promoter region was analysed in 8 informative cell 
lines determined in Chapter 3. (B) DNA methylation at the TP73 promoter was 
analysed in HESC-NL1 (passages 22, 58). In the schematic diagram, a block box 
represents exon 1, two white boxes represent untranslated regions (URTs), and a gray 
box indicates a CpG island. An arrow indicates a transcriptional start site. Numbers (-
30209 to -29902) indicate the sequence position analysed within a CpG island. The 
first and last CpG dinucleotides are numbered relative to a transcription start site. Blue 
vertical bars indicate CpG dinucleotides within the region analysed. Yellow rectangles 
indicate predominant methylation at CpG dinucleotides. Blue rectangles indicate 
predominant unmethylation at CpG dinucleotides. White rectangles indicate 
unmethylation at CpG dinucleotides.  
4.2.3 PEG10 DMR 
 
DNA methylation at 15 CpG dinucleotides at the PEG10 DMR was analysed by direct 
bisulphite sequencing (Suzuki et al., 2007). PCR with bisulphite modified genomic 
DNA of 4 informative hESC lines (see section 3.2.3, HUES5, HUES7, HUES10 and 
HUES12) and direct sequencing were performed. The degree of methylation was 
determined by the relative peak height of C and T. Differential methylation at the 
PEG10 DMR was detected in HUES7, HUES10 and HUES12 (Figure 4-7 A). 
However, PEG10 DMR was completely unmethylated in HUES5. These methylation 
patterns were confirmed by COBRA (Figure 4-7 B and C). Two BstUI restriction 
enzyme sites were analysed to determine methylation-dependent sequence differences 
in PCR products of bisulphite modified genomic DNA (Figure 4-7 B). Three digested 
bands and one undigested band were detected in HUES7, HUES10 and HUES12 cell 
lines, indicating differential methylation at the PEG10 DMR (Figure 4-7 C). However, 
only one undigested band was detected in HUES5, indicating unmethylation at PEG10 
DMR.  
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Figure 4-7. DNA methylation at the PEG10 DMR  
(A) DNA methylation at the PEG10 DMR was analysed in 4 informative cell lines 
determined in Chapter 3. In the schematic diagram, a block box represents exon 1, a 
white box represents an untranslated region (URT), and a gray box indicates a CpG 
island. An arrow indicates a transcriptional start site. Numbers (-473 to -245) indicate 
the sequence position analysed within a CpG island. The first and last CpG 
dinucleotides are numbered relative to a transcription start site. Blue vertical bars 
indicate CpG dinucleotides within the region analysed. Yellow rectangles indicate 
predominant methylation at CpG dinucleotides. Blue rectangles indicate predominant 
unmethylation at CpG dinucleotides. Grey rectangles indicate hemimethylation at 
CpG dinucleotides. White rectangles indicate unmethylation at CpG dinucleotides. (B) 
A schematic diagram shows two BstUI enzyme sites at the PEG10 DMR. (C) The 
COBRA analysis of the PEG10 DMR. M, 100 bp DNA Ladder; U, BstUI-undigested; 
D: BstUI-digested.  
4.2.4 PEG1 DMR 
 
25 CpG sites within the PEG1 DMR were subjected to DNA methylation analyses by 
direct bisulphite sequencing (Kerjean et al., 2000). PCR with bisulphite modified 
genomic DNA of 13 informative cell lines (see section 3.2.4, HUES1, HUES2, 
HUES7, HUES10, HUES12, HUES15, HUES16, HUES17, BG01, HES-2, NOTT1, 
NOTT2 and NTERA2) and direct sequencing were performed. The degree of 
methylation was determined by the relative peak height of C and T. Differential DNA 
methylation of the PEG1 DMR was detected in HUES1, HUES2, HUES7, HUES10, 
HUES12, HUES15, HUES16, HUES17, HES-2 and NOTT1 (Figure 4-8 A). However, 
the PEG1 DMR was completely unmethylated in NOTT2 and NTERA2 and 
completely methylated in BG01. These methylation patterns at the PEG1 DMR were 
confirmed by clonal bisulphite sequencing (Figure 4-8 B). Of 10 clones examined in 
HES-2, 5 clones were methylated at the PEG1 DMR (filled circles), but other 5 clones 
were unmethylated (unfilled circles), indicating differential methylation on both 
parental alleles. Moreover, NOTT1 showed differential methylation at the PEG1 
DMR (6 clones unmethylated, 4 clones methylated). However, all 10 clones were 
completely unmethylated in both NOTT2 and NTERA2. DNA methylation changes 
were detected during in vitro prolonged culture of HES-2 (passages 56, 65, 96), 
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although no DNA methylation changes were detected in NL-HESC1 (passages 22, 58). 
HES-2 (p56) showed predominant methylation or hemimethylation at 25 CpG 
dinucleotides. However, they became predominantly unmethylated in HES-2 (p65 and 
p96).  
 
Figure 4-8. DNA methylation at the PEG1 DMR  
(A) DNA methylation at the PEG1 DMR was analysed in13 informative cell lines 
determined in Chapter 3. In the schematic diagram, a block box represents exon 1, a 
white box represents an untranslated region (URT), and a gray box indicates a CpG 
island. An arrow indicates a transcriptional start site. Numbers (-32 to +159) indicate 
the sequence position analysed within a CpG island. The first and last CpG 
dinucleotides are numbered relative to a transcription start site. Yellow rectangles 
indicate predominant methylation at CpG dinucleotides. Blue rectangles indicate 
predominant unmethylation at CpG dinucleotides. Grey rectangles indicated 
hemimethylation at CpG dinucleotides. White rectangles indicate unmethylation at 
CpG dinucleotides. (B) Clonal bisulphite sequencing at the PEG1 DMR in HES-2, 
NOTT1, NOTT2 and NTERA2. Black vertical bars indicate CpG dinucleotides within 
the region analysed. A scale bar corresponds to 10 bp. Open and filled circles 
represent unmethylated and methylated CpG sites respectively.  
4.2.5 IGF2 DMR0 
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DNA methylation at 5 CpG sites in the P0 promoter region of IGF2 was analysed by 
direct bisulphite sequencing (Monk et al., 2006b). PCR with bisulphite modified 
genomic DNA of 10 informative cell lines (see section 3.2.8, HUES1, HUES5, 
HUES6, HUES8, HUES9, HUES16, HUES17, HESC-NL1, HES-2 and NOTT2) and 
direct sequencing were performed. The degree of methylation was determined by the 
relative peak height of C and T. Differential DNA methylation of the IGF2 DMR0 
was detected in all cell lines (Figure 4-9). No methylation changes at the IGF2 DMR0 
were detected during in vitro prolonged culture of HESC-NL1 (passages 22 to 58) and 
HES-2 (passages 56 and 96).  
 
Figure 4-9. DNA methylation at the IGF2 DMR0 
DNA methylation at the IGF2R DMR0 was analysed in 10 informative cell lines 
determined in Chapter 3. In the schematic diagram, a white box represents an 
untranslated region (URT), and a gray box indicates a CpG island. An arrow indicates 
a transcriptional start site. Numbers (19 to 318) indicate the sequence position 
analysed within a CpG island. Numbering refers to accession no. NM_001007139. 
Blue rectangles indicate predominant unmethylation at CpG dinucleotides. Blue 
vertical bars indicate 5 CpG dinucleotides within the region analysed.  
4.2.6 KCNQ1 promoter 
 
DNA methylation at 19 CpG dinucleotides in the promoter region of KCNQ1 was 
analysed by direct bisulphite sequencing (Monk et al., 2006a). PCR with bisulphite 
modified genomic DNA of 8 informative cell lines (see section 3.2.9, HUES1, HUES2, 
HUES6, HUES8, HUES9, HUES12, HUES13 and NOTT1), and direct sequencing 
were performed. The degree of methylation was determined by the relative peak 
height of C and T. The KCNQ1 promoter was completely unmethylated in all cell 
lines examined (Figure 4-10).  
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Figure 4-10. DNA methylation at the KCNQ1 promoter  
DNA methylation at the promoter region of KCNQ1 was analysed in 8 informative 
cell lines determined in Chapter 3. In the schematic diagram, a block box represents 
exon 1, a white box represents an untranslated region (URT), and a gray box indicates 
a CpG island. An arrow indicates a transcriptional start site. Numbers (-48 to +109) 
indicate the sequence position analysed within a CpG island (accession number: 
AJ006345). The first and last CpG dinucleotides are numbered relative to a 
transcription start site. Blue rectangles indicate predominant unmethylation at CpG 
dinucleotides. White rectangles indicate unmethylation at CpG dinucleotides. Red 
rectangles indicate the mutation of CpG dinucleotides. Blue vertical bars indicate CpG 
dinucleotides within the region analysed.  
4.2.7 KvDMR1 
 
DNA methylation at 17 CpG sites within the KvDMR1 was analysed by direct 
bisulphite sequencing (Monk et al., 2006a). PCR with bisulphite modified genomic 
DNA of 18 cell lines and direct sequencing were performed. The degree of 
methylation was determined by the relative peak height of C and T. KvDMR1 was 
differentially methylated in all cell lines (Figure 4-11). The differential methylation 
pattern at KvDMR1 was not changed during in vitro prolonged culture of HESC-NL1 
(passages 22 to 58) and HES-1 (passages 56, 65 and 96) (Figure 4-11).  
 
Figure 4-11. DNA methylation at the KvDMR1  
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DNA methylation at the KvDMR1 was analysed in 18 cell lines (KCNQ1OT1, KCNQ1, 
CDK1NC and TSSC5 informative cell lines) characterised in Chapter 3. In the 
schematic diagram, block boxes represent exon11 and exon10 respectively and a gray 
box indicates a CpG island. Numbers (255,468 to 255.607) indicate the sequence 
position analysed within a CpG island. Numbering refers to accession no. AJ006345. 
Yellow rectangles indicate predominant methylation at CpG dinucleotides. Black 
rectangles indicate methylation at CpG dinucleotides. Blue vertical bars indicate CpG 
dinucleotides within the region analysed.  
4.2.8 CDKN1C promoter 
 
DNA methylation at 26 CpG sites in the promoter region of CDKN1C was analysed 
by direct bisulphite sequencing (Monk et al., 2006a). PCR with bisulphite modified 
genomic DNA of 3 informative cell lines (see section 3.2.11, HUES4, HUES14 and 
HUES16) and direct sequencing were performed. The degree of methylation was 
determined by the relative peak height of C and T. Half of the promoter region was 
completely unmethylated (CpG sites from 2 to 13), but the other half was 
predominantly unmethylated in these cell lines (CpG sites from 14 to 25) (Figure 4-
12).  
 
Figure 4-12. DNA methylation at the CDKN1C promoter  
DNA methylation at the promoter region of CDKN1C was analysed in 3 informative 
cell lines determined in Chapter 3. In the schematic diagram, a block box represents 
exon 1, a white box represents an untranslated region (URT), and a gray box indicates 
a CpG island. An arrow indicates a transcriptional start site. Numbers (-85 to +124) 
indicate the sequence position analysed within a CpG island (accession number: 
AC005950). The first and last CpG dinucleotides are numbered relative to a 
transcription start site. A yellow rectangle indicates predominant methylation at a CpG 
dinucleotide. Blue rectangles indicate predominant unmethylation in CpG 
dinucleotides. White rectangles indicate unmethylation at CpG dinucleotides. Red 
rectangles indicate the mutation of CpG dinucleotides. Blue vertical bars indicate CpG 
dinucleotides within the region analysed.  
4.2.9 SLC22A18 promoter 
 
DNA methylation at 32 CpG sites in the promoter region of SLC22A18 was analysed 
by direct bisulphite sequencing (Monk et al., 2006a). PCR with bisulphite modified 
genomic DNA of 6 informative cell lines (see section 3.2.13, HUES5, HUES12, 
HUES13, HUES15, HESC-NL1 and NOTT2) and direct sequencing were performed. 
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The degree of methylation was determined by the relative peak height of C and T. 
SLC22A18 promoter was unmethylated in all cell lines (Figure 4-13). No methylation 
changes at the SLC22A18 promoter were detected during in vitro prolonged culture of 
HESC-NL1 (passages 22, 58) and HES-2 (passages 56, 65, 96).   
 
Figure 4-13. DNA methylation at the SLC22A18 promoter  
(A) DNA methylation at the promoter region of SLC22A18 was analysed in 6 
informative cell lines determined in Chapter 3 and (B) in the HES-2 cell line (passages 
56, 65, 96). In the schematic diagram, a block box represents exon 1, two white boxes 
represent untranslated regions (URTs), and a gray box indicates a CpG island. An 
arrow indicates a transcriptional start site. Numbers (-1240 to -915) indicate the 
sequence position analysed within a CpG island (accession number: AC013791). The 
first and last CpG dinucleotides are numbered relative to a transcription start site. Blue 
rectangles indicate predominant unmethylation at CpG dinucleotides. A Grey 
rectangle indicates hemimethylation at a CpG dinucleotide. White rectangles indicate 
unmethylation at CpG dinucleotides. Blue vertical bars indicate CpG dinucleotides 
within the region analysed. 
4.2.10 GTL2 CpG2 and DMR 
 
The GTL2 CpG2 (10 CpG dinucleotides) and GTL2 DMR (32 CpG dinucleotides) 
were subjected to analyse the DNA methylation status by direct bisulphite sequencing 
(Kawakami et al., 2006; Wylie et al., 2000). PCR with bisulphite modified genomic 
DNA of 11 informative cell lines (see section 3.2.15, HUES3, HUES7, HUES10, 
HUES12, HUES13, HUES14, HUES15, HUES17, HESC-NL1, NOTT2 and H1) and 
direct sequencing were performed. The degree of methylation was determined by the 
relative peak height of C and T. GTL2 CpG2 was completely methylated in all cell 
lines (Figure 4-14 A). Differential methylation of the GTL2 DMR was observed in 
HUES3, HUES7, HUES10, HUES12, HESC-NL1 (passage 22) and NOTT1. However, 
the GTL2 DMR was methylated in HUES13, HUES14, HUES15, HUES17 and H1. 
These DNA methylation patterns at GTL2 DMR were confirmed by COBRA (Figure 
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4-14 C and D). Two HpyCH4IV restriction enzyme sites were analysed to determine 
methylation-dependent sequences differences in PCR products of bisulphite modified 
genomic DNA (Figure 4-14 C). The COBRA analysis showed that two HpyCH4IV 
sites were methylated in HUES10, HUES13, HUES14, HUES15, HUES17 and H1 
(only two digested bands detected). However, HUES3, HUES7, HUES12, HESC-NL1 
(p22) and NOTT1 showed differential methylation on both parental alleles (one 
undigested band and two digested bands detected). DNA methylation changes at the 
GTL2 DMR were detected during in vitro prolonged culture of HESC-NL1 (passages 
22, 58) and HES-2 (passages 56, 65, 96). The GTL2 DMR was differentially 
methylated in HESC-NL1 (p22) and HES-2 (p56), but it became hypermethylated in 
HESC-NL1 (p58) and HES-2 (p65 and 96) in all CpG dinucleotides. DNA 
methylation patterns at the GTL2 CpG2 were maintained during in vitro prolonged 
culture of HESC-NL1 (passages 22 and 58) and HES-2 (passages 56, 65 and 96). 
 
Figure 4-14. DNA methylation at the GTL2 CpG2 and DMR  
(A) DNA methylation at the GTL2 CpG2 and GTL2 DMR was analysed in 11 
informative cell lines determined in Chapter 3. In the schematic diagram, two block 
boxes represent exon1 and exon2 respectively, and two gray boxes indicate CpG2 
(64,697 to 64,913) and DMR (96,617 to 97,051) respectively. An arrow indicates a 
transcriptional start site. Numbers indicate the sequence position analysed within a 
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CpG island. Numbering refers to accession no. AL117190. Blue vertical bars indicate 
CpG dinucleotides within the region analysed. (B) DNA methylation at the GTL2 
CpG2 and DMR was analysed in HES-2 (passages 56, 65, 96). Yellow rectangles 
indicate predominant methylation at CpG dinucleotides. Blue rectangles indicate 
predominant unmethylation at CpG dinucleotides. Grey rectangles indicate 
hemimethylation at CpG dinucleotides. (C) A schematic diagram shows two 
HpyCH4IV restriction enzyme sites at the GTL2 DMR. (D) The COBRA analysis of 
the GTL2 DMR. M, 100 bp DNA Ladder; U, HpyCH4IV-undigested; D: HpyCH4IV-
digested.  
4.2.11 NDN DMR 
 
DNA methylation at 26 CpG sites within the NDN DMR was analysed by direct 
bisulphite sequencing (El-Maarri et al., 2001). PCR with bisulphite modified genomic 
DNA of 7 informative cell lines (see section 3.2.16, HUES4, HUES8, HUES15, 
HUES17, BG01, H1 and NOTT2), and direct sequencing were performed. The degree 
of methylation was determined by the relative peak height of C and T. Differential 
methylation of NDN DMR was detected in HUES4, HUES8, HUES17, BG01 and H1. 
However, the NDN DMR was completely unmethylated in both HUES15 and NOTT2 
cell lines (Figure 4-15).  
 
Figure 4-15. DNA methylation at the NDN DMR  
DNA methylation at the NDN DMR was analysed in 7 informative cell lines 
determined in Chapter 3. In the schematic diagram, a block box represents exon 1 and 
a gray box indicates a CpG island. An arrow indicates a transcriptional start site. 
Numbers (-232 to -87) indicate the sequence position analysed within a CpG island. 
The first and last CpG dinucleotides are numbered relative to a transcription start site. 
Blue vertical bars indicate CpG dinucleotides within the region analysed. Yellow 
rectangles indicate predominant methylation at CpG dinucleotides. Blue rectangles 
indicate predominant unmethylation at CpG dinucleotides. Grey rectangles indicate 
hemimethylation at CpG dinucleotides. White rectangles indicate unmethylation at 
CpG dinucleotides. 
4.2.12 NESP55 DMR 
 
DNA methylation at 28 CpG sites within the NESP55 DMR was analysed by direct 
bisulphite sequencing (Judson et al., 2002). PCR with bisulphite modified genomic 
DNA of 9 informative cell lines (see section 3.2.22, HUES1, HUES4, HUES5, 
 149 
HUES9, HUES12, HUES14, HUES15, HESC-NL1 and BG01) and direct sequencing 
were performed. The degree of methylation was determined by the relative peak 
height of C and T. Differential methylation at the NESP55 DMR was detected in all 
hESC lines, except for HUES5. HUES5 showed complete unmethylation at the 
NESP55 DMR. No methylation changes of NESP55 DMR were detected during in 
vitro culture of HESC-NL1 (passages 22, 58) and HES-2 (passages 56, 65, 96) (Figure 
4-16 A and B). These methylation patterns were confirmed by clonal bisulphite 
sequencing (Figure 4-16 C) and COBRA (Figure 4-16 D and E). Clonal bisulphite 
sequencing revealed that all cell lines have differential methylation at the NESP55 
DMR, except for HUES5 (Figure 4-16 C). Consistently, the COBRA analysis showed 
that only one undigested band was detected in HUES5 indicating unmethylation 
(Figure 4-16 E). However, other cell lines showed that three digested bands and one 
undigested band together, indicating differential methylation. 
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Figure 4-16. DNA methylation at the NESP55 DMR  
(A) DNA methylation at the NESP55 DMR was analysed in 9 informative cell lines 
determined in Chapter 3 and (B) HES-2 (passages 56, 65, 96). In the schematic 
diagram, a block box represents exon 1, a white box represents an untranslated region 
(URT), and a gray box indicates a CpG island. An arrow indicates a transcriptional 
start site. Numbers (+1 to +246) indicate the sequence position analysed within a CpG 
island. The first and last CpG dinucleotides are numbered relative to a transcription 
start site. Yellow rectangles indicate predominant methylation at CpG dinucleotides. 
Blue rectangles indicate predominant unmethylation at CpG dinucleotides. Grey 
rectangles indicate hemimethylation at CpG dinucleotides. White rectangles indicate 
unmethylation at CpG dinucleotides. (C) Clonal bisulphite sequencing at the NESP55 
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DMR in HUES1, HUES4, HUES5, HUES9, HUES14, HUES15 and HES-2 (p96). 
Blue vertical bars indicate CpG dinucleotides within the region analysed. A scale bar 
corresponds to 10 bp. Open and filled circles represent unmethylated and methylated 
CpG dinucleotides respectively. (D) A schematic diagram shows two AclI enzyme 
sites at the NESP55 DMR. (E) The COBRA analysis of the NESP55 DMR. M, 100 bp 
DNA Ladder; U, AclI-undigested; D: AclI-digested.  
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Table 4-1. Summary of DNA methylation status of 12 potential imprinting regulatory regions in hESC lines 
Locus Gene region HUES1 HUES2 HUES3 HUES4 HUES5 HUES6 HUES7 HUES8 HUES9 HUES10 HUES12 HUES13 HUES14 HUES15 HUES16 HUES17 BG01 H1 HESC-NL1 HES-2 NOTT1 NOTT2 NTERA2
1p36.33 TP73 Promoter U U U U U U U U U PM
7q21 PEG10 DMR U D D D
7q32 PEG1 DMR D D D D D D D D M D D/PUa D U U
SLC22A18 Promoter U U U U U U U U
CDKN1C Promoter PU PU PU
KCNQIOTI KvDMR1 D D D D D D D D D D D D D D D D D D D D D D
KCNQ1 Promoter U U U U U U U U
IGF2 DMR0 D D D D D D D D D D
DMR D D D D M M M PM PM D/Mb D/Mb D
CpG2 M M M M M M M M M M M
15q11 NDN DMR D D U D D D U
20q13.2 NESP55 DMR D D U D D D D D D D
11p15.5
14q32 GTL2
 
U, unmethylated; M, methylated; D, differentially methylated; PM, predominantly methylated; PU, predominantly unmethylated 
a
, in vitro culture induced loss of methylation  
b
, in vitro culture induced gain of methylation
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4.3 Discussion  
 
The purpose of this study was to investigate whether overall DNA methylation at 12 
potential imprinting regulatory regions was associated with the typical expression 
status of their relevant imprinted genes in hESC lines as determined in Chapter 3. Of 
12 regions examined by bisulphite sequencing and COBRA, 6 regions (TP73 
promoter, PEG10 DMR, PEG1 DMR, SLC22A18 promoter, KvDMR1 and NESP55 
DMR) showed the association between DNA methylation and allele-specific 
expression of 8 imprinted genes (TP73, PEG10, PEG1 isoform 1, SLC22A18, KCNQ1, 
KCNQ1OT1, CDK1NC and NESP55) in hESC lines (Table 4-3), indicating a 
regulatory role for DNA methylation at these imprinted loci. However, DNA 
methylation at IGF2 DMR, GTL2 CpG2, GTL2 DMR and NDN DMR was not 
associated with allele-specific expression of IGF2, GTL2 and NDN (Table 4-3). This 
indicates that DNA methylation does not regulate allele-specific expression of at least 
some imprinted genes in hESC lines.  
 
Table 4-2. The association between DNA methylation and imprinting in 
hESC lines  
Methylation 
Locus Gene Imprinting 
status Region Status 
Association 
1p36.33 TP73 B Promoter U Associated 
M D 
7q21 PEG10 
B 
DMR 
U 
Associated 
M D PEG1 
isoform1 B U 
Associated, PEG1 isoform 2 not 
associated 
M D 7q32 
MESTIOT1 
D 
DMR 
D 
Not associated 
SLC22A18 B Promoter U Associated, but not associated with KvDMR1 
CDKN1C PM Promoter U 
KCNQIOTI M KvDMR1 D 
KCNQ1 M Promoter U 
Associated with KvDMR1 
H19 DMR * D 
DMR2 * D 
11p15.5 
IGF2 B 
DMR0 D 
Not associated 
M D/M 
B 
DMR 
M 
M D/M 
B 
CpG2 
M 
Not associated 
M - 
14q32 GTL2 
B 
CpG1 
- 
- 
15q11 NDN M DMR D/U Not associated, but associated with SNRPN-SNURF DMR * 
20q13.2 NESP55 M DMR D Associated 
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B U 
M, monoallelic expression; PM, predominant monoallelic expression; B, biallelic 
expression; U, unmethylated; M, methylated; D, differentially methylated; DMR, 
differentially methylated region; * indicates Data from Alexandra Thurston Ph.D. 
thesis (2006).  The allele-specific expression of each gene was previously described in 
Chapter3. 
4.3.1 DNA methylation associated imprinting in hESCs 
 
4.3.1.1 PEG10, PEG1 and NESP55 DMRs 
 
The differential methylation at the PEG10 DMR is associated with the monoallelic 
expression of PEG10 in HUES7, HUES10 and HUES12 (see section 3.2.3). Moreover, 
loss of methylation at the PEG10 DMR was correlated to the biallelic expression of 
PEG10 in HUES5. The PEG1 DMR was differentially methylated in 10 of PEG1 
isoform 1 monoallelic cell lines, whereas it was unmethylated in NOTT2 and 
NETRA2, exhibiting biallelic expression of PEG1 isoform1 (see section 3.2.4). 
Finally, differential methylation at the NESP55 DMR was associated with monoallelic 
expression of NESP55 in HUES1, HUES4, HUES9, HUES12, HUES14, HUES15, 
BG01 and HESC-NL1 (see section 3.2.22). Only one cell line, HUES5, showed loss 
of methylation at the NESP55 DMR that was associated with the biallelic expression 
of NESP55. These evidences indicate that PEG10, PEG1 and NESP55 imprinting in 
hESC lines mediated by differential methylation at their DMRs. This association has 
been reported in other human fetal and adult tissues including brain, kidney, placenta 
and testis (Bastepe et al., 2005; Kerjean et al., 2000; McMinn et al., 2006; Riesewijk 
et al., 1997; Suzuki et al., 2007).  
 
MESTIOT1 is previously identified as an antisense transcript of PEG1 which is 
transcribed in the opposite direction of PEG1 (Li et al., 2002; Nakabayashi et al., 
2002). Because MESTIOT1 shares the promoter region of PEG1 isoform 1, and both 
MESTIOT1 and PEG1 isoform 1 are expressed on the paternally inherited allele, it has 
been suggested that paternal allele-specific unmethylation at the PEG1 DMR can also 
direct the paternal expression of MESTIOT1 (Li et al., 2002; Nakabayashi et al., 2002). 
In this Chapter, however, no obvious relationship between DNA methylation at the 
PEG1 DMR and MESTIOT1 imprinting was detected. For instance, although the 
PEG1 DMR was differentially methylated in HUES15, MESTIOT1 was biallelically 
expressed (see section 3.2.5). Moreover, NOTT2 showed monoallelic expression of 
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MESTIOT1, although the PEG1 DMR was completely unmethylated. Thus, other 
epigenetic modifications, rather than DNA methylation, may be involved in 
MESTIOT1 imprinting. Alternatively, other undiscovered differentially methylated 
regions could direct MESTIOT1 imprinting.  
4.3.1.2 KvDMR1 
 
KCNQ1, KCNQ1OT1, CDK1NC and SLC22A18 have been identified to be clustered 
in the centromeric region on human chromosome 11p15.5 (mouse distal chromosome 
7) (Morison et al., 2005; Reik and Walter, 2001; Robertson, 2005). KvDMR1 located 
in intron 10 of KCNQ1 is differentially methylated on both parental alleles, although 
KCNQ1, CDK1NC and SLC22A18 promoters are predominantly unmethylated in 
human and mouse tissues (Fitzpatrick et al., 2007; Fitzpatrick et al., 2002; Lewis et al., 
2004; Mancini-Dinardo et al., 2006; Monk et al., 2006a; Smilinich et al., 1999). Thus, 
it has been suggested that allele-specific expression of KCNQ1, KCNQ1OT1, 
CDK1NC and SLC22A18 is guided by monoallelic methylation at the KvDMR1 
(Fitzpatrick et al., 2007; Fitzpatrick et al., 2002; Lewis et al., 2004; Mancini-Dinardo 
et al., 2006; Monk et al., 2006a; Smilinich et al., 1999). In this Chapter, KCNQ1, 
CDK1NC and SLC22A18 promoters were predominantly unmethylated or 
unmethylated in hESC lines, whereas both methylated and unmethylated alleles at the 
KvDMR1 were present across the 16 CpG dinucleotides examined, correlating with 
the monoallelic or predominant monoallelic expression of KCNQ1, KCNQ1OT1, and 
CDK1NC, but not the biallelic expression of SLC22A18. This indicates that 
differential methylation at KvDMR1 can direct KCNQ1, KCNQ1OT1, and CDK1NC, 
(but not SLC22A18) imprinting in hESC lines.  
 
Interestingly, although KvDMR1 was differentially methylated in hESC lines, 
SLC22A18 was biallelically expressed (see section 3.2.13). There are two possibilities 
to explain this. One possibility is that other epigenetic marks at histones may direct 
SLC22A18 imprinting in hESC lines. Recently, Monk et al., (2006) has demonstrated 
that, in human tissues including placentae, liver, muscle and lymphocyte, active 
histone marks (H3K4me2 and H3K9Ac) appear at the maternal allele of SLC22A18, 
whereas repressive histone marks (H3K9me2 and H3K27me3) appear at paternal 
allele, suggesting that differential histone marks lead to maternal expression of 
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SLC22A18. Another possibility is that unmethylation at the SLC22A18 promoter 
directs the biallelic specific expression of SLC22A18 in hESC lines.  
4.3.1.3 TP73 Promoter 
 
Previously, unmethylation at the TP73 promoter in normal human tissues including 
brain, ovary and cervix was reported to be associated with the biallelic expression of 
TP73 (Chen et al., 2000b; Dong et al., 2002). In this Chapter, 50 CpG dinucleotides in 
the TP73 promoter were completely unmethylated in all hESC lines examined, 
consistent with the biallelic expression of TP73 (see section 3.2.1). Importantly, 
however, no reports are currently available about the monoallelic expression of TP73 
mediated by differential methylation at the TP73 promoter. Thus, it is still unclear 
how TP73 imprinting is regulated in the human.  
 
TP73 is known to be a tumour-suppressor gene which is transcriptionally inactive in 
human brain and ovarian cancers mediated by hypermethylation at its promoter (Chen 
et al., 2000b; Dong et al., 2002). In this Chapter, similarly, hypermethylation at the 
TP73 promoter was detected in NTERA2, a testicular germ cell tumour. The mRNA 
level of TP73 in NTERA2 now needs to be examined to determine association 
between DNA methylation and gene expression.  
4.3.2 DNA methylation not associated imprinting in hESCs 
 
4.3.2.1 GTL2 CpG2 and DMR 
 
Human fetal tissues (heart, kidney, liver, lung and brain) show differential methylation 
at the GTL2 DMR that is associated with monoallelic expression of GTL2 (Kawakami 
et al., 2006; Wylie et al., 2000). In this Chapter, however, no obvious relationship 
between DNA methylation at the GTL2 DMR and its imprinting was detected. For 
example, of 32 CpG dinucleotides surrounding the GTL2 DMR, most CpG 
dinucleotides were completely methylated in HUES13, HUES14, HUES17 and H1 
that was not associated with monoallelic expression of GTL2 (see section 3.2.15). 
Furthermore, GTL2 was biallelically expressed in HUES15, inconsistent with 
complete methylation at 31 CpG dinucleotides within the GTL2 DMR. Thus, these 
evidences indicate that DNA methylation at the GTL2 DMR may be not able to direct 
allele-specific expression of GTL2 in hESC lines. There are two possibilities to 
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explain GTL2 imprinting in hESC lines. One possibility is that other regulatory 
regions can be involved in allele-specific expression of GTL2. Previous studies have 
been identified that there are two additional CpG islands (CpG1 and CpG2) in a 
cluster on human chromosome 14q32, which are also differentially methylated in 
peripheral blood lymphocytes (Astuti et al., 2005; Kawakami et al., 2006; Wylie et al., 
2000). In this Chapter, however, all 10 CpG dinucleotides examined at the GTL2 
CpG2, all CpG dinucleotides were fully methylated in all informative cell lines, 
indicating no association between DNA methylation at the GTL2 CpG2 and its 
imprinting. DNA methylation at GTL2 CpG1 now needs to be examined. Another 
possibility is that other epigenetic marks at histones can be involved in GTL2 
imprinting in hESC lines. A recent study in mice has suggested that maternal specific 
histone acetylation at the Gtl2 DMR is necessary for regulating Gtl2 imprinting (Carr 
et al., 2007). This has not been reported in human tissues.  
4.3.2.2 NDN DMR 
 
A similar discrepancy was observed in the NDN DMR, with HUES15 and NOTT2 
exhibiting unmethylated CpG dinucleotides that did not correlate with monoallelic 
expression of NDN (see section 3.2.16). This may be explained by two ways. One is 
that other epigenetic modifications can direct NDN imprinting in hESC lines. Previous 
studies in the mouse and human have suggested that differential histone acetylation 
and methylation marks on parental alleles are involved in the allele-specific 
expression of NDN (Forsberg et al., 2000; Fulmer-Smentek and Francke, 2001; Lau et 
al., 2004; Xin et al., 2003). Another explanation is that other imprinting regulatory 
regions can be involved in regulating NDN imprinting in the human. Previously, two 
ICRs (PWS ICR and AS ICR) have been indentified which can direct the allele-
specific expression of their surrounding imprinted genes including NDN, NDNL1, 
MKRN3, SNRPN, UBE3A and ATP10C in the PWS/AS imprinting cluster on human 
chromosome 15q11  (MacDonald and Wevrick, 1997; Sutcliffe et al., 1994; Tsai et al., 
1999). Alexandra Thurston (University of Nottingham) examined the DNA 
methylation status at the PWS ICR in hESC lines. The region was differentially 
methylated in all NDN informative cell lines (Alexandra Thurston Ph.D thesis 2006). 
Thus, this indicates that the PWS ICR can direct allele-specific expression of NDN in 
hESC lines.  
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4.3.2.3 IGF2 DMR0 
 
Although biallelic expression of IGF2 was detected in almost all hESC lines (see 
section 3.2.8), IGF2 DMR0 and DMR2 were differentially methylated. This indicates 
no association between DNA methylation at IGF2 DMRs and its imprinting. Previous 
studies have suggested that gain of methylation at the maternal allele of the H19 DMR 
is associated with biallelic expression of IGF2 in both human and mouse tissues (Pant 
et al., 2004; Pant et al., 2003; Thorvaldsen et al., 1998). Of 23 CpG dinucleotides 
surrounding the H19 DMR, most CpG dinucleotides were differentially methylated in 
hESC lines (Alexandra Thurston Ph.D. thesis 2006), indicating no association 
between DNA methylation at the H19 DMR and IGF2 imprinting. A recent study in 
mice has been suggested that paternal H3K27me3 and macroH2A1 at the H19 
promoter and paternal H3K9 acetylation and H3K4me at IGF2 DMRs are associated 
with the allele-specific expression of Igf2 (Han et al., 2008; Li et al., 2008). 
Furthermore, human IGF2 can be imprinted in a promoter-specific manner, 
independent of epigenetic modifications (Ekstrom et al., 1995; Vu and Hoffman, 
1994). Thus, these potential factors can be involved in biallelic expression of IGF2 in 
hESC lines. 
4.3.3 In vitro culture induced DNA methylation changes  
 
Recently, DNA methylation changes (gain or loss of methylation) at non-imprinted 
loci have been reported in in vitro long-term cultured hESC lines (Allegrucci et al., 
2007; Bibikova et al., 2006; Calvanese et al., 2008; Maitra et al., 2005). Maitra et al. 
(2005) has found that gain of methylation at the promoter region of two tumour-
suppressor genes (RASSF1 and PTPN6) in BG01, BG02, BG03, hES2, hES3, H7, H9 
and SA002 at later passages from 41 to 147, indicating in vitro culture induced 
hypermethylation. Allegrucci et al., (2007) and Bibikova et al., (2006) have 
demonstrated that DNA methylation changes can accumulate in hESC lines upon in 
vitro prolonged culture, although most changes have been detected from them at 
earlier passages from 23 to32. In this Chapter, of 8 imprinting regulatory regions 
examined, two regions (GTL2 DMR and PEG1 DMR) showed DNA methylation 
changes in in vitro long-term cultured HES-2 (passages 56, 65 and 96 examined) and 
HESC-NL1 (passages 22 and 58 examined). GTL2 DMR and PEG1 DMR were 
differentially methylated in HESC-NL1 (p22) and HES-2 (p56). However, the GTL2 
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DMR became hypermethylated in HESC-NL1 (p58) and HES-2 (p65 and p96). 
Moreover, the PEG1 DMR became hypomethylated in HES-2 (p65 and p96). Other 6 
regions (TP73 promoter, SLC22A18 promoter, KvDMR1, IGF2 DMR0, GTL2 CpG2 
and NESP55 DMR) showed no DNA methylation changes, indicating DNA 
methylation can be altered in a locus-specific manner upon in vitro culture. The 
reasons why particular imprinted loci are more or less prone to epigenetic disruptions 
than others during in vitro culture are not yet understood. Similar results have been 
detected in in vitro cultured mouse and monkey ESCs and preimplantation stage 
embryos (Dean et al., 1998; Doherty et al., 2000; Khosla et al., 2001a; Mann et al., 
2004; Mitalipov et al., 2007), demonstrating that KvDMR1 and Snrpn DMR are more 
likely stable loci and thus appear insensitive to DNA methylation changes upon in 
vitro culture (Kerjean et al., 2003; Kobayashi et al., 2007; Marques et al., 2004; Sato 
et al., 2007). However, others including Igf2, H19, Gtl2 and Peg1 DMRs appear to be 
more variable and unstably in DNA methylation changes (Kerjean et al., 2003; 
Kobayashi et al., 2007; Marques et al., 2004; Sato et al., 2007). Possibly, this may be 
due to a regionalised stability associated with the establishment of imprints that was 
previously described in section 3.3.1.    
4.3.4 Further works needed  
 
In this chapter, it was not examined whether other epigenetic factors such as histone 
methylation and acetylation can be associated with allele-specific expression of 
imprinted genes. This needs to be examined to explain the lack of detected association 
between the allele-specific expression of some imprinted genes and DNA methylation 
at their regulatory regions. DNA methylation alternations (especially, loss of 
methylation) at several imprinted regulatory regions were detected in some hESC 
lines during in vitro culture that may be overcame by overexpression of maintenance 
methyltransferase 1, DNMT1. This possibility needs to be examined.  
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5 HUMAN EMBRYONIC STEM CELL LINES 
OVEREXPRESSING  DNA Methyltransferase 1 (DNMT1)  
 
5.1 Introduction 
 
DNA methylation changes at tumour suppressor gene promoters, imprinting 
regulatory regions and certain CpG islands have been reported in in vitro cultured 
human embryonic stem cell (hESC) lines (Allegrucci et al., 2007; Bibikova et al., 
2006; Calvanese et al., 2008; Maitra et al., 2005; Rugg-Gunn et al., 2005). Bibikova et 
al., (2006) used a microarray-based assay of bisulphite treated DNA to compare the 
DNA methylation status at different passages of 14 independently derived hESC lines. 
Of 1,536 CpG loci investigated, ~ 30 CpG loci including RASSF1 (ras association 
domain family 1) EPO (Erythropoietin) and PEG10 (paternally expressed gene 10) 
underwent loss of methylation upon in vitro prolonged culture (Bibikova et al., 2006). 
Moreover, Allegrucci et al., (2007) used a restriction landmark genomic scanning 
(RLGS) technique to compare the DNA methylation status at different passages of 6 
hESC lines (NCL1, H7, HES-2, BG01, NOTT1 and HUES-7). Of ~ 2,200 CpG loci 
examined, ~ 30 CpG loci including ZC3HAV1L, SPRN and AFG3L1 became 
demethylated or hypomethylated during in vitro culture (Allegrucci et al., 2007). Thus, 
current in vitro culture conditions for hESCs may lead to loss of methylation at certain 
CpG islands. The reasons for this are not known but one possibility is that relatively 
low expression of DNMT1 in hESCs fails to maintain DNA methylation at some CpG 
islands (Emma Lucas Ph.D. thesis 2008). In this Chapter, DNMT1 overexpression is 
used to test this hypothesis.   
 
The expression level of DNMT1 (DNA methyltransferase 1) has been reported to be 
associated with the degree of DNA methylation in mammalian cells (Biniszkiewicz et 
al., 2002; Chen et al., 2007; Feltus et al., 2003; Hattori et al., 2004). For instance, loss 
of methylation at repetitive sequences and imprinting regulatory regions has been 
detected in mESCs, mouse embryonic fibroblast (MEF) cells and human cancer cells, 
when DNMT1 is not or little expressed (Chen et al., 2007; Hattori et al., 2004; 
Jackson-Grusby et al., 2001; Lei et al., 1996; Li et al., 1992). On the other hand, gain 
of methylation at pericentromeric regions, tumour-suppressor gene promoters and 
imprinting regulatory regions has been detected in mESCs, human fibroblast cells and 
cancer cells, when DNMT1 is overexpressed (Biniszkiewicz et al., 2002; Etoh et al., 
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2004; Feltus et al., 2003; Sawada et al., 2007; Vertino et al., 1996). In hESC lines, 
Emma Lucas (University of Nottingham) has used immunofluorescence and real-time 
PCR techniques to assess the relative expression level of DNMT1 associated with 
global DNA methylation (5-methylcytosine) patterns in a BJ fibroblast cell line 
(derived from human foreskin), 2 hESC lines (HUES7 and NOTT1) and a mESC line. 
The expression of DNMT1 is readily detected in the human BJ fibroblast cell line and 
mESC line, but not hESC lines (Emma Lucas Ph.D. thesis 2008). Furthermore, 5-
methylcytosine staining shows that hESC lines are 20% less methylated than the 
human BJ fibroblast cell line (Emma Lucas Ph.D. thesis 2008). Thus, relatively 
undermethylation in hESCs could be due to the low expression of DNMT1, although 
de novo methyltransferases, DNMT3A and DNMT3B, are highly expressed in hESC 
lines. Additionally, this may be one of reasons why some CpG sties in hESCs become 
demethylated during in vitro culture. 
 
Thus, this chapter aimed to determine 1) whether the overexpression of exogenous 
DNMT1 in hESCs can prevent region-specific loss of methylation upon in vitro 
prolonged culture and 2) whether an increase in the expression level of DNMT1 in 
hESCs can be associated with gain of methylation at imprinting regulatory regions, 
repetitive sequences, tumour-suppressor gene promoters and certain CpG islands.  
5.1.1 DNMT1 
 
DNMT1 is known as a maintenance methyltransferase that is responsible for the stable 
inheritance of DNA methylation patterns from the parental strand to the daughter 
stand, when DNA is replicated during S phase (Bestor et al., 1988; Leonhardt et al., 
1992; Li et al., 1992). DNMT1 is ubiquitously expressed in proliferating cells and 
localised in replication foci via proliferating cell nuclear antigen (PCNA) and 
ubiquitin-like, containing PHD and RING finger domains 1 (UHRF1; also known as 
NP95 and ICBP90) (Bostick et al., 2007; Chuang et al., 1997; Leonhardt et al., 1992; 
Sharif et al., 2007). So far, three DNMT1 isoforms derived from three different sex-
specific promoters have been indentified in the mouse and human; a somatic form 
(DNMT1s), a pachytene spermatocyte-specific form (DNMT1p) and an oocyte-
specific form (DNMT1o) (Hayward et al., 2003; Mertineit et al., 1998). Their distinct 
behaviours and roles have been previously described in section 1.2.3.1.1.  
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Mouse Dnmt1 spans 56 kb of genomic DNA, is organised into 39 exons and encodes a 
protein of 1,620 amino acids with a molecular mass of 190 kDa (Bestor et al., 1988). 
Human DNMT1 is similarly organised, except for the presence of an additional intron 
(Bestor, 2000; Cheng and Blumenthal, 2008). The DNMT1 protein is composed of 
two domains, a regulatory N-terminal domain (~ 1,100 amino acids) and a catalytic C-
terminal domain (~ 550 amino acids) (see Figure 1-3). The N-terminal domain of 
DNMT1 contains several domains including a proliferating cell nuclear antigen 
(PCNA) binding domain (PBD), a nuclear localisation signal (NLS), a DNA 
replication foci targeting sequence (RFT or TS), a cysteine-rich Zn2+ binding motif 
(ATRX), and a polybromo homology domain (PBHD) (Bestor, 2000; Cheng and 
Blumenthal, 2008). The functions of these domains have been characterised by 
various truncation mutation studies (Chuang et al., 1997; Kim et al., 2002; Leonhardt 
et al., 1992; Margot et al., 2003; Schermelleh et al., 2007). For example, RFT and 
NLS domains are responsible for targeting to sites of newly synthesised hemi-
methylated DNA in nuclei at S phase (Chuang et al., 1997; Leonhardt et al., 1992; 
Rountree et al., 2000). Moreover, an ATRX domain is responsible for binding to DNA 
sequences containing CpG dinucleotides (Cheng and Blumenthal, 2008). The C-
terminal domain of DNMT1 contains six conserved motifs (I, IV, VI, VIII, IX and X). 
These motifs are responsible for transferring methyl groups (CH3) from S-adenosyl-L-
methionine (AdoMet) to cytosines in CpG dinucleotides (Bestor et al., 1988; Lauster 
et al., 1989; Posfai et al., 1989). The distinct roles of each motif have been previously 
described in section 1.2.3.4.1.  
5.1.2 The loss- and gain-of-function of DNMT1 in mammalian cells 
 
The studies of loss- and gain-of-function of DNMT1 in mammalian cells have 
suggested that appropriate DNMT1 expression is essential for normal embryonic 
development and tissue-specific differentiation (Biniszkiewicz et al., 2002; Jackson et 
al., 2004; Lei et al., 1996; Li et al., 1992; Li et al., 2007). For example, the 
inactivation of endogenous DNMT1 in mouse and human cells leads to the extensive 
perturbation of embryonic development, cellular growth, telomere length and lineage-
specific differentiation that may be due to genome-wide demethylation at repetitive 
sequences, imprinting regulatory regions and sub-telomeric domains (Chen et al., 
2007; Gonzalo et al., 2006; Hattori et al., 2004; Jackson-Grusby et al., 2001; Jackson 
et al., 2004; Lei et al., 1996; Li et al., 1993; Li et al., 1992). Furthermore, the 
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overexpression of exogenous DNMT1 leads to the embryonic lethality in mice and 
growth retardation in human fibroblast cells that may be due to genome-wide 
hypermethylation at repetitive sequences, imprinting regulatory regions and tumour-
suppressor gene promoters (Biniszkiewicz et al., 2002; Feltus et al., 2003; Vertino et 
al., 1996).  
5.1.2.1 Loss-of-function of DNMT1  
 
5.1.2.1.1 Mouse embryonic stem cells 
 
The first Dnmt1n/n J1 ES cell line has been generated by homologous recombination of 
the N-terminal domain (the NaeI site 20bp upstream of the transcriptional start site) 
(Li et al., 1992). In addition, Lei et al., (1996) has established the Dnmt1c/c J1 ES cell 
line by homologous recombination of the C-terminal domain (the PC motif 4 and 
ENV motif 6). Although both Dnmt1n/n and Dnmt1c/c J1 ES cell lines exhibit normal 
ES cell morphology, growth rate and prolonged survival in culture, reduced 
maintenance DNMT activity, DNMT1 protein level and 5-methylcytosine content are 
detected (Jackson-Grusby et al., 2001; Jackson et al., 2004; Lei et al., 1996; Li et al., 
1992). Moreover, genome-wide and gene-specific demethylation have been detected 
in both Dnmt1n/n and Dnmt1c/c J1 ES cell lines (Hattori et al., 2004; Jackson-Grusby et 
al., 2001; Jackson et al., 2004; Lei et al., 1996; Li et al., 1992). Specifically, the 
multiple endogenous retrovirus (Mo-MuLV), pericentromeric minor satellite repeat 
(pMR150), long interspersed nuclear element-1 (LINE1) and intracisternal A particle 
(IAP) are demethylated in both cell lines (Jackson-Grusby et al., 2001; Jackson et al., 
2004; Lei et al., 1996; Li et al., 1992). Furthermore, of 1300 CpG loci examined by 
RLGS, an additional 236 spots were detected in the Dnmt1c/c J1 ES cell line, 
indicating demethylation (Hattori et al., 2004). Finally, loss of methylation at the H19 
DMR and Igf2r (insulin-like growth factor 2 receptor) DMR2 is detected in the 
Dnmt1n/n J1 ES cell line (Li et al., 1993). This is associated with the biallelic 
expression of H19 and transcriptional silencing of Igf2 (insulin-like growth factor 2) 
and Igf2r (Li et al., 1993).  
 
Importantly, Dnmt1c/c J1 ES cells show a reduced ability to differentiate into embryoid 
bodies (EBs) and specific lineages including hematopoietic (erythroid and myeloid 
colonies) and cardiac lineages, compared to heterozygous- and wide-type ES cells 
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(Jackson et al., 2004). Furthermore, Oct3/4 and Nanog transcripts (pluripotent 
markers) are still detected in differentiated Dnmt1c/c J1 ES cells and remain 
unmethylated at their promoters (Jackson et al., 2004; Li et al., 2007). 
Immunocytochemistry analysis has revealed that trophoblast-specific (Pl-1 and Tpbp), 
mesodermal (Brachyury, β h1-globin and α- globin) and endodermal (Hnf4a and 
albumin) markers are abnormally expressed in differentiated Dnmt1c/c J1 ES cells 
(Jackson et al., 2004). Finally, the injection of Dnmt1n/n and Dnmt1c/c J1 ES cells into 
diploid and tetraploid blastocyst stage mouse embryos resulted in embryonic lethality 
during postimplantation development (Lei et al., 1996; Li et al., 1992). Thus, Dnmt1 is 
essential for maintaining DNA methylation in the mammalian genome that requires 
normal embryonic development and lineage-specific differentiation.  
5.1.2.1.2 Mouse embryonic fibroblasts 
 
The Dnmt11lox/1lox MEF cell line has been generated by Cre/lox mediated deletion of 
the N-terminal domain (exon 3 to exon 6) (Jackson-Grusby et al., 2001). This cell line 
exhibits no endogenous Dnmt1 expression, as confirmed by Western blot. Extensive 
demethylation at the IAP, centromeric satellite and moloney murine leukemia virus 
loci has been demonstrated by Southern blot (Jackson-Grusby et al., 2001). 
Importantly, TUNEL assay has revealed that ~ 20% of Dnmt11lox/1lox MEF cells 
undergo apoptosis (Jackson-Grusby et al., 2001). Moreover, oligonucleotide 
microarray analysis has revealed that ~ 10% of genes are abnormally expressed in 
Dnmt11lox/1lox MEF cells, including DNA repair genes (Tdg, Rad52, Mre11a and 
Pold1), indicating that Dnmt1 is also involved in regulating genomic stability 
(Jackson-Grusby et al., 2001; Mortusewicz et al., 2005).  
5.1.2.1.3 Human colon cancer cells 
 
Two DNMT12loxP/KO cell lines (designated as 201 and 202) have been generated by 
Cre/lox mediated deletion of the catalytic domain (PC and ENV motifs) in the human 
colon cancer cell line, HCT116 (Chen et al., 2007). In addition, one DNMT1-/- cell line 
has been established by homologous recombination of the regulatory domain (exon 3 
to exon 5) in HCT116 (Rhee et al., 2002; Rhee et al., 2000). 201 and 202 cells show 
morphology changes (more enlarged and flattened) during in vitro culture, compared 
to heterozygous- and wide-type HCT116 cells (Chen et al., 2007). However, the 
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DNMT1-/- cell line shows no morphology changes (Rhee et al., 2002; Rhee et al., 
2000). This discrepancy may be due to functional differences in the different domains 
deleted. Moreover, 201 and 202 cells undergo various mitotic defects including 
broken chromosomes and anaphase bridges and they die either at the metaphase or at 
the metaphase-to-anaphase transition (Chen et al., 2007). This have not been reported 
in DNMT1-/- cells 
 
Interestingly, although significantly reduced maintenance DNMT activity (~ 90% 
reduced) and DNMT1 protein level (rarely or not detected) are observed in 201, 202 
and DNMT1-/- cells, only ~ 20% of the 5-methylcytosine content is reduced (Chen et 
al., 2007; Rhee et al., 2002; Rhee et al., 2000). Furthermore, in these cells, the analysis 
of specific genomic regions by Southern blot has revealed that genome-wide 
demethylation occurs at only classical Satellite 2 and 3 sequences, but not α-Satellite 
and Alu repeats (Chen et al., 2007; Rhee et al., 2002; Rhee et al., 2000). In addition, 
no methylation changes are detected in the number of CpG islands including MLH1, 
CDKN2A, p16INK4A and TIMP-3 promoters (Chen et al., 2007; Rhee et al., 2002; Rhee 
et al., 2000). There are three ways to explain lack of extensive perturbation of DNA 
methylation. Firstly, Egger et al., (2006) has demonstrated that a truncated DNMT1 
protein is present in cells. This truncated DNMT1 protein retains the catalytic domain 
so that is able to methylate hemimethylated CpG dinucleotides (Egger et al., 2006). 
Secondly, Chen et al., (2007) has suggested that trace amounts of DNMT1 are still 
present in cells that functionally work to maintain DNA methylation. Finally, Rhee et 
al., (2002) has suggested that DNMT3A and DNMT3B compensate loss of DNMT1 to 
maintain DNA methylation patterns in DNMT1-/- cells. Indeed, DNMT1 and DNMT3B 
DKO (double knockout) in HCT116 shows significantly loss of genomic DNA 
methylation (~ 95%) at α-Satellite and Alu repeats (Rhee et al., 2002). Moreover, the 
promoter regions of p16INK4a (a prototypic INK4 protein), TIMP-3 (tissue inhibitor of 
metalloproteinase 3) and IGF2 are completely demethylated in DKO cells (Rhee et al., 
2002).  
5.1.2.2 Gain-of-function of DNMT1 
 
5.1.2.2.1 Human lung fibroblasts  
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8 human fetal lung fibroblast (IMR90/SV40) cell lines overexpressing DNMT1 
(HMT.S41, HMT.S36, HMT.L36, HMT.S33, HMT.L41, HMT.17, HMT.19 and 
HMT.1E1) have been established by chemical transfection of the pCMVneoBam 
vector containing a full-length DNMT1 cDNA (Vertino et al., 1996). These cell lines 
have both endogenous and exogenous DNMT1, as confirmed by Western blot on a 
6.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. 
Interestingly, the expression levels of exogenous DNMT1 between cell lines are 
variable, although endogenous DNMT1 was equally expressed (Vertino et al., 1996). 
Exogenous DNMT1 was relatively highly expressed in HMT.17, HMT.19 and 
HMT.1E1 than other cell lines (HMT.S41, HMT.S36, HMT.L36, HMT.S33 and 
HMT.L41). This may to due to variations either 1) the number of exogenous DNMT1 
copies integrates in the genome of each cell line or 2) where they integrate into the 
genome.  
 
By digesting DNA with methylation sensitive restriction enzymes (e.g. NotI, SacII and 
EagI), followed by Southern blot, hypermethylation at tumour suppressor gene 
promoters and certain CpG islands has been detected in HMT.17, HMT.19 and 
HMT.1E1 (Feltus et al., 2003; Vertino et al., 1996). Of 12 tumour suppressor gene 
promoters examined, 5 genes (Estrogen receptor, Alpha Globin, E-cadherin, 
Somatostatin and HIC-1) show gain of methylation at their promoters (Vertino et al., 
1996). Moreover, Feltus et al., (2003) has examined the global DNA methylation 
status in HMT.17, HMT.19 and HMT.1E1 cell lines by RLGS. Of 1749 CpG loci 
examined, 373 spots (~ 21%) disappeared, indicating gain of methylation (Feltus et al., 
2003). Thus, the overexpression of DNMT1 is associated with genome-wide and gene-
specific hypermethylation (or de novo methylation) in human fibroblast cells.  
5.1.2.2.2 Mouse embryonic stem cells  
 
A Mouse J1 ES cell line overexpressing Dnmt1 (Dnmt1+/+;BAC) has been generated by 
chemical transfection of a 150 kb bacterial artificial chromosome (BAC) containing 
the Dnmt1 gene (Biniszkiewicz et al., 2002). Increased Dnmt1 protein level, 5-
methylcytosine content and maintenance Dnmt activity are detected in the 
Dnmt1+/+;BAC cells by Western blot, reverse-phase HPLC (high-performance liquid 
chromatography) and Dnmt activity assays (Biniszkiewicz et al., 2002). Furthermore, 
hypermethylation at repetitive sequences (including minor centromeric repeats and 
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retroviral IAP elements) is detected in the Dnmt1+/+;BAC cells by Southern blot 
(Biniszkiewicz et al., 2002). Hypermethylation at IAP in the Dnmt1+/+;BAC cells is 
correlated with transcriptional silencing of IAP. Of 6 imprinted genes (Igf2r, Peg3, 
Grf1, Snrpn, Igf2 and H19) and 3 non-imprinted genes (p21, p16 and telomerase) 
examined in Dnmt1+/+;BAC cells, hypermethylation is detected at the H19 DMR that is 
associated with biallelic expression of Igf2 and transcriptional repression of H19 
(Biniszkiewicz et al., 2002). Furthermore, the injection of Dnmt1+/+;BAC cells into 
diploid and tetraploid blastocyst stage embryos results in embryonic lethality at 14.5 
dpc. Thus, overexpression of Dnmt1 is associated with hypermethylation at imprinting 
regulatory regions and repetitive sequences that interferes with normal embryonic 
development.  
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5.2 Results 
 
5.2.1 Construction of plasmids  
 
5.2.1.1 pCAG-hDNMT1-IRES-PAC  
 
The pDsRed2-C1-hDNMT1 plasmid was produced during a previous project in the 
laboratory of Prof. Yong-Mahn Han (KAIST). This plasmid contains a 5.2kb full-
length human DNMT1 cDNA, Discosoma sp. Human codon-optimised Red 
Fluorecent protein (DsRed2) coding sequences, a human cytomegalovirus (CMV) 
immediate early promoter and kanamycin/neomycin resistant genes. To obtain 5.2 kb 
DNMT1 cDNA, pDsRed2-C1-hDNMT1 was digested by EcoRI (Figure 5-1). Two 
bands, 5,262bp (DNMT1 cDNA) and 4,686bp (pDsRed2-C1) were expected to be 
digested by EcoRI (Figure 5-1 A). However, it was difficult to discriminate between 
two bands, because they are closely located on the 8% gel (Figure 5-1 B). Thus, 
another enzyme, RsrII, was selected to digest the middle part of the pDsRed2 C1 
(Figure 5-1 C). Then, three bands (5,262bp, 2,768bp and 1,918bp) were identified on 
the 8% gel, following RsrII and EcoRI double digestion of pDsRed2 C1-hDNMT1 
(Figure 5-1 D). A 5.2kb band was cut from the gel, and DNMT1 cDNA was purified.  
 
The p336 (pCAG-eGFP-IRES-PAC) plasmid was provided by Prof. Chris Denning 
(University of Nottingham). Several transgenic approaches with this plasmid have 
been reported in hESCs and mESCs (Anderson et al., 2007; Liew et al., 2007; Ren et 
al., 2006; Vallier et al., 2004b; Ying et al., 2003b; Zaragosi et al., 2007). This plasmid 
contains a enhanced green fluorescent protein (eGFP), a chicken β-
actin/cytomegalovirus (CMV) hybrid promoter (pCAG), an internal ribosome entry 
site (IRES) and a puromycin resistant gene (Denning et al., 2006; Ying et al., 2003b). 
The p336 plasmid was digested by EcoRI (Figure 5-1 E and F). Three bands (6,383bp, 
795bp and 117bp) were identified by gel electrophoresis (Figure 5-1 F). A 6,383bp 
band was cut from the gel. The linearised p336 plasmid was purified from the gel. 
Shrimp Alkaline Phosphatase (SAP) was used to treat into the EcoRI digested p336 
plasmid to prevent self-ligation by removing 5’ phosphates groups of both EcoRI sites.  
 
Ligation between 5.2 kb of DNMT1 cDNA (EcoRI digested) and 6.3kb of p336 
(EcoRI digested and SAP treated) and transformation were performed. Individual 20 
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colonies were inoculated and cultured. From 20 colonies, 20 plasmids were extracted 
by Miniprep. Four restriction enzymes (EcoRI, PciI, XcmI and SacI) were selected to 
confirm the correct insertion of DNMT1 cDNA into p336 (Figure 5-2). 17 colonies 
(EcoRI), 9 colonies (SacI), 9 colonies (PciI) and 14 colonies (XcmI) were identified to 
be correctly inserted. Of those, two colonies (10-1 and 11-5) were selected and 
Midiprep was performed. Finally, two plasmids derived from 10-1 and 11-5 colonies 
were named as pCAG-hDNMT1-IRES-PAC #10-1 and pCAG-hDNMT1-IRES-PAC 
#11-5 for use within this Chapter.  
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Figure 5-1. The construction of the pCAG-hDNMT1-IRES-PAC plasmid 
(part 1)  
(A) The schematic diagram of pDsRed2-C1-DNMT1. Two EcoRI sites are shown in 
red. (B) Gel electrophoresis of pDsRed2-C1-DNMT1 after the EcoRI digestion. (C) 
The schematic diagram of pDsRed2-C1-DNMT1. Two EcoRI sites are shown in red 
and a RsrII site is shown in blue. (D) Gel electrophoresis of pDsRed2-C1-DNMT1 
after the EcoRI and RsrII double digestion. (E) The schematic diagram of p336. Three 
EcoRI sites are shown in green (F) Gel electrophoresis of p336 after the EcoRI 
digestion. 0.8% agarose gels were used for gel electrophoresis. The 2-Log DNA 
ladder (NEB) was used as a molecular maker. Restriction enzymes used for the 
digestion shown on the top of gel images. The molecular size of digested bands is 
shown on the left of gel images. The schematic diagrams were generated by 
pDRAW32 (A, C and E).   
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Figure 5-2. The construction of the pCAG-hDNMT1-IRES-PAC plasmid 
(part 2)  
(A) The schematic diagram of two EcoRI sites in pCAG-DNMT1-IRES-PAC. (B) Gel 
electrophoresis of pCAG-DNMT1-IRES-PAC after the EcoRI digestion. (C) The 
schematic diagram of two SacI sites in pCAG-DNMT1-IRES-PAC. (D) Gel 
electrophoresis of pCAG-DNMT1-IRES-PAC after the SacI digestion. (E) The 
schematic diagram of four PciI sites in pCAG-DNMT1-IRES-PAC. (F) Gel 
electrophoresis of pCAG-DNMT1-IRES-PAC after the PciI digestion. (G) The 
schematic diagram of three XcmI sites in pCAG-DNMT1-IRES-PAC. (H) Gel 
electrophoresis of pCAG-DNMT1-IRES-PAC after the XcmI digestion. 0.8% agarose 
gels were used for gel electrophoresis. The 2-Log DNA ladder (NEB) was used as a 
molecular maker. Colonies were numbered as shown on the top of gel images. Red 
coloured numbers indicate the correct insertion of DNMT1 cDNA into p336. The 
schematic diagrams were generated by pDRAW32 (A, C, E and G).     
5.2.1.2 pCAG-DsRed2-C1-hDNMT1-IRES-PAC 
 
The pDsRed2-C1-hDNMT1 plasmid was digested with SalI (Figure 5-3 A and B) and 
Klenow was filled in the SalI site to make a blunt end. This blunt end will ligate into 
the PmeI site of p388. Subsequently, AgeI digestion was performed in SalI 
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digested/Klenow-filled pDsRed2-C1-hDNMT1 to obtain DsRed2-DNMT1 cDNA. 
Following gel electrophoresis, two bands, 5,983bp and 3,965bp were identified 
(Figure 5-3 B). A 5,983bp band was cut from the gel and DsRed2-DNMT1 cDNA was 
purified.  
 
The p388 (p336+linker) plasmid was also provided by Prof. Chris Denning 
(University of Nottingham). p388 was double digested with PmeI and AgeI (Figure 5-
3 C and D). Two bands, 6469 bp and 21bp, were identified by gel electrophoresis 
(Figure 5-3 D). A 6469bp band was cut from the gel. The linearised p388 plasmid was 
purified from the gel.  
 
Ligation between 5.9 kb DsRed2-DNMT1 (SalI digested-Klenow filled-AgeI digested) 
and 6.4 kb p388 (PmeI and AgeI digested) and transformation were performed. From 
12 colonies were inoculated and cultured, 12 plasmids were extracted by Mini prep. 
Three restriction enzymes (BamHI, SacI and EcoRI) were selected and use to digest 
the 12 plasmids to confirm the correct insertion of DsRed2-DNMT1 cDNA into p388 
(Figure 5-4). 9 colonies were identified to be correctly inserted. Of those, two colonies 
(#7 and #12) were selected and cultured, and Midiprep was performed. Finally, two 
plasmids were derived from (#7 and #12) and named as pCAG-DsRed2 C1-hDNMT1-
IRES-PAC #7 and pCAG-DsRed2 C1-hDNMT1-IRES-PAC #12 for use within this 
Chapter.  
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Figure 5-3. The construction of the pCAG-DsRed2-C1-hDNMT1-IRES-
PAC plasmid (part 1)  
(A) The schematic diagram of pDsRed2-C1-DNMT1. AgeI and SalI sites are shown. 
(B) Gel electrophoresis of pDsRed2-C1-DNMT1 after the AgeI and SalI digestion. (C) 
The schematic diagram of p388. AgeI and PmeI sites are shown. (D) Gel 
electrophoresis of p388after the AgeI and PmeI double digestion. 0.8% agarose gels 
were used for gel electrophoresis. The 2-Log DNA ladder was used as a molecular 
maker. Restriction enzymes used for the digestion shown on the top of gel images. 
The molecular size of digested bands is shown on the left of gel images. The 
schematic diagrams were generated by pDRAW32 (A and C). 
 
 174 
 
Figure 5-4. The construction of the pCAG-DsRed2-C1-hDNMT1-IRES-
PAC plasmid (part 2)  
(A) The schematic diagram of four BamHI sites in pCAG-DsRed2-DNMT1-IRES-
PAC. (B) Gel electrophoresis of pCAG-DsRed2-DNMT1-IRES-PAC after the BamHI 
digestion. (C) The schematic diagram of three SacI sites in pCAG-DsRed2-DNMT1-
IRES-PAC. (D) Gel electrophoresis of pCAG-DsRed2-DNMT1-IRES-PAC after the 
SacI digestion. (E) The schematic diagram of four EcoRI sites in pCAG-DsRed2-
DNMT1-IRES-PAC. (F) Gel electrophoresis of pCAG-DsRed2-DNMT1-IRES-PAC 
after the EcoRI digestion. 0.8% agarose gels were used for gel electrophoresis. The 2-
Log DNA ladder (NEB) was used as a molecular maker. Colonies were numbered as 
shown on the top of gel images. Red coloured numbers indicate the correct insertion 
of DsRed-DNMT1 cDNA into p388. The schematic diagrams were generated by 
pDRAW32 (A, C and E).   
5.2.2 Transient transfection 
 
To examine whether reconstructed plasmids functionally worked into human 
embryonic stem cells (hESCs), circular p336, p388, pCAG-DsRed2-C1-hDNMT1-
IRES-PAC #7 and pCAG-hDNMT1-IRES-PAC #10-1 plasmids were transiently 
transfected in HUES7 (passage 22) using GeneJammer (Stratagene). After 48 hours, 
the expression of exogenous eGFP and DsRed2 was determined by fluorescence 
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microscope (Figure 5-5). In cells transfected by p336, green signals were detected in 
both the cytoplasm and nucleus (see an enlarged image). Furthermore, in cells 
transfected by pCAG-DsRed2-C1-hDNMT1-IRES-PAC #7, red signals were detected 
in the nucleus only (see an enlarged image), because the N-terminal domain of 
DNMT1 contained a nuclear localisation signal (NLS) domain (Bestor, 2000; Cheng 
and Blumenthal, 2008). Cells transfected by other plasmids showed no green and red 
signals, indicating that these plasmids did not contain fluorescence genes (Figure 5-5).  
 
Figure 5-5. Immunofluorescence analysis in transiently transfected 
HUES7 p22  
Circular p336, p388, pCAG-DsRed2-C1-hDNMT1-IRES-PAC #7 and pCAG-
hDNMT1-IRES-PAC #10-1 plasmids were transiently transfected in HUES7 (p22) by 
GeneJammer. Green signals were detected in cells transfected by p336. Red signals 
were detected in cells transfected by pCAG-DsRed2-C1-hDNMT1-IRES-PAC #7. No 
fluorescence signals were detected in cells transfected by p388, pCAG-hDNMT1-
IRES-PAC #10-1 and no plasmid. Top panels show brightfield images. Middle panels 
show eGFP filter images. Bottom panels show DsRed2 filter images. 
5.2.3 Stable transfection 
 
5.2.3.1 Preparation of plasmids  
 
Plasmids were linearised by AhdI and PvuI restriction enzymes. An AhdI enzyme was 
used for linearisating p336 and p388 plasmids. A PvuI enzyme was used for 
linearisating pCAG-DNMT1-IRES-PAC #10-1 and pCAG-DsRed2-C1-DNMT1-
IRES-PAC #7 plasmids (Figure 5-6). Linearised plasmids were purified by phenol-
chloroform extraction.  
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Figure 5-6. Linearisation of plasmids for stable transfection  
An AhdI enzyme was used for linearising p336 and p388 plasmids. A PvuI enzyme 
was used for linearising pCAG-hDNMT1-IRES-PAC #10-1 and pCAG-DsRed2-C1-
hDNMT1-IRES-PAC #7. Restriction enzymes used and plasmids are shown on the 
top of a gel image. A 0.8% agarose gel was used for gel electrophoresis. The 2-Log 
DNA ladder (NEB) was used as a molecular maker.  
5.2.3.2 Electroporation and puromycin selection 
 
Electroporation methods for establishing stable transfected hESC lines have been 
optimised by Prof. Chris Denning and Dr. David Anderson (University of 
Nottingham). Electroporation was performed with 1 × 106 HUES7 (p22) cells and 50 
µg of each linearised plasmid using previously optimised setting of 600 V/30 µs 
(Anderson et al., 2007; Denning et al., 2006). After 24 hours, these cells were subject 
to puromycin selection. Puromycin resistant colonies appeared after 10 days in culture 
(Figure 5-7). Interestingly, although 58 colonies were found in dishes containing cells 
transfected by p336 and p388, only 27 colonies were found in dishes containing cells 
transfected by pCAG-hDNMT1-IRES-PAC #10-1 and pCAG-DsRed2-C1-hDNMT1-
IRES-PAC #7. Furthermore, the size of colonies was comparable between control 
plasmids transfected and plasmids containing DNMT1 cDNA transfected. Colonies of 
p336 and p388 were relatively bigger than those of pCAG-hDNMT1-IRES-PAC #10-
1 and pCAG-DsRed2-C1-hDNMT1-IRES-PAC #7 (Figure 5-7). These colonies were 
handpicked by pipette, transferred into one well of a 12-well plate, and expanded until 
they were confluent in one well of a 6-well plate. Finally, 14 of p366 cell lines, 17 of 
p388 cell lines, 8 of hESOD1 (human embryonic stem cell lines overexpressing 
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DNMT1) cell lines (derived from pCAG-hDNMT1-IRES-PAC #10-1) and 11 of 
hESOrD1 (human embryonic stem cells overexpressing DsRed-DNMT1) cell lines 
(derived from pCAG-DsRed2-C1-hDNMT1-IRES-PAC #7) were established after ~ 4 
weeks of puromycin selection (Table 5-1). Once cell lines were established, they were 
named and numbered; p336 (p336 #1, -#3, -#4, -#6, -#7, -#9, -#12, -#13, -#14, -#15, -
#16, -#17, -#19, -#23), p388 (p388 #1, -#2,--#3, -#4, -#5, -#7, -#8, -#9, -#10, -#11, -
#12, -#13, -#14, -#15, -#16, -#18, -#23), pCAG-DNMT1-IRES-PAC #10-1 (hESOD1 
#1, -#2, -#3, -#4, -#5, -#6, -#7, -#9), pCAG-DsRed2-C1-DNMT1-IRES-PAC #7 
(hESOrD1 #1, -#2, -#3, -#5, -#6, -#8, -#9, -#10, -#11, -#12, -#13).  
 
Figure 5-7. The formation of puromycin resistant colonies  
Linearised plasmids were transfected into HUES7 (p22) by electoroporation. Cells 
were subject to puromycin selection. After 10 days, 27 colonies (p336), 31 colonies 
(p388), 13 colonies (pCAG-DNMT1-IRES-PAC #10-1) and 14 (pCAG-DsRed2-C1-
DNMT1-IRES-PAC #7) colonies were found. The size of p336 #1, p336 #3, p336 #9, 
p388 #8, p388 #9 and p388 #10 colonies are relatively bigger than that of hESOD #1, 
hESOD #3, hESOD #9, hESOrD #1, hESOrD #2 and hESOrD #3 colonies. All images 
were captured in brightfield microscopy.  
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Table 5-1. The number of puromycin resistant colonies and established 
cell lines 
Plasmid No. of colonies found 
No. of colonies 
picked 
No. of cell lines 
established 
p336 27 23 14 
pCAG-DNMT1-IRES-PAC #10-1 13 13 8 
p388 31 23 17 
pCAG-DsRed2-c1-DNMT1-IRES-PAC#7 14 14 11 
Without plasmida 0 0 0 
a Transfection was performed without the plasmid. During puromycin selection, all 
cells died so that no cell lines were established.   
5.2.3.3 Characterisation of cell lines overexpressing DNMT1 
 
To indentify cell lines having both endogenous and exogenous DNMT1 expression, 
Western blot was performed on the 6% SDS-PAGE gel (Figure 5-8). Then, the blot 
was probed with a polyclonal DNMT1 antibody (NEB) raised against the N-terminal 
region. Consistent with previous reports (Chen et al., 2007; Esteve et al., 2005; Esteve 
et al., 2006; Kim et al., 2002; Pradhan and Kim, 2002), one DNMT1 specific band of 
190kDa was detected in all cell lines (Figure 5-8). The expression level of DNMT1 
protein was variable between cell lines, although α-Tubulin as a loading control was 
similarly expressed. Moreover, Ponceau S staining showed that equal amounts of 
proteins were loaded in each lane. DNMT1 is highly expressed in hESOD1 #1, 
hESOD1 #3, hESOD1 #4, hESOD1 #5, hESOD1 #6, hESOD1 #9, hESOrD1 #3, 
hESOrD1 #5 and hESOrD1 #8 in comparison to control cell lines, p366 #1, p366 #9, 
p388 #8, p388 #9, p388 #10, p388 #12, transfection control (TC) and HUES7 (p25).  
 
Figure 5-8. Western blot analysis of established cell lines on the 6% 
SDS-PAGE gel  
30 µg protein extracts from each cell line were loaded onto each lane of the 6% SDS-
PAGE gel, electroblotted into the nitrocellulose membrane, and probed with DNMT1 
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and α-Tubulin antibodies. The cell lines examined are shown on the top of gel images. 
Molecular masses are shown on the left of a gel image. α-Tubulin blot and Ponceau S 
staining were used as loading controls.  
 
Although cell lines overexpressing DNMT1 were identified on the 6% SDS-PAGE gel 
(Figure 5-8), this failed to discriminate between endogenous and exogenous DNMT1 
expression. Thus, Western blot was performed on the 4% SDS-PAGE gel (Figure 5-9). 
However, this also failed to discriminate between endogenous and exogenous 
DNMT1 expression. Similar to the 6% SDS-PAGE gel, one DNMT1 specific band 
was detected around 190kDa on the 4% SDS-PAGE gel (Figure 5-9 A). The 
expression levels of DNMT1 were quantified by the Aida image analyser and 
normalised to expression levels of α-Tubulin (Figure 5-9 B). Over 3 fold increased 
DNMT1 expression was detected in hESOD1 #3 (3.0 fold), hESOD1 #4 (3.7 fold) and 
hESOD1 #9 (3.5 fold), against control cell lines (p336 #1, p336 #9, p388 #8 and p388 
#9). In addition, hESOD1 #1 (2.4 fold), hESOD1 #5 (2.5 fold) and hESOD1 #6 (2.0 
fold) showed over 2 fold increased DNMT1 expression, compared to control cell lines. 
hESOD1 #7 had a similar expression level to control cell lines. Following Western 
blot analysis, 4 control cell lines (p366#1, p336#9, p388 #8, p388 #9) and 4 hESOD1 
cell lines (hESOD1 #1, hESOD1 #3, hESOD1 #4 and hESOD1 #9) were selected for 
further studies.  
 
Figure 5-9. Western blot analysis of established cell lines on the 4% 
SDS-PAGE gel  
(A) Total 30 µg protein extracts from each cell line were loaded onto each lane of the 
4% SDS-PAGE gel, electroblotted into the nitrocellulose membrane, and probed with 
DNMT1 and α-Tubulin antibodies. The cell lines studied are shown on the top of a 
gel image. Molecular masses are shown on the left of a gel image. α-Tubulin blot and 
Ponceau S staining were used as loading controls. (B) The expression level of 
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DNMT1 was quantified by the Aida image analyser and normalised by the expression 
level of α-Tubulin.  
 
5.2.3.4 Maintenance DNMT activity assay  
 
In mammalian cells, the increased expression of DNMT1 protein has been reported to 
be associated with increased maintenance DNMT activity (Biniszkiewicz et al., 2002; 
Vertino et al., 1996). Thus, the in vitro maintenance DNMT activity assay was 
performed, as previously described by Butler et al., (2006). This assay was performed 
by Dr. Jeong-Heon Lee and Prof. David G. Skalnik (Indiana University). Nuclear 
extracts were extracted from each cell line, incubated with [3H]SAM (S-adenosyl-L-
methionine) and oligonucleotides as substrates (Figure 5-10 C) and loaded into each 
lane of a 10.5% native PAGE gel. The gel was dried, exposed to the X-ray film and 
developed (Figure 5-10 A). The maintenance DNMT activities were illustrated by the 
bands coreesponding hemi-methylated oligonuclotides (Figure 5-10 A). The intensty 
of bands was quantifed by the Aida image analyser (Figure 5-10 B). Over 2 fold 
increased maintenance DNMT activities were detected in hESOD1 #3, hESOD1 #4 
and hESOD1 #9, against control cell lines (p336#1, p336#9, p388#8 and p388#9) 
(Figure 5-10 B). Moreover, over 1.5 fold increased maintenance DNMT activities 
were detected in hESOD1 #2, hESOD1 #5, hESOD1 #6 and hESOD1 #7. Thus, 
exogenously expressed DNMT1 in hESC lines functionally worked as a maintenance 
methyltransferase.  
 
Figure 5-10. In vitro maintenance DNMT activity assay in established cell 
lines  
(A) Maintenance DNMT activity assay was performed on the 10.5% native PAGE gel. 
In vitro DNMT activity was measured by the incorporation of methyl groups (CH3) 
from [3H]SAM (S-adenosyl-L-methionine) into double-strand oligonucleotides used 
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as substrates (C). (B) The activity level of each cell line was quantified by the Aida 
image analyser.  
5.2.4 Stem cell characteristics 
 
5.2.4.1 Morphology  
 
Brightfield microscopy analysis was performed in 8 cell lines to identify potential 
morphology changes induced by exogenous DNMT1 expression. This revealed no 
morphological changes in cell lines, although exogenous DNMT1 was expressed in 
hESOD1 cell lines (Figure 5-11). 
 
Figure 5-11. The morphology analysis of established cell lines  
All cell lines were examined at passage 30. All images captured under the microscopy 
of the brightfield filter showed no morphology changes of hESOD1 lines, compared to 
control lines (p366#1, p336#9, p388 #8 and p388 #9).   
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5.2.4.2 OCT4, NANOG and SSEA4 expression  
 
Immunostaining and Western blot for pluripotency markers were performed to 
identify whether hESOD1 cell lines (p30 and p45) were maintained in an 
undifferentiated state. Immunostaining revealed that OCT3/4 and NANOG were 
expressed in the nucleus of all cell lines (Figure 5-12 A). Furthermore, SSEA4 was 
expressed in the surface of all cell lines (Figure 5-12 A). By Western blot, similar 
expression levels of OCT3/4 and NANOG were detected in all cell lines at passages 
30 and 45 (Figure 5-12 B and C). Thus, the overexpression of exogenous DNMT1 did 
not interfere with the maintenance of an undifferentiated state of hESCs. 
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Figure 5-12. OCT3/4, NANOG and SSEA4 expression in established cell 
lines  
(A) Immunostaining of OCT3/4, NANOG and SEEA4 with respective antibodies (see 
section 2.2). The nucleus is visualised by DAPI (blue) staining. (B) Western analysis 
of cell lines at passages 30 and (C) p45. Western blot was performed on 4% ~ 8% 
SDS-PAGE gels. Total 30 µg protein extracts from each cell line were loaded onto 
each lane of the gel, electroblotted into the nitrocellulose membrane, and probed with 
respective antibodies (see section 2.2). α-Tubulin blots were used as loading controls.  
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5.2.4.3 Population double time and cell cycle 
 
The population doubling (PD) time was measured during 12 days (4 passages) in 
culture to identify whether hESOD1 cell lines had normal growth rates. The number 
of cells was counted by the hemocytometer. PD times were calculated using the 
formula: log (the number of subcultures established at the each passage)/log2 
(assuming 100% cell survival at each passage) (Allegrucci et al., 2007; Denning et al., 
2006) (Figure 5-13). In control cell lines, TC, p336 #1, p336 #9, p388 #8 and p399 #9, 
PD times were 59.2h, 60.2h, 61.3h, 60h and 61.4h, respectively. However, PD times 
of hESOD1 cell lines, hESOD1 #1, hESOD1 #3, hESOD1 #4 and hESOD1 #9 were 
70.5h, 64.8h, 68.5h and 71.7h, respectively. Thus, there are ~ 10h differences between 
control cell lines and hESOD1 cell lines (p<0.05), indicating that hESOD1 cell lines 
are slow growing, compared to control cell lines.  
 
Figure 5-13. The population doubling (PD) time of established cell lines  
The number of cells was calculated by hemocytometer during 12 days. PD times were 
calculated using the log scale. The statistical analysis was performed by Post Hoc, 
Mann-Whitney and Kruskal-Wallis tests that showed there are significant differences 
between control cell lines and hESOD1 cell lines (p<0.05) (see appendix 2).  
 
Cell cycle analysis was performed by flow cytometry, following PI (propidium iodide) 
staining. Data were analysed by WinMDI and Cylchred programmes (see section 
2.3.23). Control cell lines (HUES7 p22, p336 #1, p336#9, p388 #8 and p388 #9) 
showed similar proportions of G1, S and G2-M phase cells (Figure 5-14 A and B). 
However, the proportion of S phase cells significantly decreased in hESOD1 #1, 
hESOD1 #4 and hESOD1 #9, compared to control cell lines (p<0.05). Moreover, the 
proportion of G2-M phase cells significantly increased in hESOD1 #1, hESOD1 #4 
and hESOD1 #9 (p<0.05), compared to control cell lines. Interestingly, hESOD1 #3 
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showed similar proportions of G1, S and G2-M cells of control cell lines (Figure 5-14 
B).  
 
Figure 5-14. Cell cycle analysis of established cell lines  
(A) The total cell population was examined by flow cytometry. Data were analysed by 
WinMDI and Cylchred programmes and (B) the bar chart was generated based on the 
data. Statistical analysis was performed by Post Hoc, Mann-Whitney and Kruskal-
Wallis tests that showed there are significant differences between control cell lines 
and hESOD1 cell lines (P<0.05). 
5.2.5 DNA methylation 
 
5.2.5.1 DNA methylation at 14 imprinting regulatory regions   
 
DNA methylation at 14 imprinting regulatory regions was analysed in hESOD1 cell 
lines (passages 30 and 45) by combined bisulphite restriction analysis (COBRA). In 
Chapter 4, overall DNA methylation levels at 14 imprinted regulatory regions were 
characterised in 22 hESC cell lines, when imprinted loci are informative. PCR was 
performed with bisulphite modified genomic DNA. PCR products were digested by 
appropriate restriction enzymes (Figure 5-15 and 5-16). Of 14 imprinted loci 
examined, none showed DNA methylation changes in both hESOD1 and control cell 
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lines. In detail, the promoter region of TP73, SLC22A18 and CDK1NC was 
unmethylated in both control (HUES7 p22, p336 #1, p336 #9, p388 #8 and p388 #9) 
and hESOD1 cell lines (hESOD1 #1, hESOD1 #3, hESOD1 #4 and hESOD1 #9). 
IGF2R DMR2 was methylated in all cell lines. Of other 10 imprinting regulatory 
regions (PEG10, PEG1, KvDMR1, IGF2, H19, GLT2, SNRPN, PEG3, NESP55 and 
GNAS1 XLαs DMRs) examined, all showed differential methylation on both parental 
alleles in all cell lines, except for the H19 CTCF6 AciI site.  
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Figure 5-15. DNA methylation at 14 imprinting regulatory regions in 
established cell lines (p30)  
The COBRA analysis was performed with appropriate restriction enzymes to 
determine methylation-dependent sequence differences in PCR products of bisulphite 
modified genomic DNA. 14 imprinted genes studied, appropriate restriction enzymes 
and the number of restriction enzyme sites are shown on the left side of gel images. 
The name of each cell line is shown on the top of the gel image. 3% agarose gels were 
used for gel electrophoresis. H2O was used as a negative control for PCR. The 50 bp 
DNA Ladder (NEB) was used for a molecular maker. U indicates digested and D 
indicates undigested.  
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Figure 5-16. DNA methylation at 14 imprinting regulatory regions in 
established cell lines (p45)  
The COBRA analysis was performed with appropriate restriction enzymes to 
determine methylation-dependent sequence differences in PCR products of bisulphite 
modified genomic DNA. 14 imprinted genes studied, appropriate restriction enzymes 
and the number of restriction enzyme sites are shown on the left side of gel images. 
The name of each cell line is shown on the top of the gel image. 3% agarose gels were 
used for gel electrophoresis. H2O was used as a negative control for PCR. The 50 bp 
DNA Ladder (NEB) was used for a molecular maker. U indicates digested and D 
indicates undigested.  
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5.2.5.2 DNA methylation at 9 tumour-suppressor gene promoters   
 
The overexpression of endogenous DNMT1 is associated with hypermethylation at the 
promoter regions of tumour-suppressor genes in human cancers (Etoh et al., 2004; 
Peng et al., 2006; Sawada et al., 2007). Furthermore, human fibroblast cell lines 
overexpressing exogenous DNMT1 show hypermethylation at the promoter regions of 
5 tumour-suppressor genes (Vertino et al., 1996). Thus, DNA methylation at 9 
previously reported tumour-suppressor gene promoters was analysed in hESOD1 and 
control cell lines by methylation-specific PCR (MSP). These genes were selected, 
since they are functionally known to be important for metastasis, angiogenesis, 
apoptosis, cell cycle and DNA repair (Akiyama et al., 2003; Dong et al., 2001; Evron 
et al., 2001; Herman et al., 1996; Imura et al., 2006; Zochbauer-Muller et al., 2001). 
Furthermore, some of genes (e.g. GATA4 and GATA5) are critically involved in 
embryonic development and differentiation of hESCs (Akiyama et al., 2003; Ohm et 
al., 2007). These gene promoters are previously shown to be unmethylated in the 
hESC line (WA01 also know as H1), whereas HCT116 exhibits hypermethylation 
(Ohm et al., 2007). Thus, HCT116 was used for a control for methylation. In addition, 
in vitro methylated HUES7 p21 and human liver DNA by the SssI methylase were 
used as controls for positive methylation.  
 
Of 10 gene promoters examined, most promoters were unmethylated in HUES7 p21, 
except for p16 and TIMP-3 promoters (Figure 5-17). However, 6 promoters (CCND1, 
ESR1, MGMT, GATA4, HIC-1 and p16 promoters) were methylated in HCT116. 
Interestingly, gain of methylation at MGMT, HIC-1 and GATA5 promoters was 
detected in differentiated HUES7 (EBs d27), although other promoters showed similar 
methylation patterns between undifferentiated and differentiated cells (Figure 5-17). 
In in vitro methylated HUES7 p21 and human liver DNA, either methylation or 
predominate methylation was detected at all promoters (Figure 5-17). In in vitro 
methylated HUES7 p21 DNA, TIMP-3, CCND1, ESR1, GATA5 promoters were 
completely methylated, whereas CDH1, DAPK1, MGMT, HIC-1, GATA4 and p16 
promoters were predominantly methylated. In in vitro methylated human live DNA, 
the CCND1 promoter was completely methylated and other promoters were 
predominantly methylated. Based on these observations, DNA methylation patterns at 
10 gene promoters were analysed in hESOD1 cell lines at passage 30 (Figure 5-17). 
Gain of methylation at the TIMP-3 promoter was detected in all hESOD1 cell lines. 
 190 
Moreover, gain of methylation at MGMT was detected in hESOD1#1. However, other 
promoters showed no methylation changes in hESOD1 cell lines.   
 
Figure 5-17. MSP DNA methylation analysis at 10 tumour-suppressor 
gene promoters in established cell lines (p30)  
Genes studied are shown on the left of each panel. Cell lines studied as shown on the 
top of the panel. M indicates amplified PCR products recognising methylated CpGs. U 
indicates amplified PCR products recognising unmethylated CpGs. HUES7 p21 was 
used as a control for unmethylation. HCT116, in vitro methylated HUES7 p21 and 
human liver DNA were used as controls for methylation. H2O used as a negative 
control for PCR. The 100bp DNA Ladder (NEB) was used as a molecular maker. 
 
It has been reported that DNA methylation changes accumulate in human fibroblast 
cell lines overexpressing DNMT1 during in vitro prolonged culture (Vertino et al., 
1996). Thus, the DNA methylation status at 10 tumour-suppressor gene promoter was 
analysed in hESOD1 cell lines at passage 45 (Figure 5-18). Gain of methylation at the 
TIMP-3 promoter was still retained in all hESOD1 lines (p45). Also, gain of 
methylation at MGMT promoter persisted during in vitro culture of hESOD1 #1. 
Interestingly, gain of methylation at DAPK-1 was detected in hESOD1 #9 p45 (Figure 
5-18). Furthermore, gain of methylation at the MGMT promoter was detected in 
hESOD1 #3 p45, hESOD1 #9 p45 and p388#8 p45. Thus, DNA methylation changes 
accumulated at some promoters during in vitro culture.  
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Figure 5-18. MSP DNA methylation analysis at 10 tumour-suppressor 
gene promoters in established cell lines (p45)  
Genes studied are shown on the left of each panel. Cell lines studied as shown on the 
top of the panel. M indicates amplified PCR products recognising methylated CpGs. U 
indicates amplified PCR products recognising unmethylated CpGs. HUES7 p21 was 
used as a control for unmethylation. In vitro methylated HUES7 p21 was used as a 
control for methylation. H2O used as a negative control for PCR. The 100bp DNA 
Ladder (NEB) is used as a molecular maker. 
5.2.5.2.1 Association between DNA methylation and gene expression 
 
Hypermethylation at promoter regions of tumour suppressor genes can be associated 
with transcriptional silencing of the genes (Esteller, 2007; Feinberg, 2007). Thus, RT-
PCR was performed to identify association between gain of methylation at MGMT and 
TIMP-3 promoters and transcriptional repression of the genes. TIPM-3 was expressed 
in HUES7 p22, HCT116 and EBs d27 in a similar level that was associated with 
unmethylation at its promoter (Figure 5-17 and 5-19). GATA4 and GATA5 were highly 
expressed in EBs (compared to HUES7 p22 and HCT116) that was also associated 
with unmethylation at their promoters (Figure 5-17 and 5-19). However, even if the 
GATA5 promoter was unmethylated in HCT116, its expression was not detected, 
indicating no association between DNA methylation at the region examined and gene 
expression. Furthermore, no association was detected in MGMT and HIC-1 genes. 
MGMT was expressed in HUES7 p22, HCT116 and EBs d27 in a similar level that 
was not associated with predominant methylation at its promoter in HCT116 and EBs 
d27 (Figure 5-17 and 5-19). HIC-1 is expressed in HUES7 p22, HCT116 and EBs d27 
that was not associated with predominant methylation at its promoter in HCT116 and 
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EBs d27. In a similar scenario, no associations were detected in hESOD1 cell lines. 
Although gain of methylation at MGMT and TIMP-3 promoters in hESOD1 cell lines, 
their expression levels were similar to control cell lines (Figure 5-17 and 5-19).  
 
Figure 5-19. The RT-PCR analysis of 5 tumour-suppressor genes in 
established cell lines  
PCR amplification was performed with cDNA of cell lines. 2% agarose gels were 
used for gel electrophoresis. The 100bp DNA ladder (NEB) was used as a molecular 
maker. Cell lines studied are shown on the top of the panel. Genes studied are shown 
on the left of panels. H2O was used as a negative control for PCR. RT- indicates no 
reverse transcription reaction.  
5.2.5.3 DNA methylation at repetitive sequences  
 
DNA methylation analysis was performed for LINE1, Satellite 2 and Satellite 3 by 
Southern blot. DNA was digested with either MspI which cut at the sequence CCGG 
or HpaII which dose not cut when the cytosine is methylated (Lei et al., 1996; Rhee et 
al., 2002; Rhee et al., 2000). Southern blot analysis revealed that DNA methylation 
did not vary between control and hESOD1 cell lines (Figure 5-20). In all cell lines 
examined, larger DNA fragments were detected in HpaII digests compared to MspI 
digests at LINE1, Satellite 2 and Satellite 3, indicating that these regions were heavily 
methylated in all cell lines. Interestingly, small fragments at LINE1, Satellite 2 and 
Satellite 3 were detected in HpaII digests of EBs day 27, indicating that these regions 
were less methylated in differentiated hESCs (Figure 5-20). 
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Figure 5-20. The methylation analysis at LINE1, Satellite 2 and Satellite 3 
in established cell lines  
Gel electrophoresis followed by ethidium bromide staining, (B) LINE1 blot, (C) 
Satellite 2 blot and (D) Satellite 3 blot. The methylation status was determined by 
digesting DNA with MspI (M) and HpaII (H). Digested DNA fragments were 
separated by gel electrophoresis, transferred into nitrocellulose membranes, and 
hybridised with 32P-labeled DNA probes. Cell lines studied and restriction enzymes 
are shown on the top of images. The 2-Log DNA ladder (NEB) was used as a 
molecular maker.  
5.2.5.4 DNA methylation at ~ 2,200 CpG islands 
 
RLGS analysis was performed by Jayson Bispham (University of Nottingham). All 
procedures were described in a previous report (Allegrucci et al., 2007). Of ~ 2,200 
CpG loci examined, 6 loci showed DNA methylation changes (2 loci were 
hypermethylated and 4 loci were demethylated) in p388#9 p46, against HUES7 p22 
(Table 5-2). However, only 1 or 2 loci showed DNA methylation changes (1 locus 
was hypermethylated and l locus was demethylated) in hESOD1#1 p45 and 
hESOD1#4 p45, against HUES7 p22.  
 
Table 5-2. The methylation analysis at ~ 2,200 CpG islands 
p388#9 p45 hESOD#1 p45 hESOD#4 p45 
Loci Methylation Gene 
name 
Loci Methylation Gene 
name 
Loci Methylation Gene 
name 
2CA Hypermethylated - 2E14 Hypermethylated TM7SF2 3D18 Demethylated SNIP 
2D1 Demethylated - 3D18 Demethylated SNIP    
2EJ Demethylated -       
2FC Demethylated -       
2G41 Hypermethylated -       
3E57 Demethylated 
Mouse 
AK047384 
cDNA 
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5.3 Discussion  
 
Recent studies have reported that some CpG islands within imprinted and non-
imprinted loci in hESCs undergo loss of DNA methylation during in vitro long-term 
culture (Allegrucci et al., 2007; Bibikova et al., 2006). A potential reason for loss of 
methylation may be due to relatively low expression level of endogenous DNMT1 in 
hESCs (Emma Lucas and Lorraine Young unpublished), although other potential 
factors (e.g. non-physiological culture conditions and in vitro environmental factors) 
might be involved in this (Allegrucci et al., 2004; Allegrucci et al., 2007; Steele et al., 
2005). Thus, the aim of this Chapter was to determine whether increasing DNMT1 
expression and its functional activity could prevent loss of methylation from spreading 
in the genome of hESCs during in vitro prolonged culture. In order to test this 
hypothesis, hESC lines overexpressing DNMT1 cDNA (hESOD1 lines) were 
established.  
5.3.1 The establishment of hESC lines overexpressing DNMT1 
 
To establish cell lines stably expressing a specific transgene, the optimal choice of the 
promoter and backbone plasmid (or expression cassette) is critically required (Liew et 
al., 2007; Smith et al., 2008). Previous studies have demonstrated that the generation 
of long-term stably transfected mammalian ESC lines is difficult due to transcriptional 
silencing of transgene promoters mediated by DNA methylation-dependent or -
independent mechanisms (Liew et al., 2007; Ren et al., 2006; Smith et al., 2008; 
Vallier et al., 2004a; Ying et al., 2003b). For example, enhanced green fluorescent 
protein (eGFP) expression mediated by the cytomegalovirus (CMV) immediate early 
promoter (pCMV) becomes silenced during the generation of stably transfected hESC 
lines (Liew et al., 2007). Furthermore, eGFP expression derived by other mammalian 
promoters including pUbiC (human UbiquitinC), pR26 (ROSA26) and pCAGG 
(chicken β-actin/rabbit β-globin gene hybrid promoter) in hESC and human 
embryonal carcinoma (EC) lines is substantially lost during in vitro culture (Liew et 
al., 2007). DNA methylation-dependent promoter silencing of exogenously expressed 
retroviral vectors has been reported in mESCs, mouse EC cells and hESCs (Jahner et 
al., 1982; Kameda et al., 2006; Stewart et al., 1982).  
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However, hESC lines stably expressing eGFP have been successfully established 
using the pCAG-eGFP-IRES-PAC plasmid containing a chicken β-
actin/cytomegalovirus (CMV) hybrid promoter (pGAG) linked to a polyma virus 
mutant enhancer (PyF101), an internal ribosome entry site (IRES) and a puromycin N-
acetyltranferease (PAC) resistant gene (Denning et al., 2006; Liew et al., 2007; Vallier 
et al., 2004b). Liew et al., (2007) has pointed out that PyF101 acts as an enhancer that 
is essential for maintaining stable transgene expression in hESC lines. Thus, in this 
Chapter, the pCAG-eGFP-IRES-PAC plasmid was selected as a vehicle to carry 5.2 
kb of a full-length DNMT1 cDNA into the genome of HUES7. pCAG-hDNMT1-
IRES-PAC and pCAG-DsRed2-C1-hDNMT1-IRES-PAC plasmids were generated 
and transfected into HUES7. Following puromycin selection, 9 cell lines 
overexpressing exogenous DNMT1 (hESOD1 lines) were indentified by Western blot, 
indicating that an exogenously expressed DNMT1 cDNA was stably integrated into 
the genome of HUES7, transcribed and translated. Moreover, these cell lines showed 
increased maintenance DNMT activities as measured in vitro with a hemimethylated 
oligonucleotide as substrate, indicating that the translated protein targeted to 
hemimethylated CpG dinucleotides in nuclei and functionally worked as a 
maintenance methyltransferase. Furthermore, Western blot analysis revealed that 
hESOD1 cell lines were propagated with exogenous DNMT1 expression during 
further 30 passages, indicating that no transcriptional silencing of pCAG promoter. 
Thus, the pCAG-eGFP-IRES-PAC plasmid was suitable for the generation of hESC 
lines stably expressing a specific transgene.  
 
In mESCs and human fibroblast cells, previously, cell lines overexpressing exogenous 
DNMT1 have been established, showing both increased DNMT1 protein levels and 
DNMT activities (Biniszkiewicz et al., 2002; Vertino et al., 1996). Interestingly, 
human fetal lung fibroblast (IMR90/SV40) cell lines overexpressing DNMT1 (HMT 
lines) show ~ 50 fold increased DNMT1 protein level and DNMT activity (Vertino et 
al., 1996). However, the mESC line overexpressing Dnmt1 (Dnmt1+/+;BAC ) shows 
only ~ 4 fold increased Dnmt1 protein level and ~ 2.5 fold increased Dnmt activity 
(Biniszkiewicz et al., 2002). In this Chapter, similar to a mouse study, hESOD1 cell 
lines produced ~ 3.5 fold increased amounts of DNMT1 protein and they had ~ 2.5 
fold increase in maintenance DNMT activity. The underlying mechanisms of 
differences in DNMT1 protein levels and enzymatic activities between embryonic 
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stem cells and fibroblast cells are not known. However, it can be suggested that 
embryonic stem cells have a more limited ability to express a transgene than fibroblast 
cells. This could be associated with developmental stage- or tissue-specific chromatin 
condensation (Bernstein et al., 2005; Bibikova et al., 2008; Frigola et al., 2006; Ohm 
et al., 2007).  
 
Two plasmids were generated in this Chapter. 1) The pCAG-hDNMT1-IRES-PAC 
plasmid contains a 5.2 kb full-length cDNA of human DNMT1 which is inserted into 
EcoRI restriction sites in the place of eGFP of p336, and 2) the pCAG-DsRed2-C1-
hDNMT1-IRES-PAC plasmid contains a 5.9kb DsRed2 conjugated DNMT1 cDNA 
which is inserted into PmeI and AgeI restriction sites of p388. Interestingly, cells 
transiently transfected by pCAG-DsRed2-C1-hDNMT1-IRES-PAC had DsRed2 
signals detected in nuclei using fluorescence microscopy. However, following the 
puromycin selection for ~ 4 weeks, established cell lines (hESOrD1 cell lines) showed 
no DsRed2 signals, although exogenous DNMT1 was still expressed, as determined by 
Western blot. In the pCAG-DsRed2-C1-hDNMT1-IRES-PAC plasmid, DsRed2 
coding sequences lie downstream of pCAG promoter and upstream of DNMT1 cDNA 
(see Figure 5-3 and 5-4). Thus, it was expected that both DsRed2 and exogenous 
DNMT1 were simultaneously expressed in nuclei. If the pCAG promoter is 
transcriptionally silenced by either DNA methylation-dependent or -independent 
mechanism, neither protein can be produced. However, in hESOrD cell lines, only 
exogenous DNMT1 expression was detected, implying that other mechanisms may be 
involved in the transcriptional silencing of DsRed2. Thus, hESOrD cell lines were 
excluded from further studies.  
5.3.2 Stem cell characteristics and proliferation  
 
The inactivation or overexpression of Dnmt1 in mESCs did not interfere with the 
maintenance of an undifferentiated state of the cells (Biniszkiewicz et al., 2002; Chen 
et al., 2003; Jackson et al., 2004; Li et al., 2007). For example, transcription factors 
such as Oct3/4 and Nanog were stably expressed in Dnmt1 deficient mESCs (Dnmt1n/n 
and Dnmt1c/c J1 ES cells) and mESCs overexpressing Dnmt1 (Dnmt1+/+;BAC ) and 
remained unmethylated at their promoters (Biniszkiewicz et al., 2002; Chen et al., 
2003; Jackson et al., 2004; Li et al., 2007). Moreover, they have no morphology 
changes and can be in vitro propagated as wild-type ESCs. In this chapter, Western 
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blot and immunostaining analyses revealed that normal expression patterns of OCT3/4, 
NANOG and SSEA4 upon in vitro culture (up to 30 passages). Furthermore, no 
phenotypic changes were detected in hESOD1 cell lines, showing prominent nucleoli 
and a high ratio of nucleus to cytoplasm, as expected. Thus, consistent with a previous 
finding in mESCs (Biniszkiewicz et al., 2002), exogenously expressed DNMT1 in 
hESCs did not interfere with stem cell characteristics and their phenotypic changes 
upon in vitro culture.  
 
It has been reported that Dnmt1 is critically involved in cellular differentiation of 
mESCs (Biniszkiewicz et al., 2002; Jackson et al., 2004; Li et al., 2007). The deletion 
of Dnmt1 in mESCs leads to the failure of the formation of embryoid bodies (EBs) 
and differentiation into hematopoietic and cardiac lineages (Jackson et al., 2004). 
Oct3/4 and Nanog were still expressed in differentiated Dnmt1c/c J1 ES cells, and they 
were unmethylated at their promoters (Li et al., 2007). In addition, differentiation-
specific (trophoblast, mesodermal and endodermal) markers were abnormally 
expressed in differentiated Dnmt1c/c J1 ES cells (Jackson et al., 2004). Moreover, 
embryonic lethality has been reported as a consequence of overexpression of 
exogenous Dnmt1 in mESCs (Biniszkiewicz et al., 2002). This indicates that 
appropriate DNMT1 expression is essential lineage-specific differentiation of mESCs 
(Biniszkiewicz et al., 2002; Jackson et al., 2004; Li et al., 2007). In this Chapter, all 
studies were performed with undifferentiated hESOD1 cell lines. Now, differentiation 
studies are required to examine whether DNMT1 dosage plays an important role for 
tissue-specific differentiation in hESCs. 
 
Even with no detectable morphology changes and embryonic stem cell characteristics, 
growth rates were affected in hESOD1 cell lines. hESOD1 cell lines took longer to 
expand in vitro, compared to control cell lines. Control cell lines took for ~ 3 days to 
be confluent into T25 flasks, whereas hESOD1 cell lines took for ~ 3.5 to 4 days. 
Thus, in this Chapter, population doubling (PD) time was analysed between cell lines 
over 12 days in culture. Consistent with previous reports (Allegrucci et al., 2007; 
Cowan et al., 2004; Denning et al., 2006), the PD time of HUES7 p22 and control cell 
lines was ~ 60 h. However, the PD time of hESOD1 cell lines was ~ 70 h so that there 
are ~ 10 h differences between control and hESOD1 lines. Similar results have been 
reported in human fibroblast cell lines overexprsesing DNMT1 (HMT cell lines) 
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(Vertino et al., 1996). The PD time of control cell lines (NEO cell lines) were ~ 28 h, 
whereas that of HMT cell lines were ~ 40 h (Vertino et al., 1996). One possibility to 
explain prolonged PD times in hESOD1 and HMT cell lines is that exogenous 
DNMT1 cDNA may integrate into some loci related to cellular growth and cell cycle 
that interferes with normal gene expression within these loci. This, in turn, may lead 
to the perturbation of normal cell cycle and cell proliferation. Indeed, flow cytometry 
analysis of DNA content, in this Chapter, revealed that hESOD1 cells showed ~ 20% 
increased proportion of cells in G2-M phases, compared to control cell lines, and ~ 
8% decreased proportion of cells in S phase, suggesting that prolonged PD times in 
hESOD1 cell lines may be associated with impaired cell cycle. The alteration of cell 
cycle has been reported to be associated with the abnormal expression of cell cycle 
related genes such as Cyclin B1, Cyclin E and PCNA (proliferating cell nuclear 
antigen)  (Chen et al., 2007). Thus, it is now required to determine how cell cycle 
regulators are expressed in hESOD1 cell lines.  
5.3.3 DNA methylation changes  
 
The inactivation and overexpression of Dnmt1 in mESCs lead to the perturbation of 
DNA methylation patterns at imprinting regulatory regions that is associated with loss 
of imprinting of their relative genes (Biniszkiewicz et al., 2002; Jackson-Grusby et al., 
2001; Li et al., 1993). Thus, in this Chapter, the DNA methylation status at 14 
imprinting regulatory regions was analysed in hESOD1 cell lines by combined 
bisulphite restriction analysis (COBRA). Inconsistent with a previous study 
(Biniszkiewicz et al., 2002), of 14 regions examined, none showed DNA methylation 
changes in hESOD1 cell lines. There are three possible ways to explain this. One is 
that ~ 3 fold increased expression of exogenous DNMT1 and ~ 2 fold increased 
maintenance DNMT activity could not be enough to induce DNA methylation 
changes at imprinting regulatory regions. Secondly, stably established imprints during 
gametogenesis and embryogenesis may not be susceptible to DNA methylation 
changes caused by overexpression of exogenous DNMT1 (Murrell, 2006; Reik and 
Walter, 2001; Surani, 2001). Thirdly, methylation-sensitive biding factors (e.g. CTCF, 
YY1, MBDs), which tightly bind to either the unmethylated or methylated allele of 
imprinting regulatory regions (Donohoe et al., 2007; Fitzpatrick et al., 2007; Hark et 
al., 2000; Kim et al., 2006; Schoenherr et al., 2003), may inhibit exogenous DNMT1 
from accessing into imprinting regulatory regions.   
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Vertino et al., (1996) and Feltus et al., (2003) have demonstrated that the 
overexpression of exogenous DNMT1 in human fibroblast cells is associated with 
tumour progression though transcriptional silencing of some tumour-suppressor genes 
guided by hypermethylation at their promoters. Moreover, the overexpression of 
endogenous DNMT1 is frequently found in human cancers including gastric, cervix 
and pancreatic cancers (Etoh et al., 2004; Peng et al., 2006; Sawada et al., 2007). This 
is associated with transcriptional silencing of some tumour-suppressor genes mediated 
by hyperemthylation at their promoters (Etoh et al., 2004; Peng et al., 2006; Sawada et 
al., 2007). Thus, in this Chapter, DNA methylation at 10 previously reported tumour-
suppressor gene promoters was analysed by methylation-specific PCR (MSP). 
Consistent with a previous study (Vertino et al., 1996), gain of methylation was 
detected at three gene promoters (TIMP-3, MGMT and DAPK-1)  in hESOD1 cell 
lines, but others showed no DNA methylation changes, indicating locus-specific DNA 
methylation changes caused by overexpression of exogenous DNMT1. Moreover, 
DNA methylation changes accumulated at MGMT and DAPK-1 promoters during in 
vitro culture from p30 to p45, suggesting that overexpression of DNMT1 in hESCs can 
promote time-dependent accumulation of DNA methylation at some gene promoters.  
 
Interestingly, RT-PCR analysis revealed that TIMP-3 and MGMT genes in hESOD1 
were similarly expressed to control cell lines, although their promoters were 
methylated, indicating no association DNA methylation and their gene expression. 
There are two possibilities to explain this. One is that DNA methylation alone induced 
by exogenous DNMT1 is not sufficient to mediate transcriptional silencing of TSGs. 
Other factors or co-repressors may be required for this. Indeed, previous reports have 
suggested that both histone H3 methylated Lys27 (H3K27) and Lys9 (H3K9) need to 
be co-operated with DNA hypermethylation to mediate transcriptional silencing of 
TSGs (Calvanese et al., 2008; Ohm et al., 2007). Another possibility is that DNA 
methylation has not been expanded into transcriptional regulatory regions of TIMP-3, 
MGMT and DAPK1 genes. Thus, this allows their expression in hESOD1 cell lines. 
Indeed, the MSP analysis employed in this thesis allows to examine about 100 bp (few 
CpG dinucleotides) of TSG promoters (Table 2-6). Therefore, more upstream or 
downstream regions need to be examined to identify this possibility.  
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The overexpression of Dnmt1 in mESC gives rise to genome-wide hypermethylation 
at minor centromeric repeats, endogenous C-type retrovirus repeats (pMO), minor and 
major satellite repeats and IAP elements, as confirmed by Southern blot 
(Biniszkiewicz et al., 2002; Chen et al., 2003). Thus, in this Chapter, the DNA 
methylation status at LINE1, Satellite 2 and Satellite 3 was analysed. Southern blot 
analysis revealed that three regions showed no particular DNA methylation changes in 
both control and hESOD1 cell lines. All cell lines including control cell lines were 
hypermethylated at these repetitive sequences. Because, in the human genome, ~ 80% 
CpG dinucleotides are normally hypermethylated (Lander et al., 2001; Venter et al., 
2001), it was difficult to discriminate DNA methylation changes by Southern blot. 
Thus, more sensitive approaches such as bisulphite sequencing and Hairpin-bisulphite 
PCR are required to determine DNA methylation changes in a genome-wide level. 
Alternatively, the RLGS technique and epigenome-sequencing might be useful to 
determine this.    
 
In this Chapter, the restriction landmark genome scanning (RLGS) technique was 
performed to examine an overview of DNA methylation changes between control and 
hESOD1 cell lines upon in vitro culture. Of ~2,200 CpG loci examined, 6 CpG loci 
were identified to be hypermethylated or demethylated in p388#9 p45 (compared to 
HUES7 p22), indicating in vitro culture induced DNA methylation changes over 23 
passages. This was consistent with previous finding in hESCs (Allegrucci et al., 2007). 
However, only 2 loci appeared to be hypermethylated or demethylated in hESOD1 
cell lines p45 (against HUES7 p22), indicating that overexpression of exogenous 
DNMT1 in hESCs resulted in increased epigenetic stability. However, only one cell 
line (HUES7), which is previously characterised to be epigenetically stable relative to 
other cell lines, as described in Chapter 3 and 4, and Allegrucci et al., (2007), was 
employed and more studies are required for conclusive proof.  
5.3.4 Further works needed 
 
In this Chapter, all studies were performed with undifferentiated control and hESOD1 
cell lines. Thus, in vitro differentiation studies are required to examine how the 
DNMT1 dosage is involved in tissue-specific differentiation of hESCs. The karyotype 
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analysis was not performed in this Chapter. This is also required to identify karyotypic 
stability of hESOD1 upon in vitro culture.  
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6 SUMMARY AND DISCUSSION 
 
6.1 Imprinting instability in Human embryonic stem cell lines 
 
This thesis has demonstrated that human embryonic stem cell (hESC) lines have 
altered imprinted gene expression that can be mediated by aberrant DNA methylation 
at their imprinting regulatory regions (Chapter 3 and 4). Preliminary studies of 10 
imprinted genes in 1 to 6 informative cell lines (in total 9 individually established cell 
lines examined) have suggested that hESC lines possess a substantial degree of 
imprinting stability in both the differentiated and undifferentiated state (Mitalipov, 
2006; Plaia et al., 2006; Rugg-Gunn et al., 2005; Sun et al., 2006). In this thesis, 
however, imprinting instability can be readily detected by increasing the number of 
cell lines and imprinted genes analysed (Chapter 3). Of 22 potential imprinted genes 
examined in 1 to 12 informative cell lines (in total 22 hESC lines examined), 9 genes 
(PEG10, PEG1, MESTIT1, IGF2, H19, GTL2, NESP55, PHLDA2 and ATP10C) 
showed variable allele-specific expression between cell lines, but other 12 genes 
(KCNQ1OT1, NDN, NDNL1, SNRPN, IPW, PEG3, KCNQ1, CDKN1C, TP73, IGF2R, 
WT1 and SLC22A18) showed consistent allele-specific expression in hESC lines, 
indicating that genomic imprinting can be disrupted in a gene-specific manner. This 
was consistent with a recent report of 10 imprinted genes in 3 to 24 informative cell 
lines (total 49 individually established cell lines examined), 6 genes (IGF2, PEG1, 
H19, NESP55, GTL2 and SLC22A18) showed imprinting disruptions and variations 
between cell lines (Adewumi et al., 2007). Furthermore, in this thesis, DNA 
methylation was examined at 12 potential imprinting regulatory regions to indentify 
an association between the variability observed in interline allele-specific expression 
status and DNA methylation (Chapter 4). The allele-specific expression of 8 imprinted 
genes (TP73, PEG10, PEG1 isoform1, SLC22118, CDKN1C, KCNQ1OT1, KCNQ1 
and NESP55) was associated with DNA methylation patterns at 6 regions (TP73 
promoter, PEG10 DMR, PEG1 DMR, SLC22A18 promoter, KvDMR1 and NESP55 
DMR). However, DNA methylation patterns at IGF2, GLT2 and NDN DMRs were 
not associated with the allele-specific expression of their corresponding genes. This 
indicates that DNA methylation does not regulate the allele-specific expression of 
some imprinted genes.  
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6.2 How imprinting is variable and unstable in hESC lines?    
 
Currently, the underlying mechanism how genomic imprinting can be disrupted in 
hESC lines is not clear. However, there are at least two possible ways to explain this, 
based on a larger number of studies in various animal species. (1) Genomic imprinting 
in hESC lines can be disrupted due to in vitro culture conditions. (2) Imprinting errors 
in hESC lines can be originated from donor embryos fertilised and cultured in vitro.  
6.2.1 Imprinting errors caused by in vitro culture conditions  
 
Once hESC lines are derived from human blastocyst stage embryos, they need to be in 
vitro propagated in medium to obtain sufficient cells for freezing, characterising, and 
further expanding (reviewed by Allegrucci and Young, 2007; Fenno et al., 2008; 
Hoffman and Carpenter, 2005; Laslett et al., 2003). Sometimes, they need to be long-
term cultured in medium for the purpose of scientific research. According to previous 
studies observed in preimplantation stage mouse embryos, mESCs and monkey ESCs, 
detrimental effects on the stability of imprinting caused by in vitro culture medium 
containing fetal bovine serum (FBS) and insufficient amino acids have been reported 
(Dean et al., 1998; Feil et al., 1997; Fujimoto et al., 2006; Humpherys et al., 2001; 
Mitalipov et al., 2007). For instance, imprinted gene expression and DNA methylation 
appear to be variable and unstable upon derivation and subsequent propagation of 
mouse and monkey ESC lines, as a consequence of culture medium containing fetal 
bovine serum (FBS) (Dean et al., 1998; Feil et al., 1997; Fujimoto et al., 2006; 
Mitalipov et al., 2007). Moreover, the lack of methionine and other amino acids 
supplements supplied in culture medium causes altered imprinted gene expression and 
DNA methylation in preimplantation stage mouse embryos (Doherty et al., 2000; 
Mann et al., 2004; Rinaudo and Schultz, 2004). These evidences implicates that hESC 
lines can have imprinting instability, when they are cultured in media containing non-
physiological levels of amino acids and FBS (or serum replacement, KSR) (reviewed 
by Allegrucci et al., 2005).  
 
Currently, hESC lines are cultured in media containing 15 ~ 20% of FBS or 5 ~ 20% 
of KSR (reviewed by Allegrucci et al., 2005). Moreover, current media, DMEM 
(Dulbecco’s modified Eagle medium), KO-DMEM and DMEM-F12, for culturing 
hESC lines contain non-physiological levels of amino acids and vitamins (Allegrucci 
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et al., 2005; Steele et al., 2005). Specifically, these media contain 500 ~ 1500 fold 
physiological concentration of methionine/folate cycle components (including 
methionine, folate, vitamin B6, B12, selenium, betaine and polyamines) (Allegrucci et 
al., 2005; Steele et al., 2005). Thus, these components may influence DNA 
methylation alterations of hESC lines cultured in it (Allegrucci et al., 2005; Steele et 
al., 2005). Previously, Alexandra Thurston (University of Nottingham) and Cinzia 
Allegrucci (University of Nottingham) have examined the effect of methyl cycle 
components on the DNA methylation status at imprinting regulatory regions in 
HUES7 and BG01. They are cultured up to 5 passages (~ 20 days) in either medium 
containing supra-physiological levels of methionine/folate cycle components (named 
as HMG) or custom-made KO-DMEM medium containing physiological levels of 
these components (named as PMG). Interestingly, most CpG dinucleotides within the 
PEG3 DMR retained basic methylation levels and few CpG dinucleotides became 
hypomethylated in cell lines cultured in PMG, whereas some CpG dinucleotides 
within the region became hypermethylated in cell lines cultured in HMG, (Alexandra 
Thurston Ph.D. thesis 2006). This indicates that supra-physiological levels of 
methionine/folate cycle components in culture may lead to hypermethylation at some 
CpG dinucleotides within imprinting regulatory regions (Allegrucci et al., 2007; 
Steele et al., 2005). In this thesis, gain of methylation was detected at the GTL2 DMR 
in both HES-2 and HESC-NL1 cell lines cultured up to ~ 40 passages in the HMG 
medium. In addition, hypermethylation at certain CpG islands, tumour-suppressor 
gene promoters and one imprinted locus (H19 DMR) has been reproted in additional 
21 hESC lines (including H1, HES-3 and Shef-1) cultured in DMEM based media 
across a range of studies (Allegrucci et al., 2007; Bibikova et al., 2006; Calvanese et 
al., 2008; Maitra et al., 2005; Rugg-Gunn et al., 2005). Thus, the current culture 
system is not able to maintain normal DNA methylation patterns in the genome of 
hESCs. Thus, optimal culture systems need to be developed possibly to reflect the in 
vivo environment of blastocyst cells.  
6.2.2 Imprinting errors inherited from donor embryos. 
 
hESC lines, derived from the inner cell masses (ICMs) of human embryos fertilised 
and cultured in vitro up to the blastocyst stage, can have imprinting errors originated 
from the donor embryos (Allegrucci et al., 2004; Pannetier and Feil, 2007; Rugg-
Gunn et al., 2007). According to previous studies, imprinting can be disrupted in 
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oocytes and preimplantation stage embryos, when assistant reproductive technology 
(ART) procedures (including superovulation, in vitro maturation, in vitro culture, in 
vitro fertilisation) are applied (Doherty et al., 2000; Fortier et al., 2008; Kerjean et al., 
2003; Khosla et al., 2001a; Li et al., 2005b; Mann et al., 2004; Sato et al., 2007; 
Young et al., 2001). For example, preimplantation stage mouse embryos fertilised and 
cultured in vitro result in biallelic expression of imprinted genes mediated by loss of 
methylation at their imprinting regulatory regions, whereas in vivo derived embryos 
show monoallelic expression of imprinted genes mediated by monoallelic methylation 
at their imprinting regulatory regions (Doherty et al., 2000; Khosla et al., 2001a; Li et 
al., 2005b; Mann et al., 2004). Moreover, human and mouse oocytes show that 
aberrant DNA methylation patterns at some imprinting regulatory regions have been 
detected, as a consequence of superovulation (Fortier et al., 2008; Sato et al., 2007). 
These studies have suggested that ART procedures can accelerate oocyte and embryo 
growth that may interfere with establishment and maintenance of imprints during 
oogenesis and embryogenesis (reviewed by Horsthemke and Ludwig, 2005; Lucifero 
et al., 2004a; Maher, 2005). In this manner, human oocytes and embryos can have 
epigenetic errors at imprinted loci, when they are superovulated, and in vitro fertilised 
and cultured (Allegrucci et al., 2004). Subsequently, these errors could be stably 
inherited in hESC lines during the progression of derivation and propagation. To test 
this possibility, the comparative analysis of allele-specific expression of imprinted 
genes and DNA methylation at imprinting regulatory regions is required between in 
vitro and in vivo derived human blastocyst stage embryos that may be limited by the 
availability of embryos due to practical and ethical issues.   
 
Other factors (e.g. embryo quality and cryopreservation) related to donor embryos can 
be suggested to be involved in epigenetic errors at imprinted loci in hESC lines. 
Currently, most hESC lines have been derived from supernumerary, low-grade fresh 
and/or frozen blastocyst stage embryos donated from infertile couples who underwent 
IVF treatment (reviewed by Allegrucci and Young, 2007; Hoffman and Carpenter, 
2005). In fact, almost all cell lines used in this thesis are generated from low-grade 
fresh and/or frozen embryos. Specifically, Reubinoff et al., (2002) has used 4 of low-
grade (3CC to 5CB classified by Gardner et al., (2000)) and frozen blastocyst stage 
embryos to establish HES-1 and HES-2 cell lines. Moreover, Cowan et al., (2004) has 
used 344 of frozen low-grade (3AA to 4CB) blastocyst stage embryos to derive 17 
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HUES-cell lines. The BG01 cell line is derived from a fresh 3CC blastocyst stage 
embryo (Mitalipova et al., 2003). So far, a direct evidence has not been reported 
whether the embryo quality and cryopreservation are more likely susceptible to 
epigenetic alterations at imprinted loci, than high-quality and fresh embryos. However, 
studies observed in mouse sperm and mESCs demonstrate that epigenetic alterations 
can occur at both imprinted and non-imprinted loci, as a consequence of 
cryopreservation and its related chemical,  dimethyl sulfoxide (DMSO; an 
amphipathic molecule) (Fernandez-Gonzalez et al., 2008; Iwatani et al., 2006). 
Moreover, a recent study in mice has demonstrated that aged oocytes in the ovary are 
more likely associated with loss of methylation at imprinting regulatory regions, than 
young oocytes (Liang et al., 2008). Thus, the quality of oocytes and embryos and 
cryopreservation procedures could be one of factors to give a rise to epigenetic errors 
at imprinted loci in donor embryos that can be inherited into hESC lines.  
 
During derivation of hESC lines, possibly they can acquire epigenetic errors at 
imprinted loci, because of the procedures used during derivation that may be 
physically and chemically detrimental to the donor embryos (Solter and Knowles, 
1975). In addition, the procedures are also progressed on medium containing either 
KSR or FBS (Cowan et al., 2004; Inzunza et al., 2005; Mitalipova et al., 2003; 
Reubinoff et al., 2000; Richards et al., 2002; Simon et al., 2005), that may be also 
involved in epigenetic errors at imprinted loci. For instance, in order to derive 17 
HUES-lines, 97 inner cell masses (ICMs) were isolated from 344 blastocyst stage 
embryos in medium containing 8 ~ 10% KSR, 8 ~ 10% plasmate, 5% FBS, LIF and 
bFGF (Cowan et al., 2004). Reubinoff et al., (2000) has used medium containing 20% 
FBS and LIF for isolating 4 ICMs from 4 blastocyst stage embryos to establish HES-1 
and HES-2 cell lines. VAL-1 and VAL-2 cell lines have been established from 14 
ICMs isolated from 16 blastocyst stage embryos in medium containing 20% KSR and 
bFGF (Simon et al., 2005). Furthermore, to remove zona pellucidae (ZP) and to 
isolate ICMs from blastocyst stage embryos, Reubinoff et al. (2000), Richards et al. 
(2002), Mitalipova et al. (2003) and Inzunza et al. (2005) have used pronase and 
immunosurgery and Cowan et al. (2004) has used Tyrode’s acid and immunosurgery. 
Currently, a direct evidence has not been reported whether these procedures and their 
related chemicals (including antibodies) can cause epigenetic errors at imprinted loci 
in human embryos. However, mouse studies have demonstrated that ZP-free mouse 
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embryos removed by pronase show a significant reduction in DNA methylation (5-
methylcytosine) level, compared to mechanical isolated ZP-free embryos (Ribas et al., 
2006). Moreover, the methylation analysis of immunosurgically isolated mouse ICMs 
shows the loss of methylation at imprinting regulatory regions (Mann et al., 2004). 
Thus, these factors may be also associated with epigenetic errors at imprinted loci in 
donor embryos that may be inherited into hESC lines.  
6.3 Is it important to have epigenetic stability in hESC lines?     
 
Most imprinted genes are expressed in a dosage-dependent manner (reviewed by 
Constancia et al., 2004; Ferguson-Smith and Surani, 2001; Reik and Walter, 2001). 
Thus, loss or gain of stable imprinting, resulting in biallelic expression or monoallelic 
expression, changes the dosage of corresponding gene products and their relevant 
enzymatic activities that may interfere with the expression of their downstream or 
upstream genes in mammalian cells (reviewed by Feinberg, 2007; Jaenisch and Bird, 
2003; Rugg-Gunn et al., 2007). Eventually, this may lead to abnormal cell 
proliferation and differentiation, and various diseases including cancers and congenital 
disorders (e.g. BWS, PWS and AS) during mammalian development (reviewed by 
Jelinic and Shaw, 2007; Murrell, 2006; Robertson, 2005). For example, 
overexpression of certain imprinted genes in mESCs results in myogenic 
differentiation (Prelle et al., 2000). Moreover, inappropriate expression of imprinted 
genes in preimplantation mouse embryos and mESCs causes phenotypic abnormalities 
(including polyhydramnios and interstitial bleeding), embryonic lethality and 
tumourigenesis in their derived foetuses (Dean et al., 1998; Fernandez-Gonzalez et al., 
2004; Khosla et al., 2001a; Mann et al., 2004; Okano et al., 1999). In this thesis, the 
analysis of allele-specific expression revealed that 9 genes (PEG10, PEG1, MESTIT1, 
IGF2, H19, GTL2, NESP55, PHLDA2 and ATP10C) appeared to be unstable or 
variable between cell lines (Table 3-3 and 3-4). Importantly, these genes are 
previously identified to have an important role in embryonic development, congenital 
disorders, tumorigensis and lineage-specific differentiation (Table 1-3 and section 
1.3.5). Although developmental consequences of altered imprinted gene expression 
and DNA methylation in hESC lines were not examined in this thesis, it can be 
suggested that some cell lines having imprinting errors may readily be more 
spontaneously differentiated or tumorigenic, when they are in vitro long-term cultured 
or transplanted. Thus, 12 cell lines (HUES1, HUES2, HUES5, HUES6, HUES7, 
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HUES9, HUES15, HUES16, HESC-NL1, HES-2, NOTT1 and NOTT2), which 
exhibit imprinting errors at more than one locus (Chapter 3 and 4), might be excluded 
for human therapeutic applications. Alternatively, however, these cell lines can be a 
model for understanding mechanisms of certain human diseases and a material for 
pharmaceutical screening.  
 
Currently, over 400 hESC lines are presumed to have been established over 20 
countries (reviewed by Allegrucci and Young, 2007; Fenno et al., 2008; Hoffman and 
Carpenter, 2005). Under appropriate conditions, they can have the potential to 
differentiate into all cell types of the human body that may use for treating a wide 
range of human diseases (reviewed by Pera, 2001; Thomson and Odorico, 2000; 
Unger et al., 2008). However, before they are considered to use for human therapeutic 
purpose, genetically, karyotypically and epigenetically unstable cell lines should be 
excluded. In order to screen this, established hESC lines need to be fully characterised 
using previously reported 6 criteria, including hESC-specific markers (e.g. SSEA-3 
and SSEA-4), transcription factors (e.g. OCT3/4 and NANOG), karyotyping, 
telomerase activity, teratoma formation and in vitro differentiation into three germ 
layers (endoderm, mesoderm and ectoderm) (reviewed by Allegrucci and Young, 
2007; Hoffman and Carpenter, 2005; Laslett et al., 2003). This may allow to 
determine which hESC lines have proliferative, pluripotency, differentiative capacities 
and karyotypic stability. In addition, genetic alterations and variations need to be 
identified by analysing in nuclear DNA copy numbers and mitochondrial DNA 
sequences (Maitra et al., 2005; Wu et al., 2008). Finally, it is very important to know 
the occurrence of epigenetic instability in hESC lines upon in vitro culture. This can 
be determined by additional 6 criteria; (1) variations and alterations in allele-specific 
expression of imprinted genes, (2) aberrant DNA methylation at imprinting regulatory 
regions, (3) aberrant DNA methylation and transcriptional silencing of tumour-
suppressor genes, (4) altered DNA methylation at repetitive sequences, (5) 
perturbation of X-chromosome inactivation and (6) altered expression of epigenetic 
regulators (e.g. DNMTs, G9A and HDACs) (Adewumi et al., 2007; Bibikova et al., 
2006; Calvanese et al., 2008; Maitra et al., 2005; Rugg-Gunn et al., 2005; Shen et al., 
2008). 
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hESC lines and their derivatives are limited by the problem of immune rejection 
(reviewed by Allegrucci and Young, 2007; Hoffman and Carpenter, 2005; Unger et al., 
2008). The rejection can be inhibited or prevented by immunosuppressive medications 
(Chidgey et al., 2008). However, these medications can have serious side effects and 
are so expensive (Chidgey et al., 2008). Thus, recently, patient-specific pluripotent 
stem cell lines have been established using various reprogramming approaches (e.g. 
parthenogenesis and cell fusion) in the human (Cowan et al., 2005; Revazova et al., 
2007) that may avoid the problem of immuno rejection. However, there are at least 
three limitations to utilise these cell lines as therapeutic materials; (1) the low 
efficiency of reprogramming somatic cells, (2) chromosomal duplication (tetraploid) 
and (3) epigenetic instability at imprinted loci (Humpherys et al., 2001; Lee et al., 
2002) that are not acceptable for safe human transplantation. Very recently, moreover, 
induced pluripotent stem (iPS) cell lines have been derived from somatic cells (e.g. 
lung and dermal fibroblasts) by viral introduction of transcriptional factors including 
OCT3/4 and SOX2 with either NANOG and LIN28 (Yu et al., 2007), or c-MYC and 
KLF4 (Park et al., 2008; Takahashi et al., 2007). However, these cell lines also have 
several limitations; (1) the low efficiency, (2) the integration of viral transgenes and 
(3) the use of oncogenes (e.g. c-MYC). Furthermore, it has not been defined yet 
whether iPS cell lines epigenetically stable upon in vitro derivation and propagation. 
Thus, this is urgently required.  
6.4 Can epigenetic stability be repaired by overexpression of 
exogenous DNMT1? 
 
In addition to the imprinting instability uncovered in this thesis, previous works in our 
laboratory (Allegrucci et al., 2007; Emmas Lucas and Alexandra Thurston Ph.D. 
theses) and this thesis (Chapter 4) have shown epigenetic instability in various 
genomic regions. To test whether this was due to insufficient expression of the 
maintenance methyltransferase, DNMT1, overexpression was used to examine 
whether epigenetic stability can be repaired at imprinting regulatory regions, tumour-
suppressor gene promoters, repetitive sequences and certain CpG islands (Chapter 5).  
 
Previously, DNA methylation changes (particularly loss of methylation) at certain 
CpG loci related to developmental genes, cancer-related genes, ribosomal DNA and 
cell cycle regulators are readily detected in in vitro cultured hESC lines (Allegrucci et 
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al., 2007; Bibikova et al., 2006). Some of these changes accumulate over extended 
culture, but most of them are already detected at early passages (Allegrucci et al., 
2007; Bibikova et al., 2006; Calvanese et al., 2008). This indicates that even short 
period in in vitro culture is sufficient to cause DNA methylation at some CpG loci in 
hESC lines. Currently, the underlying mechanisms for this are not clear, but one 
possibility is that relatively low expression of endogenous DNMT1 in hESCs 
(compared to mESCs and human BJ fibroblast cells) may fail to maintain DNA 
methylation patterns at some CpG islands during in vitro culture (Emmas Lucas Ph.D. 
thesis 2008), although de novo methyltransferases, DNMT3A and DNMT3B, are 
highly expressed (Adewumi et al., 2007; Sperger et al., 2003 and Emmas Lucas Ph.D. 
thesis 2008). Thus, in this thesis, 8 hESOD1 (human embryonic stem cells 
overexpressing DNMT1) cell lines were generated by utilising a transgenic approach, 
in order to test this possibility (Chapter 5).  
 
The restriction landmark genome scanning (RLGS) technique was performed to 
examine an overview of DNA methylation changes between control (only endogenous 
DNMT1 expressed) and hESOD1 cell lines (both endogenous and exogenous DNMT1 
expressed) upon in vitro culture. Of ~2,200 CpG loci examined, 6 CpG loci were 
identified to be hypermethylated or demethylated in p388#9 p45 (against HUES7 p22), 
indicating in vitro culture induced DNA methylation changes over 23 passages. 
However, only 2 loci appeared to be hypermethylated or demethylated in hESOD1 
cell lines p45 (against HUES7 p22). These evidences indicate that overexpression of 
exogenous DNMT1 in hESCs results in increased epigenetic stability. Unfortunately, 
however, of other imprinting regulatory regions, tumour-suppressor gene promoters 
and repetitive sequences examined by combined bisulphite restriction analysis 
(COBRA), methylation-specific PCR (MSP) and Southern blot, no supporting 
evidences of this were detected. Moreover, only one cell line (HUES7), which is 
previously known to be epigenetically stable upon in vitro culture, was employed in 
Chapter 5 that is too limited to be able to conclude this (Allegrucci et al., 2007). Thus, 
more cell lines are needed to be examined for conclusive proof. HUES5, HUES15 and 
BG01, which are characterised to be epigenetically unstable upon in vitro culture (see 
Chapter 3, 4 and Allegrucci et al., 2007), may be the best cell lines to follow up this 
possibility and conclusion.  
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6.5 Hypermethylation caused by overexpression of DNMT1 
 
Previously, HMT cell lines have been generated in human lung fibroblast cells by 
overexpressing DNMT1 cDNA (Vertino et al., 1996). In HMT cell lines, 
hypermethylation caused by overexpression of exogenous DNMT1 is defined by 
Southern blot and RLGS analyses (Feltus et al., 2003; Vertino et al., 1996). Of 12 
tumour-suppressor gene (TSG) promoters examined by Sothern blot, 5 TSG (ER, 
HIC-1, a-globin, CDH1 and Somatostatin) promoters are hypermethylated or de novo 
methylated in HMT cell lines (Vertino et al., 1996). Moreover, of 1,749 CpG islands 
examined by RLGS, 373 CpG islands (21%) are identified to be hypermethylated or 
de novo methylated in HMT cell lines (Feltus et al., 2003). In the thesis, however, of 
14 imprinting regulatory regions examined by COBRA, none showed DNA 
methylation changes in hESOD1 cell lines (Figure 5-15 and 5-16). Moreover, of 10 
TSG promoters examined by MSP (Figure 5-17 and 5-18), only 3 TSG (TIMP-3, 
MGMT and DAPK-1) promoters were identified to be hypermethylated (or de novo 
methylated) in hESOD1 cell lines. Finally, of ~ 2,000 CpG islands examined by 
RLGS, only 1 locus (TM7SF2) was identified to be hypermethylated in hESOD1 cell 
lines. These evidences indicate most CpG loci examined in hESOD1 cell lines are 
resistant to hypermethylation or de novo methylation caused by overexpression of 
exogenous DNMT1. The underlying mechanism is not clear, but one possibility is that 
relatively low expression of exogenous DNMT1 in hESOD1 cell lines, compared to 
HMT cell lines. Indeed, hESOD1 cell lines showed about 3.5-fold increased DNMT1 
expression and its activity (Figure 5-9), whereas HMT cell lines showed over 50-fold 
increased DNMT1 expression and its activity (Vertino et al., 1996). This was 
consistent with a previous study of 6 imprinting regulatory regions and 3 non-
imprinted loci examined in the Dnmt1+/+;BAC cell line (mouse J1 ES cell line 
overexpressing Dnmt1), exhibiting about 4-fold increased Dnmt1 protein level and 
over 2.5-fold increased Dnmt activity, only one imprinted locus is identified to be 
hypermethylated (Biniszkiewicz et al., 2002). Alternatively, HUES7 is epigenetically 
stable so that it may be not susceptible to DNA methylation alterations caused by 
overexpression of exogenous DNMT1. This possibility can also be confirmed by 
examining other cell lines (e.g. HUES5, HUES15 and BG01).  
 
The overexpression of endogenous DNMT1 is frequently found in various cancers 
associated with transcriptional silencing of some TSGs (e.g. E-cadherin, MGMT and 
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p16) mediated by hypermethylation at their promoters (Etoh et al., 2004; Peng et al., 
2006; Sawada et al., 2007). Moreover, overexpression of exogenous DNMT1 in 
human fibroblast cells is also associated with transcriptional silencing of some TGSs 
(e.g. E-cadherin, HIC-1 and Estrogen receptor) mediated by hypermethylation at their 
corresponding promoters (Vertino et al., 1996). In this thesis, of 10 TSG promoters 
examined, almost all (except for p16) were unmethylated in HUES7. This was 
consistent with a previous report of 29 TSG promoters examined in H1 cell line, all 
were unmethylated (Ohm et al., 2007). However, when exogenous DNMT1 was 
expressed in HUES7, particular three genes (TIMP-3, MGMT and DAPK1) promoters 
became hypermethylated or de novo methylated. Previously, these genes promoters 
are shown to be hypermethylated in various cancer cell lines and tumours (including 
brain, breast, colon, gastric and liver) (Ohm et al., 2007). Moreover, these genes are 
known to be associated with metastasis, invasion, angiogenesis, apoptosis and DNA 
repair in tumours (Akiyama et al., 2003; Dong et al., 2001; Evron et al., 2001; Herman 
et al., 1996; Imura et al., 2006; Zochbauer-Muller et al., 2001). Thus, hESOD1 cell 
lines could be a model for understanding mechanisms of tumour progression and a 
material for discovering and developing an anti-cancer medicine.   
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8 Appendix 1 
 
8.1 Buffers and media 
 
8.1.1 General molecular works 
8.1.1.1 10× TBE 
Reagent Volume Supplier Catalogue number 
Tris Base 108g Fisher BPE152-5 
Boric Acid 55g Sigma B1934 
Ethylenediaminetetraacetic Acid (EDTA) 9.3g Sigma E5134 
The volume was made up to 1 litre with distilled water. The solution was autoclaved 
and stored at room temperature.   
8.1.1.2  LB medium  
Reagent Volume Supplier Catalogue number 
LB Broth Power 12.50g Fisher BPE1426-500 
The volume was made up to 500 ml with distilled water. The solution was autoclaved 
and stored at room temperature.   
8.1.1.3 LB Agar 
Reagent Volume Supplier Catalogue number 
LB Broth Power 12.50g Fisher BPE1426-500 
Agar 7.50g Fisher BPE1423-500 
The volume was made up to 500 ml with distilled water. The solution was autoclaved 
and stored at room temperature.   
8.1.1.4 10% SDS 
Reagent Volume Supplier Catalogue number 
Lauryl Sulfate (SDS) 10g Sigma L4390 
The volume was made up to 100 ml with distilled water. The solution was autoclaved 
and stored at room temperature. 
8.1.1.5 5 M NaCl 
Reagent Volume Supplier Catalogue number 
Sodium Chloride 29.22 g Fisher BPE 358-1 
The volume was made up to 100 ml with distilled water. The solution was autoclaved 
and stored at room temperature. 
8.1.1.6 0.5 M EDTA (pH 8.0) 
Reagent Volume Supplier Catalogue number 
EDTA 186.1g Fluka 3677 
Sodium Hydroxide ~ 20g Fisher S/4920/60 
EDTA was dissolved in 800 ml of distilled water and the pH was adjusted to pH 8.0 
with ~ 20g of NaOH (or with ~ 50 ml of 10N NaOH). Then, the volume was made up 
to 1 litre with distilled water. The solution was autoclaved and stored at room 
temperature. 
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8.1.1.7 1M Tris-HCl (pH 8.0) 
Reagent Volume Supplier Catalogue number 
Tris base 24.2g Fisher BPE152-5 
Hydrochloric acid  ~ 9ml Fisher H/1200/PB17 
Tris base was dissolved in 180 ml of distilled water and the pH was adjusted to pH 8.0 
with ~ 9 ml of HCl. Then, the volume was made up to 200 ml with distilled water. 
The solution was autoclaved and stored at room temperature.  
8.1.1.8 3M NaOH 
Reagent Volume Supplier Catalogue number 
Sodium Hydroxide 12 g Fisher BPE359-500 
The volume was made up to 100 ml with distilled water. The solution was autoclaved 
and stored at room temperature. 
8.1.1.9 5× Gel loading solution 
Reagent Volume Supplier Catalogue number 
Gel Loading Solution - Sigma G2526 
The solution was stored at room temperature. 
 
8.1.1.10 DNA Ladder 
Reagent Volume Supplier Catalogue number 
2-Log DNA Ladder N3200S 
1 kb DNA Ladder N3232S 
100 bp DNA Ladder N3231S 
50 bp DNA Ladder 
- NEB 
N3236S 
1 µl of DNA Ladder was mixed with 1 µl of 5× Gel loading solution (see 2.4.1.9) and 
3 µl of RNase/DNase free water (see 2.4.1.20), and used as a molecular markers on 
the Agarose gel.  
 
8.1.1.11 1 M DTT 
Reagent Volume Supplier Catalogue number 
DL-Dithiothreitol 1.54 g Sigma D0632 
The volume was made up to 10 ml with distilled water. The solution was filter-
sterilised using a 10 ml syringe and a 0.2 µm minisart filter. 500 µl aliquots were 
stored at –20 ºC. 
8.1.1.12 3M NaOAc (pH 5.5) 
Reagent Volume Supplier Catalogue number 
3 M Sodium Acetate - Ambion 9740 
This solution was stored at room temperature.   
8.1.1.13 Phenol/chloroform/isoamyl alcohol 
Reagent Volume Supplier Catalogue number 
Phenol:Chloroform:Isoamyl Alcohol - Sigma P2069 
Phenol/Chloroform/Isoamyl Alcohol was stored at 4 ºC.  
8.1.1.14 2,000× Kanamycin  
Reagent Volume Supplier Catalogue number 
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Kanamycin 1 g Sigma K4000 
The volume was made up to 10 ml with distilled water. The solution was filter-
sterilised using a 10 ml syringe and a 0.2 µm minisart filter. 500 µl aliquots were 
stored at –20 ºC.  
8.1.1.15 1,000× Ampicillin 
Reagent Volume Supplier Catalogue number 
Ampicillin 500 mg Sigma A0166 
The volume was made up to 10 ml with distilled water. The solution was filter-
sterilised using a 10 ml syringe and a 0.2 µm minisart filter. 500 µl aliquots were 
stored at –20 ºC.  
8.1.1.16 Ethanol 
Reagent Volume Supplier Catalogue number 
Ethanol - Fisher E/0650DF/17 
The solution was stored at room temperature.  
8.1.1.17 Methanol 
Reagent Volume Supplier Catalogue number 
Methanol - Fisher M/4056/17 
The solution was stored at room temperature.  
8.1.1.18 Isopropanol 
Reagent Volume Supplier Catalogue number 
Propan-2-ol - Fisher P/7507/PB17 
The solution was stored at room temperature.  
8.1.1.19 β-Mercaptoethanol 
Reagent Volume Supplier Catalogue number 
β-Mercaptoethanol - Sigma M3148 
The solution was stored at room temperature.  
8.1.1.20 RNase/DNase free water 
Reagent Volume Supplier Catalogue number 
Water - Sigma W4502 
Water was stored at room temperature.  
8.1.1.21 PBS 
Reagent Volume Supplier Catalogue number 
PBS - Invitrogen 14190 
PBS was stored at room temperature.  
8.1.1.22 Lysis buffer (genomic DNA) 
Reagent Volume Supplier Catalogue number 
1M Tris-HCl (pH 8.0) 100 µl See 2.4.1.7 
5M NaCl 20 µl See 2.4.1.5 
500mM EDTA 200 µl See 2.4.1.6 
10% SDS 500 µl See 2.4.1.4 
The volume was made up to 10 ml with distilled water. Proteinase K (Roche: 
3115879001) was added into solution to give a final concentration of 50 µg·ml-1.  
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8.1.2 Western blotting works 
8.1.2.1 10× Protein electrophoresis buffer 
Reagent Volume Supplier Catalogue number 
Tris Base 30g Fisher BPE152-5 
Glycine 144g Fisher BPE381-1 
The volume was made up to 1 litre with distilled water. The solution was autoclaved 
and stored at room temperature.   
8.1.2.2 10× Protein transfer buffer 
Reagent Volume Supplier Catalogue number 
Tris Base 37.8g Fisher BPE152-5 
Glycine 180g Fisher BPE381-1 
The volume was made up to 1 litre with distilled water. The solution was autoclaved 
and stored at room temperature. 
8.1.2.3 10× TBS 
Reagent Volume Supplier Catalogue number 
Tris Base 12.11g Fisher BPE152-5 
Sodium Chloride 87.66 g Fisher BPE 358-1 
The volume was made up to 1 litre with distilled water. The solution was autoclaved 
and stored at room temperature. 
8.1.2.4 TBST 
Reagent Volume Supplier Catalogue number 
10X TBS 100 ml  See 2.4.2.3  
Tween 20 1 ml Sigma P9416 
The volume was made up to 1 litre with distilled water. 
8.1.2.5 Blocking buffer (5% Skim milk) 
Reagent Volume Supplier Catalogue number 
Skim Milk Powder  5 g Marvel - 
10X TBS 10 ml See 2.4.2.3  
The volume was made up to 100 ml with distilled water. The solution was stored at 4 
ºC. 
8.1.2.6 1M Tris-HCl (pH 6.8) 
Reagent Volume Supplier Catalogue number 
Tris base 24.2 g Fisher BPE152-5 
Hydrochloric acid (HCl) ~ 16 ml Fisher H/1200/PB17 
Tris base was dissolved in 180 ml of distilled water and the pH was adjusted to pH 6.8 
with HCl. Then, the volume was made up to 200 ml with distilled water. The solution 
was autoclaved and stored at room temperature.  
8.1.2.7 1.5M Tris-HCl (pH 8.8) 
Reagent Volume Supplier Catalogue number 
Tris base 36.3 g Fisher BPE152-5 
Hydrochloric acid  ~ 8 ml Fisher H/1200/PB17 
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Tris base was dissolved in 180 ml of distilled water and the pH was adjusted to pH 8.8 
with ~ 8ml of HCl. Then, the volume was made up to 200 ml with distilled water. The 
solution was autoclaved and stored at room temperature.  
8.1.2.8 Coomassie blue gel stain solution 
Reagent Volume Supplier Catalogue number 
Coomassie Blue R-250 1g Sigma B0149 
Methanol 450ml See 2.4.1.17 
Glacial Acetic Acid 100ml Fisher A/0400/PB17 
The volume was made up to 1 litre with distilled water. The solution was stored at 
room temperature. 
8.1.2.9 Coomassie blue gel destain solution 
Reagent Volume Supplier Catalogue number 
Methanol 100ml See 2.4.1.17 
Glacial Acetic Acid 100ml Fisher A/0400/PB17 
The volume was made up to 1 litre with distilled water. The solution was stored at 
room temperature. 
8.1.2.10 50% Glycerol 
Reagent Volume Supplier Catalogue number 
Glycerol  50 ml Sigma G5516 
The volume was made up to 100 ml with distilled water. The solution was stored at 
room temperature. 
8.1.2.11 1% Bromophenole blue 
Reagent Volume Supplier Catalogue number 
Bromophenole Blue 100 mg Sigma B8026 
The volume was made up to 10 ml with distilled water. The solution was filter-
sterilised using a 10 ml syringe and a 0.2 µm minisart filter and stored at –20 ºC.  
8.1.2.12 10% APS 
Reagent Volume Supplier Catalogue number 
Amonium Persulfate (APS) 0.5 g Fisher BPE179-25 
The volume was made up to 5 ml with distilled water. The solution was filter-
sterilised using a 10 ml syringe and a 0.2 µm minisart filter. 500 µl aliquots were 
placed into eppendorf tubes and stored at –20 ºC.  
8.1.2.13 5% NP40 
Reagent Volume Supplier Catalogue number 
Igepal CA-630 5 ml Sigma I3021 
The volume was made up to 100 ml with distilled water. The solution was filter-
sterilised using a 50 ml syringe and a 0.2 µm minisart filter and stored at room 
temperature. 
8.1.2.14 RIPA buffer 
Reagent Volume Supplier Catalogue number 
1M Tris-HCl (pH 8.0) 2.5ml See 2.4.1.7 
5M NaCl 4.2ml See 2.4.1.5 
500mM EDTA 100µl See 2.4.1.6 
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5% NP40 2ml See 2.4.2.13 
The volume was made up to 50 ml with distilled water. The solution was stored at 4ºC.  
8.1.2.15 Protein loading buffer 
Reagent Volume Supplier Catalogue number 
1M Tris (pH 6.8) 600µl  See 2.4.2.6 
50% Glycerol 5ml  See 2.4.2.10 
10% SDS 2ml  See 2.4.1.4 
β-Mercaptoethanol 500µl  See 2.4.1.19 
1% Bromophenole Blue (BPB) 1ml  See 2.4.2.11 
The volume was made up to 10 ml with distilled water. The solution was filter-
sterilised using a 10 ml syringe and a 0.2 µm minisart filter. 500 µl aliquots were 
stored at –20 ºC.  
8.1.2.16 Protein maker 
Reagent Volume Supplier Catalogue number 
Prestained Protein Marker, Broad Rindge - NEB P7708S 
18 µl aliquots were stored at -20 ºC. 
8.1.2.17 Bradford solution 
Reagent Volume Supplier Catalogue number 
Protein assay - Bio-Rad 500-0006 
The solution was stored at 4 ºC. 
8.1.2.18 Ponceau S solution 
Reagent Volume Supplier Catalogue number 
Ponceau S 200 mg Sigma P3504 
Glacial Acetic Acid 10 ml Fisher A/0400/PB17 
The volume was made up to 200 ml with distilled water. The solution was filter-
sterilised using a 50 ml syringe and a 0.2 µm minisart filter. The solution was stored at 
room temperature.     
8.1.3 Immunostaining works 
8.1.3.1 2% Blocking solution 
Reagent Volume Supplier Catalogue number 
BSA 2g Sigma A2153 
The volume was made up to 100 ml PBS. The solution was filter-sterilised using a 50 
ml syringe and a 0.2 µm minisart filter and stored at –20 ºC. 
8.1.3.2 0.2% Triton ×-100 
Reagent Volume Supplier Catalogue number 
Triton X-100 200µl Sigma T8787 
The volume was made up to 100 ml with PBS (see 2.4.1.21). The solution was filter-
sterilised using a 50 ml syringe and a 0.2 µm minisart filter. The solution was stored at 
room temperature.     
8.1.3.3 0.2% Tween20 
Reagent Volume Supplier Catalogue number 
Tween20 200µl Sigma P9416 
 249 
The volume was made up to 100 ml with PBS (see 2.4.1.21). The solution was filter-
sterilised using a 50 ml syringe and a 0.2 µm minisart filter. The solution was stored at 
room temperature.     
8.1.3.4 4 M HCl 
Reagent Volume Supplier Catalogue number 
Hydrochloric acid  10 ml Fisher H/1200/PB17 
Distilled water 30 ml - 
The solution was stored at room temperature. 
8.1.3.5 Mounting solution 
Reagent Volume Supplier Catalogue number 
VECTASHIELD® Mounting Medium with DAPI - Vector H-1200 
The solution was stored at 4 ºC.  
8.1.3.6 Hypotonic solution 
Reagent Volume Supplier Catalogue number 
Potassium Chloride 200 mg BDH 101985M 
Sodium Citrate 200 mg Fisher BPE 327-500 
Potassium chloride and Sodium citrate were respectively dissolved in each 50 ml of 
distilled water. Two solutions were mixed together to give a final volume of 100 ml.  
8.1.3.7 Fixative solution 
Reagent Volume Supplier Catalogue number 
Methanol 15 ml Fisher M/4056/17 
Glacial Acetic Acid 5 ml Fisher A/0400/PB17 
Two solutions were mixed together in a ratio of 1:3. 
8.1.3.8 4% PFA 
Reagent Volume Supplier Catalogue number 
Paraformaldehyde 4 Sigma P6148 
The volume was made up to 100 ml with PBS. The solution was incubated at 60ºC for 
2 h with shaking. 5 ml aliquots were stored at -20ºC. 
8.1.4 Southern blotting works 
8.1.4.1 20× SSC 
Reagent Volume Supplier Catalogue number 
Sodium Chloride 175.3 Fisher BPE 358-1 
Sodium Citrate 88.2 Fisher BPE 327-500 
Sodium Chloride and Sodium Citrate were dissolved in 800 ml of distilled water and 
the pH was adjusted up to pH 7.0 with HCl. Then, the volume was made up to 1 liter 
with distilled water. The solution was autoclaved and stored at room temperature.  
8.1.4.2 2× SSC 
Reagent Volume Supplier Catalogue number 
20x SSC 100 ml See 2.4.4.1 
Distilled water 900 ml - 
The solution was autoclaved and stored at room temperature. 
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8.1.4.3 10% PVP 
Reagent Volume Supplier Catalogue number 
Polyvinylpyrrolidone 5 g Sigma P5288 
The volume was made up to 50 ml with distilled water. The solution stored at room 
temperature.   
8.1.4.4 10% Ficoll 
Reagent Volume Supplier Catalogue number 
Ficoll 5 g GE Healthcare 17-0300-10 
The volume was made up to 50 ml with distilled water. The solution was stored at 
room temperature.   
8.1.4.5 10% BSA 
Reagent Volume Supplier Catalogue number 
BSA 5g Sigma A2153 
The volume was made up to 50 ml with distilled water. The solution was filter-
sterilised using a 50 ml syringe and a 0.2 µm minisart filter and stored at –20 ºC. 
8.1.4.6 1mg·ml-1 Heparin 
Reagent Volume Supplier Catalogue number 
Heparin 100 mg Fluka 51550 
The volume was made up to 100 ml with distilled water. The solution was filter-
sterilised using a 50 ml syringe and a 0.2 µm minisart filter and stored at –20 ºC.  
8.1.4.7 2mg·ml-1 ssDNA 
Reagent Volume Supplier Catalogue number 
Salmon sperm DNA 1 g Sigma D1626 
The volume was made up to 500 ml with distilled water. The solution was stored at –
20 ºC. 
8.1.4.8 Pre-hybridisation solution for LINE-1 
Reagent Volume Supplier Catalogue number 
20X SSC 7.5 ml See 2.4.4.1 
0.5M EDTA 1 ml See 2.4.1.6 
10% PVP 1 ml See 2.4.4.3 
10% Ficoll 1 ml See 2.4.4.4 
10% BSA 1 ml See 2.4.4.5 
10% SDS 0.5 ml See 2.4.1.4 
1 mg/ml Heparin 0.5 ml See 2.4.4.6 
2 mg/ml ssDNA 1 ml See 2.4.4.7 
The volume was made up to 50 ml with distilled water. 
8.1.4.9 Hybridisation solution for LINE-1 
Reagent Volume Supplier Catalogue number 
20X SSC 3.75 ml See 2.4.4.1 
0.5M EDTA 0.5 ml See 2.4.1.6 
10% PVP 0.5 ml See 2.4.4.3 
10% Ficoll 0.5 ml See 2.4.4.4 
10% BSA 0.5 ml See 2.4.4.5 
10% SDS 0.25 ml See 2.4.1.4 
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1 mg/ml Heparin 0.25 ml See 2.4.4.6 
2 mg/ml ssDNA 0.5 ml See 2.4.4.7 
Dextran Sulfate 2.25 g Sigma D8906 
The volume was made up to 25 ml with distilled water.  
8.1.4.10 0.4 M NaOH 
Reagent Volume Supplier Catalogue number 
Sodium Hydroxide 16 g Fisher BPE359-500 
The volume was made up to 1 liter with distilled water. The solution was autoclaved 
and stored at room temperature. 
8.1.4.11 2× SSC/0.1% SDS 
Reagent Volume Supplier Catalogue number 
20×SSC 100 ml See 2.4.4.1 
10% SDS 10 ml See 2.4.1.4 
The solution was autoclaved and stored at room temperature. 
8.1.4.12 0.1× SSC/0.1% SDS 
Reagent Volume Supplier Catalogue number 
20×SSC 5 ml See 2.4.4.1 
10% SDS 10 ml See 2.4.1.4 
The solution was autoclaved and stored at room temperature. 
8.1.4.13 20× SSPE 
Reagent Volume Supplier Catalogue number 
Sodium Chloride 175.3 g Fisher BPE 358-1 
Sodium Phosphate Monobasic 27.6 g Sigma S8282 
EDTA 9.4 g Fluka 3677 
Sodium Chloride, Sodium Phosphate Monobasic and EDTA were dissolved in 800 ml 
of distilled water and the pH was adjusted to pH 7.4 with NaOH (~ 27 ml/litre of 10 N 
NaOH). Then, the volume was made up to 1 liter with distilled water. The solution 
was autoclaved and stored at room temperature.  
8.1.4.14 5× SSPE 
Reagent Volume Supplier Catalogue number 
20× SSPE 250 ml See 2.4.4.13 
The solution was autoclaved and stored at room temperature.  
8.1.4.15 50× Denhardt’s solution 
Reagent Volume Supplier Catalogue number 
Polyvinylpyrrolidone 10 g Sigma P5288 
Ficoll 10 g GE Healthcare 17-0300-10 
BSA 10 g Fluka 3677 
The volume was made up to 100 ml with distilled water. The solution was stored at 
room temperature.  
8.1.4.16 Hybridisation solution for oligonucleotide probe 
Reagent Volume Supplier Catalogue number 
20x SSPE 12.5 ml See 2.4.4.13 
50x Denhardt's solution 10 ml See 2.4.4.15 
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10% SDS 0.5 ml See 2.4.1.4  
2 mg/ml ssDNA 1 ml See 2.4.4.7 
The volume was made up to 50 ml with distilled water. 
8.1.5 Cell culture works 
8.1.5.1 MEFs medium  
Reagent Volume Supplier Catalogue number 
Dulbecco's Modifed Eagle Media (DMEM) 500ml Invitrogen 21969-035 
Fetal Bovine Serum (FBS) 50ml Invitrogen 10106-169 
100X MEM Non-Essential Amino Acids (NEAA) 5ml Invitrogen 11140-050 
200mM L-Glutamine 5ml Invitrogen 25030-149 
FBS, NEAA and L-Glutamine were added and mixed together in a universal tube. The 
mixture was added into DMEM by filter-sterilisation using a 50 ml syringe and a 0.2 
µm minisart filter (Sartorius: SM16532K). 
8.1.5.2 Mitomycin C 
Reagent Volume Supplier Catalogue number 
Mitomycin C (MMC) 2mg Sigma M4287 
2 mg of Mitomycin C was dissolved in 200 ml of MEFs medium (see 2.4.5.1) to give 
a final concentration of 10 µg·ml-1. The solution was filter-sterilised using a 50 ml 
syringe and a 0.2 µm minisart filter. 5 ml aliquots were stored at –20 ºC. 
8.1.5.3 BG-K medium  
Reagent Volume Supplier Catalogue number 
DMEM-12 500ml Invitrogen 11320-058 
Knockout Serum Replacement (KSR) 90ml Invitrogen 10828-028 
100X NEAA 6ml Invitrogen 11140-035 
200mM Glutamax-I supplement 6ml Invitrogen 25030-024 
1M β-Mercaptoethanol 60µl Sigma M7522 
4 µg/ml Fibroblast Growth Factor (FGF) 600µl Sigma F0291 
KSR, NEAA, Glutamax and 1M β-Mercaptoethanol were added and mixed together in 
a container. The mixture was added into DMEM-12 by filter-sterilisation using a 50 
ml syringe and a 0.2 µm minisart filter (Sartorius: SM16532K). To make 1 M β-
Mercaptoethanol, 1 ml of 14.3 M β-Mercaptoethanol was mixed with 13.3 ml of water 
(Sigma: W3500). The solution was filter-sterilised using a 50 ml syringe and a 0.2 µm 
minisart filter and stored at 4ºC. To make 4 µg·ml-1 bFGF, 1 mg bFGF was dissolved 
in 246.80 ml of PBS. 3.25 ml of 7.5% BSA was added into the bFGF solution. Then, 
the solution was filter-sterilised using a 0.20 µm filter (Sartorius: 17597K). 2 ml 
aliquots were stored at -80 ºC. 
8.1.5.4 Matrigel 
Reagent Volume Supplier Catalogue number 
Matrigel Basement Membrane Matrix - BD Biosciences 354234 
The Matrigel was thawed on ice in the fridge overnight. 0.5 ml aliquots were placed 
into chilled tubes by a chilled 5 ml pipette. Immediately, aliquots were stored at –80 
ºC. 
8.1.5.5 Trypsin EDTA 
Reagent Volume Supplier Catalogue number 
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0.05% Trypsin EDTA  100ml Invitrogen 25300-054 
Trypsin EDTA was thawed in the fridge overnight. Once completely thawed, 20 ml 
aliquots were placed into universal tubes. They were stored at –20 ºC. 
8.1.5.6 Cryopreservation medium 
Reagent Volume Supplier Catalogue number 
Hyclone ES FBS 4 ml Perbio  
DMSO 1 ml Sigma D5879 
4 parts of Hyclone FBS and 1 part of DMSO were mixed together. The solution was 
filter-sterilised using a 10 ml syringe and a 0.2 µm minisart filter and stored at 4ºC. 
8.1.5.7 0.1% Gelatine solution   
Reagent Volume Supplier  Catalogue number 
Gelatin 500mg Sigma G9391 
Gelatin was dissolved in 500 ml of distilled water. The solution was autoclaved and 
stored at room temperature.  
8.1.5.8 KaryoMax     
Reagent Volume Supplier Catalogue number 
Karyo MAX® Colcemide® - Invitrogen 15212-046 
This solution was stored at 4ºC. 
8.1.5.9 GeneJammer® transfection reagent  
Reagent Volume Supplier Catalogue number 
GeneJammer® transfection reagent - Stratagene 204132 
The reagent was stored at 4ºC. 
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9 Appendix 2 
 
 
List of Suppliers Details 
Company Website 
Abcam, Plc. http://www.abcam.com  
Alpha Laboratories (UK) http://www.alphalabs.co.uk  
Amaxa AG http://www.amaxa.com  
Ambion, Inc. C/O Applied Biosystems http://www.ambion.com  
Applied Biosystems http://www.appliedbiosystems.com  
Axygen Scientific, Inc. http://www.axygen.com  
Beckman Coulter (UK), Ltd. http://www.beckmancoulter.co.uk  
BDH, C/O VWR International (UK), Ltd. http://uk.vwr.com  
Cambio (UK), Ltd. http://www.cambio.co.uk  
Charles River Laboratories, Inc. http://www.criver.com  
Chemicon Europe, Ltd. http://www.chemicon.com  
Clontech-Takara Bio Europe http://www.clontech.com  
Eppendorf (UK), Ltd. http://www.eppendorf.co.uk  
Fermentas http://www.fermentas.com  
Fisher Scientific (UK), Ltd. http://www.fisher.co.uk  
GE Healthcare http://www.gehealthcare.com  
Grant Instruments (UK), Ltd. http://www.grant.co.uk  
Hyclone http://www.hyclone.com  
Improvision http://www.improvision.com 
Invitrogen, Ltd. http://www.invitrogen.com  
Jackson Immunoresearch Laboratories, Inc. http://www.jacksonimmuno.com 
Leica Microsystems  http://www.leicamicrosystems.com  
Menzel-Glaser http://www.menzel.de  
Merck Chemicals (UK), Ltd. http://www.merckbiosciences.co.uk  
NanoDrop Technologies http://www.nanodrop.com  
New England Biolabs (UK), Ltd. http://www.neb.uk.com  
Nikon Ltd. http://www.europe-nikon.com  
Nalge Nunc International http://www.nuncbrand.com  
Qiagen, Ltd. http://www.qiagen.com  
Raytek Scientific (UK), Ltd. http://www.raytek.co.uk   
Roche Diagnostics Ltd. http://www.rocheuk.com  
Sartorius (UK), Ltd. http://www.sartorius.co.uk  
Santa Cruz Biotechnology, Inc. http://www.scbt.com  
Scientific Laboratory Supplies, Ltd. http://www.scientificlabs.eu  
Sigma-Genosys/ Sigma-Aldrich Ltd. http://www.sigmaaldrich.com  
SPSS (UK), Ltd. http://www.ssps.com/uk  
Vector Laboratories, Ltd. http://www.vectorlabs.com  
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10 Appendix 3 
 
Post Hoc Tests 
 
Multiple Comparisons 
 (I) Group (J) Group 
Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
   
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Tukey HSD TC p336 #1 .08135 .07742 .969 -.2249 .3876 
  p336 #9 .16691 .07742 .495 -.1394 .4732 
  p388 #8 .09063 .07742 .945 -.2157 .3969 
  p388 #9 .13804 .07742 .692 -.1683 .4443 
  hESOD1 #1 .76784(*) .07742 .000 .4616 1.0741 
  hESDO1 #3 .42107(*) .07742 .007 .1148 .7274 
  hESOD1 #4 .65802(*) .07742 .000 .3517 .9643 
  hESOD1 #9 .78141(*) .07742 .000 .4751 1.0877 
 p336 #1 TC -.08135 .07742 .969 -.3876 .2249 
  p336 #9 .08557 .07742 .959 -.2207 .3919 
  p388 #8 .00928 .07742 1.000 -.2970 .3156 
  p388 #9 .05669 .07742 .997 -.2496 .3630 
  hESOD1 #1 .68649(*) .07742 .000 .3802 .9928 
  hESDO1 #3 .33972(*) .07742 .028 .0334 .6460 
  hESOD1 #4 .57667(*) .07742 .001 .2704 .8830 
  hESOD1 #9 .70007(*) .07742 .000 .3938 1.0064 
 p336 #9 TC -.16691 .07742 .495 -.4732 .1394 
  p336 #1 -.08557 .07742 .959 -.3919 .2207 
  p388 #8 -.07629 .07742 .978 -.3826 .2300 
  p388 #9 -.02888 .07742 1.000 -.3352 .2774 
  hESOD1 #1 .60092(*) .07742 .001 .2946 .9072 
  hESDO1 #3 .25415 .07742 .125 -.0521 .5604 
  hESOD1 #4 .49110(*) .07742 .002 .1848 .7974 
  hESOD1 #9 .61450(*) .07742 .000 .3082 .9208 
 p388 #8 TC -.09063 .07742 .945 -.3969 .2157 
  p336 #1 -.00928 .07742 1.000 -.3156 .2970 
  p336 #9 .07629 .07742 .978 -.2300 .3826 
  p388 #9 .04741 .07742 .999 -.2589 .3537 
  hESOD1 #1 .67721(*) .07742 .000 .3709 .9835 
  hESDO1 #3 .33044(*) .07742 .033 .0242 .6367 
  hESOD1 #4 .56739(*) .07742 .001 .2611 .8737 
  hESOD1 #9 .69079(*) .07742 .000 .3845 .9971 
 p388 #9 TC -.13804 .07742 .692 -.4443 .1683 
  p336 #1 -.05669 .07742 .997 -.3630 .2496 
  p336 #9 .02888 .07742 1.000 -.2774 .3352 
  p388 #8 -.04741 .07742 .999 -.3537 .2589 
  hESOD1 #1 .62980(*) .07742 .000 .3235 .9361 
  hESDO1 #3 .28303 .07742 .075 -.0233 .5893 
  hESOD1 #4 .51998(*) .07742 .002 .2137 .8263 
  hESOD1 #9 .64338(*) .07742 .000 .3371 .9497 
 hESOD1 #1 TC -.76784(*) .07742 .000 -1.0741 -.4616 
  p336 #1 -.68649(*) .07742 .000 -.9928 -.3802 
  p336 #9 -.60092(*) .07742 .001 -.9072 -.2946 
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  p388 #8 -.67721(*) .07742 .000 -.9835 -.3709 
  p388 #9 -.62980(*) .07742 .000 -.9361 -.3235 
  hESDO1 #3 -.34677(*) .07742 .025 -.6531 -.0405 
  hESOD1 #4 -.10982 .07742 .866 -.4161 .1965 
  hESOD1 #9 .01358 .07742 1.000 -.2927 .3199 
 hESDO1 #3 TC -.42107(*) .07742 .007 -.7274 -.1148 
  p336 #1 -.33972(*) .07742 .028 -.6460 -.0334 
  p336 #9 -.25415 .07742 .125 -.5604 .0521 
  p388 #8 -.33044(*) .07742 .033 -.6367 -.0242 
  p388 #9 -.28303 .07742 .075 -.5893 .0233 
  hESOD1 #1 .34677(*) .07742 .025 .0405 .6531 
  hESOD1 #4 .23695 .07742 .167 -.0693 .5432 
  hESOD1 #9 .36034(*) .07742 .020 .0541 .6666 
 hESOD1 #4 TC -.65802(*) .07742 .000 -.9643 -.3517 
  p336 #1 -.57667(*) .07742 .001 -.8830 -.2704 
  p336 #9 -.49110(*) .07742 .002 -.7974 -.1848 
  p388 #8 -.56739(*) .07742 .001 -.8737 -.2611 
  p388 #9 -.51998(*) .07742 .002 -.8263 -.2137 
  hESOD1 #1 .10982 .07742 .866 -.1965 .4161 
  hESDO1 #3 -.23695 .07742 .167 -.5432 .0693 
  hESOD1 #9 .12339 .07742 .788 -.1829 .4297 
 hESOD1 #9 TC -.78141(*) .07742 .000 -1.0877 -.4751 
  p336 #1 -.70007(*) .07742 .000 -1.0064 -.3938 
  p336 #9 -.61450(*) .07742 .000 -.9208 -.3082 
  p388 #8 -.69079(*) .07742 .000 -.9971 -.3845 
  p388 #9 -.64338(*) .07742 .000 -.9497 -.3371 
  hESOD1 #1 -.01358 .07742 1.000 -.3199 .2927 
  hESDO1 #3 -.36034(*) .07742 .020 -.6666 -.0541 
  hESOD1 #4 -.12339 .07742 .788 -.4297 .1829 
Bonferroni TC p336 #1 .08135 .07742 1.000 -.2708 .4335 
  p336 #9 .16691 .07742 1.000 -.1852 .5191 
  p388 #8 .09063 .07742 1.000 -.2615 .4428 
  p388 #9 .13804 .07742 1.000 -.2141 .4902 
  hESOD1 #1 .76784(*) .07742 .000 .4157 1.1200 
  hESDO1 #3 .42107(*) .07742 .015 .0689 .7732 
  hESOD1 #4 .65802(*) .07742 .000 .3059 1.0102 
  hESOD1 #9 .78141(*) .07742 .000 .4293 1.1336 
 p336 #1 TC -.08135 .07742 1.000 -.4335 .2708 
  p336 #9 .08557 .07742 1.000 -.2666 .4377 
  p388 #8 .00928 .07742 1.000 -.3429 .3614 
  p388 #9 .05669 .07742 1.000 -.2955 .4088 
  hESOD1 #1 .68649(*) .07742 .000 .3343 1.0386 
  hESDO1 #3 .33972 .07742 .063 -.0124 .6919 
  hESOD1 #4 .57667(*) .07742 .001 .2245 .9288 
  hESOD1 #9 .70007(*) .07742 .000 .3479 1.0522 
 p336 #9 TC -.16691 .07742 1.000 -.5191 .1852 
  p336 #1 -.08557 .07742 1.000 -.4377 .2666 
  p388 #8 -.07629 .07742 1.000 -.4284 .2759 
  p388 #9 -.02888 .07742 1.000 -.3810 .3233 
  hESOD1 #1 .60092(*) .07742 .001 .2488 .9531 
  hESDO1 #3 .25415 .07742 .342 -.0980 .6063 
  hESOD1 #4 .49110(*) .07742 .005 .1389 .8433 
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  hESOD1 #9 .61450(*) .07742 .001 .2623 .9667 
 p388 #8 TC -.09063 .07742 1.000 -.4428 .2615 
  p336 #1 -.00928 .07742 1.000 -.3614 .3429 
  p336 #9 .07629 .07742 1.000 -.2759 .4284 
  p388 #9 .04741 .07742 1.000 -.3047 .3996 
  hESOD1 #1 .67721(*) .07742 .000 .3251 1.0294 
  hESDO1 #3 .33044 .07742 .075 -.0217 .6826 
  hESOD1 #4 .56739(*) .07742 .002 .2152 .9195 
  hESOD1 #9 .69079(*) .07742 .000 .3386 1.0429 
 p388 #9 TC -.13804 .07742 1.000 -.4902 .2141 
  p336 #1 -.05669 .07742 1.000 -.4088 .2955 
  p336 #9 .02888 .07742 1.000 -.3233 .3810 
  p388 #8 -.04741 .07742 1.000 -.3996 .3047 
  hESOD1 #1 .62980(*) .07742 .001 .2776 .9820 
  hESDO1 #3 .28303 .07742 .190 -.0691 .6352 
  hESOD1 #4 .51998(*) .07742 .003 .1678 .8721 
  hESOD1 #9 .64338(*) .07742 .001 .2912 .9955 
 hESOD1 #1 TC -.76784(*) .07742 .000 -1.1200 -.4157 
  p336 #1 -.68649(*) .07742 .000 -1.0386 -.3343 
  p336 #9 -.60092(*) .07742 .001 -.9531 -.2488 
  p388 #8 -.67721(*) .07742 .000 -1.0294 -.3251 
  p388 #9 -.62980(*) .07742 .001 -.9820 -.2776 
  hESDO1 #3 -.34677 .07742 .055 -.6989 .0054 
  hESOD1 #4 -.10982 .07742 1.000 -.4620 .2423 
  hESOD1 #9 .01358 .07742 1.000 -.3386 .3657 
 hESDO1 #3 TC -.42107(*) .07742 .015 -.7732 -.0689 
  p336 #1 -.33972 .07742 .063 -.6919 .0124 
  p336 #9 -.25415 .07742 .342 -.6063 .0980 
  p388 #8 -.33044 .07742 .075 -.6826 .0217 
  p388 #9 -.28303 .07742 .190 -.6352 .0691 
  hESOD1 #1 .34677 .07742 .055 -.0054 .6989 
  hESOD1 #4 .23695 .07742 .488 -.1152 .5891 
  hESOD1 #9 .36034(*) .07742 .043 .0082 .7125 
 hESOD1 #4 TC -.65802(*) .07742 .000 -1.0102 -.3059 
  p336 #1 -.57667(*) .07742 .001 -.9288 -.2245 
  p336 #9 -.49110(*) .07742 .005 -.8433 -.1389 
  p388 #8 -.56739(*) .07742 .002 -.9195 -.2152 
  p388 #9 -.51998(*) .07742 .003 -.8721 -.1678 
  hESOD1 #1 .10982 .07742 1.000 -.2423 .4620 
  hESDO1 #3 -.23695 .07742 .488 -.5891 .1152 
  hESOD1 #9 .12339 .07742 1.000 -.2288 .4756 
 hESOD1 #9 TC -.78141(*) .07742 .000 -1.1336 -.4293 
  p336 #1 -.70007(*) .07742 .000 -1.0522 -.3479 
  p336 #9 -.61450(*) .07742 .001 -.9667 -.2623 
  p388 #8 -.69079(*) .07742 .000 -1.0429 -.3386 
  p388 #9 -.64338(*) .07742 .001 -.9955 -.2912 
  hESOD1 #1 -.01358 .07742 1.000 -.3657 .3386 
  hESDO1 #3 -.36034(*) .07742 .043 -.7125 -.0082 
  hESOD1 #4 -.12339 .07742 1.000 -.4756 .2288 
*  The mean difference is significant at the .05 level. 
 
Homogeneous Subsets  
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N Subset for alpha = .05 
 Group 
1 2 3 4 1 
hESOD1 #9 2 4.0804    
hESOD1 #1 2 4.0940    
hESOD1 #4 2 4.2038 4.2038   
hESDO1 #3 2  4.4408 4.4408  
p336 #9 2   4.6949 4.6949 
p388 #9 2   4.7238 4.7238 
p388 #8 2    4.7712 
p336 #1 2    4.7805 
TC 2    4.8618 
Tukey 
HSD(a) 
Sig.  .788 .167 .075 .495 
hESOD1 #9 2 4.0804    
hESOD1 #1 2 4.0940    
hESOD1 #4 2 4.2038 4.2038   
hESDO1 #3 2  4.4408   
p336 #9 2   4.6949  
p388 #9 2   4.7238  
p388 #8 2   4.7712  
p336 #1 2   4.7805  
Tukey B(a) 
TC 2   4.8618  
Means for groups in homogeneous subsets are displayed. 
a Uses Harmonic Mean Sample Size = 2.000. 
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Kruskal-Wallis Test 
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Ranks 
 Group N Mean Rank 
TC 2 17.50 
p336 #1 2 14.50 
p336 #9 2 10.50 
p388 #8 2 13.50 
p388 #9 2 11.50 
hESOD1 #1 2 2.50 
hESDO1 #3 2 7.50 
hESOD1 #4 2 5.00 
hESOD1 #9 2 3.00 
Growth 
Total 18  
 
Test Statistics(a,b) 
 Growth 
Chi-Square 15.825 
df 8 
Asymp. Sig. .045 
a Kruskal Wallis Test 
b Grouping Variable: Group 
 
Mann-Whitney Test 
 
Ranks 
 Group N Mean Rank Sum of Ranks 
Growth 1.00 2 1.50 3.00 
 2.00 8 6.50 52.00 
 Total 10   
 
Test Statistics(b) 
 Growth 
Mann-Whitney U .000 
Wilcoxon W 3.000 
Z -2.089 
Asymp. Sig. (2-tailed) .037 
Exact Sig. [2*(1-tailed Sig.)] .044(a) 
Exact Sig. (2-tailed) .044 
Exact Sig. (1-tailed) .022 
Point Probability .022 
a Not corrected for ties. 
b Grouping Variable: Group 
 
